CINXE.COM

<!DOCTYPE html><html lang="en"><head><meta charSet="utf-8"/><meta name="viewport" content="width=device-width"/><script src="https://cmp.osano.com/6olh2SicG0V81Mlk/1f9d883d-3834-40b9-9a96-6f89a1cda98b/osano.js"></script><title>Non-Hodgkin Lymphoma (NHL) </title><meta name="description" content="The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms."/><meta property="og:url" content="https://www.ajmc.com/compendium/nhl "/><meta property="og:title" content="Non-Hodgkin Lymphoma (NHL) "/><meta property="og:image" content="https://s3.amazonaws.com/mjhlifesciences.com/sitelogos/AJMC_1200x637.png"/><meta property="og:site_name" content="AJMC"/><meta property="og:description" content="The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms."/><meta name="twitter:card" content="summary"/><meta name="twitter:title" content="Non-Hodgkin Lymphoma (NHL) "/><meta name="twitter:image" content="https://s3.amazonaws.com/mjhlifesciences.com/sitelogos/AJMC_1200x637.png"/><meta name="twitter:site" content="@@AJMC_Journal"/><meta name="twitter:description" content="The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms."/><meta name="robots" content="max-image-preview:large"/><meta name="robots" content="max-video-preview:-1"/><link rel="preconnect dns-prefetch" href="https://cmp.osano.com"/><link rel="preconnect dns-prefetch" href="https://res.lassomarketing.io"/><link rel="preconnect dns-prefetch" href="https://www.lightboxcdn.com"/><link rel="preconnect dns-prefetch" href="https://pub.doubleverify.com"/><link rel="preconnect dns-prefetch" href="https://cdn.doubleverify.com"/><link rel="preconnect dns-prefetch" href="https://cdn.segment.com"/><link rel="preconnect dns-prefetch" href="https://securepubads.g.doubleclick.net"/><link rel="preconnect dns-prefetch" href="https://pagead2.googlesyndication.com"/><link rel="preconnect dns-prefetch" href="https://cdn.sanity.io"/><link rel="preconnect dns-prefetch" href="https://www.google-analytics.com"/><link rel="preconnect dns-prefetch" href="https://www.googletagmanager.com"/><link rel="preconnect dns-prefetch" href="https://player.vimeo.com"/><link rel="preconnect dns-prefetch" href="https://youtube.com"/><link rel="preconnect dns-prefetch" href="https://connect.facebook.net"/><link rel="preconnect dns-prefetch" href="https://www.facebook.com"/><link rel="preconnect dns-prefetch" href="https://static.ads-twitter.com"/><link rel="preconnect dns-prefetch" href="https://ad.doubleclick.net"/><link rel="preload" href="https://securepubads.g.doubleclick.net/tag/js/gpt.js"/><link rel="preload" href="https://pub.doubleverify.com/signals/pub.js#ctx=20083417&cmp=DV464021"/><link rel="icon" href="/favicon.ico"/><script async="" src="https://securepubads.g.doubleclick.net/tag/js/gpt.js"></script><script src="https://pub.doubleverify.com/signals/pub.js#ctx=20083417&cmp=DV464021"></script><script src="https://one.ajmc.com/tagmanager/scripts/one.js"></script><script>window.dataLayer = window.dataLayer || []; window.dataLayer.push({ event: "page_dimensions", pageTitle: "Non-Hodgkin Lymphoma (NHL) ", dimension9: "compendium/nhl", dimension11: "", dimension12: "", dimension13: "", dimension14: "", dimension15: "compendium/nhl", dimension18: "", dimension19: "", dimension20: "", });</script><script type="module"> (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start': new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0], j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src= 'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f); })(window,document,'script','dataLayer','GTM-NK5KQXS'); </script><script type="module"> var ALGOLIA_INSIGHTS_SRC = "https://cdn.jsdelivr.net/npm/search-insights@2.4.0"; !function(e,a,t,n,s,i,c){e.AlgoliaAnalyticsObject=s,e[s]=e[s]||function(){ (e[s].queue=e[s].queue||[]).push(arguments)},i=a.createElement(t),c=a.getElementsByTagName(t)[0], i.async=1,i.src=n,c.parentNode.insertBefore(i,c) }(window,document,"script",ALGOLIA_INSIGHTS_SRC,"aa");</script><link rel="canonical" href="https://www.ajmc.com/compendium/nhl"/><meta name="next-head-count" content="10"/><script async="" type="text/javascript" src="https://www.lightboxcdn.com/static/lightbox_mjh.js"></script><script defer="" src="https://res.lassomarketing.io/scripts/lasso-imp-id-min.js" type="text/javascript"></script> <script defer="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js"></script> <script type="module"> !function(){var analytics=window.analytics=window.analytics||[];if(!analytics.initialize)if(analytics.invoked)window.console&&console.error&&console.error("Segment snippet included twice.");else{analytics.invoked=!0;analytics.methods=["trackSubmit","trackClick","trackLink","trackForm","pageview","identify","reset","group","track","ready","alias","debug","page","once","off","on","addSourceMiddleware","addIntegrationMiddleware","setAnonymousId","addDestinationMiddleware"];analytics.factory=function(e){return function(){var t=Array.prototype.slice.call(arguments);t.unshift(e);analytics.push(t);return analytics}};for(var e=0;e<analytics.methods.length;e++){var key=analytics.methods[e];analytics[key]=analytics.factory(key)}analytics.load=function(key,e){var t=document.createElement("script");t.type="text/javascript";t.async=!0;t.src="https://cdn.segment.com/analytics.js/v1/" + key + "/analytics.min.js";var n=document.getElementsByTagName("script")[0];n.parentNode.insertBefore(t,n);analytics._loadOptions=e};analytics.SNIPPET_VERSION="4.13.1"; window.LassoImpressionID = lassoImpID(); analytics.load("BBbKMoOjmhsxPnbd2nO6osz3zq67DzuN"); analytics.page({ 'LassoImpressionID': window.LassoImpressionID }); }}(); </script> <link rel="preload" href="/_next/static/css/e5225e6dc4ca333b.css" as="style"/><link rel="stylesheet" href="/_next/static/css/e5225e6dc4ca333b.css" data-n-g=""/><link rel="preload" href="/_next/static/css/1fd9d1dcb68b7a42.css" as="style"/><link rel="stylesheet" href="/_next/static/css/1fd9d1dcb68b7a42.css" data-n-p=""/><link rel="preload" href="/_next/static/css/73c00cd95dc66651.css" as="style"/><link rel="stylesheet" href="/_next/static/css/73c00cd95dc66651.css" data-n-p=""/><link rel="preload" href="/_next/static/css/0f1de527bcd6b2b3.css" as="style"/><link rel="stylesheet" href="/_next/static/css/0f1de527bcd6b2b3.css" data-n-p=""/><noscript data-n-css=""></noscript><script defer="" nomodule="" src="/_next/static/chunks/polyfills-c67a75d1b6f99dc8.js"></script><script src="/_next/static/chunks/webpack-7bb91bc5bbba1ada.js" defer=""></script><script src="/_next/static/chunks/framework-45ce3d09104a2cae.js" defer=""></script><script src="/_next/static/chunks/main-c1ce322a402d266c.js" defer=""></script><script src="/_next/static/chunks/pages/_app-c3a05645a08041c3.js" defer=""></script><script src="/_next/static/chunks/8eec4907-bd18a9d50c17fbc1.js" defer=""></script><script src="/_next/static/chunks/065a3ddb-42216585c327b2a5.js" defer=""></script><script src="/_next/static/chunks/9814d858-cb162ab048445baf.js" defer=""></script><script src="/_next/static/chunks/69bd6bf3-c7219ac9ecb38ac9.js" defer=""></script><script src="/_next/static/chunks/f36c6662-e730e1316f9aa347.js" defer=""></script><script src="/_next/static/chunks/72585f70-0d4479e14d41a365.js" defer=""></script><script src="/_next/static/chunks/59b4e022-12a1c6f09c31aa87.js" defer=""></script><script src="/_next/static/chunks/aeb74aa0-4e0b515016d20a9f.js" defer=""></script><script src="/_next/static/chunks/e893f787-08b93252db7fc864.js" defer=""></script><script src="/_next/static/chunks/e1efa4cc-06e900eb45581c19.js" defer=""></script><script src="/_next/static/chunks/c8eae200-9f0c2beb62006a40.js" defer=""></script><script src="/_next/static/chunks/a29ae703-70c961c34719afa8.js" defer=""></script><script src="/_next/static/chunks/4592-37f767f9d2e595fc.js" defer=""></script><script src="/_next/static/chunks/1212-e69ee8c76b24c02a.js" defer=""></script><script src="/_next/static/chunks/4179-91956f2d2c4bf724.js" defer=""></script><script src="/_next/static/chunks/9879-c84885d45ee98d34.js" defer=""></script><script src="/_next/static/chunks/9355-c793747e2dd7fab4.js" defer=""></script><script src="/_next/static/chunks/3499-b4daf1c9382343af.js" defer=""></script><script src="/_next/static/chunks/4386-1eb6319d7e5f2437.js" defer=""></script><script src="/_next/static/chunks/8421-a4cb4c694745bc83.js" defer=""></script><script src="/_next/static/chunks/8412-bd07abe8ce76d08f.js" defer=""></script><script src="/_next/static/chunks/430-ec5773e97694cd78.js" defer=""></script><script src="/_next/static/chunks/173-0c8dbb3c1f76b4a8.js" defer=""></script><script src="/_next/static/chunks/7707-950f90aec08fbabe.js" defer=""></script><script src="/_next/static/chunks/475-90949f2271d616fd.js" defer=""></script><script src="/_next/static/chunks/9323-6b03066a987bc392.js" defer=""></script><script src="/_next/static/chunks/4978-ee388caa09ad5169.js" defer=""></script><script src="/_next/static/chunks/4063-ea283543a8930e92.js" defer=""></script><script src="/_next/static/chunks/pages/%5B...slug%5D-1b8b61a43bc98d83.js" defer=""></script><script src="/_next/static/jIKMoC-9mMyLq4v4Ma7Tv/_buildManifest.js" defer=""></script><script src="/_next/static/jIKMoC-9mMyLq4v4Ma7Tv/_ssgManifest.js" defer=""></script><style id="__jsx-1661e6713d4eb9b5">.leaderboardAdWrapper.jsx-1661e6713d4eb9b5{min-height:90px;background:#fff}.leaderboardAdWrapper.jsx-1661e6713d4eb9b5 .AD728x90.jsx-1661e6713d4eb9b5{}@media screen and (min-width:768px){.leader-fixed.jsx-1661e6713d4eb9b5{position:fixed;margin-top:1rem;z-index:999999}}.leaderboardAdWrapper.jsx-1661e6713d4eb9b5 .AD728x90.jsx-1661e6713d4eb9b5 div[id*="google_ads_iframe"].jsx-1661e6713d4eb9b5:empty{height:0px!important}@media screen and (max-width:668px){.leaderboardAdWrapper.jsx-1661e6713d4eb9b5{min-height:0px;position:fixed;background:white;left:0;right:0;top:55px;padding-top:.5rem;padding-bottom:.25rem;z-index:9999}}</style><style id="__jsx-1215160397">.bottomDiv.jsx-1215160397{width:100%;display:block;position:relative;top:-10px;height:300px;z-index:99;background:#fff;text-align:center;font-size:.875rem;-webkit-text-decoration-line:none;-moz-text-decoration-line:none;text-decoration-line:none}.bottomDiv.jsx-1215160397::before{content:" ";display:block;width:100%;height:280px;border-top:8px solid var(--primary);left:-54px!important;-webkit-transform:rotate(7.5deg)!important;-moz-transform:rotate(7.5deg)!important;-ms-transform:rotate(7.5deg)!important;-o-transform:rotate(7.5deg)!important;transform:rotate(7.5deg)!important;position:absolute!important;background:white;z-index:1;top:-7px}.bottomDiv.jsx-1215160397::after{content:" ";display:block;width:100%;height:280px;border-top:8px solid var(--primary);left:20px!important;top:-2px;background:white;-webkit-transform:rotate(-7.5deg)!important;-moz-transform:rotate(-7.5deg)!important;-ms-transform:rotate(-7.5deg)!important;-o-transform:rotate(-7.5deg)!important;transform:rotate(-7.5deg)!important;position:absolute!important;z-index:1}.border-div.jsx-1215160397{content:" ";display:block;width:100%;height:280px;left:-50px!important;-webkit-transform:rotate(7.5deg)!important;-moz-transform:rotate(7.5deg)!important;-ms-transform:rotate(7.5deg)!important;-o-transform:rotate(7.5deg)!important;transform:rotate(7.5deg)!important;position:relative;background:white;z-index:99;top:-116px}.content-button.jsx-1215160397{position:relative;border:1px solid var(--primary);min-width:40px;width:-webkit-fit-content;width:-moz-fit-content;width:fit-content;padding:5px 10px;font-weight:bold;-webkit-border-radius:5px;-moz-border-radius:5px;border-radius:5px;font-size:.75rem;z-index:9999;background:var(--primary);color:white;top:150px;left:70px}.content-wrap.jsx-1215160397{width:100%;height:-webkit-fit-content;height:-moz-fit-content;height:fit-content;z-index:99;display:-webkit-box;display:-webkit-flex;display:-moz-box;display:-ms-flexbox;display:flex;-webkit-box-orient:vertical;-webkit-box-direction:normal;-webkit-flex-direction:column;-moz-box-orient:vertical;-moz-box-direction:normal;-ms-flex-direction:column;flex-direction:column}#viewMore0undefined.jsx-1215160397:hover{background:var(--secondary)}.view-more-wrap0undefined.jsx-1215160397{width:100%;height:10%;display:-webkit-box;display:-webkit-flex;display:-moz-box;display:-ms-flexbox;display:flex;background:var(--primary);-webkit-box-pack:justify;-webkit-justify-content:space-between;-moz-box-pack:justify;-ms-flex-pack:justify;justify-content:space-between;-webkit-box-align:center;-webkit-align-items:center;-moz-box-align:center;-ms-flex-align:center;align-items:center;position:absolute;top:90%;z-index:999;background:-webkit-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:-moz-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:-o-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:linear-gradient(to right,var(--primary)50%,var(--secondary)50%);-webkit-background-size:200%100%;-moz-background-size:200%100%;-o-background-size:200%100%;background-size:200%100%;background-position:left bottom;-webkit-transition:all 150ms ease;-moz-transition:all 150ms ease;-o-transition:all 150ms ease;transition:all 150ms ease}.view#more-wrap0undefined.jsx-1215160397:hover{background-position:right bottom}.view-more-wrap-wipe.jsx-1215160397{background-position:right bottom}.text-white.jsx-1215160397{color:var(--primary)}</style><style id="__jsx-1637274924">.bottomDiv.jsx-1637274924{width:100%;display:block;position:relative;top:-10px;height:300px;z-index:99;background:#fff;text-align:center;font-size:.875rem;-webkit-text-decoration-line:none;-moz-text-decoration-line:none;text-decoration-line:none}.bottomDiv.jsx-1637274924::before{content:" ";display:block;width:100%;height:280px;border-top:8px solid var(--primary);left:-54px!important;-webkit-transform:rotate(7.5deg)!important;-moz-transform:rotate(7.5deg)!important;-ms-transform:rotate(7.5deg)!important;-o-transform:rotate(7.5deg)!important;transform:rotate(7.5deg)!important;position:absolute!important;background:white;z-index:1;top:-7px}.bottomDiv.jsx-1637274924::after{content:" ";display:block;width:100%;height:280px;border-top:8px solid var(--primary);left:20px!important;top:-2px;background:white;-webkit-transform:rotate(-7.5deg)!important;-moz-transform:rotate(-7.5deg)!important;-ms-transform:rotate(-7.5deg)!important;-o-transform:rotate(-7.5deg)!important;transform:rotate(-7.5deg)!important;position:absolute!important;z-index:1}.border-div.jsx-1637274924{content:" ";display:block;width:100%;height:280px;left:-50px!important;-webkit-transform:rotate(7.5deg)!important;-moz-transform:rotate(7.5deg)!important;-ms-transform:rotate(7.5deg)!important;-o-transform:rotate(7.5deg)!important;transform:rotate(7.5deg)!important;position:relative;background:white;z-index:99;top:-116px}.content-button.jsx-1637274924{position:relative;border:1px solid var(--primary);min-width:40px;width:-webkit-fit-content;width:-moz-fit-content;width:fit-content;padding:5px 10px;font-weight:bold;-webkit-border-radius:5px;-moz-border-radius:5px;border-radius:5px;font-size:.75rem;z-index:9999;background:var(--primary);color:white;top:150px;left:70px}.content-wrap.jsx-1637274924{width:100%;height:-webkit-fit-content;height:-moz-fit-content;height:fit-content;z-index:99;display:-webkit-box;display:-webkit-flex;display:-moz-box;display:-ms-flexbox;display:flex;-webkit-box-orient:vertical;-webkit-box-direction:normal;-webkit-flex-direction:column;-moz-box-orient:vertical;-moz-box-direction:normal;-ms-flex-direction:column;flex-direction:column}#viewMore1undefined.jsx-1637274924:hover{background:var(--secondary)}.view-more-wrap1undefined.jsx-1637274924{width:100%;height:10%;display:-webkit-box;display:-webkit-flex;display:-moz-box;display:-ms-flexbox;display:flex;background:var(--primary);-webkit-box-pack:justify;-webkit-justify-content:space-between;-moz-box-pack:justify;-ms-flex-pack:justify;justify-content:space-between;-webkit-box-align:center;-webkit-align-items:center;-moz-box-align:center;-ms-flex-align:center;align-items:center;position:absolute;top:90%;z-index:999;background:-webkit-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:-moz-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:-o-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:linear-gradient(to right,var(--primary)50%,var(--secondary)50%);-webkit-background-size:200%100%;-moz-background-size:200%100%;-o-background-size:200%100%;background-size:200%100%;background-position:left bottom;-webkit-transition:all 150ms ease;-moz-transition:all 150ms ease;-o-transition:all 150ms ease;transition:all 150ms ease}.view#more-wrap1undefined.jsx-1637274924:hover{background-position:right bottom}.view-more-wrap-wipe.jsx-1637274924{background-position:right bottom}.text-white.jsx-1637274924{color:var(--primary)}</style><style id="__jsx-286612495">.bottomDiv.jsx-286612495{width:100%;display:block;position:relative;top:-10px;height:300px;z-index:99;background:#fff;text-align:center;font-size:.875rem;-webkit-text-decoration-line:none;-moz-text-decoration-line:none;text-decoration-line:none}.bottomDiv.jsx-286612495::before{content:" ";display:block;width:100%;height:280px;border-top:8px solid var(--primary);left:-54px!important;-webkit-transform:rotate(7.5deg)!important;-moz-transform:rotate(7.5deg)!important;-ms-transform:rotate(7.5deg)!important;-o-transform:rotate(7.5deg)!important;transform:rotate(7.5deg)!important;position:absolute!important;background:white;z-index:1;top:-7px}.bottomDiv.jsx-286612495::after{content:" ";display:block;width:100%;height:280px;border-top:8px solid var(--primary);left:20px!important;top:-2px;background:white;-webkit-transform:rotate(-7.5deg)!important;-moz-transform:rotate(-7.5deg)!important;-ms-transform:rotate(-7.5deg)!important;-o-transform:rotate(-7.5deg)!important;transform:rotate(-7.5deg)!important;position:absolute!important;z-index:1}.border-div.jsx-286612495{content:" ";display:block;width:100%;height:280px;left:-50px!important;-webkit-transform:rotate(7.5deg)!important;-moz-transform:rotate(7.5deg)!important;-ms-transform:rotate(7.5deg)!important;-o-transform:rotate(7.5deg)!important;transform:rotate(7.5deg)!important;position:relative;background:white;z-index:99;top:-116px}.content-button.jsx-286612495{position:relative;border:1px solid var(--primary);min-width:40px;width:-webkit-fit-content;width:-moz-fit-content;width:fit-content;padding:5px 10px;font-weight:bold;-webkit-border-radius:5px;-moz-border-radius:5px;border-radius:5px;font-size:.75rem;z-index:9999;background:var(--primary);color:white;top:150px;left:70px}.content-wrap.jsx-286612495{width:100%;height:-webkit-fit-content;height:-moz-fit-content;height:fit-content;z-index:99;display:-webkit-box;display:-webkit-flex;display:-moz-box;display:-ms-flexbox;display:flex;-webkit-box-orient:vertical;-webkit-box-direction:normal;-webkit-flex-direction:column;-moz-box-orient:vertical;-moz-box-direction:normal;-ms-flex-direction:column;flex-direction:column}#viewMore2undefined.jsx-286612495:hover{background:var(--secondary)}.view-more-wrap2undefined.jsx-286612495{width:100%;height:10%;display:-webkit-box;display:-webkit-flex;display:-moz-box;display:-ms-flexbox;display:flex;background:var(--primary);-webkit-box-pack:justify;-webkit-justify-content:space-between;-moz-box-pack:justify;-ms-flex-pack:justify;justify-content:space-between;-webkit-box-align:center;-webkit-align-items:center;-moz-box-align:center;-ms-flex-align:center;align-items:center;position:absolute;top:90%;z-index:999;background:-webkit-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:-moz-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:-o-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:linear-gradient(to right,var(--primary)50%,var(--secondary)50%);-webkit-background-size:200%100%;-moz-background-size:200%100%;-o-background-size:200%100%;background-size:200%100%;background-position:left bottom;-webkit-transition:all 150ms ease;-moz-transition:all 150ms ease;-o-transition:all 150ms ease;transition:all 150ms ease}.view#more-wrap2undefined.jsx-286612495:hover{background-position:right bottom}.view-more-wrap-wipe.jsx-286612495{background-position:right bottom}.text-white.jsx-286612495{color:var(--primary)}</style><style id="__jsx-2915913710">.bottomDiv.jsx-2915913710{width:100%;display:block;position:relative;top:-10px;height:300px;z-index:99;background:#fff;text-align:center;font-size:.875rem;-webkit-text-decoration-line:none;-moz-text-decoration-line:none;text-decoration-line:none}.bottomDiv.jsx-2915913710::before{content:" ";display:block;width:100%;height:280px;border-top:8px solid var(--primary);left:-54px!important;-webkit-transform:rotate(7.5deg)!important;-moz-transform:rotate(7.5deg)!important;-ms-transform:rotate(7.5deg)!important;-o-transform:rotate(7.5deg)!important;transform:rotate(7.5deg)!important;position:absolute!important;background:white;z-index:1;top:-7px}.bottomDiv.jsx-2915913710::after{content:" ";display:block;width:100%;height:280px;border-top:8px solid var(--primary);left:20px!important;top:-2px;background:white;-webkit-transform:rotate(-7.5deg)!important;-moz-transform:rotate(-7.5deg)!important;-ms-transform:rotate(-7.5deg)!important;-o-transform:rotate(-7.5deg)!important;transform:rotate(-7.5deg)!important;position:absolute!important;z-index:1}.border-div.jsx-2915913710{content:" ";display:block;width:100%;height:280px;left:-50px!important;-webkit-transform:rotate(7.5deg)!important;-moz-transform:rotate(7.5deg)!important;-ms-transform:rotate(7.5deg)!important;-o-transform:rotate(7.5deg)!important;transform:rotate(7.5deg)!important;position:relative;background:white;z-index:99;top:-116px}.content-button.jsx-2915913710{position:relative;border:1px solid var(--primary);min-width:40px;width:-webkit-fit-content;width:-moz-fit-content;width:fit-content;padding:5px 10px;font-weight:bold;-webkit-border-radius:5px;-moz-border-radius:5px;border-radius:5px;font-size:.75rem;z-index:9999;background:var(--primary);color:white;top:150px;left:70px}.content-wrap.jsx-2915913710{width:100%;height:-webkit-fit-content;height:-moz-fit-content;height:fit-content;z-index:99;display:-webkit-box;display:-webkit-flex;display:-moz-box;display:-ms-flexbox;display:flex;-webkit-box-orient:vertical;-webkit-box-direction:normal;-webkit-flex-direction:column;-moz-box-orient:vertical;-moz-box-direction:normal;-ms-flex-direction:column;flex-direction:column}#viewMore3undefined.jsx-2915913710:hover{background:var(--secondary)}.view-more-wrap3undefined.jsx-2915913710{width:100%;height:10%;display:-webkit-box;display:-webkit-flex;display:-moz-box;display:-ms-flexbox;display:flex;background:var(--primary);-webkit-box-pack:justify;-webkit-justify-content:space-between;-moz-box-pack:justify;-ms-flex-pack:justify;justify-content:space-between;-webkit-box-align:center;-webkit-align-items:center;-moz-box-align:center;-ms-flex-align:center;align-items:center;position:absolute;top:90%;z-index:999;background:-webkit-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:-moz-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:-o-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:linear-gradient(to right,var(--primary)50%,var(--secondary)50%);-webkit-background-size:200%100%;-moz-background-size:200%100%;-o-background-size:200%100%;background-size:200%100%;background-position:left bottom;-webkit-transition:all 150ms ease;-moz-transition:all 150ms ease;-o-transition:all 150ms ease;transition:all 150ms ease}.view#more-wrap3undefined.jsx-2915913710:hover{background-position:right bottom}.view-more-wrap-wipe.jsx-2915913710{background-position:right bottom}.text-white.jsx-2915913710{color:var(--primary)}</style><style id="__jsx-2363373513">.bottomDiv.jsx-2363373513{width:100%;display:block;position:relative;top:-10px;height:300px;z-index:99;background:#fff;text-align:center;font-size:.875rem;-webkit-text-decoration-line:none;-moz-text-decoration-line:none;text-decoration-line:none}.bottomDiv.jsx-2363373513::before{content:" ";display:block;width:100%;height:280px;border-top:8px solid var(--primary);left:-54px!important;-webkit-transform:rotate(7.5deg)!important;-moz-transform:rotate(7.5deg)!important;-ms-transform:rotate(7.5deg)!important;-o-transform:rotate(7.5deg)!important;transform:rotate(7.5deg)!important;position:absolute!important;background:white;z-index:1;top:-7px}.bottomDiv.jsx-2363373513::after{content:" ";display:block;width:100%;height:280px;border-top:8px solid var(--primary);left:20px!important;top:-2px;background:white;-webkit-transform:rotate(-7.5deg)!important;-moz-transform:rotate(-7.5deg)!important;-ms-transform:rotate(-7.5deg)!important;-o-transform:rotate(-7.5deg)!important;transform:rotate(-7.5deg)!important;position:absolute!important;z-index:1}.border-div.jsx-2363373513{content:" ";display:block;width:100%;height:280px;left:-50px!important;-webkit-transform:rotate(7.5deg)!important;-moz-transform:rotate(7.5deg)!important;-ms-transform:rotate(7.5deg)!important;-o-transform:rotate(7.5deg)!important;transform:rotate(7.5deg)!important;position:relative;background:white;z-index:99;top:-116px}.content-button.jsx-2363373513{position:relative;border:1px solid var(--primary);min-width:40px;width:-webkit-fit-content;width:-moz-fit-content;width:fit-content;padding:5px 10px;font-weight:bold;-webkit-border-radius:5px;-moz-border-radius:5px;border-radius:5px;font-size:.75rem;z-index:9999;background:var(--primary);color:white;top:150px;left:70px}.content-wrap.jsx-2363373513{width:100%;height:-webkit-fit-content;height:-moz-fit-content;height:fit-content;z-index:99;display:-webkit-box;display:-webkit-flex;display:-moz-box;display:-ms-flexbox;display:flex;-webkit-box-orient:vertical;-webkit-box-direction:normal;-webkit-flex-direction:column;-moz-box-orient:vertical;-moz-box-direction:normal;-ms-flex-direction:column;flex-direction:column}#viewMore4undefined.jsx-2363373513:hover{background:var(--secondary)}.view-more-wrap4undefined.jsx-2363373513{width:100%;height:10%;display:-webkit-box;display:-webkit-flex;display:-moz-box;display:-ms-flexbox;display:flex;background:var(--primary);-webkit-box-pack:justify;-webkit-justify-content:space-between;-moz-box-pack:justify;-ms-flex-pack:justify;justify-content:space-between;-webkit-box-align:center;-webkit-align-items:center;-moz-box-align:center;-ms-flex-align:center;align-items:center;position:absolute;top:90%;z-index:999;background:-webkit-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:-moz-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:-o-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:linear-gradient(to right,var(--primary)50%,var(--secondary)50%);-webkit-background-size:200%100%;-moz-background-size:200%100%;-o-background-size:200%100%;background-size:200%100%;background-position:left bottom;-webkit-transition:all 150ms ease;-moz-transition:all 150ms ease;-o-transition:all 150ms ease;transition:all 150ms ease}.view#more-wrap4undefined.jsx-2363373513:hover{background-position:right bottom}.view-more-wrap-wipe.jsx-2363373513{background-position:right bottom}.text-white.jsx-2363373513{color:var(--primary)}</style><style id="__jsx-19ede9f0a5a45918">.jsx-19ede9f0a5a45918::-webkit-scrollbar{display:none}</style><style id="__jsx-3886647465">.bottomDiv.jsx-3886647465{width:100%;display:block;position:relative;top:-10px;height:300px;z-index:99;background:#fff;text-align:center;font-size:.875rem;-webkit-text-decoration-line:none;-moz-text-decoration-line:none;text-decoration-line:none}.bottomDiv.jsx-3886647465::before{content:" ";display:block;width:100%;height:280px;border-top:8px solid var(--primary);left:-54px!important;-webkit-transform:rotate(7.5deg)!important;-moz-transform:rotate(7.5deg)!important;-ms-transform:rotate(7.5deg)!important;-o-transform:rotate(7.5deg)!important;transform:rotate(7.5deg)!important;position:absolute!important;background:white;z-index:1;top:-7px}.bottomDiv.jsx-3886647465::after{content:" ";display:block;width:100%;height:280px;border-top:8px solid var(--primary);left:20px!important;top:-2px;background:white;-webkit-transform:rotate(-7.5deg)!important;-moz-transform:rotate(-7.5deg)!important;-ms-transform:rotate(-7.5deg)!important;-o-transform:rotate(-7.5deg)!important;transform:rotate(-7.5deg)!important;position:absolute!important;z-index:1}.border-div.jsx-3886647465{content:" ";display:block;width:100%;height:280px;left:-50px!important;-webkit-transform:rotate(7.5deg)!important;-moz-transform:rotate(7.5deg)!important;-ms-transform:rotate(7.5deg)!important;-o-transform:rotate(7.5deg)!important;transform:rotate(7.5deg)!important;position:relative;background:white;z-index:99;top:-116px}.content-button.jsx-3886647465{position:relative;border:1px solid var(--primary);min-width:40px;width:-webkit-fit-content;width:-moz-fit-content;width:fit-content;padding:5px 10px;font-weight:bold;-webkit-border-radius:5px;-moz-border-radius:5px;border-radius:5px;font-size:.75rem;z-index:9999;background:var(--primary);color:white;top:150px;left:70px}.content-wrap.jsx-3886647465{width:100%;height:-webkit-fit-content;height:-moz-fit-content;height:fit-content;z-index:99;display:-webkit-box;display:-webkit-flex;display:-moz-box;display:-ms-flexbox;display:flex;-webkit-box-orient:vertical;-webkit-box-direction:normal;-webkit-flex-direction:column;-moz-box-orient:vertical;-moz-box-direction:normal;-ms-flex-direction:column;flex-direction:column}#viewMore0355d9b46-713d-4d48-84a7-2968d82157e5.jsx-3886647465:hover{background:var(--secondary)}.view-more-wrap0355d9b46-713d-4d48-84a7-2968d82157e5.jsx-3886647465{width:100%;height:10%;display:-webkit-box;display:-webkit-flex;display:-moz-box;display:-ms-flexbox;display:flex;background:var(--primary);-webkit-box-pack:justify;-webkit-justify-content:space-between;-moz-box-pack:justify;-ms-flex-pack:justify;justify-content:space-between;-webkit-box-align:center;-webkit-align-items:center;-moz-box-align:center;-ms-flex-align:center;align-items:center;position:absolute;top:90%;z-index:999;background:-webkit-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:-moz-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:-o-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:linear-gradient(to right,var(--primary)50%,var(--secondary)50%);-webkit-background-size:200%100%;-moz-background-size:200%100%;-o-background-size:200%100%;background-size:200%100%;background-position:left bottom;-webkit-transition:all 150ms ease;-moz-transition:all 150ms ease;-o-transition:all 150ms ease;transition:all 150ms ease}.view#more-wrap0355d9b46-713d-4d48-84a7-2968d82157e5.jsx-3886647465:hover{background-position:right bottom}.view-more-wrap-wipe.jsx-3886647465{background-position:right bottom}.text-white.jsx-3886647465{color:var(--primary)}</style><style id="__jsx-3945728741">.bottomDiv.jsx-3945728741{width:100%;display:block;position:relative;top:-10px;height:300px;z-index:99;background:#fff;text-align:center;font-size:.875rem;-webkit-text-decoration-line:none;-moz-text-decoration-line:none;text-decoration-line:none}.bottomDiv.jsx-3945728741::before{content:" ";display:block;width:100%;height:280px;border-top:8px solid var(--primary);left:-54px!important;-webkit-transform:rotate(7.5deg)!important;-moz-transform:rotate(7.5deg)!important;-ms-transform:rotate(7.5deg)!important;-o-transform:rotate(7.5deg)!important;transform:rotate(7.5deg)!important;position:absolute!important;background:white;z-index:1;top:-7px}.bottomDiv.jsx-3945728741::after{content:" ";display:block;width:100%;height:280px;border-top:8px solid var(--primary);left:20px!important;top:-2px;background:white;-webkit-transform:rotate(-7.5deg)!important;-moz-transform:rotate(-7.5deg)!important;-ms-transform:rotate(-7.5deg)!important;-o-transform:rotate(-7.5deg)!important;transform:rotate(-7.5deg)!important;position:absolute!important;z-index:1}.border-div.jsx-3945728741{content:" ";display:block;width:100%;height:280px;left:-50px!important;-webkit-transform:rotate(7.5deg)!important;-moz-transform:rotate(7.5deg)!important;-ms-transform:rotate(7.5deg)!important;-o-transform:rotate(7.5deg)!important;transform:rotate(7.5deg)!important;position:relative;background:white;z-index:99;top:-116px}.content-button.jsx-3945728741{position:relative;border:1px solid var(--primary);min-width:40px;width:-webkit-fit-content;width:-moz-fit-content;width:fit-content;padding:5px 10px;font-weight:bold;-webkit-border-radius:5px;-moz-border-radius:5px;border-radius:5px;font-size:.75rem;z-index:9999;background:var(--primary);color:white;top:150px;left:70px}.content-wrap.jsx-3945728741{width:100%;height:-webkit-fit-content;height:-moz-fit-content;height:fit-content;z-index:99;display:-webkit-box;display:-webkit-flex;display:-moz-box;display:-ms-flexbox;display:flex;-webkit-box-orient:vertical;-webkit-box-direction:normal;-webkit-flex-direction:column;-moz-box-orient:vertical;-moz-box-direction:normal;-ms-flex-direction:column;flex-direction:column}#viewMore13b3937de-a7a5-4ebd-bb5c-6192a7da7102.jsx-3945728741:hover{background:var(--secondary)}.view-more-wrap13b3937de-a7a5-4ebd-bb5c-6192a7da7102.jsx-3945728741{width:100%;height:10%;display:-webkit-box;display:-webkit-flex;display:-moz-box;display:-ms-flexbox;display:flex;background:var(--primary);-webkit-box-pack:justify;-webkit-justify-content:space-between;-moz-box-pack:justify;-ms-flex-pack:justify;justify-content:space-between;-webkit-box-align:center;-webkit-align-items:center;-moz-box-align:center;-ms-flex-align:center;align-items:center;position:absolute;top:90%;z-index:999;background:-webkit-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:-moz-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:-o-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:linear-gradient(to right,var(--primary)50%,var(--secondary)50%);-webkit-background-size:200%100%;-moz-background-size:200%100%;-o-background-size:200%100%;background-size:200%100%;background-position:left bottom;-webkit-transition:all 150ms ease;-moz-transition:all 150ms ease;-o-transition:all 150ms ease;transition:all 150ms ease}.view#more-wrap13b3937de-a7a5-4ebd-bb5c-6192a7da7102.jsx-3945728741:hover{background-position:right bottom}.view-more-wrap-wipe.jsx-3945728741{background-position:right bottom}.text-white.jsx-3945728741{color:var(--primary)}</style><style id="__jsx-3745364856">.bottomDiv.jsx-3745364856{width:100%;display:block;position:relative;top:-10px;height:300px;z-index:99;background:#fff;text-align:center;font-size:.875rem;-webkit-text-decoration-line:none;-moz-text-decoration-line:none;text-decoration-line:none}.bottomDiv.jsx-3745364856::before{content:" ";display:block;width:100%;height:280px;border-top:8px solid var(--primary);left:-54px!important;-webkit-transform:rotate(7.5deg)!important;-moz-transform:rotate(7.5deg)!important;-ms-transform:rotate(7.5deg)!important;-o-transform:rotate(7.5deg)!important;transform:rotate(7.5deg)!important;position:absolute!important;background:white;z-index:1;top:-7px}.bottomDiv.jsx-3745364856::after{content:" ";display:block;width:100%;height:280px;border-top:8px solid var(--primary);left:20px!important;top:-2px;background:white;-webkit-transform:rotate(-7.5deg)!important;-moz-transform:rotate(-7.5deg)!important;-ms-transform:rotate(-7.5deg)!important;-o-transform:rotate(-7.5deg)!important;transform:rotate(-7.5deg)!important;position:absolute!important;z-index:1}.border-div.jsx-3745364856{content:" ";display:block;width:100%;height:280px;left:-50px!important;-webkit-transform:rotate(7.5deg)!important;-moz-transform:rotate(7.5deg)!important;-ms-transform:rotate(7.5deg)!important;-o-transform:rotate(7.5deg)!important;transform:rotate(7.5deg)!important;position:relative;background:white;z-index:99;top:-116px}.content-button.jsx-3745364856{position:relative;border:1px solid var(--primary);min-width:40px;width:-webkit-fit-content;width:-moz-fit-content;width:fit-content;padding:5px 10px;font-weight:bold;-webkit-border-radius:5px;-moz-border-radius:5px;border-radius:5px;font-size:.75rem;z-index:9999;background:var(--primary);color:white;top:150px;left:70px}.content-wrap.jsx-3745364856{width:100%;height:-webkit-fit-content;height:-moz-fit-content;height:fit-content;z-index:99;display:-webkit-box;display:-webkit-flex;display:-moz-box;display:-ms-flexbox;display:flex;-webkit-box-orient:vertical;-webkit-box-direction:normal;-webkit-flex-direction:column;-moz-box-orient:vertical;-moz-box-direction:normal;-ms-flex-direction:column;flex-direction:column}#viewMore29453bbb8-c0d5-459e-9058-a97e9e0cdb97.jsx-3745364856:hover{background:var(--secondary)}.view-more-wrap29453bbb8-c0d5-459e-9058-a97e9e0cdb97.jsx-3745364856{width:100%;height:10%;display:-webkit-box;display:-webkit-flex;display:-moz-box;display:-ms-flexbox;display:flex;background:var(--primary);-webkit-box-pack:justify;-webkit-justify-content:space-between;-moz-box-pack:justify;-ms-flex-pack:justify;justify-content:space-between;-webkit-box-align:center;-webkit-align-items:center;-moz-box-align:center;-ms-flex-align:center;align-items:center;position:absolute;top:90%;z-index:999;background:-webkit-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:-moz-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:-o-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:linear-gradient(to right,var(--primary)50%,var(--secondary)50%);-webkit-background-size:200%100%;-moz-background-size:200%100%;-o-background-size:200%100%;background-size:200%100%;background-position:left bottom;-webkit-transition:all 150ms ease;-moz-transition:all 150ms ease;-o-transition:all 150ms ease;transition:all 150ms ease}.view#more-wrap29453bbb8-c0d5-459e-9058-a97e9e0cdb97.jsx-3745364856:hover{background-position:right bottom}.view-more-wrap-wipe.jsx-3745364856{background-position:right bottom}.text-white.jsx-3745364856{color:var(--primary)}</style><style id="__jsx-2629720111">.bottomDiv.jsx-2629720111{width:100%;display:block;position:relative;top:-10px;height:300px;z-index:99;background:#fff;text-align:center;font-size:.875rem;-webkit-text-decoration-line:none;-moz-text-decoration-line:none;text-decoration-line:none}.bottomDiv.jsx-2629720111::before{content:" ";display:block;width:100%;height:280px;border-top:8px solid var(--primary);left:-54px!important;-webkit-transform:rotate(7.5deg)!important;-moz-transform:rotate(7.5deg)!important;-ms-transform:rotate(7.5deg)!important;-o-transform:rotate(7.5deg)!important;transform:rotate(7.5deg)!important;position:absolute!important;background:white;z-index:1;top:-7px}.bottomDiv.jsx-2629720111::after{content:" ";display:block;width:100%;height:280px;border-top:8px solid var(--primary);left:20px!important;top:-2px;background:white;-webkit-transform:rotate(-7.5deg)!important;-moz-transform:rotate(-7.5deg)!important;-ms-transform:rotate(-7.5deg)!important;-o-transform:rotate(-7.5deg)!important;transform:rotate(-7.5deg)!important;position:absolute!important;z-index:1}.border-div.jsx-2629720111{content:" ";display:block;width:100%;height:280px;left:-50px!important;-webkit-transform:rotate(7.5deg)!important;-moz-transform:rotate(7.5deg)!important;-ms-transform:rotate(7.5deg)!important;-o-transform:rotate(7.5deg)!important;transform:rotate(7.5deg)!important;position:relative;background:white;z-index:99;top:-116px}.content-button.jsx-2629720111{position:relative;border:1px solid var(--primary);min-width:40px;width:-webkit-fit-content;width:-moz-fit-content;width:fit-content;padding:5px 10px;font-weight:bold;-webkit-border-radius:5px;-moz-border-radius:5px;border-radius:5px;font-size:.75rem;z-index:9999;background:var(--primary);color:white;top:150px;left:70px}.content-wrap.jsx-2629720111{width:100%;height:-webkit-fit-content;height:-moz-fit-content;height:fit-content;z-index:99;display:-webkit-box;display:-webkit-flex;display:-moz-box;display:-ms-flexbox;display:flex;-webkit-box-orient:vertical;-webkit-box-direction:normal;-webkit-flex-direction:column;-moz-box-orient:vertical;-moz-box-direction:normal;-ms-flex-direction:column;flex-direction:column}#viewMore354fbd28a-f02c-44b9-8d31-f0863e5d2455.jsx-2629720111:hover{background:var(--secondary)}.view-more-wrap354fbd28a-f02c-44b9-8d31-f0863e5d2455.jsx-2629720111{width:100%;height:10%;display:-webkit-box;display:-webkit-flex;display:-moz-box;display:-ms-flexbox;display:flex;background:var(--primary);-webkit-box-pack:justify;-webkit-justify-content:space-between;-moz-box-pack:justify;-ms-flex-pack:justify;justify-content:space-between;-webkit-box-align:center;-webkit-align-items:center;-moz-box-align:center;-ms-flex-align:center;align-items:center;position:absolute;top:90%;z-index:999;background:-webkit-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:-moz-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:-o-linear-gradient(left,var(--primary)50%,var(--secondary)50%);background:linear-gradient(to right,var(--primary)50%,var(--secondary)50%);-webkit-background-size:200%100%;-moz-background-size:200%100%;-o-background-size:200%100%;background-size:200%100%;background-position:left bottom;-webkit-transition:all 150ms ease;-moz-transition:all 150ms ease;-o-transition:all 150ms ease;transition:all 150ms ease}.view#more-wrap354fbd28a-f02c-44b9-8d31-f0863e5d2455.jsx-2629720111:hover{background-position:right bottom}.view-more-wrap-wipe.jsx-2629720111{background-position:right bottom}.text-white.jsx-2629720111{color:var(--primary)}</style><style id="__jsx-ad50481d5ee26850">@media(min-width:980px)and (max-width:1200px){.article-detail.jsx-ad50481d5ee26850{width:47%}}@media(min-width:1201px)and (max-width:1400px){.article-detail.jsx-ad50481d5ee26850{width:55%}}</style></head><body><div id="__next" data-reactroot=""><div class="-mb-6"><div id="frame-nav" class="sticky top-0 z-[999999]"><div class="h-full w-full"><nav role="navigation" class=" w-full mx-auto hidden lg:block bg-white shadow-md relative"><div class="bg-primary" id="topnav"><div class="container px-4 relative justify-between h-16 flex items-center md:items-stretch mx-auto "><div class="h-full flex items-center flex-1 justify-between mr-4"><a role="img" aria-label="logo" class="focus:outline-none relative h-12 w-40 mr-6 flex items-center" href="/"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:contain;object-position:left"/><noscript><img sizes="100vw" srcSet="/_next/image?url=%2Fajmc_logo_inverted.png&w=640&q=75 640w, /_next/image?url=%2Fajmc_logo_inverted.png&w=750&q=75 750w, /_next/image?url=%2Fajmc_logo_inverted.png&w=828&q=75 828w, /_next/image?url=%2Fajmc_logo_inverted.png&w=1080&q=75 1080w, /_next/image?url=%2Fajmc_logo_inverted.png&w=1200&q=75 1200w, /_next/image?url=%2Fajmc_logo_inverted.png&w=1920&q=75 1920w, /_next/image?url=%2Fajmc_logo_inverted.png&w=2048&q=75 2048w, /_next/image?url=%2Fajmc_logo_inverted.png&w=3840&q=75 3840w" src="/_next/image?url=%2Fajmc_logo_inverted.png&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:contain;object-position:left" loading="lazy"/></noscript></span></a><div class="hidden md:block"><div class="bg-primary py-2 whitespace-nowrap"><div class="mx-auto md:max-w-4xl lg:max-w-5xl xl:max-w-7xl "><div class="flex gap-4 items-end"><div class=" isolate z-[10000] " data-headlessui-state=""><button class="focus:outline-none border-b-2 border-transparent text-[15px] cursor-pointer h-full flex items-center tracking-normal capitalize text-white" type="button" aria-expanded="false" data-headlessui-state="">News<svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 24 24" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="m11.998 17 7-8h-14z"></path></svg></button><div class="sr-only"><a href="/news" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">All News</a><a href="/press-release" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Press Releases</a><a href="/approvals-launches" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Product Approvals and Launches</a></div></div><div class=" isolate z-[10000] " data-headlessui-state=""><button class="focus:outline-none border-b-2 border-transparent text-[15px] cursor-pointer h-full flex items-center tracking-normal capitalize text-white" type="button" aria-expanded="false" data-headlessui-state="">Video<svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 24 24" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="m11.998 17 7-8h-14z"></path></svg></button><div class="sr-only"><a href="/video-hub" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">All Video Types</a><a href="/interviews" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">AJMC TV</a><a href="/insights" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Insights</a><a href="/onlocation" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">OnLocation</a><a href="/payer-perspectives" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Payer Perspectives</a><a href="/peer-exchange" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Peer Exchange</a><a href="/post-conference-perspectives" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Post Conference Perspectives</a><a href="/stakeholder-summit" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Stakeholder Summit</a></div></div><a class="focus:outline-none border-b-2 border-transparent text-[15px] cursor-pointer h-full flex items-center text-sm tracking-normal capitalize text-white" href="/podcasts">Podcasts</a><div class=" isolate z-[10000] " data-headlessui-state=""><button class="focus:outline-none border-b-2 border-transparent text-[15px] cursor-pointer h-full flex items-center tracking-normal capitalize text-white" type="button" aria-expanded="false" data-headlessui-state="">Conferences<svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 24 24" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="m11.998 17 7-8h-14z"></path></svg></button><div class="sr-only"><a href="/latest-conference" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Conference Coverage</a><a href="/conference" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Conference Listing</a><a href="/post-conference-perspectives" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Post Conference Perspectives</a></div></div><div class=" isolate z-[10000] " data-headlessui-state=""><button class="focus:outline-none border-b-2 border-transparent text-[15px] cursor-pointer h-full flex items-center tracking-normal capitalize text-white" type="button" aria-expanded="false" data-headlessui-state="">Journals<svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 24 24" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="m11.998 17 7-8h-14z"></path></svg></button><div class="sr-only"><a href="/publications" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">All Journals</a><a href="/publications/issue" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">The American Journal of Managed Care</a><a href="/publications/ajac" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Population Health, Equity & Outcomes</a><a href="/publications/evidence-based-oncology" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Evidence-Based Oncology</a><a href="/supplement" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">About Supplements and Featured Publications</a><a href="/publications/supplement" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Supplements and Featured Publications Issues</a><a href="/submit-a-manuscript" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Submit a Manuscript</a></div></div><div class=" isolate z-[10000] " data-headlessui-state=""><button class="focus:outline-none border-b-2 border-transparent text-[15px] cursor-pointer h-full flex items-center tracking-normal capitalize text-white" type="button" aria-expanded="false" data-headlessui-state="">Events<svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 24 24" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="m11.998 17 7-8h-14z"></path></svg></button><div class="sr-only"><a href="/ivbmevents" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Institute for Value-Based Medicine</a><a href="https://pcoc.ajmc.com/" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Patient-Centered Oncology Care</a></div></div><div class=" isolate z-[10000] " data-headlessui-state=""><button class="focus:outline-none border-b-2 border-transparent text-[15px] cursor-pointer h-full flex items-center tracking-normal capitalize text-white" type="button" aria-expanded="false" data-headlessui-state="">Resources<svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 24 24" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="m11.998 17 7-8h-14z"></path></svg></button><div class="sr-only"><a href="/interactive-tools" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Interactive Tools</a><a href="/clinical-spotlight" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Clinical Spotlight</a><a href="/custom-email" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Microsites</a><a href="/sponsored" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Sponsored Content</a></div></div><a class="focus:outline-none border-b-2 border-transparent text-[15px] cursor-pointer h-full flex items-center text-sm tracking-normal capitalize text-white" href="/continuing-education">CE</a><div class=" isolate z-[10000] " data-headlessui-state=""><button class="focus:outline-none border-b-2 border-transparent text-[15px] cursor-pointer h-full flex items-center tracking-normal capitalize text-white" type="button" aria-expanded="false" data-headlessui-state="">About AJMC<svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 24 24" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="m11.998 17 7-8h-14z"></path></svg></button><div class="sr-only"><a href="/editorial" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">AJMC Staff</a><a href="/anniversary" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Anniversary</a><a href="/about/seema-sonnad-nomination" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Seema Sonnad Award</a><a href="/partners" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Strategic Alliance Partners</a></div></div></div></div></div></div></div><div class="md:flex items-center justify-end hidden"><div class="flex items-center"><div class="md:pr-10 lg:pr-0 h-full flex items-center"><button class="w-6 h-6 relative"><svg xmlns="http://www.w3.org/2000/svg" class="text-white stroke-current icon icon-tabler icon-tabler-search" viewBox="0 0 24 24" stroke-width="1.5" stroke="currentColor" fill="none" stroke-linecap="round" stroke-linejoin="round"><path stroke="none" d="M0 0h24v24H0z"></path><circle cx="10" cy="10" r="7"></circle><line x1="21" y1="21" x2="15" y2="15"></line></svg></button><div class="hidden bg-secondary p-4 rounded shadow-lg top-16 right-0 overflow-hidden absolute grid place-items-center z-[99999] "><form method="GET" action="/search"><div class="relative"><div class="text-gray-600 absolute ml-3 inset-0 m-auto lg:w-4 lg:h-4 md:w-6 md:h-6"><button aria-label="submit" type="submit" class="absolute block inset-0"><svg xmlns="http://www.w3.org/2000/svg" class="text-gray-600 stroke-current icon icon-tabler icon-tabler-search" viewBox="0 0 24 24" stroke-width="2" stroke="currentColor" fill="none" stroke-linecap="round" stroke-linejoin="round"><path stroke="none" d="M0 0h24v24H0z"></path><circle cx="10" cy="10" r="7"></circle><line x1="21" y1="21" x2="15" y2="15"></line></svg></button></div><input type="text" required="" name="searchTerm" class="block border border-gray-200 focus:outline-none focus:border-indigo-700 lg:w-48 xl:w-64 rounded text-sm text-gray-800 pl-8 py-2" placeholder="Search"/></div></form></div></div></div><a href="https://one.ajmc.com/subscribe" class="bg-subscribe-btn rounded text-white py-1.5 px-3 text-[14px] ml-4 uppercase font-semibold">Subscribe</a></div></div></div><div class="bg-white" id="bottomnav"><div style="max-height:60px" class="px-4 transition-all container justify-between h-14 flex items-center md:items-stretch mx-auto"><div class="h-full w-full flex items-center justify-between relative"><div class="flex flex-row gap-2 mr-4"><div class="relative"><div class="block"><div class=""><div class="mx-auto md:max-w-4xl lg:max-w-5xl xl:max-w-7xl "><div class="flex gap-4 justify-start"><div class=" isolate z-[9999] " data-headlessui-state=""><button class="focus:outline-none rounded font-medium cursor-pointer h-full flex items-center text-xs md:text-sm h-[34px] px-2 py-2 md:px-4 tracking-normal capitalize brightness-[85%] bg-primary text-gray-50 lg:min-w-[140px] justify-between" type="button" aria-expanded="false" data-headlessui-state="">Specialty Area<svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 24 24" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="m11.998 17 7-8h-14z"></path></svg></button><nav role="navigation" aria-label="Specialty Area" class="sr-only"><div><a href="/compendium/biosimilars" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Biosimilars</a></div><div><span class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Cardiorenalmetabolic</span><a href="/compendium/cardiovascular" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Cardiovascular</a><a href="/compendium/ckd" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Chronic Kidney Disease</a><a href="/compendium/diabetes" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Diabetes</a><a href="/compendium/heart-failure" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Heart Failure</a><a href="/compendium/type1diabetes" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Type 1 Diabetes</a></div><div><a href="/compendium/dermatology" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Dermatology</a><a href="/compendium/alopecia" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Alopecia</a><a href="/compendium/atopic-dermatitis" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Atopic Dermatitis</a><a href="/compendium/psoriasis" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Psoriasis</a></div><div><a href="/compendium/hematology" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Hematology</a><a href="/compendium/all" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">ALL/AML</a><a href="/compendium/cll" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">CLL/SLL</a><a href="/compendium/gvhd" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">GVHD</a><a href="/compendium/hemophilia" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Hemophilia</a><a href="/compendium/multiple-myeloma" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Multiple Myeloma</a><a href="/compendium/myelodysplastic-syndromes" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Myelodysplastic Syndromes</a><a href="/compendium/mpn" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Myeloproliferative Neoplasms</a><a href="/compendium/nhl" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Non-Hodgkin Lymphoma</a><a href="/compendium/rareblood" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Rare Blood</a></div><div><span class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Hepatology</span><a href="/compendium/liver-cancer" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Liver</a></div><div><a href="/compendium/immunology" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Immunology</a><a href="/compendium/autoimmune" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Autoimmune</a><a href="/compendium/Inflammation" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Inflammation</a><a href="/compendium/lupus" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Lupus</a><a href="/compendium/myasthenia-gravis" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Myasthenia Gravis</a></div><div><a href="/compendium/infectious-disease" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Infectious Disease</a><a href="/compendium/covid-19" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">COVID-19</a><a href="/compendium/hiv" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">HIV</a><a href="/compendium/rsv" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">RSV</a><a href="/compendium/vaccines" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Vaccines</a></div><div><a href="/compendium/mental-health" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Mental Health</a><a href="/compendium/mdd" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Major Depressive Disorder</a><a href="/compendium/sleep" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Sleep</a></div><div><span class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Neurology</span><a href="/compendium/dmd" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Duchenne Muscular Dystrophy</a><a href="/compendium/epilepsy" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Epilepsy</a><a href="/compendium/multiple-sclerosis" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Multiple Sclerosis</a><a href="/compendium/parkinson" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Parkinson Disease</a></div><div><a href="/compendium/obesity" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Obesity</a></div><div><a href="/compendium/oncology" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Oncology</a><a href="/compendium/breast-cancer" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Breast Cancer</a><a href="/compendium/cholangiocarcinoma" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Cholangiocarcinoma</a><a href="/compendium/colorectal-cancer" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Colorectal Cancer</a><a href="/compendium/immuno-oncology" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Immuno-Oncology</a><a href="/compendium/liver-cancer" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Liver Cancer</a><a href="/compendium/lung-cancer" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Lung Cancer</a><a href="/compendium/nsclc" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Non–Small Cell Lung Cancer</a><a href="/compendium/ovarian-cancer" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Ovarian Cancer</a><a href="/compendium/prostate-cancer" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Prostate Cancer</a><a href="/compendium/skincancer" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Skin Cancer</a><a href="/compendium/soft-tissue-sarcoma" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Soft Tissue Sarcoma</a></div><div><a href="/compendium/ophthalmology" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Ophthalmology</a></div><div><span class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Pulmonology</span><a href="/compendium/copd" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">COPD</a><a href="/compendium/pah" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Pulmonary Arterial Hypertension</a></div><div><a href="/compendium/raredisease" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Rare Disease</a><a href="/compendium/sma" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Spinal Muscular Atrophy</a></div><div><a href="/compendium/respiratory" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Respiratory</a><a href="/compendium/asthma" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Asthma</a><a href="/compendium/ipf" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Idiopathic Pulmonary Fibrosis</a></div><div><a href="/compendium/rheumatology" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Rheumatology</a></div><div><a href="/compendium/womens-health" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Women's Health</a></div></nav></div></div></div></div></div></div><div class="relative"><div class="block"><div class=""><div class="mx-auto md:max-w-4xl lg:max-w-5xl xl:max-w-7xl "><div class="flex gap-4 justify-start"><div class=" isolate z-[9999] " data-headlessui-state=""><button class="focus:outline-none rounded font-medium cursor-pointer h-full flex items-center text-xs md:text-sm h-[34px] px-2 py-2 md:px-4 tracking-normal capitalize brightness-[85%] bg-primary text-gray-50 lg:min-w-[140px] justify-between" type="button" aria-expanded="false" data-headlessui-state="">Topics<svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 24 24" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="m11.998 17 7-8h-14z"></path></svg></button><nav role="navigation" aria-label="Topics" class="sr-only"><div><a href="/compendium/biosimilars" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Biosimilars</a></div><div><a href="/topic/center-on-health-equity-and-access" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Center on Health Equity & Access</a></div><div><a href="/compendium/digital-health" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Digital Health</a></div><div><a href="/formulary" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Formulary</a></div><div><a href="/compendium/gene-therapy" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Gene Therapy</a></div><div><a href="/guidelines" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Guidelines</a></div><div><a href="/topic/healthcare-cost" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Health Care Cost</a></div><div><a href="/topic/healthcare-delivery" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Health Care Delivery</a></div><div><a href="/topic/insurance" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Insurance</a></div><div><a href="/topic/policy" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Policy</a></div><div><a href="/compendium/population" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Population Health</a></div><div><a href="/approvals-launches" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Product Approvals and Launches</a></div><div><a href="/topic/technology" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Technology</a></div><div><a href="/topic/value-based-care" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Value-Based Care</a></div></nav></div></div></div></div></div></div></div><div class="flex flex-1 items-center gap-3 overflow-hidden justify-start"><span class="text-md font-semibold whitespace-pre !text-primary filter brightness-75">Spotlight</span><ul id="spotlight-links" class="flex gap-2 h-4 overflow-hidden flex-wrap"><li class="text-xs pt-0.5 whitespace-pre cursor-pointer hover:underline text-gray-800"><a href="/ivbmevents?display=home">Free In-Person Regional Events Focused on Oncology and Population Health</a></li></ul></div></div></div></div></nav><nav class="lg:hidden"><div class="w-full shadow-md bg-primary sticky top-0 z-40"><div class="flex mx-auto container"><div class=" py-4 flex items-stretch justify-between mx-4 items-center w-full"><div class="flex items-center justify-end"><div class="flex items-center"><div class="h-full flex items-center"><button id="menu" aria-label="open menu" aria-expanded="false" class="focus:outline-none focus:ring-2 focus:ring-gray-700 rounded-md text-white"><svg width="30" height="30" viewBox="0 0 24 24" fill="none" xmlns="http://www.w3.org/2000/svg"><path d="M21 10H3" stroke="#fff" stroke-width="1.5" stroke-linecap="round" stroke-linejoin="round"></path><path d="M21 6H3" stroke="#fff" stroke-width="1.5" stroke-linecap="round" stroke-linejoin="round"></path><path d="M21 14H3" stroke="#fff" stroke-width="1.5" stroke-linecap="round" stroke-linejoin="round"></path><path d="M21 18H3" stroke="#fff" stroke-width="1.5" stroke-linecap="round" stroke-linejoin="round"></path></svg></button></div></div></div><div aria-label="logo" role="img" tabindex="0" class="focus:outline-none relative h-10 w-40"><a role="img" aria-label="logo" class="focus:outline-none relative h-12 w-40 mr-6 flex items-center" href="/"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:contain;object-position:center"/><noscript><img sizes="100vw" srcSet="/_next/image?url=%2Fajmc_logo_inverted.png&w=640&q=75 640w, /_next/image?url=%2Fajmc_logo_inverted.png&w=750&q=75 750w, /_next/image?url=%2Fajmc_logo_inverted.png&w=828&q=75 828w, /_next/image?url=%2Fajmc_logo_inverted.png&w=1080&q=75 1080w, /_next/image?url=%2Fajmc_logo_inverted.png&w=1200&q=75 1200w, /_next/image?url=%2Fajmc_logo_inverted.png&w=1920&q=75 1920w, /_next/image?url=%2Fajmc_logo_inverted.png&w=2048&q=75 2048w, /_next/image?url=%2Fajmc_logo_inverted.png&w=3840&q=75 3840w" src="/_next/image?url=%2Fajmc_logo_inverted.png&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:contain;object-position:center" loading="lazy"/></noscript></span></a></div><div class="relative w-8 h-8 my grid items-center"><a class="absolute lg:hidden inset-0 mt-1" href="/search"><svg xmlns="http://www.w3.org/2000/svg" class="text-white stroke-current icon icon-tabler icon-tabler-search" viewBox="0 0 24 24" stroke-width="1.5" stroke="currentColor" fill="none" stroke-linecap="round" stroke-linejoin="round"><path stroke="none" d="M0 0h24v24H0z"></path><circle cx="10" cy="10" r="7"></circle><line x1="21" y1="21" x2="15" y2="15"></line></svg></a></div></div></div><div style="max-height:50px" class="bg-white px-4 transition-all h-12 md:items-stretch mx-auto" id="bottomnav-mobile"><div class="container justify-between h-12 flex items-center md:items-stretch mx-auto"><div class="h-full w-full flex items-center justify-between relative"><div class="flex flex-1 justify-center xs:justify-start items-center relative group h-full z-50 gap-2"><div class="z-1 relative"><div class="block"><div class=""><div class="mx-auto md:max-w-4xl lg:max-w-5xl xl:max-w-7xl "><div class="flex gap-4 justify-start"><div class=" isolate z-[9999] " data-headlessui-state=""><button class="focus:outline-none rounded font-medium cursor-pointer h-full flex items-center text-xs md:text-sm h-[34px] px-2 py-2 md:px-4 tracking-normal capitalize brightness-[85%] bg-primary text-gray-50 lg:min-w-[140px] justify-between" type="button" aria-expanded="false" data-headlessui-state="">Specialty Area<svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 24 24" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="m11.998 17 7-8h-14z"></path></svg></button><nav role="navigation" aria-label="Specialty Area" class="sr-only"><div><a href="/compendium/biosimilars" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Biosimilars</a></div><div><span class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Cardiorenalmetabolic</span><a href="/compendium/cardiovascular" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Cardiovascular</a><a href="/compendium/ckd" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Chronic Kidney Disease</a><a href="/compendium/diabetes" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Diabetes</a><a href="/compendium/heart-failure" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Heart Failure</a><a href="/compendium/type1diabetes" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Type 1 Diabetes</a></div><div><a href="/compendium/dermatology" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Dermatology</a><a href="/compendium/alopecia" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Alopecia</a><a href="/compendium/atopic-dermatitis" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Atopic Dermatitis</a><a href="/compendium/psoriasis" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Psoriasis</a></div><div><a href="/compendium/hematology" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Hematology</a><a href="/compendium/all" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">ALL/AML</a><a href="/compendium/cll" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">CLL/SLL</a><a href="/compendium/gvhd" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">GVHD</a><a href="/compendium/hemophilia" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Hemophilia</a><a href="/compendium/multiple-myeloma" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Multiple Myeloma</a><a href="/compendium/myelodysplastic-syndromes" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Myelodysplastic Syndromes</a><a href="/compendium/mpn" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Myeloproliferative Neoplasms</a><a href="/compendium/nhl" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Non-Hodgkin Lymphoma</a><a href="/compendium/rareblood" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Rare Blood</a></div><div><span class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Hepatology</span><a href="/compendium/liver-cancer" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Liver</a></div><div><a href="/compendium/immunology" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Immunology</a><a href="/compendium/autoimmune" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Autoimmune</a><a href="/compendium/Inflammation" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Inflammation</a><a href="/compendium/lupus" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Lupus</a><a href="/compendium/myasthenia-gravis" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Myasthenia Gravis</a></div><div><a href="/compendium/infectious-disease" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Infectious Disease</a><a href="/compendium/covid-19" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">COVID-19</a><a href="/compendium/hiv" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">HIV</a><a href="/compendium/rsv" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">RSV</a><a href="/compendium/vaccines" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Vaccines</a></div><div><a href="/compendium/mental-health" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Mental Health</a><a href="/compendium/mdd" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Major Depressive Disorder</a><a href="/compendium/sleep" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Sleep</a></div><div><span class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Neurology</span><a href="/compendium/dmd" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Duchenne Muscular Dystrophy</a><a href="/compendium/epilepsy" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Epilepsy</a><a href="/compendium/multiple-sclerosis" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Multiple Sclerosis</a><a href="/compendium/parkinson" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Parkinson Disease</a></div><div><a href="/compendium/obesity" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Obesity</a></div><div><a href="/compendium/oncology" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Oncology</a><a href="/compendium/breast-cancer" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Breast Cancer</a><a href="/compendium/cholangiocarcinoma" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Cholangiocarcinoma</a><a href="/compendium/colorectal-cancer" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Colorectal Cancer</a><a href="/compendium/immuno-oncology" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Immuno-Oncology</a><a href="/compendium/liver-cancer" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Liver Cancer</a><a href="/compendium/lung-cancer" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Lung Cancer</a><a href="/compendium/nsclc" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Non–Small Cell Lung Cancer</a><a href="/compendium/ovarian-cancer" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Ovarian Cancer</a><a href="/compendium/prostate-cancer" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Prostate Cancer</a><a href="/compendium/skincancer" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Skin Cancer</a><a href="/compendium/soft-tissue-sarcoma" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Soft Tissue Sarcoma</a></div><div><a href="/compendium/ophthalmology" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Ophthalmology</a></div><div><span class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Pulmonology</span><a href="/compendium/copd" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">COPD</a><a href="/compendium/pah" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Pulmonary Arterial Hypertension</a></div><div><a href="/compendium/raredisease" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Rare Disease</a><a href="/compendium/sma" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Spinal Muscular Atrophy</a></div><div><a href="/compendium/respiratory" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Respiratory</a><a href="/compendium/asthma" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Asthma</a><a href="/compendium/ipf" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Idiopathic Pulmonary Fibrosis</a></div><div><a href="/compendium/rheumatology" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Rheumatology</a></div><div><a href="/compendium/womens-health" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Women's Health</a></div></nav></div></div></div></div></div></div><div class="z-1 relative"><div class="block"><div class=""><div class="mx-auto md:max-w-4xl lg:max-w-5xl xl:max-w-7xl "><div class="flex gap-4 justify-start"><div class=" isolate z-[9999] " data-headlessui-state=""><button class="focus:outline-none rounded font-medium cursor-pointer h-full flex items-center text-xs md:text-sm h-[34px] px-2 py-2 md:px-4 tracking-normal capitalize brightness-[85%] bg-primary text-gray-50 lg:min-w-[140px] justify-between" type="button" aria-expanded="false" data-headlessui-state="">Topics<svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 24 24" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="m11.998 17 7-8h-14z"></path></svg></button><nav role="navigation" aria-label="Topics" class="sr-only"><div><a href="/compendium/biosimilars" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Biosimilars</a></div><div><a href="/topic/center-on-health-equity-and-access" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Center on Health Equity & Access</a></div><div><a href="/compendium/digital-health" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Digital Health</a></div><div><a href="/formulary" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Formulary</a></div><div><a href="/compendium/gene-therapy" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Gene Therapy</a></div><div><a href="/guidelines" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Guidelines</a></div><div><a href="/topic/healthcare-cost" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Health Care Cost</a></div><div><a href="/topic/healthcare-delivery" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Health Care Delivery</a></div><div><a href="/topic/insurance" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Insurance</a></div><div><a href="/topic/policy" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Policy</a></div><div><a href="/compendium/population" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Population Health</a></div><div><a href="/approvals-launches" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Product Approvals and Launches</a></div><div><a href="/topic/technology" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Technology</a></div><div><a href="/topic/value-based-care" class="flex gap-x-4 py-2 text-sm font-semibold leading-6 text-blue-600 underline">Value-Based Care</a></div></nav></div></div></div></div></div></div></div></div></div></div></div><div class="fixed top-0 w-[85vw] h-full transform -translate-x-full z-40 transition duration-300 lg:hidden min-h-screen bg-primary shadow-lg" id="mobile-nav"><div class="w-full h-full shadow-lg z-40 fixed overflow-y-auto top-0 flex-col justify-between xl:hidden pb-4 transition duration-500 ease-in-out"><div class="px-5 h-full"><div class="flex flex-col justify-between h-full w-full"><div><div class="mt-6 flex w-full items-center justify-between"><div class="border-b border-gray-200 pb-2 flex items-center justify-between w-full"><div aria-label="logo" role="img" tabindex="0" class="focus:outline-none relative h-16 w-40 "><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:contain;object-position:left"/><noscript><img sizes="100vw" srcSet="/_next/image?url=%2Fajmc_logo_inverted.png&w=640&q=75 640w, /_next/image?url=%2Fajmc_logo_inverted.png&w=750&q=75 750w, /_next/image?url=%2Fajmc_logo_inverted.png&w=828&q=75 828w, /_next/image?url=%2Fajmc_logo_inverted.png&w=1080&q=75 1080w, /_next/image?url=%2Fajmc_logo_inverted.png&w=1200&q=75 1200w, /_next/image?url=%2Fajmc_logo_inverted.png&w=1920&q=75 1920w, /_next/image?url=%2Fajmc_logo_inverted.png&w=2048&q=75 2048w, /_next/image?url=%2Fajmc_logo_inverted.png&w=3840&q=75 3840w" src="/_next/image?url=%2Fajmc_logo_inverted.png&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:contain;object-position:left" loading="lazy"/></noscript></span></div><button aria-label="close menu" class="focus:outline-none focus:ring-2 rounded-md text-white pl-8 font-bold"><svg width="18" height="18" viewBox="0 0 14 14" fill="#fff" xmlns="http://www.w3.org/2000/svg"><path d="M13 1L1 13" stroke="#fff" stroke-linecap="round" stroke-width="2" stroke-linejoin="round"></path><path d="M1 1L13 13" stroke="#fff" stroke-linecap="round" stroke-width="2" stroke-linejoin="round"></path></svg></button></div></div><ul role="list" class="flex flex-1 flex-col gap-y-7 mt-6"><li><ul role="list" class="-mx-2 space-y-1"><li><div data-headlessui-state=""><button class="hover:bg-gray-500 flex items-center w-full text-left p-2 gap-x-3 text-sm leading-6 font-semibold text-gray-50" id="headlessui-disclosure-button-undefined" type="button" aria-expanded="false" data-headlessui-state=""><svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 320 512" class="text-gray-50 h-5 w-5 shrink-0" aria-hidden="true" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="M285.476 272.971L91.132 467.314c-9.373 9.373-24.569 9.373-33.941 0l-22.667-22.667c-9.357-9.357-9.375-24.522-.04-33.901L188.505 256 34.484 101.255c-9.335-9.379-9.317-24.544.04-33.901l22.667-22.667c9.373-9.373 24.569-9.373 33.941 0L285.475 239.03c9.373 9.372 9.373 24.568.001 33.941z"></path></svg>Spotlight</button></div></li><li><div data-headlessui-state=""><button class="hover:bg-gray-500 flex items-center w-full text-left p-2 gap-x-3 text-sm leading-6 font-semibold text-gray-50" id="headlessui-disclosure-button-undefined" type="button" aria-expanded="false" data-headlessui-state=""><svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 320 512" class="text-gray-50 h-5 w-5 shrink-0" aria-hidden="true" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="M285.476 272.971L91.132 467.314c-9.373 9.373-24.569 9.373-33.941 0l-22.667-22.667c-9.357-9.357-9.375-24.522-.04-33.901L188.505 256 34.484 101.255c-9.335-9.379-9.317-24.544.04-33.901l22.667-22.667c9.373-9.373 24.569-9.373 33.941 0L285.475 239.03c9.373 9.372 9.373 24.568.001 33.941z"></path></svg>News</button></div></li><li><div data-headlessui-state=""><button class="hover:bg-gray-500 flex items-center w-full text-left p-2 gap-x-3 text-sm leading-6 font-semibold text-gray-50" id="headlessui-disclosure-button-undefined" type="button" aria-expanded="false" data-headlessui-state=""><svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 320 512" class="text-gray-50 h-5 w-5 shrink-0" aria-hidden="true" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="M285.476 272.971L91.132 467.314c-9.373 9.373-24.569 9.373-33.941 0l-22.667-22.667c-9.357-9.357-9.375-24.522-.04-33.901L188.505 256 34.484 101.255c-9.335-9.379-9.317-24.544.04-33.901l22.667-22.667c9.373-9.373 24.569-9.373 33.941 0L285.475 239.03c9.373 9.372 9.373 24.568.001 33.941z"></path></svg>Video</button></div></li><li><a class="hover:bg-gray-500 block rounded-md py-2 pr-2 pl-10 text-sm leading-6 font-semibold text-gray-50" href="/podcasts"><span>Podcasts</span></a></li><li><div data-headlessui-state=""><button class="hover:bg-gray-500 flex items-center w-full text-left p-2 gap-x-3 text-sm leading-6 font-semibold text-gray-50" id="headlessui-disclosure-button-undefined" type="button" aria-expanded="false" data-headlessui-state=""><svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 320 512" class="text-gray-50 h-5 w-5 shrink-0" aria-hidden="true" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="M285.476 272.971L91.132 467.314c-9.373 9.373-24.569 9.373-33.941 0l-22.667-22.667c-9.357-9.357-9.375-24.522-.04-33.901L188.505 256 34.484 101.255c-9.335-9.379-9.317-24.544.04-33.901l22.667-22.667c9.373-9.373 24.569-9.373 33.941 0L285.475 239.03c9.373 9.372 9.373 24.568.001 33.941z"></path></svg>Conferences</button></div></li><li><div data-headlessui-state=""><button class="hover:bg-gray-500 flex items-center w-full text-left p-2 gap-x-3 text-sm leading-6 font-semibold text-gray-50" id="headlessui-disclosure-button-undefined" type="button" aria-expanded="false" data-headlessui-state=""><svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 320 512" class="text-gray-50 h-5 w-5 shrink-0" aria-hidden="true" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="M285.476 272.971L91.132 467.314c-9.373 9.373-24.569 9.373-33.941 0l-22.667-22.667c-9.357-9.357-9.375-24.522-.04-33.901L188.505 256 34.484 101.255c-9.335-9.379-9.317-24.544.04-33.901l22.667-22.667c9.373-9.373 24.569-9.373 33.941 0L285.475 239.03c9.373 9.372 9.373 24.568.001 33.941z"></path></svg>Journals</button></div></li><li><div data-headlessui-state=""><button class="hover:bg-gray-500 flex items-center w-full text-left p-2 gap-x-3 text-sm leading-6 font-semibold text-gray-50" id="headlessui-disclosure-button-undefined" type="button" aria-expanded="false" data-headlessui-state=""><svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 320 512" class="text-gray-50 h-5 w-5 shrink-0" aria-hidden="true" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="M285.476 272.971L91.132 467.314c-9.373 9.373-24.569 9.373-33.941 0l-22.667-22.667c-9.357-9.357-9.375-24.522-.04-33.901L188.505 256 34.484 101.255c-9.335-9.379-9.317-24.544.04-33.901l22.667-22.667c9.373-9.373 24.569-9.373 33.941 0L285.475 239.03c9.373 9.372 9.373 24.568.001 33.941z"></path></svg>Events</button></div></li><li><div data-headlessui-state=""><button class="hover:bg-gray-500 flex items-center w-full text-left p-2 gap-x-3 text-sm leading-6 font-semibold text-gray-50" id="headlessui-disclosure-button-undefined" type="button" aria-expanded="false" data-headlessui-state=""><svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 320 512" class="text-gray-50 h-5 w-5 shrink-0" aria-hidden="true" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="M285.476 272.971L91.132 467.314c-9.373 9.373-24.569 9.373-33.941 0l-22.667-22.667c-9.357-9.357-9.375-24.522-.04-33.901L188.505 256 34.484 101.255c-9.335-9.379-9.317-24.544.04-33.901l22.667-22.667c9.373-9.373 24.569-9.373 33.941 0L285.475 239.03c9.373 9.372 9.373 24.568.001 33.941z"></path></svg>Resources</button></div></li><li><a class="hover:bg-gray-500 block rounded-md py-2 pr-2 pl-10 text-sm leading-6 font-semibold text-gray-50" href="/continuing-education"><span>CE</span></a></li><li><div data-headlessui-state=""><button class="hover:bg-gray-500 flex items-center w-full text-left p-2 gap-x-3 text-sm leading-6 font-semibold text-gray-50" id="headlessui-disclosure-button-undefined" type="button" aria-expanded="false" data-headlessui-state=""><svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 320 512" class="text-gray-50 h-5 w-5 shrink-0" aria-hidden="true" height="1em" width="1em" xmlns="http://www.w3.org/2000/svg"><path d="M285.476 272.971L91.132 467.314c-9.373 9.373-24.569 9.373-33.941 0l-22.667-22.667c-9.357-9.357-9.375-24.522-.04-33.901L188.505 256 34.484 101.255c-9.335-9.379-9.317-24.544.04-33.901l22.667-22.667c9.373-9.373 24.569-9.373 33.941 0L285.475 239.03c9.373 9.372 9.373 24.568.001 33.941z"></path></svg>About AJMC</button></div></li><li><a class="hover:bg-gray-500 block rounded-md py-2 pr-2 pl-10 text-sm leading-6 font-semibold text-gray-50" href="https://one.ajmc.com/subscribe"><span>Subscribe</span></a></li></ul></li></ul><div class="flex md:hidden mt-4 items-center gap-2 mt-6 pt-6 border-t"><a rel="noreferrer noopener" target="_blank" href="https://www.facebook.com/TheAmericanJournalOfManagedCare"><svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 448 512" color="#fff" style="color:#fff" height="24" width="24" xmlns="http://www.w3.org/2000/svg"><path d="M400 32H48A48 48 0 0 0 0 80v352a48 48 0 0 0 48 48h137.25V327.69h-63V256h63v-54.64c0-62.15 37-96.48 93.67-96.48 27.14 0 55.52 4.84 55.52 4.84v61h-31.27c-30.81 0-40.42 19.12-40.42 38.73V256h68.78l-11 71.69h-57.78V480H400a48 48 0 0 0 48-48V80a48 48 0 0 0-48-48z"></path></svg></a><a rel="noreferrer noopener" target="_blank" href="https://twitter.com/AJMC_Journal"><svg xmlns="http://www.w3.org/2000/svg" version="1.1" width="21" height="21" viewBox="12.65 12.65 118.02 118.02"><g transform="translate(1.4065934065934016 1.4065934065934016) scale(2.81 2.81)"><path d="M 11 4 C 7.134 4 4 7.134 4 11 L 4 39 C 4 42.866 7.134 46 11 46 L 39 46 C 42.866 46 46 42.866 46 39 L 46 11 C 46 7.134 42.866 4 39 4 L 11 4 z M 13.085938 13 L 21.023438 13 L 26.660156 21.009766 L 33.5 13 L 36 13 L 27.789062 22.613281 L 37.914062 37 L 29.978516 37 L 23.4375 27.707031 L 15.5 37 L 13 37 L 22.308594 26.103516 L 13.085938 13 z M 16.914062 15 L 31.021484 35 L 34.085938 35 L 19.978516 15 L 16.914062 15 z" fill="#FFFFFF"></path></g></svg></a><a rel="noreferrer noopener" target="_blank" href="https://www.linkedin.com/company/american-journal-of-managed-care/"><svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 448 512" color="#fff" style="color:#fff" height="27" width="27" xmlns="http://www.w3.org/2000/svg"><path d="M416 32H31.9C14.3 32 0 46.5 0 64.3v383.4C0 465.5 14.3 480 31.9 480H416c17.6 0 32-14.5 32-32.3V64.3c0-17.8-14.4-32.3-32-32.3zM135.4 416H69V202.2h66.5V416zm-33.2-243c-21.3 0-38.5-17.3-38.5-38.5S80.9 96 102.2 96c21.2 0 38.5 17.3 38.5 38.5 0 21.3-17.2 38.5-38.5 38.5zm282.1 243h-66.4V312c0-24.8-.5-56.7-34.5-56.7-34.6 0-39.9 27-39.9 54.9V416h-66.4V202.2h63.7v29.2h.9c8.9-16.8 30.6-34.5 62.9-34.5 67.2 0 79.7 44.3 79.7 101.9V416z"></path></svg></a><a rel="noreferrer noopener" target="_blank" href="https://www.instagram.com/ajmcjournal/"><svg stroke="currentColor" fill="currentColor" stroke-width="0" viewBox="0 0 448 512" color="#fff" style="color:#fff" height="24" width="24" xmlns="http://www.w3.org/2000/svg"><path d="M224,202.66A53.34,53.34,0,1,0,277.36,256,53.38,53.38,0,0,0,224,202.66Zm124.71-41a54,54,0,0,0-30.41-30.41c-21-8.29-71-6.43-94.3-6.43s-73.25-1.93-94.31,6.43a54,54,0,0,0-30.41,30.41c-8.28,21-6.43,71.05-6.43,94.33S91,329.26,99.32,350.33a54,54,0,0,0,30.41,30.41c21,8.29,71,6.43,94.31,6.43s73.24,1.93,94.3-6.43a54,54,0,0,0,30.41-30.41c8.35-21,6.43-71.05,6.43-94.33S357.1,182.74,348.75,161.67ZM224,338a82,82,0,1,1,82-82A81.9,81.9,0,0,1,224,338Zm85.38-148.3a19.14,19.14,0,1,1,19.13-19.14A19.1,19.1,0,0,1,309.42,189.74ZM400,32H48A48,48,0,0,0,0,80V432a48,48,0,0,0,48,48H400a48,48,0,0,0,48-48V80A48,48,0,0,0,400,32ZM382.88,322c-1.29,25.63-7.14,48.34-25.85,67s-41.4,24.63-67,25.85c-26.41,1.49-105.59,1.49-132,0-25.63-1.29-48.26-7.15-67-25.85s-24.63-41.42-25.85-67c-1.49-26.42-1.49-105.61,0-132,1.29-25.63,7.07-48.34,25.85-67s41.47-24.56,67-25.78c26.41-1.49,105.59-1.49,132,0,25.63,1.29,48.33,7.15,67,25.85s24.63,41.42,25.85,67.05C384.37,216.44,384.37,295.56,382.88,322Z"></path></svg></a><a rel="noreferrer noopener" target="_blank" href="/rss"></a></div></div></div></div></div></div></nav></div></div><div class="container px-4 mx-auto pl-2 pr-2 sm:h-[98px] sm:w-[728px]"><div id="leaderboardWrapper" class="jsx-1661e6713d4eb9b5 leaderboardAdWrapper mx-auto mt-1 flex min-h-0 md:min-h-[90px] justify-center items-center flex-col relative z-[99999] "><div class="jsx-1661e6713d4eb9b5 bg-white md:-translate-x-4"><div class="jsx-1661e6713d4eb9b5 text-[8px] text-center text-gray-600 hidden relative">Advertisement</div><div id="div-gpt-ad-top" class="jsx-1661e6713d4eb9b5 AD728x90 mx-auto text-center x"></div></div></div></div><hr class="mt-8 pt-8 -mb-4 pb-0"/><div id="nhl" class="container mx-auto flex m-1 min-h-[57vh] px-4"><div class="flex-auto w-[calc(100%-300px)] pr-0 md:pr-6 mt-16 sm:mt-0"><div class="pb-24 my-2"><div class="flex"><h1 class="text-[19px] mt-1 md:mt-0 md:text-3xl mb-2">Non-Hodgkin Lymphoma (NHL) </h1><div class="flex justify-center px-0 -mt-1 sm:-mt-2 align-center"></div></div><div class="w-full mb-2 border border-secondary"></div><div id="description-summary" class="text-sm text-gray-500"><div class="blockText_blockContent__TbCXh"></div><div class="clear-both"></div></div><div class="border-b-[2px] border-[#EEE] "><div class="m-2"><div class="hidden xs:flex justify-between items-center"><h2 class="text-3xl">Latest News</h2></div><div class="xs:my-6 my-4 xs:block hidden"><div class="flex"><div class="flex sm:pr-[35px] pr-[20px] flex-col w-[40%] border-r-[2px] border-[#EEE]"><div class="lg:h-[220px] h-[170px] relative bg-default-logo-background "><a class="0 w-full" href="/view/higher-tmb-pd-l1-expression-correlate-with-shorter-survival-in-hematologic-malignancies"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="object-contain" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="" sizes="100vw" srcSet="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fd51b9738c42ccbde57b68d8ab61bfa5566fd66c3-2445x1787.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=640&q=75 640w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fd51b9738c42ccbde57b68d8ab61bfa5566fd66c3-2445x1787.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=750&q=75 750w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fd51b9738c42ccbde57b68d8ab61bfa5566fd66c3-2445x1787.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=828&q=75 828w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fd51b9738c42ccbde57b68d8ab61bfa5566fd66c3-2445x1787.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1080&q=75 1080w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fd51b9738c42ccbde57b68d8ab61bfa5566fd66c3-2445x1787.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1200&q=75 1200w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fd51b9738c42ccbde57b68d8ab61bfa5566fd66c3-2445x1787.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1920&q=75 1920w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fd51b9738c42ccbde57b68d8ab61bfa5566fd66c3-2445x1787.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=2048&q=75 2048w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fd51b9738c42ccbde57b68d8ab61bfa5566fd66c3-2445x1787.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 3840w" src="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fd51b9738c42ccbde57b68d8ab61bfa5566fd66c3-2445x1787.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" class="object-contain" loading="lazy"/></noscript></span></a></div><div class="border-t-gray-100 border-t-2 flex-auto py-2 "><span class="text-sm text-gray-500 py-2">October 30th 2024</span><div class="py-3"><a class="lg:text-[20px] text-[19px] font-[500]" href="/view/higher-tmb-pd-l1-expression-correlate-with-shorter-survival-in-hematologic-malignancies">Higher TMB, PD-L1 Expression Correlate With Shorter Survival in Hematologic Malignancies </a></div><div class="pb-2"><div><span class="text-md "><span class="mr-1 italic">By </span><a class="mr-1 text-sky-800 hover:text-primary" href="/authors/gayle-turim-dickstein"><i>Gayle Turim Dickstein</i></a></span></div></div><a href="/view/higher-tmb-pd-l1-expression-correlate-with-shorter-survival-in-hematologic-malignancies"><a href="/view/higher-tmb-pd-l1-expression-correlate-with-shorter-survival-in-hematologic-malignancies"><p class="mt-1 text-gray-800 text-[13px] line-clamp-6 text-hidden">A new analysis of real-world data show that just as in solid tumors, higher tumor mutational burden (TMB) and PD-L1 expression in blood cancers are linked to less-optimistic prognoses.</p></a></a></div></div><div class="flex-wrap w-[60%] flex "><a class="flex w-[50%] flex-col sm:pl-[35px] pl-[20px] pb-[35px] " href="/view/miles-matter-the-geographic-disparity-that-impacts-access-to-car-t-therapy"><div class="w-full lg:h-[134px] h-[100px] relative bg-default-logo-background "><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="lg:object-cover object-contain " style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="" sizes="100vw" srcSet="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F3d97f41753d5036fe06a27339f606f5bb4fd9d8f-2400x1600.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=640&q=75 640w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F3d97f41753d5036fe06a27339f606f5bb4fd9d8f-2400x1600.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=750&q=75 750w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F3d97f41753d5036fe06a27339f606f5bb4fd9d8f-2400x1600.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=828&q=75 828w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F3d97f41753d5036fe06a27339f606f5bb4fd9d8f-2400x1600.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1080&q=75 1080w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F3d97f41753d5036fe06a27339f606f5bb4fd9d8f-2400x1600.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1200&q=75 1200w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F3d97f41753d5036fe06a27339f606f5bb4fd9d8f-2400x1600.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1920&q=75 1920w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F3d97f41753d5036fe06a27339f606f5bb4fd9d8f-2400x1600.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=2048&q=75 2048w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F3d97f41753d5036fe06a27339f606f5bb4fd9d8f-2400x1600.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 3840w" src="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F3d97f41753d5036fe06a27339f606f5bb4fd9d8f-2400x1600.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" class="lg:object-cover object-contain " loading="lazy"/></noscript></span></div><div class="border-t-gray-100 border-t-2 pt-2 pb-2 flex-auto "><a href="/view/miles-matter-the-geographic-disparity-that-impacts-access-to-car-t-therapy"><span class="text-sm text-gray-500">October 13th 2024</span></a><div><a class="text-[14px]" href="/view/miles-matter-the-geographic-disparity-that-impacts-access-to-car-t-therapy"><p class="line-clamp-4 text-hidden font-[500]">Miles Matter: The Geographic Disparity That Impacts Access to CAR T Therapy</p></a></div><div class="py-2"><div><span class="text-md "><span class="mr-1 italic">By </span><a class="mr-1 text-sky-800 hover:text-primary" href="/authors/ryan-flinn"><i>Ryan Flinn</i></a></span></div></div></div></a><a class="flex w-[50%] flex-col sm:pl-[35px] pl-[20px] pb-[35px] " href="/view/preclinical-model-suggests-efficacy-of-combining-capivasertib-with-venetoclax-against-dlbcl"><div class="w-full lg:h-[134px] h-[100px] relative bg-default-logo-background "><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="lg:object-cover object-contain " style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="" sizes="100vw" srcSet="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fa329387e322ca781d0a66405a3ad00034bd346e8-1280x853.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=640&q=75 640w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fa329387e322ca781d0a66405a3ad00034bd346e8-1280x853.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=750&q=75 750w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fa329387e322ca781d0a66405a3ad00034bd346e8-1280x853.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=828&q=75 828w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fa329387e322ca781d0a66405a3ad00034bd346e8-1280x853.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1080&q=75 1080w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fa329387e322ca781d0a66405a3ad00034bd346e8-1280x853.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1200&q=75 1200w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fa329387e322ca781d0a66405a3ad00034bd346e8-1280x853.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1920&q=75 1920w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fa329387e322ca781d0a66405a3ad00034bd346e8-1280x853.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=2048&q=75 2048w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fa329387e322ca781d0a66405a3ad00034bd346e8-1280x853.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 3840w" src="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fa329387e322ca781d0a66405a3ad00034bd346e8-1280x853.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" class="lg:object-cover object-contain " loading="lazy"/></noscript></span></div><div class="border-t-gray-100 border-t-2 pt-2 pb-2 flex-auto "><a href="/view/preclinical-model-suggests-efficacy-of-combining-capivasertib-with-venetoclax-against-dlbcl"><span class="text-sm text-gray-500">October 8th 2024</span></a><div><a class="text-[14px]" href="/view/preclinical-model-suggests-efficacy-of-combining-capivasertib-with-venetoclax-against-dlbcl"><p class="line-clamp-4 text-hidden font-[500]">Preclinical Model Suggests Efficacy of Combining Capivasertib With Venetoclax Against DLBCL</p></a></div><div class="py-2"><div><span class="text-md "><span class="mr-1 italic">By </span><a class="mr-1 text-sky-800 hover:text-primary" href="/authors/karen-jacobson-sive"><i>Karen Jacobson-Sive</i></a></span></div></div></div></a><a class="flex w-[50%] flex-col sm:pl-[35px] pl-[20px] pb-[35px] " href="/view/combination-of-magrolimab-and-rituximab-well-tolerated-in-patients-with-refractory-relapsed-indolent-nhl"><div class="w-full lg:h-[134px] h-[100px] relative bg-default-logo-background "><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="lg:object-cover object-contain " style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="" sizes="100vw" srcSet="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F14565e78f839b82f71b7c7b220c5d33d373e67b2-1200x724.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=640&q=75 640w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F14565e78f839b82f71b7c7b220c5d33d373e67b2-1200x724.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=750&q=75 750w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F14565e78f839b82f71b7c7b220c5d33d373e67b2-1200x724.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=828&q=75 828w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F14565e78f839b82f71b7c7b220c5d33d373e67b2-1200x724.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1080&q=75 1080w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F14565e78f839b82f71b7c7b220c5d33d373e67b2-1200x724.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1200&q=75 1200w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F14565e78f839b82f71b7c7b220c5d33d373e67b2-1200x724.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1920&q=75 1920w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F14565e78f839b82f71b7c7b220c5d33d373e67b2-1200x724.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=2048&q=75 2048w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F14565e78f839b82f71b7c7b220c5d33d373e67b2-1200x724.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 3840w" src="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F14565e78f839b82f71b7c7b220c5d33d373e67b2-1200x724.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" class="lg:object-cover object-contain " loading="lazy"/></noscript></span></div><div class="border-t-gray-100 border-t-2 pt-2 pb-2 flex-auto "><a href="/view/combination-of-magrolimab-and-rituximab-well-tolerated-in-patients-with-refractory-relapsed-indolent-nhl"><span class="text-sm text-gray-500">September 25th 2024</span></a><div><a class="text-[14px]" href="/view/combination-of-magrolimab-and-rituximab-well-tolerated-in-patients-with-refractory-relapsed-indolent-nhl"><p class="line-clamp-4 text-hidden font-[500]">Combination of Magrolimab and Rituximab Well Tolerated in Patients With Refractory/Relapsed Indolent NHL</p></a></div><div class="py-2"><div><span class="text-md "><span class="mr-1 italic">By </span><a class="mr-1 text-sky-800 hover:text-primary" href="/authors/nameera-temkar-md"><i>Nameera Temkar, MD</i></a></span></div></div></div></a><a class="flex w-[50%] flex-col sm:pl-[35px] pl-[20px] pb-[35px] " href="/view/lenalidomide-obinutuzumab-combo-yields-promising-results-in-relapsed-nhl"><div class="w-full lg:h-[134px] h-[100px] relative bg-default-logo-background "><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="lg:object-cover object-contain " style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="" sizes="100vw" srcSet="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F357ec216737f69151df0afb267a2b92d55922db3-8064x5376.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=640&q=75 640w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F357ec216737f69151df0afb267a2b92d55922db3-8064x5376.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=750&q=75 750w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F357ec216737f69151df0afb267a2b92d55922db3-8064x5376.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=828&q=75 828w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F357ec216737f69151df0afb267a2b92d55922db3-8064x5376.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1080&q=75 1080w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F357ec216737f69151df0afb267a2b92d55922db3-8064x5376.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1200&q=75 1200w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F357ec216737f69151df0afb267a2b92d55922db3-8064x5376.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1920&q=75 1920w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F357ec216737f69151df0afb267a2b92d55922db3-8064x5376.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=2048&q=75 2048w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F357ec216737f69151df0afb267a2b92d55922db3-8064x5376.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 3840w" src="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F357ec216737f69151df0afb267a2b92d55922db3-8064x5376.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" class="lg:object-cover object-contain " loading="lazy"/></noscript></span></div><div class="border-t-gray-100 border-t-2 pt-2 pb-2 flex-auto "><a href="/view/lenalidomide-obinutuzumab-combo-yields-promising-results-in-relapsed-nhl"><span class="text-sm text-gray-500">September 21st 2024</span></a><div><a class="text-[14px]" href="/view/lenalidomide-obinutuzumab-combo-yields-promising-results-in-relapsed-nhl"><p class="line-clamp-4 text-hidden font-[500]">Lenalidomide-Obinutuzumab Combo Yields Promising Results in Relapsed NHL</p></a></div><div class="py-2"><div><span class="text-md "><span class="mr-1 italic">By </span><a class="mr-1 text-sky-800 hover:text-primary" href="/authors/kimberly-rath-pharmd"><i>Kimberly Rath, PharmD</i></a></span></div></div></div></a></div></div></div><div class="xs:hidden block"><div class="jsx-19ede9f0a5a45918 py-4 relative px-0"><div class="flex justify-between items-center py-1 space-x-4 border-0 select-none"><div class="w-full xs:my-6 my-4 #000 text-3xl">Latest News</div></div><div style="scroll-snap-type:none" class="jsx-19ede9f0a5a45918 flex items-start overflow-x-auto space-x-4 py-4 relative mx-auto w-[calc(100%-64px)]"><a target="" style="scroll-snap-align:center;text-decoration:none" class="jsx-1215160397 sm:w-[280px] xs:w-[240px] w-[65%] h-auto flex flex-col space-y-3 flex-none select-none no-underline" href="/view/higher-tmb-pd-l1-expression-correlate-with-shorter-survival-in-hematologic-malignancies"><div class="jsx-1215160397 w-full h-full flex flex-col overflow-hidden relative bg-white text-center"><div class="jsx-1215160397 relative w-full shadow-md shadow-grey-800 aspect-video"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="object-cover" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="" sizes="100vw" srcSet="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fd51b9738c42ccbde57b68d8ab61bfa5566fd66c3-2445x1787.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=640&q=75 640w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fd51b9738c42ccbde57b68d8ab61bfa5566fd66c3-2445x1787.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=750&q=75 750w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fd51b9738c42ccbde57b68d8ab61bfa5566fd66c3-2445x1787.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=828&q=75 828w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fd51b9738c42ccbde57b68d8ab61bfa5566fd66c3-2445x1787.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1080&q=75 1080w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fd51b9738c42ccbde57b68d8ab61bfa5566fd66c3-2445x1787.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1200&q=75 1200w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fd51b9738c42ccbde57b68d8ab61bfa5566fd66c3-2445x1787.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1920&q=75 1920w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fd51b9738c42ccbde57b68d8ab61bfa5566fd66c3-2445x1787.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=2048&q=75 2048w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fd51b9738c42ccbde57b68d8ab61bfa5566fd66c3-2445x1787.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 3840w" src="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fd51b9738c42ccbde57b68d8ab61bfa5566fd66c3-2445x1787.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" class="object-cover" loading="lazy"/></noscript></span></div><div class="jsx-1215160397 content-wrap"><span class="jsx-1215160397 py-3 text-sm text-gray-500 text-left"><i class="jsx-1215160397">October 30th 2024</i></span><div class="jsx-1215160397 w-full h-fit mb-4"><p class="jsx-1215160397 text-[18px] font-bold text-[#000000] text-left line-clamp-3 text-hidden">Higher TMB, PD-L1 Expression Correlate With Shorter Survival in Hematologic Malignancies </p></div><div class="jsx-1215160397 pb-2 text-left ]"><div><span class="text-md "><span class="mr-1 italic">By </span><a class="mr-1 text-sky-800 hover:text-primary" href="/authors/gayle-turim-dickstein"><i>Gayle Turim Dickstein</i></a></span></div></div></div></div></a><a target="" style="scroll-snap-align:center;text-decoration:none" class="jsx-1637274924 sm:w-[280px] xs:w-[240px] w-[65%] h-auto flex flex-col space-y-3 flex-none select-none no-underline" href="/view/miles-matter-the-geographic-disparity-that-impacts-access-to-car-t-therapy"><div class="jsx-1637274924 w-full h-full flex flex-col overflow-hidden relative bg-white text-center"><div class="jsx-1637274924 relative w-full shadow-md shadow-grey-800 aspect-video"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="object-cover" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="" sizes="100vw" srcSet="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F3d97f41753d5036fe06a27339f606f5bb4fd9d8f-2400x1600.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=640&q=75 640w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F3d97f41753d5036fe06a27339f606f5bb4fd9d8f-2400x1600.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=750&q=75 750w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F3d97f41753d5036fe06a27339f606f5bb4fd9d8f-2400x1600.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=828&q=75 828w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F3d97f41753d5036fe06a27339f606f5bb4fd9d8f-2400x1600.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1080&q=75 1080w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F3d97f41753d5036fe06a27339f606f5bb4fd9d8f-2400x1600.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1200&q=75 1200w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F3d97f41753d5036fe06a27339f606f5bb4fd9d8f-2400x1600.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1920&q=75 1920w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F3d97f41753d5036fe06a27339f606f5bb4fd9d8f-2400x1600.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=2048&q=75 2048w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F3d97f41753d5036fe06a27339f606f5bb4fd9d8f-2400x1600.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 3840w" src="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F3d97f41753d5036fe06a27339f606f5bb4fd9d8f-2400x1600.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" class="object-cover" loading="lazy"/></noscript></span></div><div class="jsx-1637274924 content-wrap"><span class="jsx-1637274924 py-3 text-sm text-gray-500 text-left"><i class="jsx-1637274924">October 13th 2024</i></span><div class="jsx-1637274924 w-full h-fit mb-4"><p class="jsx-1637274924 text-[18px] font-bold text-[#000000] text-left line-clamp-3 text-hidden">Miles Matter: The Geographic Disparity That Impacts Access to CAR T Therapy</p></div><div class="jsx-1637274924 pb-2 text-left ]"><div><span class="text-md "><span class="mr-1 italic">By </span><a class="mr-1 text-sky-800 hover:text-primary" href="/authors/ryan-flinn"><i>Ryan Flinn</i></a></span></div></div></div></div></a><a target="" style="scroll-snap-align:center;text-decoration:none" class="jsx-286612495 sm:w-[280px] xs:w-[240px] w-[65%] h-auto flex flex-col space-y-3 flex-none select-none no-underline" href="/view/preclinical-model-suggests-efficacy-of-combining-capivasertib-with-venetoclax-against-dlbcl"><div class="jsx-286612495 w-full h-full flex flex-col overflow-hidden relative bg-white text-center"><div class="jsx-286612495 relative w-full shadow-md shadow-grey-800 aspect-video"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="object-cover" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="" sizes="100vw" srcSet="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fa329387e322ca781d0a66405a3ad00034bd346e8-1280x853.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=640&q=75 640w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fa329387e322ca781d0a66405a3ad00034bd346e8-1280x853.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=750&q=75 750w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fa329387e322ca781d0a66405a3ad00034bd346e8-1280x853.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=828&q=75 828w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fa329387e322ca781d0a66405a3ad00034bd346e8-1280x853.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1080&q=75 1080w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fa329387e322ca781d0a66405a3ad00034bd346e8-1280x853.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1200&q=75 1200w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fa329387e322ca781d0a66405a3ad00034bd346e8-1280x853.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1920&q=75 1920w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fa329387e322ca781d0a66405a3ad00034bd346e8-1280x853.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=2048&q=75 2048w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fa329387e322ca781d0a66405a3ad00034bd346e8-1280x853.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 3840w" src="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fa329387e322ca781d0a66405a3ad00034bd346e8-1280x853.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" class="object-cover" loading="lazy"/></noscript></span></div><div class="jsx-286612495 content-wrap"><span class="jsx-286612495 py-3 text-sm text-gray-500 text-left"><i class="jsx-286612495">October 8th 2024</i></span><div class="jsx-286612495 w-full h-fit mb-4"><p class="jsx-286612495 text-[18px] font-bold text-[#000000] text-left line-clamp-3 text-hidden">Preclinical Model Suggests Efficacy of Combining Capivasertib With Venetoclax Against DLBCL</p></div><div class="jsx-286612495 pb-2 text-left ]"><div><span class="text-md "><span class="mr-1 italic">By </span><a class="mr-1 text-sky-800 hover:text-primary" href="/authors/karen-jacobson-sive"><i>Karen Jacobson-Sive</i></a></span></div></div></div></div></a><a target="" style="scroll-snap-align:center;text-decoration:none" class="jsx-2915913710 sm:w-[280px] xs:w-[240px] w-[65%] h-auto flex flex-col space-y-3 flex-none select-none no-underline" href="/view/combination-of-magrolimab-and-rituximab-well-tolerated-in-patients-with-refractory-relapsed-indolent-nhl"><div class="jsx-2915913710 w-full h-full flex flex-col overflow-hidden relative bg-white text-center"><div class="jsx-2915913710 relative w-full shadow-md shadow-grey-800 aspect-video"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="object-cover" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="" sizes="100vw" srcSet="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F14565e78f839b82f71b7c7b220c5d33d373e67b2-1200x724.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=640&q=75 640w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F14565e78f839b82f71b7c7b220c5d33d373e67b2-1200x724.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=750&q=75 750w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F14565e78f839b82f71b7c7b220c5d33d373e67b2-1200x724.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=828&q=75 828w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F14565e78f839b82f71b7c7b220c5d33d373e67b2-1200x724.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1080&q=75 1080w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F14565e78f839b82f71b7c7b220c5d33d373e67b2-1200x724.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1200&q=75 1200w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F14565e78f839b82f71b7c7b220c5d33d373e67b2-1200x724.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1920&q=75 1920w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F14565e78f839b82f71b7c7b220c5d33d373e67b2-1200x724.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=2048&q=75 2048w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F14565e78f839b82f71b7c7b220c5d33d373e67b2-1200x724.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 3840w" src="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F14565e78f839b82f71b7c7b220c5d33d373e67b2-1200x724.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" class="object-cover" loading="lazy"/></noscript></span></div><div class="jsx-2915913710 content-wrap"><span class="jsx-2915913710 py-3 text-sm text-gray-500 text-left"><i class="jsx-2915913710">September 25th 2024</i></span><div class="jsx-2915913710 w-full h-fit mb-4"><p class="jsx-2915913710 text-[18px] font-bold text-[#000000] text-left line-clamp-3 text-hidden">Combination of Magrolimab and Rituximab Well Tolerated in Patients With Refractory/Relapsed Indolent NHL</p></div><div class="jsx-2915913710 pb-2 text-left ]"><div><span class="text-md "><span class="mr-1 italic">By </span><a class="mr-1 text-sky-800 hover:text-primary" href="/authors/nameera-temkar-md"><i>Nameera Temkar, MD</i></a></span></div></div></div></div></a><a target="" style="scroll-snap-align:center;text-decoration:none" class="jsx-2363373513 sm:w-[280px] xs:w-[240px] w-[65%] h-auto flex flex-col space-y-3 flex-none select-none no-underline" href="/view/lenalidomide-obinutuzumab-combo-yields-promising-results-in-relapsed-nhl"><div class="jsx-2363373513 w-full h-full flex flex-col overflow-hidden relative bg-white text-center"><div class="jsx-2363373513 relative w-full shadow-md shadow-grey-800 aspect-video"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="object-cover" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="" sizes="100vw" srcSet="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F357ec216737f69151df0afb267a2b92d55922db3-8064x5376.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=640&q=75 640w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F357ec216737f69151df0afb267a2b92d55922db3-8064x5376.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=750&q=75 750w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F357ec216737f69151df0afb267a2b92d55922db3-8064x5376.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=828&q=75 828w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F357ec216737f69151df0afb267a2b92d55922db3-8064x5376.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1080&q=75 1080w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F357ec216737f69151df0afb267a2b92d55922db3-8064x5376.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1200&q=75 1200w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F357ec216737f69151df0afb267a2b92d55922db3-8064x5376.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=1920&q=75 1920w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F357ec216737f69151df0afb267a2b92d55922db3-8064x5376.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=2048&q=75 2048w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F357ec216737f69151df0afb267a2b92d55922db3-8064x5376.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 3840w" src="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F357ec216737f69151df0afb267a2b92d55922db3-8064x5376.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" class="object-cover" loading="lazy"/></noscript></span></div><div class="jsx-2363373513 content-wrap"><span class="jsx-2363373513 py-3 text-sm text-gray-500 text-left"><i class="jsx-2363373513">September 21st 2024</i></span><div class="jsx-2363373513 w-full h-fit mb-4"><p class="jsx-2363373513 text-[18px] font-bold text-[#000000] text-left line-clamp-3 text-hidden">Lenalidomide-Obinutuzumab Combo Yields Promising Results in Relapsed NHL</p></div><div class="jsx-2363373513 pb-2 text-left ]"><div><span class="text-md "><span class="mr-1 italic">By </span><a class="mr-1 text-sky-800 hover:text-primary" href="/authors/kimberly-rath-pharmd"><i>Kimberly Rath, PharmD</i></a></span></div></div></div></div></a></div></div></div></div></div><div class="border-b-[2px] border-[#EEE] "><div class="jsx-19ede9f0a5a45918 py-4 relative px-0"><div class="flex justify-between items-center py-1 space-x-4 border-0 select-none"><div class="w-[70%] mr-3 xs:my-6 my-4 #000 text-3xl">Video Interviews</div><a href="/interviews" class="w-[30%] text-right text-[#0AA2BE] text-[16px] underline"><span>View All</span></a></div><div style="scroll-snap-type:none" class="jsx-19ede9f0a5a45918 flex items-start overflow-x-auto space-x-4 py-4 relative mx-auto w-[calc(100%-64px)]"><a target="" style="scroll-snap-align:center;text-decoration:none" class="jsx-1215160397 sm:w-[280px] xs:w-[240px] w-[65%] h-auto flex flex-col space-y-3 flex-none select-none no-underline" href="/view/dr-anna-sureda-on-the-evolving-treatment-landscape-for-relapsed-refractory-dlbcl-follicular-lymphoma"><div class="jsx-1215160397 w-full h-full flex flex-col overflow-hidden relative bg-white text-center"><div class="jsx-1215160397 relative w-full shadow-md shadow-grey-800 aspect-video"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="object-cover" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="" sizes="100vw" srcSet="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F7cbfb6054c666afc203e8f14d149579ef87dc41d-2786x1570.png%2FScreenshot%25202024-07-12%2520at%25201.57.28%25E2%2580%25AFPM.png%3Ffit%3Dcrop%26auto%3Dformat&w=640&q=75 640w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F7cbfb6054c666afc203e8f14d149579ef87dc41d-2786x1570.png%2FScreenshot%25202024-07-12%2520at%25201.57.28%25E2%2580%25AFPM.png%3Ffit%3Dcrop%26auto%3Dformat&w=750&q=75 750w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F7cbfb6054c666afc203e8f14d149579ef87dc41d-2786x1570.png%2FScreenshot%25202024-07-12%2520at%25201.57.28%25E2%2580%25AFPM.png%3Ffit%3Dcrop%26auto%3Dformat&w=828&q=75 828w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F7cbfb6054c666afc203e8f14d149579ef87dc41d-2786x1570.png%2FScreenshot%25202024-07-12%2520at%25201.57.28%25E2%2580%25AFPM.png%3Ffit%3Dcrop%26auto%3Dformat&w=1080&q=75 1080w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F7cbfb6054c666afc203e8f14d149579ef87dc41d-2786x1570.png%2FScreenshot%25202024-07-12%2520at%25201.57.28%25E2%2580%25AFPM.png%3Ffit%3Dcrop%26auto%3Dformat&w=1200&q=75 1200w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F7cbfb6054c666afc203e8f14d149579ef87dc41d-2786x1570.png%2FScreenshot%25202024-07-12%2520at%25201.57.28%25E2%2580%25AFPM.png%3Ffit%3Dcrop%26auto%3Dformat&w=1920&q=75 1920w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F7cbfb6054c666afc203e8f14d149579ef87dc41d-2786x1570.png%2FScreenshot%25202024-07-12%2520at%25201.57.28%25E2%2580%25AFPM.png%3Ffit%3Dcrop%26auto%3Dformat&w=2048&q=75 2048w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F7cbfb6054c666afc203e8f14d149579ef87dc41d-2786x1570.png%2FScreenshot%25202024-07-12%2520at%25201.57.28%25E2%2580%25AFPM.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 3840w" src="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2F7cbfb6054c666afc203e8f14d149579ef87dc41d-2786x1570.png%2FScreenshot%25202024-07-12%2520at%25201.57.28%25E2%2580%25AFPM.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" class="object-cover" loading="lazy"/></noscript></span></div><div class="jsx-1215160397 content-wrap"><span class="jsx-1215160397 py-3 text-sm text-gray-500 text-left"><i class="jsx-1215160397">July 13th 2024</i></span><div class="jsx-1215160397 w-full h-fit mb-4"><p class="jsx-1215160397 text-[18px] font-bold text-[#000000] text-left line-clamp-3 text-hidden">Dr Anna Sureda on the Evolving Treatment Landscape for Relapsed/Refractory DLBCL, Follicular Lymphoma</p></div></div></div></a><a target="" style="scroll-snap-align:center;text-decoration:none" class="jsx-1637274924 sm:w-[280px] xs:w-[240px] w-[65%] h-auto flex flex-col space-y-3 flex-none select-none no-underline" href="/view/dr-ann-lacasce-t-cell-engagers-have-improved-dlbcl-outcomes-but-questions-on-optimal-use-remain"><div class="jsx-1637274924 w-full h-full flex flex-col overflow-hidden relative bg-white text-center"><div class="jsx-1637274924 relative w-full shadow-md shadow-grey-800 aspect-video"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="object-cover" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="" sizes="100vw" srcSet="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fb3cf913180d16149af8afb7d582c55f389b097f4-882x500.png%2FScreen%2520Shot%25202024-02-02%2520at%25204.33.23%2520PM.png%3Ffit%3Dcrop%26auto%3Dformat&w=640&q=75 640w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fb3cf913180d16149af8afb7d582c55f389b097f4-882x500.png%2FScreen%2520Shot%25202024-02-02%2520at%25204.33.23%2520PM.png%3Ffit%3Dcrop%26auto%3Dformat&w=750&q=75 750w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fb3cf913180d16149af8afb7d582c55f389b097f4-882x500.png%2FScreen%2520Shot%25202024-02-02%2520at%25204.33.23%2520PM.png%3Ffit%3Dcrop%26auto%3Dformat&w=828&q=75 828w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fb3cf913180d16149af8afb7d582c55f389b097f4-882x500.png%2FScreen%2520Shot%25202024-02-02%2520at%25204.33.23%2520PM.png%3Ffit%3Dcrop%26auto%3Dformat&w=1080&q=75 1080w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fb3cf913180d16149af8afb7d582c55f389b097f4-882x500.png%2FScreen%2520Shot%25202024-02-02%2520at%25204.33.23%2520PM.png%3Ffit%3Dcrop%26auto%3Dformat&w=1200&q=75 1200w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fb3cf913180d16149af8afb7d582c55f389b097f4-882x500.png%2FScreen%2520Shot%25202024-02-02%2520at%25204.33.23%2520PM.png%3Ffit%3Dcrop%26auto%3Dformat&w=1920&q=75 1920w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fb3cf913180d16149af8afb7d582c55f389b097f4-882x500.png%2FScreen%2520Shot%25202024-02-02%2520at%25204.33.23%2520PM.png%3Ffit%3Dcrop%26auto%3Dformat&w=2048&q=75 2048w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fb3cf913180d16149af8afb7d582c55f389b097f4-882x500.png%2FScreen%2520Shot%25202024-02-02%2520at%25204.33.23%2520PM.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 3840w" src="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Fb3cf913180d16149af8afb7d582c55f389b097f4-882x500.png%2FScreen%2520Shot%25202024-02-02%2520at%25204.33.23%2520PM.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" class="object-cover" loading="lazy"/></noscript></span></div><div class="jsx-1637274924 content-wrap"><span class="jsx-1637274924 py-3 text-sm text-gray-500 text-left"><i class="jsx-1637274924">February 8th 2024</i></span><div class="jsx-1637274924 w-full h-fit mb-4"><p class="jsx-1637274924 text-[18px] font-bold text-[#000000] text-left line-clamp-3 text-hidden">Dr Ann LaCasce: T-Cell Engagers Have Improved DLBCL Outcomes, but Questions on Optimal Use Remain</p></div></div></div></a><a target="" style="scroll-snap-align:center;text-decoration:none" class="jsx-286612495 sm:w-[280px] xs:w-[240px] w-[65%] h-auto flex flex-col space-y-3 flex-none select-none no-underline" href="/view/epcoritamab-approval-expands-treatment-armamentarium-for-dlbcl"><div class="jsx-286612495 w-full h-full flex flex-col overflow-hidden relative bg-white text-center"><div class="jsx-286612495 relative w-full shadow-md shadow-grey-800 aspect-video"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="object-cover" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="" sizes="100vw" srcSet="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Ffdb7f0c1219bd696ea4df915749776882346572b-1682x972.png%2FScreen%2520Shot%25202023-06-09%2520at%25203.43.53%2520PM.png%3Ffit%3Dcrop%26auto%3Dformat&w=640&q=75 640w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Ffdb7f0c1219bd696ea4df915749776882346572b-1682x972.png%2FScreen%2520Shot%25202023-06-09%2520at%25203.43.53%2520PM.png%3Ffit%3Dcrop%26auto%3Dformat&w=750&q=75 750w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Ffdb7f0c1219bd696ea4df915749776882346572b-1682x972.png%2FScreen%2520Shot%25202023-06-09%2520at%25203.43.53%2520PM.png%3Ffit%3Dcrop%26auto%3Dformat&w=828&q=75 828w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Ffdb7f0c1219bd696ea4df915749776882346572b-1682x972.png%2FScreen%2520Shot%25202023-06-09%2520at%25203.43.53%2520PM.png%3Ffit%3Dcrop%26auto%3Dformat&w=1080&q=75 1080w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Ffdb7f0c1219bd696ea4df915749776882346572b-1682x972.png%2FScreen%2520Shot%25202023-06-09%2520at%25203.43.53%2520PM.png%3Ffit%3Dcrop%26auto%3Dformat&w=1200&q=75 1200w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Ffdb7f0c1219bd696ea4df915749776882346572b-1682x972.png%2FScreen%2520Shot%25202023-06-09%2520at%25203.43.53%2520PM.png%3Ffit%3Dcrop%26auto%3Dformat&w=1920&q=75 1920w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Ffdb7f0c1219bd696ea4df915749776882346572b-1682x972.png%2FScreen%2520Shot%25202023-06-09%2520at%25203.43.53%2520PM.png%3Ffit%3Dcrop%26auto%3Dformat&w=2048&q=75 2048w, /_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Ffdb7f0c1219bd696ea4df915749776882346572b-1682x972.png%2FScreen%2520Shot%25202023-06-09%2520at%25203.43.53%2520PM.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 3840w" src="/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fajmc%2Ffdb7f0c1219bd696ea4df915749776882346572b-1682x972.png%2FScreen%2520Shot%25202023-06-09%2520at%25203.43.53%2520PM.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" class="object-cover" loading="lazy"/></noscript></span></div><div class="jsx-286612495 content-wrap"><span class="jsx-286612495 py-3 text-sm text-gray-500 text-left"><i class="jsx-286612495">June 9th 2023</i></span><div class="jsx-286612495 w-full h-fit mb-4"><p class="jsx-286612495 text-[18px] font-bold text-[#000000] text-left line-clamp-3 text-hidden">Epcoritamab Approval Expands Treatment Armamentarium for DLBCL</p></div></div></div></a></div></div></div><div class="border-b-[2px] border-[#EEE] my-4"><div class="jsx-19ede9f0a5a45918 py-4 relative px-0"><div class="flex justify-between items-center py-1 space-x-4 border-0 select-none"><div class="w-[70%] mr-3 xs:my-6 my-4 #000 text-3xl">Continuing Medical Education</div><a href="/continuing-education" class="w-[30%] text-right text-[#0AA2BE] text-[16px] underline"><span>View All</span></a></div><div style="scroll-snap-type:none" class="jsx-19ede9f0a5a45918 flex items-start overflow-x-auto space-x-4 py-4 relative mx-auto w-[calc(100%-64px)]"><a target="_blank" style="scroll-snap-align:center;text-decoration:none" class="jsx-3886647465 sm:w-[280px] xs:w-[240px] w-[65%] h-auto flex flex-col space-y-3 flex-none select-none no-underline" href="https://www.pharmacytimes.org/courses/ash-annual-meeting-coverage-highlighting-the-recent-updates-in-tki-use-in-the-treatment-of-cml-insights-and-application-for-managed-care?utm_source=undefined&utm_medium=undefined&utm_campaign=cmeDeck"><div class="jsx-3886647465 w-full h-full flex flex-col overflow-hidden relative bg-white text-center"><div class="jsx-3886647465 relative w-full shadow-md shadow-grey-800 aspect-video"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="object-cover" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="" sizes="100vw" srcSet="/_next/image?url=https%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2Fd2afb412-3c3e-4f73-b3d6-2388078622a3%2Fs7o31mkufl76-PTCE_ASH-CML_Webinar_110524v1_800x385.png&w=640&q=75 640w, /_next/image?url=https%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2Fd2afb412-3c3e-4f73-b3d6-2388078622a3%2Fs7o31mkufl76-PTCE_ASH-CML_Webinar_110524v1_800x385.png&w=750&q=75 750w, /_next/image?url=https%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2Fd2afb412-3c3e-4f73-b3d6-2388078622a3%2Fs7o31mkufl76-PTCE_ASH-CML_Webinar_110524v1_800x385.png&w=828&q=75 828w, /_next/image?url=https%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2Fd2afb412-3c3e-4f73-b3d6-2388078622a3%2Fs7o31mkufl76-PTCE_ASH-CML_Webinar_110524v1_800x385.png&w=1080&q=75 1080w, /_next/image?url=https%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2Fd2afb412-3c3e-4f73-b3d6-2388078622a3%2Fs7o31mkufl76-PTCE_ASH-CML_Webinar_110524v1_800x385.png&w=1200&q=75 1200w, /_next/image?url=https%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2Fd2afb412-3c3e-4f73-b3d6-2388078622a3%2Fs7o31mkufl76-PTCE_ASH-CML_Webinar_110524v1_800x385.png&w=1920&q=75 1920w, /_next/image?url=https%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2Fd2afb412-3c3e-4f73-b3d6-2388078622a3%2Fs7o31mkufl76-PTCE_ASH-CML_Webinar_110524v1_800x385.png&w=2048&q=75 2048w, /_next/image?url=https%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2Fd2afb412-3c3e-4f73-b3d6-2388078622a3%2Fs7o31mkufl76-PTCE_ASH-CML_Webinar_110524v1_800x385.png&w=3840&q=75 3840w" src="/_next/image?url=https%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2Fd2afb412-3c3e-4f73-b3d6-2388078622a3%2Fs7o31mkufl76-PTCE_ASH-CML_Webinar_110524v1_800x385.png&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" class="object-cover" loading="lazy"/></noscript></span></div><div class="jsx-3886647465 content-wrap"><span class="jsx-3886647465 py-3 text-sm text-gray-500 text-left"><i class="jsx-3886647465">November 23rd 2024</i></span><div class="jsx-3886647465 w-full h-fit mb-4"><p class="jsx-3886647465 text-[18px] font-bold text-[#000000] text-left line-clamp-3 text-hidden">ASH Annual Meeting Coverage: Highlighting the Recent Updates in TKI Use in the Treatment of CML – Insights and Application for Managed Care</p></div><div class="jsx-3886647465 text-left text-[12px] text-[#000] py-6">December 18, 2024 | 1:00 PM & 8:00 PM ET</div></div></div></a><a target="_blank" style="scroll-snap-align:center;text-decoration:none" class="jsx-3945728741 sm:w-[280px] xs:w-[240px] w-[65%] h-auto flex flex-col space-y-3 flex-none select-none no-underline" href="https://www.pharmacytimes.org/courses/recent-advances-in-bcma-directed-treatment-in-multiple-myeloma-insights-and-application-for-managed-care-enduring?utm_source=undefined&utm_medium=undefined&utm_campaign=cmeDeck"><div class="jsx-3945728741 w-full h-full flex flex-col overflow-hidden relative bg-white text-center"><div class="jsx-3945728741 relative w-full shadow-md shadow-grey-800 aspect-video"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="object-cover" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="" sizes="100vw" srcSet="/_next/image?url=https%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2Fd2afb412-3c3e-4f73-b3d6-2388078622a3%2Fd051f9s6a2ac-PTCE_MM_Webinar_111623v1_800x385.png&w=640&q=75 640w, /_next/image?url=https%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2Fd2afb412-3c3e-4f73-b3d6-2388078622a3%2Fd051f9s6a2ac-PTCE_MM_Webinar_111623v1_800x385.png&w=750&q=75 750w, /_next/image?url=https%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2Fd2afb412-3c3e-4f73-b3d6-2388078622a3%2Fd051f9s6a2ac-PTCE_MM_Webinar_111623v1_800x385.png&w=828&q=75 828w, /_next/image?url=https%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2Fd2afb412-3c3e-4f73-b3d6-2388078622a3%2Fd051f9s6a2ac-PTCE_MM_Webinar_111623v1_800x385.png&w=1080&q=75 1080w, /_next/image?url=https%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2Fd2afb412-3c3e-4f73-b3d6-2388078622a3%2Fd051f9s6a2ac-PTCE_MM_Webinar_111623v1_800x385.png&w=1200&q=75 1200w, /_next/image?url=https%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2Fd2afb412-3c3e-4f73-b3d6-2388078622a3%2Fd051f9s6a2ac-PTCE_MM_Webinar_111623v1_800x385.png&w=1920&q=75 1920w, /_next/image?url=https%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2Fd2afb412-3c3e-4f73-b3d6-2388078622a3%2Fd051f9s6a2ac-PTCE_MM_Webinar_111623v1_800x385.png&w=2048&q=75 2048w, /_next/image?url=https%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2Fd2afb412-3c3e-4f73-b3d6-2388078622a3%2Fd051f9s6a2ac-PTCE_MM_Webinar_111623v1_800x385.png&w=3840&q=75 3840w" src="/_next/image?url=https%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2Fd2afb412-3c3e-4f73-b3d6-2388078622a3%2Fd051f9s6a2ac-PTCE_MM_Webinar_111623v1_800x385.png&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" class="object-cover" loading="lazy"/></noscript></span></div><div class="jsx-3945728741 content-wrap"><span class="jsx-3945728741 py-3 text-sm text-gray-500 text-left"><i class="jsx-3945728741">November 23rd 2024</i></span><div class="jsx-3945728741 w-full h-fit mb-4"><p class="jsx-3945728741 text-[18px] font-bold text-[#000000] text-left line-clamp-3 text-hidden">Recent Advances in BCMA-Directed Treatment in Multiple Myeloma: Insights and Application for Managed Care</p></div><div class="jsx-3945728741 text-left text-[12px] text-[#000] py-6">1.0 Credits / Hematologic Cancer, Oncology</div></div></div></a><a target="_blank" style="scroll-snap-align:center;text-decoration:none" class="jsx-3745364856 sm:w-[280px] xs:w-[240px] w-[65%] h-auto flex flex-col space-y-3 flex-none select-none no-underline" href="https://www.pharmacytimes.org/courses/keeping-pace-with-new-developments-in-multiple-myeloma-updates-and-strategies-to-optimize-bispecific-antibodies-and-car-t-cell-therapy-tcdv?utm_source=undefined&utm_medium=undefined&utm_campaign=cmeDeck"><div class="jsx-3745364856 w-full h-full flex flex-col overflow-hidden relative bg-white text-center"><div class="jsx-3745364856 relative w-full shadow-md shadow-grey-800 aspect-video"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="object-cover" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="" sizes="100vw" srcSet="/_next/image?url=https%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2Fd2afb412-3c3e-4f73-b3d6-2388078622a3%2Fhvzihm9lmt65-PTCE_AMCP-2024_MM_Enduring_043024v1_800x385.png&w=640&q=75 640w, /_next/image?url=https%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2Fd2afb412-3c3e-4f73-b3d6-2388078622a3%2Fhvzihm9lmt65-PTCE_AMCP-2024_MM_Enduring_043024v1_800x385.png&w=750&q=75 750w, /_next/image?url=https%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2Fd2afb412-3c3e-4f73-b3d6-2388078622a3%2Fhvzihm9lmt65-PTCE_AMCP-2024_MM_Enduring_043024v1_800x385.png&w=828&q=75 828w, /_next/image?url=https%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2Fd2afb412-3c3e-4f73-b3d6-2388078622a3%2Fhvzihm9lmt65-PTCE_AMCP-2024_MM_Enduring_043024v1_800x385.png&w=1080&q=75 1080w, /_next/image?url=https%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2Fd2afb412-3c3e-4f73-b3d6-2388078622a3%2Fhvzihm9lmt65-PTCE_AMCP-2024_MM_Enduring_043024v1_800x385.png&w=1200&q=75 1200w, /_next/image?url=https%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2Fd2afb412-3c3e-4f73-b3d6-2388078622a3%2Fhvzihm9lmt65-PTCE_AMCP-2024_MM_Enduring_043024v1_800x385.png&w=1920&q=75 1920w, /_next/image?url=https%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2Fd2afb412-3c3e-4f73-b3d6-2388078622a3%2Fhvzihm9lmt65-PTCE_AMCP-2024_MM_Enduring_043024v1_800x385.png&w=2048&q=75 2048w, /_next/image?url=https%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2Fd2afb412-3c3e-4f73-b3d6-2388078622a3%2Fhvzihm9lmt65-PTCE_AMCP-2024_MM_Enduring_043024v1_800x385.png&w=3840&q=75 3840w" src="/_next/image?url=https%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2Fd2afb412-3c3e-4f73-b3d6-2388078622a3%2Fhvzihm9lmt65-PTCE_AMCP-2024_MM_Enduring_043024v1_800x385.png&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" class="object-cover" loading="lazy"/></noscript></span></div><div class="jsx-3745364856 content-wrap"><span class="jsx-3745364856 py-3 text-sm text-gray-500 text-left"><i class="jsx-3745364856">November 23rd 2024</i></span><div class="jsx-3745364856 w-full h-fit mb-4"><p class="jsx-3745364856 text-[18px] font-bold text-[#000000] text-left line-clamp-3 text-hidden">Keeping Pace With New Developments in Multiple Myeloma: Updates and Strategies to Optimize Bispecific Antibodies and CAR T-Cell Therapy</p></div><div class="jsx-3745364856 text-left text-[12px] text-[#000] py-6">1.5 Credits / Oncology, Hematology, Hematologic Cancer</div></div></div></a><a target="_blank" style="scroll-snap-align:center;text-decoration:none" class="jsx-2629720111 sm:w-[280px] xs:w-[240px] w-[65%] h-auto flex flex-col space-y-3 flex-none select-none no-underline" href="https://www.pharmacytimes.org/courses/addressing-the-gaps-and-clinical-challenges-in-chronic-lymphocytic-leukemia-updates-and-strategies-for-managed-care-dxq5?utm_source=undefined&utm_medium=undefined&utm_campaign=cmeDeck"><div class="jsx-2629720111 w-full h-full flex flex-col overflow-hidden relative bg-white text-center"><div class="jsx-2629720111 relative w-full shadow-md shadow-grey-800 aspect-video"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="object-cover" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="" sizes="100vw" srcSet="/_next/image?url=https%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2Fd2afb412-3c3e-4f73-b3d6-2388078622a3%2F22wqid3lilcb-PTCE_AMCP-2024_CLL_Enduring_043024v2_800x385.png&w=640&q=75 640w, /_next/image?url=https%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2Fd2afb412-3c3e-4f73-b3d6-2388078622a3%2F22wqid3lilcb-PTCE_AMCP-2024_CLL_Enduring_043024v2_800x385.png&w=750&q=75 750w, /_next/image?url=https%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2Fd2afb412-3c3e-4f73-b3d6-2388078622a3%2F22wqid3lilcb-PTCE_AMCP-2024_CLL_Enduring_043024v2_800x385.png&w=828&q=75 828w, /_next/image?url=https%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2Fd2afb412-3c3e-4f73-b3d6-2388078622a3%2F22wqid3lilcb-PTCE_AMCP-2024_CLL_Enduring_043024v2_800x385.png&w=1080&q=75 1080w, /_next/image?url=https%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2Fd2afb412-3c3e-4f73-b3d6-2388078622a3%2F22wqid3lilcb-PTCE_AMCP-2024_CLL_Enduring_043024v2_800x385.png&w=1200&q=75 1200w, /_next/image?url=https%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2Fd2afb412-3c3e-4f73-b3d6-2388078622a3%2F22wqid3lilcb-PTCE_AMCP-2024_CLL_Enduring_043024v2_800x385.png&w=1920&q=75 1920w, /_next/image?url=https%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2Fd2afb412-3c3e-4f73-b3d6-2388078622a3%2F22wqid3lilcb-PTCE_AMCP-2024_CLL_Enduring_043024v2_800x385.png&w=2048&q=75 2048w, /_next/image?url=https%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2Fd2afb412-3c3e-4f73-b3d6-2388078622a3%2F22wqid3lilcb-PTCE_AMCP-2024_CLL_Enduring_043024v2_800x385.png&w=3840&q=75 3840w" src="/_next/image?url=https%3A%2F%2Fd36ai2hkxl16us.cloudfront.net%2Fthoughtindustries%2Fimage%2Fupload%2Fv1%2Fcourse-uploads%2Fd2afb412-3c3e-4f73-b3d6-2388078622a3%2F22wqid3lilcb-PTCE_AMCP-2024_CLL_Enduring_043024v2_800x385.png&w=3840&q=75" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" class="object-cover" loading="lazy"/></noscript></span></div><div class="jsx-2629720111 content-wrap"><span class="jsx-2629720111 py-3 text-sm text-gray-500 text-left"><i class="jsx-2629720111">November 23rd 2024</i></span><div class="jsx-2629720111 w-full h-fit mb-4"><p class="jsx-2629720111 text-[18px] font-bold text-[#000000] text-left line-clamp-3 text-hidden">Addressing the Gaps and Clinical Challenges in Chronic Lymphocytic Leukemia: Updates and Strategies for Managed Care</p></div><div class="jsx-2629720111 text-left text-[12px] text-[#000] py-6">1.5 Credits / Hematology, Hematologic Cancer, Oncology</div></div></div></a></div></div></div><div class="flex items-center space-x-4 border-0 border-b border-secondary select-none py-1"><h2 class="text-3xl text-primary">More News</h2></div><div class="flex flex-wrap w-full pb-4"><div class="jsx-ad50481d5ee26850 w-full h-full"><div><div><div class="text-[8px] text-center text-gray-500 hidden">Advertisement</div><div id="div-gpt-ad-infeed-1"></div></div></div><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/patients-with-b-cell-cancers-have-history-of-increased-antimicrobial-use"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/241bc75607121b543e32cbafca5a25a1e956e30f-1200x724.jpg?fit=crop&auto=format" alt="Lymphoma diagnosis | Image Credit: © Vitalii Vodolazskyi - stock.adobe.com" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">September 13th 2024</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/patients-with-b-cell-cancers-have-history-of-increased-antimicrobial-use">Patients With B-Cell Cancers Have History of Increased Antimicrobial Use</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/nameera-temkar-md">Nameera Temkar, MD</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/patients-with-b-cell-cancers-have-history-of-increased-antimicrobial-use"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">Danish patients who were diagnosed with certain lymphomas and other B-cell malignancies demonstrated increased antimicrobial use for at least a decade before their diagnosis.</div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/recombinant-hirudin-may-help-treat-diffuse-large-b-cell-lymphoma"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/1ba373f5a004b284e540407fa01abbcee009de21-3265x1837.jpg?fit=crop&auto=format" alt="Recombinant Hirudin shows promise in the treament of DLBCL | image credit: David A Litman - stock.adobe.com" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">September 5th 2024</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/recombinant-hirudin-may-help-treat-diffuse-large-b-cell-lymphoma">Recombinant Hirudin May Help Treat Diffuse Large B-Cell Lymphoma  </a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/karen-jacobson-sive">Karen Jacobson-Sive</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/recombinant-hirudin-may-help-treat-diffuse-large-b-cell-lymphoma"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">Recombinant Hirudin (rH) inhibited the polarization of M2-type macrophages and protease-activated receptor-1 (PAR-1) in diffuse large B-cell lymphoma (DLBCL). </div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex md:hidden justify-center items-center"></div><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/dr-jason-romancik-on-novel-lymphoma-therapies-increasing-costs-of-care"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/cda142b257d0655a16c489985cf85b380e8e7d91-665x372.png?fit=crop&auto=format" alt="Dr Jason Romancik, Emory Winship Cancer Institute" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">August 30th 2024</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/dr-jason-romancik-on-novel-lymphoma-therapies-increasing-costs-of-care">Dr Jason Romancik on Novel Lymphoma Therapies, Increasing Costs of Care</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/rose-mcnulty">Rose McNulty</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/dr-jason-romancik-on-novel-lymphoma-therapies-increasing-costs-of-care"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">Jason Romancik, MD, a board-certified hematologist at Emory Winship Cancer Institute, discusses the current treatment landscape in aggressive lymphoma and drivers of high care costs. </div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/multiplex-spatial-analysis-highlights-mechanisms-of-refractory-chl"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/abdffcc1d1893ce84e07f271631073945bd321a2-6336x4224.jpg?fit=crop&auto=format" alt="Cancerous cells | image credit: Dr_Microbe - stock.adobe.com" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">August 26th 2024</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/multiplex-spatial-analysis-highlights-mechanisms-of-refractory-chl">Multiplex Spatial Analysis Highlights Mechanisms of Refractory cHL </a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/jared-kaltwasser">Jared Kaltwasser</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/multiplex-spatial-analysis-highlights-mechanisms-of-refractory-chl"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">Improvements in multiplex immunofluorescence and spatial analysis have enabled a better understanding of the ways classical Hodgkin lymphoma evades the immune system. </div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/phase-3-trial-of-tafasitamab-in-follicular-lymphoma-meets-primary-end-point"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/9834a2d3a21450debd7c29165ab12a131d9d1eff-1280x848.jpg?fit=crop&auto=format" alt="Full results from the inMIND trial of of lenalidomide and rituximab with or without tafasitamab in lymphoma are expected to be submitted for presentation at an upcoming medical meeting. | Image credit: airdone - stock.adobe.com" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">August 21st 2024</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/phase-3-trial-of-tafasitamab-in-follicular-lymphoma-meets-primary-end-point">Phase 3 Trial of Tafasitamab in Follicular Lymphoma Meets Primary End Point</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/jordyn-sava">Jordyn Sava</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/phase-3-trial-of-tafasitamab-in-follicular-lymphoma-meets-primary-end-point"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">The phase 3 inMIND trial evaluating tafasitamab in combination with lenalidomide and rituximab in relapsed or refractory follicular lymphoma showed promising progression-free survival findings, according to topline results.</div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/cytokine-release-syndrome-in-car-t--cell-therapy-a-common-yet-controllable-complication-in-dlbcl"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/cabd8bc05398941e25b517f3128c29223f4a0f94-5824x3264.jpg?fit=crop&auto=format" alt="Cytokine release concept | image credit: Bijac - stock.adobe.com" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">August 16th 2024</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/cytokine-release-syndrome-in-car-t--cell-therapy-a-common-yet-controllable-complication-in-dlbcl">Cytokine Release Syndrome in CAR T-Cell Therapy: A Common Yet Controllable Complication in DLBCL </a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/kimberly-rath-pharmd">Kimberly Rath, PharmD</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/cytokine-release-syndrome-in-car-t--cell-therapy-a-common-yet-controllable-complication-in-dlbcl"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">CAR T-cell therapy results in a high incidence of cytokine release syndrome, but it is manageable in most cases. </div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div><div><div class="text-[8px] text-center text-gray-500 hidden">Advertisement</div><div id="div-gpt-ad-infeed-7"></div></div></div><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/advancements-in-r-r-lymphoma-bispecific-antibodies-in-focus"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/0921f83c5cd84e16b5d9d18e84aac24e2617f185-1200x738.png?fit=crop&auto=format" alt="Anna Sureda, MD, PhD" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">August 10th 2024</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/advancements-in-r-r-lymphoma-bispecific-antibodies-in-focus">Advancements in R/R Lymphoma: Bispecific Antibodies in Focus</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/brooke-mccormick">Brooke McCormick</a><span class="jsx-ad50481d5ee26850 mr-1 ml-[1px]"> </span><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/maggie-l-shaw">Maggie L. Shaw</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/advancements-in-r-r-lymphoma-bispecific-antibodies-in-focus"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">In part 1 of our interview with Anna Sureda, MD, PhD, president of the European Group for Blood and Marrow Transplantation, she summarized the current treatment landscape for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) and follicular lymphoma (FL). </div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/scant-infection-data-for-patients-with-r-r-mm-nhl-treated-with-bsabs"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/14565e78f839b82f71b7c7b220c5d33d373e67b2-1200x724.jpg?fit=crop&auto=format" alt="The current lack of comprehensive data reflects an urgent need for more robust data and reporting with regard to BsAbs in R/R non-Hodgkin lymphoma and multiple myeloma. | Image credit: Vitalii Vodolazskyi - stock.adobe.com" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">August 8th 2024</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/scant-infection-data-for-patients-with-r-r-mm-nhl-treated-with-bsabs">Scant Infection Data for Patients With R/R MM, NHL Treated With BsAbs </a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/jared-kaltwasser">Jared Kaltwasser</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/scant-infection-data-for-patients-with-r-r-mm-nhl-treated-with-bsabs"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">Better reporting is needed to create better guidelines for tracking infection risk in patients with relapsed or refractory non-Hodgkin lymphoma or multiple myeloma, investigators concluded. </div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex md:hidden justify-center items-center"></div><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/accurately-capturing-experiences-of-patients-with-nhl"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/80a8f95e0313817a4704e7987cf07f82a83f8662-1200x738.jpg?fit=crop&auto=format" alt="doc interviewing patient | Image Credit: ChasingMagic/peopleimages.com-stock.adobe.com" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">August 1st 2024</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/accurately-capturing-experiences-of-patients-with-nhl">Accurately Capturing Experiences of Patients With NHL</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/jared-kaltwasser">Jared Kaltwasser</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/accurately-capturing-experiences-of-patients-with-nhl"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">Investigators wanted to know how well the NFlymSI-18 assessment was able to assess patient-reported outcomes in people with indolent B-cell non-Hodgkin lymphoma (NHL).</div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/fda-approval-of-epcoritamab-offers-new-hope-for-r-r-follicular-lymphoma-treatment"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/8a4011123b4f413b2b54850ba3133172cd35061b-2879x1612.png?fit=crop&auto=format" alt="Yasmin H. Karimi, MD" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">July 25th 2024</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/fda-approval-of-epcoritamab-offers-new-hope-for-r-r-follicular-lymphoma-treatment">FDA Approval of Epcoritamab Offers New Hope for R/R Follicular Lymphoma Treatment</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/hayden-e-klein">Hayden E. Klein</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/fda-approval-of-epcoritamab-offers-new-hope-for-r-r-follicular-lymphoma-treatment"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">“It's nice to have another option that we can discuss with patients,” said Yasmin H. Karimi, MD, University of Michigan, about epcoritamab’s label expansion for difficult-to-treat relapsed/refractory (R/R) follicular lymphoma.</div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/beigene-opens-800m-flagship-us-facility-in-new-jersey"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/332dd5dc31b4059b008ece9c602d639f4e72d617-480x320.jpg?fit=crop&auto=format" alt="BeiGene Hopewell facility | Image credit: BeiGene" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">July 23rd 2024</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/beigene-opens-800m-flagship-us-facility-in-new-jersey">BeiGene Opens $800M Flagship US Facility in New Jersey</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/mary-caffrey">Mary Caffrey</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/beigene-opens-800m-flagship-us-facility-in-new-jersey"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">New Jersey Governor Phil Murphy joined BeiGene CEO John Oyler and about 300 guests to open the facility, located in Hopewell, New Jersey. A version of this article appeared in the August issue of Evidence-Based Oncology.</div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/in-lbcl-barriers-to-car-t-remain-sdoh-and-more"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/8221a6bc7f23de994c5e2045cd76cd6eb0bb6393-1200x738.jpg?fit=crop&auto=format" alt="CAR T | Image Credit: Christoph Burgstedt-stock.adobe.com" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">July 23rd 2024</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/in-lbcl-barriers-to-car-t-remain-sdoh-and-more">In LBCL, Barriers to CAR T Remain: SDOH and More</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/gayle-turim-dickstein">Gayle Turim Dickstein</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/in-lbcl-barriers-to-car-t-remain-sdoh-and-more"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">The social determinants of health (SDOH) that need to be tackled most urgently when it comes to which patients with large B-cell lymphoma (LBCL) do and do not receive chimeric antigen receptor T-cell therapy (CAR T) are age, sex, income, and race/ethnicity.</div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div><div><div class="text-[8px] text-center text-gray-500 hidden">Advertisement</div><div id="div-gpt-ad-infeed-13"></div></div></div><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/the-importance-of-treatment-sequencing-in-mantle-cell-lymphoma"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/63e5891e9acccbc13ee44b62a86d8faf5af8fb5b-1200x724.jpg?fit=crop&auto=format" alt="Tycel Phillips, MD, City of Hope" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">July 16th 2024</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/the-importance-of-treatment-sequencing-in-mantle-cell-lymphoma">The Importance of Treatment Sequencing in Mantle Cell Lymphoma</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/mary-caffrey">Mary Caffrey</a><span class="jsx-ad50481d5ee26850 mr-1 ml-[1px]"> </span><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/maggie-l-shaw">Maggie L. Shaw</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/the-importance-of-treatment-sequencing-in-mantle-cell-lymphoma"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">We recently spoke with Tycel Phillips, MD, associate professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, about his team’s interim analysis of their dose-escalation study of glofitamab against relapsed/refractory B-cell non-Hodgkin lymphoma.</div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/da-epoch-rituximab-successfully-treating-pmbcl-in-a-transgender-woman"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/241bc75607121b543e32cbafca5a25a1e956e30f-1200x724.jpg?fit=crop&auto=format" alt="Lymphoma diagnosis | Image Credit: © Vitalii Vodolazskyi - stock.adobe.com" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">July 10th 2024</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/da-epoch-rituximab-successfully-treating-pmbcl-in-a-transgender-woman">DA-EPOCH-Rituximab: Successfully Treating PMBCL in a Transgender Woman</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/gayle-turim-dickstein">Gayle Turim Dickstein</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/da-epoch-rituximab-successfully-treating-pmbcl-in-a-transgender-woman"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">A case study describes the disparate factors that played into the chemotherapy and other treatment decisions made by a team in Japan when addressing their patient’s primary mediastinal large B-cell lymphoma (PMBCL).</div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/late-effects-of-car-t-cell-therapy-in-lymphoma"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/60a762ddea051a34205a8876249e3f8028aa5e74-1200x728.jpg?fit=crop&auto=format" alt="CART and gene therapy | Image Credit: ArtemisDiana-stock.adobe.com" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">July 9th 2024</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/late-effects-of-car-t-cell-therapy-in-lymphoma">Late Effects of CAR T-Cell Therapy in Lymphoma</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/kimberly-rath-pharmd">Kimberly Rath, PharmD</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/late-effects-of-car-t-cell-therapy-in-lymphoma"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">In this new analysis, investigators review the late adverse events associated with anti-CD19 chimeric antigen receptor (CAR) T-cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma.</div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/study-to-quantify-non-hodgkin-lymphoma-risk-in-hiv"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/010ed192a482703b2eb80f0fcb19407b06ab504b-1200x728.jpg?fit=crop&auto=format" alt="non-Hodgkin lymphoma | Image Credit: MQ-Illustrations-stock.adobe.com" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">July 6th 2024</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/study-to-quantify-non-hodgkin-lymphoma-risk-in-hiv">Study to Quantify Non-Hodgkin Lymphoma Risk in HIV</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/karen-jacobson-sive">Karen Jacobson-Sive</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/study-to-quantify-non-hodgkin-lymphoma-risk-in-hiv"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">This meta-analysis study will estimate the global and regional burden of HIV-associated non-Hodgkin lymphoma to aid the development of prevention and control strategies.</div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex md:hidden justify-center items-center"></div><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/vipor-novel-targeted-therapy-combination-shows-potential-in-relapsed-dlbcl"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/55e878efc551f05bedbb6f72d799e5d1d9c6ac11-1200x728.jpg?fit=crop&auto=format" alt="DLBCL | Image Credit: Image Credit: laszlo-stock.adobe.com" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">July 1st 2024</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/vipor-novel-targeted-therapy-combination-shows-potential-in-relapsed-dlbcl">ViPOR: Novel Targeted Therapy Combination Shows Potential in Relapsed DLBCL </a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/gayle-turim-dickstein">Gayle Turim Dickstein</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/vipor-novel-targeted-therapy-combination-shows-potential-in-relapsed-dlbcl"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">The 5 agents in ViPOR—including venetoclax and lenalidomide—worked better together in a phase 1b/2 trial than they previously have, individually, in treating patients with certain diffuse large B-cell lymphoma (DLBCL) subtypes. </div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/epcoritamab-gets-label-expansion-for-difficult-to-treat-r-r-follicular-lymphoma"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/2ca0e3cfdd22a31e0ffd78c9ba3b7bc976f74890-3873x3873.jpg?fit=crop&auto=format" alt="FDA approved | Image credit: ArtEternal – stock.adobe.com" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">June 27th 2024</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/epcoritamab-gets-label-expansion-for-difficult-to-treat-r-r-follicular-lymphoma">Epcoritamab Gets Label Expansion for Difficult-to-Treat R/R Follicular Lymphoma</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/hayden-e-klein">Hayden E. Klein</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/epcoritamab-gets-label-expansion-for-difficult-to-treat-r-r-follicular-lymphoma"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">The FDA approved epcoritamab-bysp to treat adults with relapsed or refractory (R/R) follicular lymphoma after 2 or more lines of systemic therapy.</div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div><div><div class="text-[8px] text-center text-gray-500 hidden">Advertisement</div><div id="div-gpt-ad-infeed-19"></div></div></div><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/polatuzumab-vedotin-review-spotlights-its-use-promise-in-dlbcl"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/d636e0b1d802d3df3660c9e263f854084e129057-1200x628.jpg?fit=crop&auto=format" alt="microscopic image of DLBCL | Image Credit: David A Litman-stock.adobe.com" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">June 17th 2024</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/polatuzumab-vedotin-review-spotlights-its-use-promise-in-dlbcl">Polatuzumab Vedotin: Review Spotlights Its Use, Promise in DLBCL</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/gayle-turim-dickstein">Gayle Turim Dickstein</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/polatuzumab-vedotin-review-spotlights-its-use-promise-in-dlbcl"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">With its recent approvals around the world to treat newly diagnosed and relapsed/refractory diffuse large B-cell lymphoma (DLBCL), the antibody-drug conjugate polatuzumab vedotin is changing regimens for current and future patients, with manageable adverse effects.</div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/dr-catherine-diefenbach-on-the-evolving-dlbcl-treatment-landscape"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/1e602bba35858bd62230432132517d1d42061e3d-1280x800.jpg?fit=crop&auto=format" alt="Medical technology | Image credit: ipopba - stock.adobe.com" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">June 14th 2024</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/dr-catherine-diefenbach-on-the-evolving-dlbcl-treatment-landscape">Dr Catherine Diefenbach on the Evolving DLBCL Treatment Landscape</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/rose-mcnulty">Rose McNulty</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/dr-catherine-diefenbach-on-the-evolving-dlbcl-treatment-landscape"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">Catherine Diefenbach, MD, an American Society of Hematology expert and director of the Clinical Lymphoma Program at NYU Langone's Perlmutter Cancer Center, discussed the evolving state of diffuse large B-cell lymphoma (DLBCL) therapeutics and exciting areas of research.</div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/case-reports-managing-dlbcl-associated-with-papillary-thyroid-carcinoma"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/be86ef6bccb9979df807ed51615e693b9e4a0a89-1200x800.jpg?fit=crop&auto=format" alt="Case Reports: Managing DLBCL Associated With Papillary Thyroid Carcinoma " width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">June 12th 2024</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/case-reports-managing-dlbcl-associated-with-papillary-thyroid-carcinoma">Case Reports: Managing DLBCL Associated With Papillary Thyroid Carcinoma </a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/kimberly-rath-pharmd">Kimberly Rath, PharmD</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/case-reports-managing-dlbcl-associated-with-papillary-thyroid-carcinoma"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">Case reports and systematic review found the combination of surgery, chemotherapy, and radiotherapy can effectively manage diffuse large B-cell lymphoma (DLBCL) associated with papillary thyroid carcinoma. </div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/obinutuzumab-and-radiation-combo-shows-promise-for-refractory-dlbcl"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/e825022f10d04a8c8b873d06455d4327ec5a3449-1200x800.jpg?fit=crop&auto=format" alt="Stethoscope chart graph data | Image Credit: © amazing studio - stock.adobe.com" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">June 7th 2024</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/obinutuzumab-and-radiation-combo-shows-promise-for-refractory-dlbcl">Obinutuzumab and Radiation Combo Shows Promise for Refractory DLBCL</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/kimberly-rath-pharmd">Kimberly Rath, PharmD</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/obinutuzumab-and-radiation-combo-shows-promise-for-refractory-dlbcl"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">A small retrospective study found that combining obinutuzumab with radiation therapy may offer a viable and well-tolerated treatment option for patients with refractory diffuse large B-cell lymphoma (DLBCL). </div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/how-the-tumor-microenvironment-affects-dlbcl-prognosis-treatment"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/be86ef6bccb9979df807ed51615e693b9e4a0a89-1200x800.jpg?fit=crop&auto=format" alt="dlbcl | Image Credit: laszlo-stock.adobe.com" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">June 3rd 2024</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/how-the-tumor-microenvironment-affects-dlbcl-prognosis-treatment">How the Tumor Microenvironment Affects DLBCL Prognosis, Treatment </a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/gayle-turim-dickstein">Gayle Turim Dickstein</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/how-the-tumor-microenvironment-affects-dlbcl-prognosis-treatment"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">Further acknowledgement and study of the tumor microenvironment in diffuse large B-cell lymphoma (DLBCL) could eventually result in much more personalized—and effective—treatments. </div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/key-features-of-rare-fibrin-assisted-diffuse-large-b-cell-lymphoma"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/14565e78f839b82f71b7c7b220c5d33d373e67b2-1200x724.jpg?fit=crop&auto=format" alt="Lymphoma word block image | Image Credit: © airdone - stock.adobe.com" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">May 27th 2024</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/key-features-of-rare-fibrin-assisted-diffuse-large-b-cell-lymphoma">Key Features of Rare Fibrin-Assisted Diffuse Large B-Cell Lymphoma</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/kimberly-rath-pharmd">Kimberly Rath, PharmD</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/key-features-of-rare-fibrin-assisted-diffuse-large-b-cell-lymphoma"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">A case study details the cytological and histological features of fibrin-assisted diffuse large B-cell lymphoma in a patient with no clinical symptoms, highlighting the diagnostic challenges of this condition.</div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div><div><div class="text-[8px] text-center text-gray-500 hidden">Advertisement</div><div id="div-gpt-ad-infeed-25"></div></div></div><div class="jsx-ad50481d5ee26850 flex md:hidden justify-center items-center"></div><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/ivig-shows-promise-in-protecting-older-patients-with-lymphoma-from-covid-19"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/9ae4cccd2425a595c476ba177f37bd90492eb355-1200x801.jpg?fit=crop&auto=format" alt="Nurse holding older woman's hands | Image Credit: © Cecilie Arcurs/peopleimages.com - stock.adobe.com" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">May 24th 2024</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/ivig-shows-promise-in-protecting-older-patients-with-lymphoma-from-covid-19">IVIG Shows Promise in Protecting Older Patients With Lymphoma From COVID-19</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/kimberly-rath-pharmd">Kimberly Rath, PharmD</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/ivig-shows-promise-in-protecting-older-patients-with-lymphoma-from-covid-19"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">Prophylactic intravenous immunoglobulin reduces COVID-19 infection rates in older patients with DLBCL with hypogammaglobulinemia undergoing reduced-intensity R-CHOP therapy.</div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/patient-physician-teamwork-treating-a-rare-oral-presentation-of-dlbcl"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/05a0a6fe2181863bf5f8b0c2d961e10600eb4aef-1200x724.jpg?fit=crop&auto=format" alt="Photomicrograph of a diffuse large B-cell lymphoma | Image Credit: ©DavidALitman - stock.adobe.com" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">May 16th 2024</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/patient-physician-teamwork-treating-a-rare-oral-presentation-of-dlbcl">Patient/Physician Teamwork: Treating a Rare Oral Presentation of DLBCL</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/gayle-turim-dickstein">Gayle Turim Dickstein</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/patient-physician-teamwork-treating-a-rare-oral-presentation-of-dlbcl"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">A very unusual case of lip-based diffuse large B-cell lymphoma (DLBCL) was treated successfully thanks to prompt diagnosis and chemotherapy treatments. </div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/study-care-costs-for-r-r-dlbcl-increase-with-each-line-of-therapy"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/5903e177f109160ec92a1fda6341609ca4dc7154-1280x789.jpg?fit=crop&auto=format" alt="Health costs | Image credit: utah51 - stock.adobe.com" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">May 8th 2024</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/study-care-costs-for-r-r-dlbcl-increase-with-each-line-of-therapy">Study: Care Costs for R/R DLBCL Increase With Each Line of Therapy</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/jared-kaltwasser">Jared Kaltwasser</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/study-care-costs-for-r-r-dlbcl-increase-with-each-line-of-therapy"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">New therapies are helping patients, but are also driving up overall costs of care.</div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/much-improved-outcomes-for-follicular-lymphoma-transformed-to-dlbcl-in-the-rituximab-era-study-finds"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/52e57b002a8ee4f36d0e991c03bd3f660fe2c87c-1200x724.jpg?fit=crop&auto=format" alt="Lymphoma graphic | Image Credit: © MP Studion - stock.adobe.com" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">May 2nd 2024</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/much-improved-outcomes-for-follicular-lymphoma-transformed-to-dlbcl-in-the-rituximab-era-study-finds">Much-Improved Outcomes for Follicular Lymphoma Transformed to DLBCL in the Rituximab Era, Study Finds</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/gayle-turim-dickstein">Gayle Turim Dickstein</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/much-improved-outcomes-for-follicular-lymphoma-transformed-to-dlbcl-in-the-rituximab-era-study-finds"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">Although histological transformation to diffuse large B-cell lymphoma (DLBCL) remains a common complication of follicular lymphoma, patient survival has increased significantly since the introduction of rituximab about 2 decades ago.</div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/polatuzumab-vedotin-and-r-chp-appropriate-for-untreated-dlbcl"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/20d163c7d750e5b10e32a841db89b682efaaabf4-1200x724.jpg?fit=crop&auto=format" alt="IV chemotherapy | Image Credit: Aidman - stock.adobe.com" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">April 24th 2024</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/polatuzumab-vedotin-and-r-chp-appropriate-for-untreated-dlbcl">Polatuzumab Vedotin and R-CHP Appropriate for Untreated DLBCL </a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/luke-halpern">Luke Halpern</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/polatuzumab-vedotin-and-r-chp-appropriate-for-untreated-dlbcl"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">Population pharmacokinetic and exposure-response analyses revealed a favorable benefit-risk profilane for the treatment combination of polatuzumab vedotin and rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP). </div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div><div class="jsx-ad50481d5ee26850 w-full h-full"><div class="jsx-ad50481d5ee26850 flex flex-col sm:flex-row justify-between my-4 "><a class="jsx-ad50481d5ee26850" href="/view/real-world-study-reveals-key-insights-into-dlbcl-treatment-patterns-outcomes"><img src="https://cdn.sanity.io/images/0vv8moc6/ajmc/bb6bc65988ebb2feb7711ac168d6dd6e58c3eb51-1200x724.jpg?fit=crop&auto=format" alt="Doctors discussing a case | Image Credit: DelmaineDonson - stock.adobe.com" width="288" class="jsx-ad50481d5ee26850 w-full xs:w-[288px] "/></a><div class="jsx-ad50481d5ee26850 article-detail flex flex-col gap-[0.2rem] w-full sm:w-[46%] md:w-[65%]"><span class="jsx-ad50481d5ee26850 font-bold article-publish-date block italic text-sm text-gray-500 mt-[1rem] sm:mt-0">April 18th 2024</span><p class="jsx-ad50481d5ee26850 article-title font-bold text-[1rem]"><a class="jsx-ad50481d5ee26850" href="/view/real-world-study-reveals-key-insights-into-dlbcl-treatment-patterns-outcomes">Real-World Study Reveals Key Insights Into DLBCL Treatment Patterns, Outcomes</a></p><div class="jsx-ad50481d5ee26850 authors flex-row wrap gap-[0.2rem]"><a class="jsx-ad50481d5ee26850 text-[#000] text-sm italic" href="/authors/kimberly-rath-pharmd">Kimberly Rath, PharmD</a></div><div class="jsx-ad50481d5ee26850 article-summary"><a class="jsx-ad50481d5ee26850" href="/view/real-world-study-reveals-key-insights-into-dlbcl-treatment-patterns-outcomes"><div class="jsx-ad50481d5ee26850 text-sm text-gray-500 py-1">A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management. </div></a></div></div></div><div style="border-bottom:1px solid #CCCCCC" class="jsx-ad50481d5ee26850"></div></div></div><div class="w-full text-center flex justify-center pb-24"><a class="px-4 py-2 border-y border-r bg-primary text-white" href="/compendium/nhl?page=1">1</a><a class="px-4 py-2 border-y border-r " href="/compendium/nhl?page=2">2</a><a class="px-4 py-2 border-y border-r " href="/compendium/nhl?page=3">3</a><a class="px-4 py-2 border-y border-r" href="/compendium/nhl?page=2">></a></div></div></div><div class="flex-none w-[300px] z-[9999] relative hidden md:block"><div style="top:5rem" class="sticky custom-spacing"><div class="collapse-container " style="overflow:hidden;max-height:900px;transition:max-height .4s ease-in-out"></div></div></div></div><div id="div-gpt-ad-pixel" style="width:1px;height:1px" class=""></div><noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-NK5KQXS" height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript><div id="footerOuterWrap" class=" mx-auto flex"><div class="bg-[#00598D] xl:w-[70%] w-[70%] py-12 pl-auto"><div class="xxl:w-[75%] w-[90%] ml-auto"><div><span style="box-sizing:border-box;display:inline-block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:relative;max-width:100%"><span style="box-sizing:border-box;display:block;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;max-width:100%"><img style="display:block;max-width:100%;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0" alt="" aria-hidden="true" src="data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%27300%27%20height=%2744%27/%3e"/></span><img alt="" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="intrinsic" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="" srcSet="/_next/image?url=%2Fan_mjhls_brand_ko.png&w=384&q=75 1x, /_next/image?url=%2Fan_mjhls_brand_ko.png&w=640&q=75 2x" src="/_next/image?url=%2Fan_mjhls_brand_ko.png&w=640&q=75" decoding="async" data-nimg="intrinsic" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" loading="lazy"/></noscript></span></div><div class="flex"><div class="flex justify-between pt-6"><div class="w-[40%]"><div class="text-footer-text-color text-xs"><p>2 Commerce Drive<br/>Suite 100<br/>Cranbury, NJ 08512</p></div><div class="self-start py-6" style="display:flex;flex-wrap:wrap"><a rel="noreferrer noopener" class="pr-1" target="_blank" href="https://www.facebook.com/TheAmericanJournalOfManagedCare"><p> <svg width='25px' height='25px' viewBox='0 0 512 512' version='1.1' xmlns='http://www.w3.org/2000/svg'> <g id='Page-1' stroke='none' strokeWidth='1' fill='none' fillRule='evenodd'> <g id='facebook' fill='#FFFFFF' fillRule='nonzero'> <path d='M512,256 C512,114.6 397.4,0 256,0 C114.6,0 0,114.6 0,256 C0,397.4 114.6,512 256,512 C257.5,512 259,512 260.5,511.9 L260.5,312.7 L205.5,312.7 L205.5,248.6 L260.5,248.6 L260.5,201.4 C260.5,146.7 293.9,116.9 342.7,116.9 C366.1,116.9 386.2,118.6 392,119.4 L392,176.6 L358.4,176.6 C331.9,176.6 326.7,189.2 326.7,207.7 L326.7,248.5 L390.2,248.5 L381.9,312.6 L326.7,312.6 L326.7,502.1 C433.7,471.4 512,372.9 512,256 Z' id='Path' /> </g> </g> </svg> </p></a><a rel="noreferrer noopener" class="pr-1" href="https://twitter.com/AJMC_Journal"><svg xmlns="http://www.w3.org/2000/svg" version="1.1" width="25" height="25" viewBox="1.41 1.41 252.9 252.9"><g transform="translate(1.4065934065934016 1.4065934065934016) scale(2.81 2.81)"><polygon points="24.89,23.01 57.79,66.99 65.24,66.99 32.34,23.01" fill="#FFFFFF" transform="matrix(1 0 0 1 0 0)"></polygon><path d="M 45 0 L 45 0 C 20.147 0 0 20.147 0 45 v 0 c 0 24.853 20.147 45 45 45 h 0 c 24.853 0 45 -20.147 45 -45 v 0 C 90 20.147 69.853 0 45 0 z M 56.032 70.504 L 41.054 50.477 L 22.516 70.504 h -4.765 L 38.925 47.63 L 17.884 19.496 h 16.217 L 47.895 37.94 l 17.072 -18.444 h 4.765 L 50.024 40.788 l 22.225 29.716 H 56.032 z" fill="#FFFFFF" transform="matrix(1 0 0 1 0 0)" stroke-linecap="round"></path></g></svg></a><a rel="noreferrer noopener" class="pr-1" target="_blank" href="https://www.linkedin.com/company/american-journal-of-managed-care/"><p> <svg width='25px' height='25px' viewBox='0 0 512 512' version='1.1' xmlns='http://www.w3.org/2000/svg'> <g id='Page-1' stroke='none' strokeWidth='1' fill='none' fillRule='evenodd'> <g id='linkedin' fill='#FFFFFF' fillRule='nonzero'> <path d='M256,0 C114.636719,0 0,114.636719 0,256 C0,397.363281 114.636719,512 256,512 C397.363281,512 512,397.363281 512,256 C512,114.636719 397.363281,0 256,0 Z M181.609375,387 L119.261719,387 L119.261719,199.425781 L181.609375,199.425781 L181.609375,387 Z M150.4375,173.8125 L150.03125,173.8125 C129.109375,173.8125 115.578125,159.410156 115.578125,141.410156 C115.578125,123.003906 129.523438,109 150.851562,109 C172.179688,109 185.304688,123.003906 185.710938,141.410156 C185.710938,159.410156 172.179688,173.8125 150.4375,173.8125 Z M406.421875,387 L344.082031,387 L344.082031,286.652344 C344.082031,261.433594 335.054688,244.234375 312.496094,244.234375 C295.273438,244.234375 285.015625,255.835938 280.507812,267.035156 C278.859375,271.042969 278.457031,276.644531 278.457031,282.25 L278.457031,387 L216.113281,387 C216.113281,387 216.929688,217.023438 216.113281,199.425781 L278.457031,199.425781 L278.457031,225.984375 C286.742188,213.203125 301.566406,195.023438 334.644531,195.023438 C375.664062,195.023438 406.421875,221.832031 406.421875,279.445312 L406.421875,387 Z' id='Shape' /> </g> </g> </svg> </p></a><a rel="noreferrer noopener" class="pr-1" target="_blank" href="https://www.instagram.com/ajmcjournal/"><p> <svg width='25px' height='25px' viewBox='0 0 512 512' version='1.1' xmlns='http://www.w3.org/2000/svg'> <g id='Page-1' stroke='none' strokeWidth='1' fill='none' fillRule='evenodd'> <g id='instagram' fill='#FFFFFF' fillRule='nonzero'> <path d='M305,256 C305,283.0625 283.0625,305 256,305 C228.9375,305 207,283.0625 207,256 C207,228.9375 228.9375,207 256,207 C283.0625,207 305,228.9375 305,256 Z' id='Path' /> <path d='M370.59375,169.304688 C368.238281,162.921875 364.480469,157.144531 359.597656,152.402344 C354.855469,147.519531 349.082031,143.761719 342.695312,141.40625 C337.515625,139.394531 329.734375,137 315.402344,136.347656 C299.898438,135.640625 295.25,135.488281 256,135.488281 C216.746094,135.488281 212.097656,135.636719 196.597656,136.34375 C182.265625,137 174.480469,139.394531 169.304688,141.40625 C162.917969,143.761719 157.140625,147.519531 152.402344,152.402344 C147.519531,157.144531 143.761719,162.917969 141.402344,169.304688 C139.390625,174.484375 136.996094,182.269531 136.34375,196.601562 C135.636719,212.101562 135.484375,216.75 135.484375,256.003906 C135.484375,295.253906 135.636719,299.902344 136.34375,315.40625 C136.996094,329.738281 139.390625,337.519531 141.402344,342.699219 C143.761719,349.085938 147.515625,354.859375 152.398438,359.601562 C157.140625,364.484375 162.914062,368.242188 169.300781,370.597656 C174.480469,372.613281 182.265625,375.007812 196.597656,375.660156 C212.097656,376.367188 216.742188,376.515625 255.996094,376.515625 C295.253906,376.515625 299.902344,376.367188 315.398438,375.660156 C329.730469,375.007812 337.515625,372.613281 342.695312,370.597656 C355.515625,365.652344 365.648438,355.519531 370.59375,342.699219 C372.605469,337.519531 375,329.738281 375.65625,315.40625 C376.363281,299.902344 376.511719,295.253906 376.511719,256.003906 C376.511719,216.75 376.363281,212.101562 375.65625,196.601562 C375.003906,182.269531 372.609375,174.484375 370.59375,169.304688 L370.59375,169.304688 Z M256,331.484375 C214.308594,331.484375 180.511719,297.691406 180.511719,256 C180.511719,214.308594 214.308594,180.515625 256,180.515625 C297.6875,180.515625 331.484375,214.308594 331.484375,256 C331.484375,297.691406 297.6875,331.484375 256,331.484375 Z M334.46875,195.171875 C324.726562,195.171875 316.828125,187.273438 316.828125,177.53125 C316.828125,167.789062 324.726562,159.890625 334.46875,159.890625 C344.210938,159.890625 352.109375,167.789062 352.109375,177.53125 C352.105469,187.273438 344.210938,195.171875 334.46875,195.171875 Z' id='Shape' /> <path d='M256,0 C114.636719,0 0,114.636719 0,256 C0,397.363281 114.636719,512 256,512 C397.363281,512 512,397.363281 512,256 C512,114.636719 397.363281,0 256,0 Z M402.113281,316.605469 C401.402344,332.253906 398.914062,342.9375 395.28125,352.289062 C387.644531,372.035156 372.035156,387.644531 352.289062,395.28125 C342.941406,398.914062 332.253906,401.398438 316.609375,402.113281 C300.933594,402.828125 295.925781,403 256.003906,403 C216.078125,403 211.074219,402.828125 195.394531,402.113281 C179.75,401.398438 169.0625,398.914062 159.714844,395.28125 C149.902344,391.589844 141.019531,385.804688 133.675781,378.324219 C126.199219,370.984375 120.414062,362.097656 116.722656,352.289062 C113.089844,342.941406 110.601562,332.253906 109.890625,316.609375 C109.167969,300.929688 109,295.921875 109,256 C109,216.078125 109.167969,211.070312 109.886719,195.394531 C110.597656,179.746094 113.082031,169.0625 116.714844,159.710938 C120.40625,149.902344 126.195312,141.015625 133.675781,133.675781 C141.015625,126.195312 149.902344,120.410156 159.710938,116.71875 C169.0625,113.085938 179.746094,110.601562 195.394531,109.886719 C211.070312,109.171875 216.078125,109 256,109 C295.921875,109 300.929688,109.171875 316.605469,109.890625 C332.253906,110.601562 342.9375,113.085938 352.289062,116.714844 C362.097656,120.40625 370.984375,126.195312 378.328125,133.675781 C385.804688,141.019531 391.59375,149.902344 395.28125,159.710938 C398.917969,169.0625 401.402344,179.746094 402.117188,195.394531 C402.832031,211.070312 403,216.078125 403,256 C403,295.921875 402.832031,300.929688 402.113281,316.605469 L402.113281,316.605469 Z' id='Shape' /> </g> </g> </svg> </p></a><a rel="noreferrer noopener" class="pr-1" target="_blank" href="/rss"><p><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:svgjs="http://svgjs.com/svgjs" version="1.1" width="25px" height="25px" x="0" y="0" viewBox="0 0 512 512" style="enable-background:new 0 0 512 512" xml:space="preserve"> <g> <path xmlns="http://www.w3.org/2000/svg" d="m437.019531 74.980469c-48.351562-48.351563-112.640625-74.980469-181.019531-74.980469s-132.667969 26.628906-181.019531 74.980469c-48.351563 48.351562-74.980469 112.640625-74.980469 181.019531s26.628906 132.667969 74.980469 181.019531c48.351562 48.351563 112.640625 74.980469 181.019531 74.980469s132.667969-26.628906 181.019531-74.980469c48.351563-48.351562 74.980469-112.640625 74.980469-181.019531s-26.628906-132.667969-74.980469-181.019531zm-267.757812 292.957031c-13.730469 0-24.90625-11.171875-24.90625-24.90625s11.175781-24.90625 24.90625-24.90625c13.734375 0 24.90625 11.171875 24.90625 24.90625s-11.171875 24.90625-24.90625 24.90625zm80.277343 4.925781c-8.28125 0-15-6.714843-15-15 0-44.171875-35.9375-80.109375-80.109374-80.109375-8.285157 0-15-6.71875-15-15 0-8.285156 6.714843-15 15-15 60.714843 0 110.109374 49.394532 110.109374 110.109375 0 8.285157-6.714843 15-15 15zm67.09375 0c-8.285156 0-15-6.714843-15-15 0-81.167969-66.035156-147.203125-147.203124-147.203125-8.285157 0-15-6.714844-15-15s6.714843-15 15-15c97.710937 0 177.203124 79.492188 177.203124 177.203125 0 8.285157-6.714843 15-15 15zm66.292969 0c-8.28125 0-15-6.714843-15-15 0-117.722656-95.773437-213.496093-213.496093-213.496093-8.285157 0-15-6.714844-15-15 0-8.285157 6.714843-15 15-15 65.039062 0 126.1875 25.328124 172.179687 71.316406 45.988281 45.992187 71.316406 107.140625 71.316406 172.179687 0 8.285157-6.714843 15-15 15zm0 0" fill="#ffffff" data-original="#000000" style=""/> </g> </svg></p></a></div><div class="text-footer-text-color text-xs"><p>© 2024 MJH Life Sciences<sup>®</sup> and AJMC®.<br/> All rights reserved.</p></div></div><div class="flex flex-row flex-wrap self-start w-[60%]"><div class="w-[50%] pb-3 px-2 my-0 cursor-pointer text-footer-text-color hover:text-footer-text-color/80 hover:underline"><a class="text-md" target="_self" href="/about-us">About</a></div><div class="w-[50%] pb-3 px-2 my-0 cursor-pointer text-footer-text-color hover:text-footer-text-color/80 hover:underline"><a class="text-md" target="_self" href="/contactus">Contact</a></div><div class="w-[50%] pb-3 px-2 my-0 cursor-pointer text-footer-text-color hover:text-footer-text-color/80 hover:underline"><a class="text-md" target="_self" href="/editorial-boards">Editorial Boards</a></div><div class="w-[50%] pb-3 px-2 my-0 cursor-pointer text-footer-text-color hover:text-footer-text-color/80 hover:underline"><a class="text-md" target="_self" href="/advertise">Advertise</a></div><div class="w-[50%] pb-3 px-2 my-0 cursor-pointer text-footer-text-color hover:text-footer-text-color/80 hover:underline"><a class="text-md" target="_blank" href="https://www.mjhlifesciences.com/ccpa?domain=www.ajmc.com">Do Not Sell My Information</a></div><div class="w-[50%] pb-3 px-2 my-0 cursor-pointer text-footer-text-color hover:text-footer-text-color/80 hover:underline"><a class="text-md" target="_self" href="/terms">Terms & Conditions</a></div><div class="w-[50%] pb-3 px-2 my-0 cursor-pointer text-footer-text-color hover:text-footer-text-color/80 hover:underline"><a class="text-md" target="_self" href="/privacy">Privacy Policy</a></div></div><div class="flex items-start mr-6 lg:mr-10"><span style="box-sizing:border-box;display:inline-block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:relative;max-width:100%"><span style="box-sizing:border-box;display:block;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;max-width:100%"><img style="display:block;max-width:100%;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0" alt="" aria-hidden="true" src="data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%27251%27%20height=%2768%27/%3e"/></span><img alt="AJMC Managed Markets Network Logo" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="intrinsic" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="AJMC Managed Markets Network Logo" srcSet="/_next/image?url=%2FAJMC_MMN_logo_light.png&w=256&q=75 1x, /_next/image?url=%2FAJMC_MMN_logo_light.png&w=640&q=75 2x" src="/_next/image?url=%2FAJMC_MMN_logo_light.png&w=640&q=75" decoding="async" data-nimg="intrinsic" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" loading="lazy"/></noscript></span></div></div></div></div></div><div class="w-[30%] bg-[#003767] flex items-center justify-center "><div class="flex flex-col justify-between "><a target="_self" rel="noopener noreferrer" class="my-2 px-8" href="/topic/center-on-health-equity-and-access"><span style="box-sizing:border-box;display:inline-block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:relative;max-width:100%"><span style="box-sizing:border-box;display:block;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;max-width:100%"><img style="display:block;max-width:100%;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0" alt="" aria-hidden="true" src="data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%27315%27%20height=%2777%27/%3e"/></span><img alt="CH Logo" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="intrinsic" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="CH Logo" srcSet="/_next/image?url=%2FCHA_Logo.png&w=384&q=75 1x, /_next/image?url=%2FCHA_Logo.png&w=640&q=75 2x" src="/_next/image?url=%2FCHA_Logo.png&w=640&q=75" decoding="async" data-nimg="intrinsic" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" loading="lazy"/></noscript></span></a><a target="_blank" rel="noopener noreferrer" class="my-2 px-8" href="https://www.centerforbiosimilars.com/"><span style="box-sizing:border-box;display:inline-block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:relative;max-width:100%"><span style="box-sizing:border-box;display:block;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;max-width:100%"><img style="display:block;max-width:100%;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0" alt="" aria-hidden="true" src="data:image/svg+xml,%3csvg%20xmlns=%27http://www.w3.org/2000/svg%27%20version=%271.1%27%20width=%27315%27%20height=%2777%27/%3e"/></span><img alt="Center for Biosimilars Logo" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="intrinsic" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%"/><noscript><img alt="Center for Biosimilars Logo" srcSet="/_next/image?url=%2FCB.png&w=384&q=75 1x, /_next/image?url=%2FCB.png&w=640&q=75 2x" src="/_next/image?url=%2FCB.png&w=640&q=75" decoding="async" data-nimg="intrinsic" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%" loading="lazy"/></noscript></span></a></div></div></div></div></div><script id="__NEXT_DATA__" type="application/json">{"props":{"pageProps":{"pageProps":{},"cache":{"main_menu":[{"_type":"mainNavigation","_id":"e8c503ba-34b9-43d5-8ce1-e8603c4e4b6b","_updatedAt":"2020-04-14T13:26:21Z","_createdAt":"2020-04-14T13:26:14Z","navParent":null,"sortOrder":1,"name":"News","is_active":true,"subQuery":[{"_updatedAt":"2020-04-14T13:30:35Z","navParent":{"_ref":"e8c503ba-34b9-43d5-8ce1-e8603c4e4b6b","_type":"reference"},"children":[],"is_active":true,"_rev":"sBk7YzjWMuBuhiatU3YIhQ","_id":"1376963d-32e8-4647-bb5e-59c984e35893","url":"/news","_createdAt":"2020-04-14T13:30:35Z","_type":"mainNavigation","name":"All News"},{"_type":"mainNavigation","name":"Press Releases","_createdAt":"2020-04-14T13:30:57Z","_id":"2af5da5e-78c2-42c8-90b8-3900f8c89889","_updatedAt":"2020-04-14T13:30:57Z","is_active":true,"_rev":"QxOJBWa4XErmibN6Cb5OcA","url":"/press-release","navParent":{"_ref":"e8c503ba-34b9-43d5-8ce1-e8603c4e4b6b","_type":"reference"},"children":[]},{"_updatedAt":"2022-01-07T20:44:44Z","_rev":"jvOgZ3KZdbRHfWlt9ePmOA","navParent":{"_ref":"e8c503ba-34b9-43d5-8ce1-e8603c4e4b6b","_type":"reference"},"_type":"mainNavigation","is_active":true,"children":[],"_createdAt":"2021-07-29T12:15:49Z","name":"Product Approvals and Launches","_id":"854a1ad1-9831-4387-bda9-ffb93a074ace","url":"/approvals-launches"}],"_rev":"Yw6MEKZDMdk6hC2JCRdGN7"},{"_rev":"rcwwj6TiN2Q0ymhqDzIFjO","name":"Video","navParent":null,"subQuery":[{"_updatedAt":"2024-05-24T16:52:54Z","is_active":true,"sortOrder":1,"children":[],"navParent":{"_ref":"821e259a-db55-4862-985a-5cd089bbf894","_type":"reference"},"_createdAt":"2024-05-24T16:37:06Z","_rev":"rcwwj6TiN2Q0ymhqDzJ8ty","_type":"mainNavigation","name":"All Video Types","_id":"f51d85fa-cabc-4c7d-85d0-11301088b7f6","url":"/video-hub"},{"_type":"mainNavigation","name":"AJMC TV","url":"/interviews","_id":"a99a3683-5173-46b3-94b0-21b7d6b06a24","children":[],"is_active":true,"navParent":{"_ref":"821e259a-db55-4862-985a-5cd089bbf894","_type":"reference"},"_updatedAt":"2024-05-28T19:38:54Z","_createdAt":"2024-05-24T16:38:14Z","_rev":"LJrwYxwtzLC9JsOYMk8TBr"},{"_id":"b03ccbf6-6387-48de-8edc-4f1f23debe40","_updatedAt":"2020-04-14T13:43:45Z","_rev":"Yw6MEKZDMdk6hC2JCRda8Z","_type":"mainNavigation","_createdAt":"2020-04-14T13:43:45Z","name":"Insights","children":[],"is_active":true,"url":"/insights","navParent":{"_ref":"821e259a-db55-4862-985a-5cd089bbf894","_type":"reference"}},{"_createdAt":"2020-04-14T13:44:19Z","_rev":"k6N5FycA5UhVnvpzSEa3Rp","_updatedAt":"2020-04-14T13:44:19Z","navParent":{"_ref":"821e259a-db55-4862-985a-5cd089bbf894","_type":"reference"},"children":[],"_type":"mainNavigation","name":"OnLocation","_id":"f3d69d10-636b-4927-8ff4-4f54fabc940a","url":"/onlocation","is_active":true},{"_createdAt":"2022-10-05T15:29:11Z","is_active":true,"navParent":{"_ref":"821e259a-db55-4862-985a-5cd089bbf894","_type":"reference"},"name":"Payer Perspectives","url":"/payer-perspectives","_type":"mainNavigation","_rev":"37PW14Mg02p9z7FTF1SGE9","_id":"d4e3d69c-8a07-4191-af89-27d7e838af08","_updatedAt":"2022-10-05T15:29:11Z","children":[]},{"_createdAt":"2020-04-14T13:44:43Z","_id":"8f602f1e-1840-4c32-8cdb-9a26d6c0e873","_updatedAt":"2020-04-14T13:44:43Z","navParent":{"_ref":"821e259a-db55-4862-985a-5cd089bbf894","_type":"reference"},"_rev":"VdTcsTJkAuZveXGf2i9Pes","is_active":true,"url":"/peer-exchange","_type":"mainNavigation","name":"Peer Exchange","children":[]},{"_updatedAt":"2024-05-24T18:27:43Z","_type":"mainNavigation","url":"/post-conference-perspectives","is_active":true,"children":[],"_createdAt":"2024-05-24T18:27:43Z","navParent":{"_ref":"821e259a-db55-4862-985a-5cd089bbf894","_type":"reference"},"_rev":"Jz2W7keLhiw1UYkGHgA51N","name":"Post Conference Perspectives","_id":"0f532685-cd4c-4350-89cd-b8a388e6495b"},{"_id":"bbc55ff8-1532-475e-9f51-f9d5eb39e369","_updatedAt":"2020-12-01T22:43:26Z","children":[],"_createdAt":"2020-12-01T22:43:10Z","_type":"mainNavigation","url":"/stakeholder-summit","is_active":true,"navParent":{"_ref":"821e259a-db55-4862-985a-5cd089bbf894","_type":"reference"},"_rev":"y3lsbm3yQTliOnC9CU5TiR","name":"Stakeholder Summit"}],"_type":"mainNavigation","_id":"821e259a-db55-4862-985a-5cd089bbf894","_updatedAt":"2024-05-24T16:36:15Z","is_active":true,"_createdAt":"2020-04-14T13:26:30Z","sortOrder":2},{"sortOrder":3,"is_active":true,"_createdAt":"2024-05-24T16:40:58Z","_updatedAt":"2024-05-24T16:41:18Z","navParent":null,"subQuery":[],"url":"/podcasts","_rev":"rcwwj6TiN2Q0ymhqDzIUb7","name":"Podcasts","_id":"4939ee15-ae6f-4aba-8481-9ee27ce729d3","_type":"mainNavigation"},{"_createdAt":"2020-04-14T13:27:01Z","sortOrder":4,"_rev":"rcwwj6TiN2Q0ymhqDzIVAU","name":"Conferences","_updatedAt":"2024-05-24T16:41:40Z","is_active":true,"_type":"mainNavigation","_id":"6841664a-93f2-4f56-8760-836ec9c7b483","navParent":null,"subQuery":[{"name":"Conference Coverage","_type":"mainNavigation","url":"/latest-conference","navParent":{"_ref":"6841664a-93f2-4f56-8760-836ec9c7b483","_type":"reference"},"children":[],"_updatedAt":"2020-08-21T22:11:23Z","is_active":true,"_createdAt":"2020-06-12T15:17:29Z","sortOrder":1,"_id":"f45b532b-23e3-4b44-8d7f-2f3c13c9ae81","_rev":"pI9SawGKsTP14Lioy589Kx"},{"is_active":true,"_rev":"FxFuWbqTkFGbPWgBBSR6xp","_id":"004461ae-46cb-45ef-916e-f03c6d99d6d3","_updatedAt":"2020-06-12T15:19:26Z","url":"/conference","children":[],"navParent":{"_ref":"6841664a-93f2-4f56-8760-836ec9c7b483","_type":"reference"},"_createdAt":"2020-06-12T15:18:28Z","sortOrder":2,"_type":"mainNavigation","name":"Conference Listing"},{"is_active":true,"_createdAt":"2024-07-03T19:00:13Z","_type":"mainNavigation","name":"Post Conference Perspectives","sortOrder":3,"_id":"a006d0df-0cc9-4386-abfb-b1931a3918d4","url":"/post-conference-perspectives","navParent":{"_ref":"6841664a-93f2-4f56-8760-836ec9c7b483","_type":"reference"},"_rev":"ZU3dXbR1BZtBbbPuRGxz53","_updatedAt":"2024-07-03T19:00:13Z","children":[]}]},{"sortOrder":5,"navParent":null,"subQuery":[{"_updatedAt":"2024-05-24T16:42:23Z","_createdAt":"2020-05-04T21:06:00Z","sortOrder":1,"_id":"48193abd-ecf4-4c90-b0ae-984ca2be88c9","is_active":true,"navParent":{"_type":"reference","_ref":"94f13109-c3cc-47b5-bf49-96ed727c8150"},"_type":"mainNavigation","name":"All Journals","url":"/publications","_rev":"rcwwj6TiN2Q0ymhqDzIVyQ","children":[]},{"_type":"mainNavigation","_createdAt":"2020-04-14T13:55:29Z","_rev":"rcwwj6TiN2Q0ymhqDzIWug","navParent":{"_ref":"94f13109-c3cc-47b5-bf49-96ed727c8150","_type":"reference"},"children":[],"_id":"08081ddf-ffd8-4b17-a2ff-dfe6a0ac64a3","sortOrder":2,"name":"The American Journal of Managed Care","url":"/publications/issue","is_active":true,"_updatedAt":"2024-05-24T16:42:39Z"},{"name":"Population Health, Equity \u0026 Outcomes","_createdAt":"2020-04-14T13:56:01Z","sortOrder":3,"is_active":true,"navParent":{"_ref":"94f13109-c3cc-47b5-bf49-96ed727c8150","_type":"reference"},"_id":"47782239-2714-4bd1-99e6-750443bd39ea","_updatedAt":"2024-09-16T13:23:11Z","url":"/publications/ajac","_rev":"4fso9RuTzczLhlxmnMQ1bu","_type":"mainNavigation","children":[]},{"_updatedAt":"2024-05-24T16:43:12Z","children":[],"navParent":{"_ref":"94f13109-c3cc-47b5-bf49-96ed727c8150","_type":"reference"},"_rev":"uJbbwQWkLESsncBrcLL4uf","sortOrder":4,"_id":"b99cc54f-5801-46e9-bd20-e690623ed12c","_type":"mainNavigation","is_active":true,"name":"Evidence-Based Oncology","url":"/publications/evidence-based-oncology","_createdAt":"2020-04-14T13:56:21Z"},{"url":"/supplement","_createdAt":"2024-05-23T20:59:41Z","_id":"6e7e3485-ef8b-40e3-8320-3c434df6bbb5","_updatedAt":"2024-05-24T16:43:26Z","children":[],"name":"About Supplements and Featured Publications","_type":"mainNavigation","navParent":{"_ref":"94f13109-c3cc-47b5-bf49-96ed727c8150","_type":"reference"},"sortOrder":5,"is_active":true,"_rev":"rcwwj6TiN2Q0ymhqDzIY1L"},{"url":"/publications/supplement","_type":"mainNavigation","_rev":"uJbbwQWkLESsncBrcLL5w0","name":"Supplements and Featured Publications Issues","_id":"a2112c87-8e92-4b64-b42d-3117117f67a3","is_active":true,"sortOrder":6,"children":[],"_updatedAt":"2024-05-24T16:43:32Z","navParent":{"_ref":"94f13109-c3cc-47b5-bf49-96ed727c8150","_type":"reference"},"_createdAt":"2020-04-14T13:56:51Z"},{"_rev":"rcwwj6TiN2Q0ymhqDzIYDp","_updatedAt":"2024-05-24T16:43:38Z","is_active":true,"sortOrder":7,"children":[],"_id":"fa8c9edc-3d32-4e9e-b68b-47d5c15694a5","url":"/submit-a-manuscript","navParent":{"_ref":"94f13109-c3cc-47b5-bf49-96ed727c8150","_type":"reference"},"_createdAt":"2023-03-14T13:29:11Z","_type":"mainNavigation","name":"Submit a Manuscript"}],"_type":"mainNavigation","_updatedAt":"2024-05-24T16:41:49Z","is_active":true,"_createdAt":"2020-04-14T13:27:20Z","_rev":"uJbbwQWkLESsncBrcLL0hr","name":"Journals","_id":"94f13109-c3cc-47b5-bf49-96ed727c8150"},{"is_active":true,"navParent":null,"subQuery":[{"url":"/ivbmevents","_type":"mainNavigation","name":"Institute for Value-Based Medicine","is_active":true,"_updatedAt":"2024-05-24T18:26:23Z","children":[],"navParent":{"_ref":"ad5c19be-040c-4ea8-b639-807f54c9a1aa","_type":"reference"},"_rev":"Jz2W7keLhiw1UYkGHgA4Yf","_id":"de4fe195-3db9-4d12-842d-f26100fbea5b","_createdAt":"2024-05-24T16:44:43Z"},{"_updatedAt":"2024-05-24T18:26:42Z","url":"https://pcoc.ajmc.com/","is_active":true,"children":[],"name":"Patient-Centered Oncology Care","navParent":{"_ref":"ad5c19be-040c-4ea8-b639-807f54c9a1aa","_type":"reference"},"_createdAt":"2024-05-24T16:45:02Z","_rev":"Jz2W7keLhiw1UYkGHgA4eP","_type":"mainNavigation","_id":"dddfc37d-8958-4e0a-91e3-0634bb6502a3"}],"_type":"mainNavigation","_id":"ad5c19be-040c-4ea8-b639-807f54c9a1aa","_updatedAt":"2020-05-08T20:03:10Z","_createdAt":"2020-04-14T13:27:17Z","name":"Events","url":"/events","sortOrder":6,"_rev":"8ZvheBjSwe5Dc4gCmgsR0M"},{"_id":"86b03e38-f3d2-41d1-89e7-c3175c571a55","is_active":true,"_createdAt":"2020-04-14T13:29:34Z","navParent":null,"subQuery":[{"navParent":{"_ref":"86b03e38-f3d2-41d1-89e7-c3175c571a55","_type":"reference"},"sortOrder":1,"_id":"4a08b5fc-379c-4952-bec1-0d9dacb11170","_rev":"rcwwj6TiN2Q0ymhqDzIfXP","_updatedAt":"2024-05-24T16:46:13Z","url":"/interactive-tools","children":[],"is_active":true,"_createdAt":"2020-04-14T13:51:39Z","name":"Interactive Tools","_type":"mainNavigation"},{"_rev":"rcwwj6TiN2Q0ymhqDyFVrf","name":"Clinical Spotlight","_updatedAt":"2024-05-23T20:32:07Z","is_active":true,"navParent":{"_ref":"86b03e38-f3d2-41d1-89e7-c3175c571a55","_type":"reference"},"_type":"mainNavigation","children":[],"url":"/clinical-spotlight","_id":"43960f88-0c8d-404b-b9d9-d90432c2c516","_createdAt":"2020-10-16T13:03:47Z"},{"is_active":true,"navParent":{"_ref":"86b03e38-f3d2-41d1-89e7-c3175c571a55","_type":"reference"},"_type":"mainNavigation","_updatedAt":"2024-05-24T16:46:44Z","name":"Microsites","url":"/custom-email","_createdAt":"2024-05-24T16:46:44Z","_id":"38aa3af0-8a34-4ae6-898c-37214580d384","_rev":"rcwwj6TiN2Q0ymhqDzIhDR","children":[]},{"_type":"mainNavigation","name":"Sponsored Content","url":"/sponsored","_createdAt":"2024-05-24T16:47:05Z","is_active":true,"children":[],"_rev":"rcwwj6TiN2Q0ymhqDzIiDr","navParent":{"_ref":"86b03e38-f3d2-41d1-89e7-c3175c571a55","_type":"reference"},"_updatedAt":"2024-05-24T16:47:05Z","_id":"d0b0683f-18e1-4e75-89fd-fb4e578a562f"}],"_rev":"rcwwj6TiN2Q0ymhqDzIdco","_type":"mainNavigation","name":"Resources","_updatedAt":"2024-05-24T16:45:37Z","sortOrder":7},{"_createdAt":"2020-04-14T14:00:08Z","_type":"mainNavigation","_rev":"LtkInV1jlQdtEIFjVpi9sG","_updatedAt":"2024-08-27T15:31:04Z","navParent":null,"name":"CE","url":"/continuing-education","is_active":true,"sortOrder":8,"_id":"621fccf5-dcdb-40a9-af70-9bf3ccf79278","subQuery":[]},{"name":"About AJMC","_id":"c14e4637-909c-4bf6-bf81-64eeb6005352","navParent":null,"sortOrder":9,"_rev":"rcwwj6TiN2Q0ymhqDzIlc0","subQuery":[{"navParent":{"_ref":"c14e4637-909c-4bf6-bf81-64eeb6005352","_type":"reference"},"_type":"mainNavigation","_updatedAt":"2024-05-24T19:05:57Z","_rev":"Jz2W7keLhiw1UYkGHgBp6D","name":"AJMC Staff","_id":"be637b3b-f72a-4049-91b8-409809b2d815","children":[],"url":"/editorial","_createdAt":"2024-05-24T19:05:57Z","is_active":true},{"navParent":{"_ref":"c14e4637-909c-4bf6-bf81-64eeb6005352","_type":"reference"},"_type":"mainNavigation","name":"Anniversary","_createdAt":"2024-05-24T16:48:30Z","children":[],"_rev":"rcwwj6TiN2Q0ymhqDzIn5Y","_id":"5298152f-5135-4c2c-a46e-a14ad0300bf4","_updatedAt":"2024-05-24T16:48:30Z","url":"/anniversary","is_active":true},{"_type":"mainNavigation","name":"Seema Sonnad Award","_id":"28d33143-d9a9-45bd-af63-bed8d2198118","_updatedAt":"2024-07-23T13:38:48Z","url":"/about/seema-sonnad-nomination","is_active":true,"navParent":{"_type":"reference","_ref":"c14e4637-909c-4bf6-bf81-64eeb6005352"},"_rev":"AGf4LvcO2r7q1La1cjR7dD","_createdAt":"2024-05-24T18:24:23Z","children":[]},{"_updatedAt":"2024-05-24T16:49:00Z","_type":"mainNavigation","children":[],"_id":"acb7dc53-dfab-462a-b2e9-b0cfc8675da4","navParent":{"_ref":"c14e4637-909c-4bf6-bf81-64eeb6005352","_type":"reference"},"name":"Strategic Alliance Partners","_createdAt":"2024-05-24T16:49:00Z","_rev":"uJbbwQWkLESsncBrcLLVEZ","url":"/partners","is_active":true}],"_type":"mainNavigation","_updatedAt":"2024-05-24T16:48:11Z","is_active":true,"_createdAt":"2024-05-24T16:48:11Z"},{"_updatedAt":"2024-03-11T14:58:15Z","blank":true,"is_active":true,"_rev":"gFXie0Ldruy1o91XppbLLd","_type":"mainNavigation","name":"Subscribe","_id":"1e279576-0b33-4e57-8782-b6b1edbf68da","sortOrder":9,"_createdAt":"2020-06-22T20:56:33Z","url":"https://one.ajmc.com/subscribe","navParent":null,"subQuery":[]}],"sub_menu":[{"sortOrder":1,"_id":"97a2a8fe-1a67-45d7-b1f8-294ab1f64c1e","url":"/compendium","is_active":true,"subQuery":[{"_createdAt":"2024-05-24T05:06:44Z","_type":"subNavigation","name":"Biosimilars","navParent":{"_ref":"97a2a8fe-1a67-45d7-b1f8-294ab1f64c1e","_type":"reference"},"is_active":true,"children":[],"url":"/compendium/biosimilars","_rev":"Jz2W7keLhiw1UYkGHfbM3A","_id":"aa3904f3-c0d8-495d-a77f-afcc41f27045","_updatedAt":"2024-05-24T05:06:44Z"},{"_updatedAt":"2024-06-11T20:17:38Z","is_active":true,"_rev":"G7uWgc8ggxb5zBvm8zNQqB","_id":"6c47e32a-ae7f-4f3a-92e2-c99d54ae28ab","navParent":{"_ref":"97a2a8fe-1a67-45d7-b1f8-294ab1f64c1e","_type":"reference"},"_createdAt":"2024-05-24T05:30:27Z","_type":"subNavigation","name":"Cardiorenalmetabolic","children":[{"_updatedAt":"2024-05-24T05:30:54Z","navParent":{"_ref":"6c47e32a-ae7f-4f3a-92e2-c99d54ae28ab","_type":"reference"},"_id":"c3566f20-e7c6-4b38-bf9f-7d52055698b1","_rev":"Jz2W7keLhiw1UYkGHfbquf","_type":"subNavigation","name":"Cardiovascular","url":"/compendium/cardiovascular","is_active":true,"_createdAt":"2024-05-24T05:30:54Z"},{"is_active":true,"navParent":{"_ref":"6c47e32a-ae7f-4f3a-92e2-c99d54ae28ab","_type":"reference"},"_createdAt":"2024-05-24T05:32:42Z","_id":"f3a69e16-dc38-4135-886e-d70e18532bf4","_rev":"Jz2W7keLhiw1UYkGHfbumO","_type":"subNavigation","name":"Chronic Kidney Disease","_updatedAt":"2024-05-24T05:32:42Z","url":"/compendium/ckd"},{"name":"Diabetes","_updatedAt":"2024-05-24T05:31:14Z","is_active":true,"_type":"subNavigation","_rev":"Jz2W7keLhiw1UYkGHfbrEl","_id":"79c02dc8-3c2d-451b-9797-008b25d61d4d","url":"/compendium/diabetes","navParent":{"_type":"reference","_ref":"6c47e32a-ae7f-4f3a-92e2-c99d54ae28ab"},"_createdAt":"2024-05-24T05:31:14Z"},{"is_active":true,"navParent":{"_ref":"6c47e32a-ae7f-4f3a-92e2-c99d54ae28ab","_type":"reference"},"_type":"subNavigation","_id":"84c7dd54-fb21-4bc5-86bc-9bbf39a7f836","_updatedAt":"2024-05-24T05:31:38Z","url":"/compendium/heart-failure","_createdAt":"2024-05-24T05:31:38Z","_rev":"Jz2W7keLhiw1UYkGHfbrQF","name":"Heart Failure"},{"is_active":true,"_rev":"Jz2W7keLhiw1UYkGHfbsbS","_id":"aadd9bdc-4dd1-4ac1-be4f-2afb4315b6cb","name":"Type 1 Diabetes","_updatedAt":"2024-05-24T05:32:00Z","url":"/compendium/type1diabetes","navParent":{"_ref":"6c47e32a-ae7f-4f3a-92e2-c99d54ae28ab","_type":"reference"},"_createdAt":"2024-05-24T05:32:00Z","_type":"subNavigation"}]},{"is_active":true,"_rev":"Jz2W7keLhiw1UYkGHfbSVf","_updatedAt":"2024-05-24T05:10:35Z","children":[{"_type":"subNavigation","_id":"04523862-a8a1-4626-b288-95b3d4114267","_updatedAt":"2024-05-24T05:12:43Z","url":"/compendium/alopecia","_createdAt":"2024-05-23T21:42:49Z","_rev":"Jz2W7keLhiw1UYkGHfbTPe","name":"Alopecia","is_active":true,"navParent":{"_ref":"7599f50b-36ff-42a5-8d72-82814db9b988","_type":"reference"}},{"is_active":true,"_rev":"Jz2W7keLhiw1UYkGHfbSvV","_type":"subNavigation","name":"Atopic Dermatitis","_id":"637a0b1e-1b12-42bf-81a3-e6db5a997021","_updatedAt":"2024-05-24T05:12:02Z","url":"/compendium/atopic-dermatitis","navParent":{"_ref":"7599f50b-36ff-42a5-8d72-82814db9b988","_type":"reference"},"_createdAt":"2024-05-24T05:12:02Z"},{"_rev":"Jz2W7keLhiw1UYkGHfbTJu","_type":"subNavigation","is_active":true,"navParent":{"_ref":"7599f50b-36ff-42a5-8d72-82814db9b988","_type":"reference"},"_id":"a9dcce80-4f29-488e-b7ef-51f0fb562a5a","_updatedAt":"2024-05-24T05:12:36Z","url":"/compendium/psoriasis","_createdAt":"2024-05-24T05:12:30Z","name":"Psoriasis"}],"_type":"subNavigation","name":"Dermatology","url":"/compendium/dermatology","_createdAt":"2024-05-24T05:10:35Z","navParent":{"_ref":"97a2a8fe-1a67-45d7-b1f8-294ab1f64c1e","_type":"reference"},"_id":"7599f50b-36ff-42a5-8d72-82814db9b988"},{"_createdAt":"2024-05-24T05:13:48Z","_type":"subNavigation","_id":"d1c6a8fa-d54d-4aa5-84e5-0e1ee2b639d4","navParent":{"_ref":"97a2a8fe-1a67-45d7-b1f8-294ab1f64c1e","_type":"reference"},"_rev":"Jz2W7keLhiw1UYkGHfbU3q","name":"Hematology","_updatedAt":"2024-05-24T05:13:48Z","children":[{"navParent":{"_ref":"d1c6a8fa-d54d-4aa5-84e5-0e1ee2b639d4","_type":"reference"},"_rev":"Iat2IZiT321TmGHwkF66wB","_id":"d79f2b30-e7f2-4915-bef8-1a73a9190a91","_updatedAt":"2024-05-29T15:28:26Z","is_active":true,"_createdAt":"2024-05-29T15:28:26Z","_type":"subNavigation","name":"ALL/AML","url":"/compendium/all"},{"_id":"664a6ece-64dd-41f8-87a0-7f5a47323c3b","_rev":"Iat2IZiT321TmGHwkF65Md","_type":"subNavigation","name":"CLL/SLL","_updatedAt":"2024-05-29T15:27:46Z","url":"/compendium/cll","is_active":true,"navParent":{"_ref":"d1c6a8fa-d54d-4aa5-84e5-0e1ee2b639d4","_type":"reference"},"_createdAt":"2024-05-29T15:26:57Z"},{"_createdAt":"2024-05-29T15:28:51Z","_type":"subNavigation","name":"GVHD","url":"/compendium/gvhd","_updatedAt":"2024-05-29T15:28:51Z","is_active":true,"navParent":{"_ref":"d1c6a8fa-d54d-4aa5-84e5-0e1ee2b639d4","_type":"reference"},"_rev":"Iat2IZiT321TmGHwkF67tn","_id":"32cf626c-1ce6-4fb5-9dd7-088522dc46e6"},{"_id":"4dd2ce64-8f4d-4285-bc1a-ec40ffc99b51","_updatedAt":"2024-05-24T05:14:15Z","url":"/compendium/hemophilia","_createdAt":"2024-05-24T05:14:15Z","_type":"subNavigation","name":"Hemophilia","is_active":true,"navParent":{"_ref":"d1c6a8fa-d54d-4aa5-84e5-0e1ee2b639d4","_type":"reference"},"_rev":"Jz2W7keLhiw1UYkGHfbUDt"},{"is_active":true,"navParent":{"_ref":"d1c6a8fa-d54d-4aa5-84e5-0e1ee2b639d4","_type":"reference"},"_updatedAt":"2024-05-29T15:35:07Z","url":"/compendium/multiple-myeloma","_createdAt":"2024-05-24T05:45:17Z","_rev":"Iat2IZiT321TmGHwkF6NtX","_type":"subNavigation","name":"Multiple Myeloma","_id":"84e2d674-0fe1-4bd1-9d97-2f8bc8589ba0"},{"url":"/compendium/myelodysplastic-syndromes","is_active":true,"_createdAt":"2024-05-24T05:45:36Z","_rev":"Iat2IZiT321TmGHwkF6a5X","_type":"subNavigation","name":"Myelodysplastic Syndromes","_id":"3a327f90-a5fc-4d87-9a18-02f54cb40b8e","_updatedAt":"2024-05-29T15:35:22Z","navParent":{"_type":"reference","_ref":"d1c6a8fa-d54d-4aa5-84e5-0e1ee2b639d4"}},{"_type":"subNavigation","name":"Myeloproliferative Neoplasms","_id":"a6003c4f-e7f0-422a-8129-49a2d78eb113","is_active":true,"_createdAt":"2024-05-29T15:29:21Z","_updatedAt":"2024-06-05T20:02:27Z","url":"/compendium/mpn","navParent":{"_ref":"d1c6a8fa-d54d-4aa5-84e5-0e1ee2b639d4","_type":"reference"},"_rev":"Up1TL5YPo1fhI8V2tpNnMb"},{"name":"Non-Hodgkin Lymphoma","_id":"fc247a6b-0b33-4e18-ae78-56e677c6bb18","_updatedAt":"2024-06-25T17:42:12Z","_rev":"rmdpbbz4U7GL9ExaGp96DY","navParent":{"_ref":"d1c6a8fa-d54d-4aa5-84e5-0e1ee2b639d4","_type":"reference"},"_createdAt":"2024-05-24T05:43:54Z","_type":"subNavigation","url":"/compendium/nhl","is_active":true},{"navParent":{"_ref":"d1c6a8fa-d54d-4aa5-84e5-0e1ee2b639d4","_type":"reference"},"_createdAt":"2024-05-24T05:14:40Z","_type":"subNavigation","name":"Rare Blood","_id":"85e2fc3e-ac5c-4b47-8b14-411d730d20d9","is_active":true,"_rev":"Jz2W7keLhiw1UYkGHfbUPN","_updatedAt":"2024-05-24T05:14:40Z","url":"/compendium/rareblood"}],"url":"/compendium/hematology","is_active":true},{"navParent":{"_ref":"97a2a8fe-1a67-45d7-b1f8-294ab1f64c1e","_type":"reference"},"children":[{"_createdAt":"2024-05-24T05:34:54Z","_rev":"Jz2W7keLhiw1UYkGHfbwkP","_id":"2aefee8c-db97-4e7d-b600-efb48e6bcb6c","_updatedAt":"2024-05-24T05:34:54Z","url":"/compendium/liver-cancer","is_active":true,"navParent":{"_ref":"a96e7dbc-b037-41f4-bd5e-d96abf8f3c7d","_type":"reference"},"_type":"subNavigation","name":"Liver"}],"_type":"subNavigation","name":"Hepatology","_id":"a96e7dbc-b037-41f4-bd5e-d96abf8f3c7d","_createdAt":"2024-05-24T05:34:29Z","_rev":"N7mKycgLbGtEq6btkLqjkf","_updatedAt":"2024-06-11T20:17:54Z","is_active":true},{"children":[{"is_active":true,"_rev":"Jz2W7keLhiw1UYkGHfbkp8","name":"Autoimmune","_updatedAt":"2024-05-24T05:23:39Z","navParent":{"_type":"reference","_ref":"1b1e3727-8b82-42da-9a62-b20472b9c797"},"_createdAt":"2024-05-24T05:23:39Z","_type":"subNavigation","_id":"b3daefd0-0ac3-4be2-ad23-f9c3fa37cf37","url":"/compendium/autoimmune"},{"_rev":"Jz2W7keLhiw1UYkGHfbkzB","_type":"subNavigation","_updatedAt":"2024-05-24T05:23:59Z","is_active":true,"navParent":{"_ref":"1b1e3727-8b82-42da-9a62-b20472b9c797","_type":"reference"},"_createdAt":"2024-05-24T05:23:59Z","name":"Inflammation","_id":"6016d41d-9d43-49fa-99b6-7caca304f30d","url":"/compendium/Inflammation"},{"is_active":true,"navParent":{"_ref":"1b1e3727-8b82-42da-9a62-b20472b9c797","_type":"reference"},"name":"Lupus","_createdAt":"2024-05-24T05:24:47Z","_rev":"Jz2W7keLhiw1UYkGHfbmd6","_type":"subNavigation","_id":"b537fcea-aea3-40ca-83c1-0907fdc9ccb5","_updatedAt":"2024-05-24T05:24:47Z","url":"/compendium/lupus"},{"is_active":true,"navParent":{"_ref":"1b1e3727-8b82-42da-9a62-b20472b9c797","_type":"reference"},"_type":"subNavigation","_id":"ef6c4efc-5932-4148-b626-cbf42e1c49c3","url":"/compendium/myasthenia-gravis","_createdAt":"2024-05-24T05:25:23Z","_rev":"Jz2W7keLhiw1UYkGHfbn7F","name":"Myasthenia Gravis","_updatedAt":"2024-05-24T05:25:23Z"}],"is_active":true,"navParent":{"_ref":"97a2a8fe-1a67-45d7-b1f8-294ab1f64c1e","_type":"reference"},"_createdAt":"2024-05-24T05:23:19Z","_rev":"Jz2W7keLhiw1UYkGHfbkam","name":"Immunology","_updatedAt":"2024-05-24T05:23:19Z","url":"/compendium/immunology","_type":"subNavigation","_id":"1b1e3727-8b82-42da-9a62-b20472b9c797"},{"_createdAt":"2024-05-24T05:35:38Z","name":"Infectious Disease","children":[{"_createdAt":"2024-05-24T05:36:03Z","_rev":"rcwwj6TiN2Q0ymhqDyeyP3","_type":"subNavigation","_id":"ffcd30d0-169f-4a8f-9f01-616142f33712","url":"/compendium/covid-19","is_active":true,"navParent":{"_ref":"b62af616-818b-4bda-b606-bd64287f9a85","_type":"reference"},"name":"COVID-19","_updatedAt":"2024-05-24T05:36:03Z"},{"navParent":{"_ref":"b62af616-818b-4bda-b606-bd64287f9a85","_type":"reference"},"_createdAt":"2024-05-24T05:36:22Z","_id":"a53004c6-9fe2-4b9c-a86a-ad74f9204b3a","_updatedAt":"2024-05-24T05:36:29Z","url":"/compendium/hiv","is_active":true,"_rev":"Jz2W7keLhiw1UYkGHfcAxn","_type":"subNavigation","name":"HIV"},{"navParent":{"_type":"reference","_ref":"b62af616-818b-4bda-b606-bd64287f9a85"},"_type":"subNavigation","_id":"ca70e9ab-a981-4629-a766-81f7890b3977","url":"/compendium/rsv","_updatedAt":"2024-05-24T05:37:06Z","is_active":true,"_createdAt":"2024-05-24T05:37:06Z","_rev":"rcwwj6TiN2Q0ymhqDyezNO","name":"RSV"},{"_id":"a0ec0591-b4a1-4723-b984-b681c957523f","url":"/compendium/vaccines","_createdAt":"2024-05-24T05:37:53Z","name":"Vaccines","_rev":"Jz2W7keLhiw1UYkGHfcFFM","_type":"subNavigation","_updatedAt":"2024-05-24T05:37:53Z","is_active":true,"navParent":{"_ref":"b62af616-818b-4bda-b606-bd64287f9a85","_type":"reference"}}],"_rev":"Jz2W7keLhiw1UYkGHfcA9Y","_type":"subNavigation","url":"/compendium/infectious-disease","is_active":true,"navParent":{"_ref":"97a2a8fe-1a67-45d7-b1f8-294ab1f64c1e","_type":"reference"},"_id":"b62af616-818b-4bda-b606-bd64287f9a85","_updatedAt":"2024-05-24T05:35:38Z"},{"children":[{"_updatedAt":"2024-05-24T05:38:58Z","url":"/compendium/mdd","is_active":true,"navParent":{"_ref":"db67ff69-2c58-4931-ad3d-767a636e38b0","_type":"reference"},"_createdAt":"2024-05-24T05:38:58Z","_rev":"rcwwj6TiN2Q0ymhqDyf7Qk","name":"Major Depressive Disorder","_type":"subNavigation","_id":"efcab5a8-97d8-4f5a-ba99-0a0555531f5a"},{"_updatedAt":"2024-05-24T05:39:18Z","is_active":true,"_createdAt":"2024-05-24T05:39:18Z","_type":"subNavigation","name":"Sleep","navParent":{"_ref":"db67ff69-2c58-4931-ad3d-767a636e38b0","_type":"reference"},"_rev":"rcwwj6TiN2Q0ymhqDyf96m","_id":"f52dbfa9-aefe-4d21-b432-7052a136ae98","url":"/compendium/sleep"}],"_type":"subNavigation","name":"Mental Health","_id":"db67ff69-2c58-4931-ad3d-767a636e38b0","navParent":{"_ref":"97a2a8fe-1a67-45d7-b1f8-294ab1f64c1e","_type":"reference"},"_updatedAt":"2024-05-24T05:38:33Z","is_active":true,"_rev":"rcwwj6TiN2Q0ymhqDyf4PU","url":"/compendium/mental-health","_createdAt":"2024-05-24T05:38:33Z"},{"_rev":"G7uWgc8ggxb5zBvm8zNRmt","children":[{"is_active":true,"navParent":{"_ref":"bafe1c52-a8b5-4786-bcee-668409d14a11","_type":"reference"},"_type":"subNavigation","_id":"3e24f5af-027e-4f0b-a7e2-a3ffaf756a35","_updatedAt":"2024-05-24T05:40:18Z","_createdAt":"2024-05-24T05:40:18Z","_rev":"rcwwj6TiN2Q0ymhqDyfERb","name":"Duchenne Muscular Dystrophy","url":"/compendium/dmd"},{"_rev":"rcwwj6TiN2Q0ymhqDyfIhq","_type":"subNavigation","_id":"d4e270df-2a59-4109-a7be-9c10f80722a7","_updatedAt":"2024-05-24T05:40:38Z","navParent":{"_ref":"bafe1c52-a8b5-4786-bcee-668409d14a11","_type":"reference"},"_createdAt":"2024-05-24T05:40:30Z","url":"/compendium/epilepsy","is_active":true,"name":"Epilepsy"},{"_createdAt":"2024-05-24T05:41:07Z","name":"Multiple Sclerosis","url":"/compendium/multiple-sclerosis","is_active":true,"navParent":{"_ref":"bafe1c52-a8b5-4786-bcee-668409d14a11","_type":"reference"},"_id":"7539f9b5-8f2a-4e1b-a10f-8cc748cd1489","_updatedAt":"2024-05-24T05:41:07Z","_rev":"rcwwj6TiN2Q0ymhqDyfJRc","_type":"subNavigation"},{"is_active":true,"navParent":{"_ref":"bafe1c52-a8b5-4786-bcee-668409d14a11","_type":"reference"},"_createdAt":"2024-05-24T05:41:29Z","_type":"subNavigation","name":"Parkinson Disease","_rev":"rcwwj6TiN2Q0ymhqDyfJiG","_id":"90ebd8e7-e6d1-4128-8010-0b205fedb430","_updatedAt":"2024-05-24T05:41:29Z","url":"/compendium/parkinson"}],"_updatedAt":"2024-06-11T20:18:36Z","is_active":true,"navParent":{"_ref":"97a2a8fe-1a67-45d7-b1f8-294ab1f64c1e","_type":"reference"},"_createdAt":"2024-05-24T05:39:38Z","_id":"bafe1c52-a8b5-4786-bcee-668409d14a11","_type":"subNavigation","name":"Neurology"},{"_updatedAt":"2024-09-04T14:25:34Z","is_active":true,"_rev":"B2kOGngERQtEUh1WG5WXvd","navParent":{"_ref":"97a2a8fe-1a67-45d7-b1f8-294ab1f64c1e","_type":"reference"},"children":[],"_id":"fe48de19-78d2-4ed0-83fa-8884fb340de2","url":"/compendium/obesity","_type":"subNavigation","name":"Obesity","_createdAt":"2024-09-04T14:25:34Z"},{"_type":"subNavigation","_id":"90b398eb-3349-4b6a-b205-780a34cb4717","url":"/compendium/oncology","is_active":true,"_rev":"rcwwj6TiN2Q0ymhqDyfKov","navParent":{"_ref":"97a2a8fe-1a67-45d7-b1f8-294ab1f64c1e","_type":"reference"},"name":"Oncology","_createdAt":"2024-05-24T05:41:55Z","_updatedAt":"2024-05-24T05:41:55Z","children":[{"is_active":true,"_type":"subNavigation","name":"Breast Cancer","_id":"03ea9371-55cd-42e2-b300-7078b94ff467","_updatedAt":"2024-05-24T05:42:17Z","url":"/compendium/breast-cancer","navParent":{"_ref":"90b398eb-3349-4b6a-b205-780a34cb4717","_type":"reference"},"_createdAt":"2024-05-24T05:42:17Z","_rev":"rcwwj6TiN2Q0ymhqDyfMpl"},{"navParent":{"_ref":"90b398eb-3349-4b6a-b205-780a34cb4717","_type":"reference"},"_createdAt":"2024-05-24T05:42:35Z","_rev":"rcwwj6TiN2Q0ymhqDyfatY","_type":"subNavigation","name":"Cholangiocarcinoma","_updatedAt":"2024-05-24T05:42:35Z","url":"/compendium/cholangiocarcinoma","is_active":true,"_id":"8b57fc91-4191-420c-a224-cb869f8fa0d7"},{"navParent":{"_ref":"90b398eb-3349-4b6a-b205-780a34cb4717","_type":"reference"},"_rev":"Jz2W7keLhiw1UYkGHfcTh6","_type":"subNavigation","name":"Colorectal Cancer","_id":"e45ff858-e1bc-4b4a-9398-e12877b61607","is_active":true,"_createdAt":"2024-05-24T05:43:23Z","_updatedAt":"2024-05-24T05:43:23Z","url":"/compendium/colorectal-cancer"},{"_id":"289f747b-dffd-4006-a27d-4933a46fd7c1","_updatedAt":"2024-05-24T13:25:09Z","url":"/compendium/immuno-oncology","_type":"subNavigation","name":"Immuno-Oncology","_createdAt":"2024-05-24T05:44:17Z","_rev":"Jz2W7keLhiw1UYkGHfsKT5","is_active":true,"navParent":{"_ref":"90b398eb-3349-4b6a-b205-780a34cb4717","_type":"reference"}},{"is_active":true,"_createdAt":"2024-05-29T15:32:02Z","_rev":"Iat2IZiT321TmGHwkF6F4B","_type":"subNavigation","name":"Liver Cancer","navParent":{"_ref":"90b398eb-3349-4b6a-b205-780a34cb4717","_type":"reference"},"_id":"9d17bccc-3f33-4793-90e3-0adecfa71fa1","_updatedAt":"2024-05-29T15:32:02Z","url":"/compendium/liver-cancer"},{"_createdAt":"2024-05-24T05:44:58Z","_updatedAt":"2024-05-24T05:44:58Z","is_active":true,"navParent":{"_ref":"90b398eb-3349-4b6a-b205-780a34cb4717","_type":"reference"},"_rev":"rcwwj6TiN2Q0ymhqDyfff0","_type":"subNavigation","name":"Lung Cancer","_id":"89f99f56-72a9-4dcd-9d8c-3d717d66a5f0","url":"/compendium/lung-cancer"},{"_updatedAt":"2024-05-24T13:24:22Z","url":"/compendium/nsclc","_createdAt":"2024-05-24T05:45:56Z","_rev":"Jz2W7keLhiw1UYkGHfsIwL","_type":"subNavigation","name":"Non–Small Cell Lung Cancer","_id":"85d30c37-d6a1-4028-9c0f-ecdf36de220d","is_active":true,"navParent":{"_ref":"90b398eb-3349-4b6a-b205-780a34cb4717","_type":"reference"}},{"_id":"5a67adcb-11d8-48a6-8c39-b2956f5f3e86","_updatedAt":"2024-05-24T05:46:17Z","is_active":true,"_type":"subNavigation","name":"Ovarian Cancer","url":"/compendium/ovarian-cancer","navParent":{"_ref":"90b398eb-3349-4b6a-b205-780a34cb4717","_type":"reference"},"_createdAt":"2024-05-24T05:46:17Z","_rev":"Jz2W7keLhiw1UYkGHfcbF4"},{"is_active":true,"navParent":{"_ref":"90b398eb-3349-4b6a-b205-780a34cb4717","_type":"reference"},"_rev":"rcwwj6TiN2Q0ymhqDyfmoB","name":"Prostate Cancer","_id":"bcfe0d88-7498-4268-95e6-875c94a2dab5","_updatedAt":"2024-05-24T05:47:42Z","_createdAt":"2024-05-24T05:47:42Z","_type":"subNavigation","url":"/compendium/prostate-cancer"},{"url":"/compendium/skincancer","is_active":true,"_createdAt":"2024-05-24T05:48:18Z","_type":"subNavigation","name":"Skin Cancer","_id":"a3a04e72-c707-450d-b9d3-f9ebacc9f997","navParent":{"_ref":"90b398eb-3349-4b6a-b205-780a34cb4717","_type":"reference"},"_rev":"rcwwj6TiN2Q0ymhqDyfpKE","_updatedAt":"2024-05-24T05:48:18Z"},{"_createdAt":"2024-05-29T15:30:06Z","_type":"subNavigation","_updatedAt":"2024-05-29T15:30:06Z","url":"/compendium/soft-tissue-sarcoma","is_active":true,"navParent":{"_type":"reference","_ref":"90b398eb-3349-4b6a-b205-780a34cb4717"},"_rev":"Iat2IZiT321TmGHwkF69Qd","name":"Soft Tissue Sarcoma","_id":"6d1dc4b4-1be8-41ee-9bba-90ad4ce546b3"}]},{"navParent":{"_ref":"97a2a8fe-1a67-45d7-b1f8-294ab1f64c1e","_type":"reference"},"_type":"subNavigation","name":"Ophthalmology","url":"/compendium/ophthalmology","children":[],"_rev":"Jz2W7keLhiw1UYkGHfcePj","_updatedAt":"2024-05-24T05:48:54Z","is_active":true,"_createdAt":"2024-05-24T05:48:54Z","_id":"eee19078-eb50-46e7-a97c-8f16d79eea97"},{"_createdAt":"2024-05-24T05:49:11Z","_rev":"5DUHcaiKRKj5c8wHOPlDws","_type":"subNavigation","_id":"e6c5e55f-7a5a-4f23-add2-fbf91df76400","_updatedAt":"2024-06-03T20:54:07Z","name":"Pulmonology","is_active":true,"navParent":{"_ref":"97a2a8fe-1a67-45d7-b1f8-294ab1f64c1e","_type":"reference"},"children":[{"navParent":{"_ref":"e6c5e55f-7a5a-4f23-add2-fbf91df76400","_type":"reference"},"_rev":"rcwwj6TiN2Q0ymhqDyfrwW","_id":"3a19d535-d61e-43b1-bf6a-d6ced486a0b9","url":"/compendium/copd","is_active":true,"_createdAt":"2024-05-24T05:49:28Z","_type":"subNavigation","name":"COPD","_updatedAt":"2024-05-24T05:49:28Z"},{"is_active":true,"_type":"subNavigation","_updatedAt":"2024-05-24T05:49:52Z","url":"/compendium/pah","navParent":{"_ref":"e6c5e55f-7a5a-4f23-add2-fbf91df76400","_type":"reference"},"_createdAt":"2024-05-24T05:49:52Z","_rev":"rcwwj6TiN2Q0ymhqDyfuBv","name":"Pulmonary Arterial Hypertension","_id":"474080cd-4295-4a70-907d-e1fc93c435cc"}]},{"name":"Rare Disease","url":"/compendium/raredisease","is_active":true,"children":[{"_id":"9e780f76-2008-441b-ab5f-00d3a6d1a5b0","navParent":{"_ref":"de690920-3cdc-4c43-a27e-ba4e38a62059","_type":"reference"},"_rev":"rcwwj6TiN2Q0ymhqDyg1k4","_type":"subNavigation","name":"Spinal Muscular Atrophy","_updatedAt":"2024-05-24T05:51:19Z","url":"/compendium/sma","is_active":true,"_createdAt":"2024-05-24T05:51:19Z"}],"_rev":"rcwwj6TiN2Q0ymhqDyg1Ah","_createdAt":"2024-05-24T05:50:50Z","navParent":{"_ref":"97a2a8fe-1a67-45d7-b1f8-294ab1f64c1e","_type":"reference"},"_type":"subNavigation","_id":"de690920-3cdc-4c43-a27e-ba4e38a62059","_updatedAt":"2024-05-24T05:50:50Z"},{"url":"/compendium/respiratory","_type":"subNavigation","_updatedAt":"2024-05-24T05:50:22Z","is_active":true,"children":[{"is_active":true,"_type":"subNavigation","url":"/compendium/asthma","navParent":{"_ref":"f2a34114-0396-44cb-b241-11ef7b175500","_type":"reference"},"_createdAt":"2024-05-24T05:52:02Z","_rev":"rcwwj6TiN2Q0ymhqDyg2wy","name":"Asthma","_id":"b2b2802f-2918-4431-8f4f-3bc7e6e6042f","_updatedAt":"2024-05-24T05:52:02Z"},{"navParent":{"_ref":"f2a34114-0396-44cb-b241-11ef7b175500","_type":"reference"},"_rev":"5DUHcaiKRKj5c8wHOPKtuf","_updatedAt":"2024-06-03T18:31:07Z","is_active":true,"_createdAt":"2024-06-03T18:31:07Z","_type":"subNavigation","name":"Idiopathic Pulmonary Fibrosis","_id":"4dac47d5-8dd1-4e90-b4be-b6b5e605f6f5","url":"/compendium/ipf"}],"_rev":"Jz2W7keLhiw1UYkGHfcjSf","name":"Respiratory","_id":"f2a34114-0396-44cb-b241-11ef7b175500","_createdAt":"2024-05-24T05:50:22Z","navParent":{"_ref":"97a2a8fe-1a67-45d7-b1f8-294ab1f64c1e","_type":"reference"}},{"_type":"subNavigation","_updatedAt":"2024-05-24T05:52:28Z","children":[],"_rev":"Jz2W7keLhiw1UYkGHfcm6J","is_active":true,"navParent":{"_type":"reference","_ref":"97a2a8fe-1a67-45d7-b1f8-294ab1f64c1e"},"name":"Rheumatology","_id":"3ecb2952-6710-46b1-ab05-36997bfb4a33","url":"/compendium/rheumatology","_createdAt":"2024-05-24T05:52:28Z"},{"_updatedAt":"2024-05-24T05:52:51Z","is_active":true,"_createdAt":"2024-05-24T05:52:51Z","navParent":{"_type":"reference","_ref":"97a2a8fe-1a67-45d7-b1f8-294ab1f64c1e"},"_type":"subNavigation","name":"Women's Health","children":[],"url":"/compendium/womens-health","_rev":"Jz2W7keLhiw1UYkGHfcmDU","_id":"ead467ba-7c17-4a1b-9deb-a7af56a7366e"}],"_rev":"Jz2W7keLhiw1UYkGHfbRHa","_createdAt":"2020-04-14T14:04:25Z","_type":"subNavigation","name":"Specialty Area","_updatedAt":"2024-05-24T05:08:37Z","navParent":null},{"name":"Spotlight","_updatedAt":"2024-05-23T21:04:52Z","subQuery":[{"is_active":true,"_rev":"uJbbwQWkLESsncBrcJSd1N","_createdAt":"2024-05-23T21:04:56Z","_type":"subNavigation","_updatedAt":"2024-05-23T21:05:49Z","children":[],"url":"/ivbmevents?display=home","navParent":{"_ref":"db56b0e2-ad58-4407-aff2-5c27cb3145c1","_type":"reference"},"name":"Free In-Person Regional Events Focused on Oncology and Population Health","_id":"f5b2c97b-d6d4-468b-8a9a-4814364994c8"}],"_createdAt":"2024-05-23T20:47:34Z","sortOrder":2,"_id":"db56b0e2-ad58-4407-aff2-5c27cb3145c1","is_active":true,"navParent":null,"_rev":"rcwwj6TiN2Q0ymhqDyHDJ3","_type":"subNavigation"},{"_id":"8f999f83-7d66-4c5d-a82c-ecf6b72037f2","is_active":true,"_type":"subNavigation","_createdAt":"2020-04-14T14:05:54Z","_rev":"iEeBpgQLYwZXMeCflboLMu","name":"Topics","navParent":null,"subQuery":[{"_type":"subNavigation","name":"Biosimilars","is_active":true,"sortOrder":1,"_updatedAt":"2024-05-24T05:05:19Z","navParent":{"_ref":"8f999f83-7d66-4c5d-a82c-ecf6b72037f2","_type":"reference"},"_createdAt":"2024-05-24T05:05:19Z","_id":"43207521-4e5f-42d2-b013-34763a4d964c","children":[],"url":"/compendium/biosimilars","_rev":"Jz2W7keLhiw1UYkGHfbHQ4"},{"name":"Center on Health Equity \u0026 Access","url":"/topic/center-on-health-equity-and-access","children":[],"is_active":true,"_createdAt":"2022-12-23T21:04:41Z","_id":"4161ff97-2901-4526-80ee-3749b6dc6345","navParent":{"_ref":"8f999f83-7d66-4c5d-a82c-ecf6b72037f2","_type":"reference"},"_type":"subNavigation","_rev":"N7mKycgLbGtEq6btkPIW3d","_updatedAt":"2024-06-12T13:58:35Z"},{"name":"Digital Health","_rev":"rcwwj6TiN2Q0ymhqDygl51","is_active":true,"_type":"subNavigation","navParent":{"_ref":"8f999f83-7d66-4c5d-a82c-ecf6b72037f2","_type":"reference"},"_updatedAt":"2024-05-24T05:56:42Z","children":[],"_createdAt":"2024-05-24T05:56:42Z","_id":"232e30a0-2f7d-4ce1-9e4d-cc0cee73b20a","url":"/compendium/digital-health"},{"name":"Formulary","_rev":"Jz2W7keLhiw1UYkGHfdAmX","_type":"subNavigation","is_active":true,"_id":"3887cee2-5461-4cb3-b54f-297fcceb11ee","url":"/formulary","navParent":{"_ref":"8f999f83-7d66-4c5d-a82c-ecf6b72037f2","_type":"reference"},"_createdAt":"2024-05-24T05:57:01Z","_updatedAt":"2024-05-24T05:57:01Z","children":[]},{"navParent":{"_ref":"8f999f83-7d66-4c5d-a82c-ecf6b72037f2","_type":"reference"},"_type":"subNavigation","_updatedAt":"2024-05-24T05:57:41Z","_rev":"rcwwj6TiN2Q0ymhqDygmDl","is_active":true,"_id":"56aff93b-4f24-48fc-9dda-2d394397f956","_createdAt":"2024-05-24T05:57:41Z","name":"Gene Therapy","url":"/compendium/gene-therapy","children":[]},{"_type":"subNavigation","_id":"69723346-76b2-4896-b2d9-2db53ed5da96","navParent":{"_ref":"8f999f83-7d66-4c5d-a82c-ecf6b72037f2","_type":"reference"},"children":[],"_updatedAt":"2024-05-24T06:00:55Z","is_active":true,"_createdAt":"2024-05-24T06:00:55Z","_rev":"rcwwj6TiN2Q0ymhqDygv9D","name":"Guidelines","url":"/guidelines"},{"children":[{"_type":"subNavigation","is_active":true,"navParent":{"_ref":"cd6edcff-faa3-4bee-9071-042f8186052d","_type":"reference"},"_createdAt":"2024-05-24T05:58:26Z","_rev":"rcwwj6TiN2Q0ymhqDz6EMB","name":"Employers","_id":"83fca4ec-4ff0-4766-9e49-0376d44179e8","_updatedAt":"2024-05-24T13:53:42Z","url":"/compendium/employers"},{"url":"/compendium/medicare","is_active":true,"_createdAt":"2024-05-24T05:58:44Z","_rev":"rcwwj6TiN2Q0ymhqDz6F3s","_type":"subNavigation","_updatedAt":"2024-05-24T13:53:53Z","navParent":{"_ref":"cd6edcff-faa3-4bee-9071-042f8186052d","_type":"reference"},"name":"Medicare","_id":"5647b438-aca9-4b57-9d4d-2df660b5a6ce"},{"navParent":{"_ref":"cd6edcff-faa3-4bee-9071-042f8186052d","_type":"reference"},"_rev":"rcwwj6TiN2Q0ymhqDz6G8S","_type":"subNavigation","_id":"2c8ff713-9c43-4afc-aaca-e33ceb98f00c","_updatedAt":"2024-05-24T13:54:23Z","url":"/compendium/reimbursement","is_active":true,"name":"Reimbursement","_createdAt":"2024-05-24T05:59:16Z"}],"url":"/","_createdAt":"2024-05-24T13:53:24Z","is_active":true,"navParent":{"_ref":"8f999f83-7d66-4c5d-a82c-ecf6b72037f2","_type":"reference"},"_id":"cd6edcff-faa3-4bee-9071-042f8186052d","_updatedAt":"2024-05-24T14:10:39Z","_type":"subNavigation","_rev":"rcwwj6TiN2Q0ymhqDz7eaC","name":"Health Care Administration"},{"navParent":{"_ref":"8f999f83-7d66-4c5d-a82c-ecf6b72037f2","_type":"reference"},"_id":"c9a8f6fd-0ad0-4a82-a385-13c03fe688d0","_updatedAt":"2021-02-25T17:30:59Z","name":"Health Care Cost","_createdAt":"2020-04-14T14:06:29Z","_rev":"wx7I38TXtYeZdHCfn60Syn","url":"/topic/healthcare-cost","children":[],"_type":"subNavigation","is_active":true},{"_id":"d01b9875-6e51-42d1-bdf5-93fd8771855c","url":"/topic/healthcare-delivery","_createdAt":"2020-04-14T14:06:43Z","_rev":"YN5IiYQkhJ3hq0R7jM8DQW","_type":"subNavigation","name":"Health Care Delivery","is_active":true,"navParent":{"_ref":"8f999f83-7d66-4c5d-a82c-ecf6b72037f2","_type":"reference"},"_updatedAt":"2021-02-25T17:29:58Z","children":[]},{"_type":"subNavigation","name":"Insurance","navParent":{"_ref":"8f999f83-7d66-4c5d-a82c-ecf6b72037f2","_type":"reference"},"_createdAt":"2020-04-14T14:07:01Z","_rev":"lslStCipHxtG437RQOGJ7p","_updatedAt":"2022-12-21T19:05:52Z","is_active":true,"children":[],"url":"/topic/insurance","_id":"d8eab058-f5ec-4c42-a95a-941c0a506543"},{"_rev":"T035zdq5xruIFPyK3OzgdQ","children":[],"_updatedAt":"2020-04-14T14:07:15Z","url":"/topic/policy","name":"Policy","_createdAt":"2020-04-14T14:07:15Z","is_active":true,"navParent":{"_ref":"8f999f83-7d66-4c5d-a82c-ecf6b72037f2","_type":"reference"},"_id":"fd066f36-78ee-4112-a121-4e02f8e45b0b","_type":"subNavigation"},{"_id":"d7893fef-5eb0-4b2d-b13d-a0bec73b2c14","url":"/compendium/population","_updatedAt":"2024-05-24T06:01:29Z","children":[],"_createdAt":"2024-05-24T05:59:24Z","_type":"subNavigation","name":"Population Health","is_active":true,"navParent":{"_type":"reference","_ref":"8f999f83-7d66-4c5d-a82c-ecf6b72037f2"},"_rev":"rcwwj6TiN2Q0ymhqDygvgV"},{"_id":"6188ac2f-7ec8-4cbb-a154-5822f606f3fa","navParent":{"_ref":"8f999f83-7d66-4c5d-a82c-ecf6b72037f2","_type":"reference"},"_type":"subNavigation","is_active":true,"_rev":"Jz2W7keLhiw1UYkGHfsKLu","name":"Product Approvals and Launches","_updatedAt":"2024-05-24T13:24:58Z","url":"/approvals-launches","_createdAt":"2024-05-24T06:01:51Z","children":[]},{"name":"Technology","_id":"4e2fe99b-3ac4-4b48-89ed-774dd51675df","is_active":true,"navParent":{"_type":"reference","_ref":"8f999f83-7d66-4c5d-a82c-ecf6b72037f2"},"_type":"subNavigation","children":[],"url":"/topic/technology","_createdAt":"2020-04-14T14:07:28Z","_rev":"QxOJBWa4XErmibN6Cb5bN0","_updatedAt":"2020-04-14T14:07:28Z"},{"_createdAt":"2020-04-14T14:07:42Z","is_active":true,"navParent":{"_ref":"8f999f83-7d66-4c5d-a82c-ecf6b72037f2","_type":"reference"},"name":"Value-Based Care","_id":"22bd1bd6-88a6-4278-a846-e086cf30b141","_updatedAt":"2020-04-14T14:07:42Z","_rev":"T035zdq5xruIFPyK3OzhkC","_type":"subNavigation","url":"/topic/value-based-care","children":[]}],"sortOrder":2,"_updatedAt":"2020-08-21T22:11:57Z","url":"/topic"},{"navParent":null,"subQuery":[{"url":"/ivbm","navParent":{"_ref":"6389c35d-3d2d-41db-978d-b3aa4d10cb8e","_type":"reference"},"_id":"f7379c68-40be-45e4-9747-484dcec584d3","name":"All Coverage","is_active":true,"_rev":"cyKVTGb2fpu5E4X0UMrv4p","_type":"subNavigation","children":[],"_updatedAt":"2020-05-06T13:11:16Z","_createdAt":"2020-05-06T13:11:16Z"},{"_rev":"k2D4PisPM2pBS5NIl95QbN","_type":"subNavigation","name":"Event Coverage","is_active":true,"_createdAt":"2020-04-27T18:49:41Z","navParent":{"_ref":"6389c35d-3d2d-41db-978d-b3aa4d10cb8e","_type":"reference"},"_id":"cc8a827f-3e94-413a-aa0c-0d8b40eb5f18","_updatedAt":"2020-04-27T18:49:41Z","children":[],"url":"/ivbm/event-coverage"},{"url":"/ivbm/interviews","_createdAt":"2020-04-27T18:50:03Z","name":"Interviews","is_active":true,"navParent":{"_ref":"6389c35d-3d2d-41db-978d-b3aa4d10cb8e","_type":"reference"},"_rev":"k2D4PisPM2pBS5NIl95RlO","_updatedAt":"2020-04-27T18:50:03Z","_type":"subNavigation","_id":"aa3f3bb8-9e8c-457d-aeb6-7b94b968395a","children":[]},{"children":[],"_type":"subNavigation","_createdAt":"2020-04-27T18:50:34Z","navParent":{"_ref":"6389c35d-3d2d-41db-978d-b3aa4d10cb8e","_type":"reference"},"_updatedAt":"2020-04-27T18:50:34Z","url":"/ivbm/news","is_active":true,"name":"News","_id":"1be7e99c-8d37-4d70-a009-67eb03fae5ba","_rev":"XtnP0djhkej33kSTbdUgmN"}],"sortOrder":3,"name":"Institute for Value-Based Medicine","_id":"6389c35d-3d2d-41db-978d-b3aa4d10cb8e","_updatedAt":"2020-04-27T18:48:23Z","url":"/ivbm","is_active":true,"_type":"subNavigation","_createdAt":"2020-04-27T18:48:09Z","_rev":"N0LuVAjtHhQSyVgQyS0Kyv"},{"_id":"9a07b754-3383-43ac-9d2d-a370d44406d1","is_active":true,"_type":"subNavigation","name":"About AJMC","_createdAt":"2020-04-14T14:09:11Z","sortOrder":4,"_rev":"lsW1cEPdRFwwIdupAS8Stb","navParent":null,"subQuery":[{"_id":"4e10ead3-6a42-43df-b251-b93b912a24cb","_updatedAt":"2020-05-07T17:05:52Z","url":"/about","_createdAt":"2020-05-07T17:05:52Z","children":[],"_rev":"NGYpFwzJghlKjBIAt48VzS","_type":"subNavigation","name":"AJMC Journals","is_active":true,"navParent":{"_type":"reference","_ref":"9a07b754-3383-43ac-9d2d-a370d44406d1"}},{"_rev":"rHX8vIEJKWyjgUO02y82fe","_type":"subNavigation","is_active":true,"name":"Anniversary","navParent":{"_ref":"9a07b754-3383-43ac-9d2d-a370d44406d1","_type":"reference"},"_updatedAt":"2020-04-14T14:09:38Z","_createdAt":"2020-04-14T14:09:38Z","_id":"4451f4fa-a919-45b4-b6e5-282668cd792e","url":"/anniversary","children":[]},{"_createdAt":"2020-04-14T14:10:37Z","_type":"subNavigation","_id":"99bccc8e-9329-496f-b588-ec3d080f0859","url":"/authorshipforms","navParent":{"_ref":"9a07b754-3383-43ac-9d2d-a370d44406d1","_type":"reference"},"_updatedAt":"2020-06-09T11:44:06Z","is_active":true,"name":"Author Forms","children":[],"_rev":"VmKMEDy0rHs5jzhO3eZVVM"},{"_type":"subNavigation","navParent":{"_ref":"9a07b754-3383-43ac-9d2d-a370d44406d1","_type":"reference"},"children":[],"name":"Authors","_createdAt":"2020-04-14T14:10:19Z","url":"/authors","_rev":"0JTsteyxJPdyCvciQ9yBPv","is_active":true,"_id":"518317a5-297f-4c4f-9d2a-6da7b8c98d9c","_updatedAt":"2020-05-06T12:53:11Z"},{"_rev":"m6BzyPIGe9IGx2bV3pSCbq","name":"Nominate a Rising Leader","is_active":true,"navParent":{"_ref":"9a07b754-3383-43ac-9d2d-a370d44406d1","_type":"reference"},"_type":"subNavigation","_createdAt":"2020-06-15T17:13:51Z","children":[],"_updatedAt":"2020-06-15T17:13:51Z","url":"/seema-sonnad-nomination","_id":"a96a44c9-4d51-47c6-8f81-4263bd2f58b4"},{"navParent":{"_ref":"9a07b754-3383-43ac-9d2d-a370d44406d1","_type":"reference"},"name":"Submit a Manuscript","is_active":true,"_createdAt":"2023-03-14T13:29:28Z","_rev":"TctAtfg0qER1kILh39bPC4","_id":"4420e458-acb4-4edb-9f33-c4fc4504ff41","_updatedAt":"2023-03-14T13:29:28Z","url":"/submit-a-manuscript","_type":"subNavigation","children":[]}],"_updatedAt":"2020-04-27T18:48:27Z"}],"site_setting":{"description":"The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.","creativeLayoutLatestNews":null,"_type":"siteSettings","siteURL":"www.ajmc.com","gaID":"UA-155582410-5,UA-11140057-3","socialLinks":[{"_type":"urlArray","_key":"5a09ae68c48c","title":"Facebook","url":"https://www.facebook.com/TheAmericanJournalOfManagedCare","blank":true},{"blank":true,"_type":"urlArray","_key":"ad6b3d250e0b","title":"Twitter","url":"https://twitter.com/AJMC_Journal"},{"title":"LinkedIn","url":"https://www.linkedin.com/company/american-journal-of-managed-care/","blank":true,"_type":"urlArray","_key":"7d1e53fa7d09"},{"blank":true,"_type":"urlArray","_key":"2478204aa05c","title":"Instagram","url":"https://www.instagram.com/ajmcjournal/"},{"_type":"urlArray","_key":"0ba4cf990c2f","title":"RSS","url":"/rss","blank":true}],"footerLinks":[{"_type":"urlArray","_key":"6170fdefc8129a5a7ef9dfdd78a2573e","title":"About","url":"/about-us"},{"_type":"urlArray","_key":"281c240875d5","title":"Contact","url":"/contactus"},{"_type":"urlArray","_key":"25e9e6fb7b4422cd0ac20e1a1d993228","title":"Editorial Boards","url":"/editorial-boards"},{"_type":"urlArray","_key":"20a44c137e8d","title":"Advertise","url":"/advertise"},{"title":"Do Not Sell My Information","url":"https://www.mjhlifesciences.com/ccpa?domain=www.ajmc.com","blank":true,"_type":"urlArray","_key":"21b84fcc9b6e"},{"_type":"urlArray","_key":"2f35307aab1f","title":"Terms \u0026 Conditions","url":"/terms"},{"_type":"urlArray","_key":"50ecd8627d01","title":"Privacy Policy","url":"/privacy"}],"enableSanity2":true,"_createdAt":"2020-04-14T14:14:32Z","_updatedAt":"2024-06-04T19:08:40Z","keywords":["American Journal of Managed Care","AJMC"],"copyRightText":"AJMC®","creativeLayout":null,"_id":"siteSettings","_rev":"4ivhMQjTvj4eF8IoNFokPn","name":"AJMC - Managed Care News, Research, and Expert Insights","salesforceDMPId":"tr3xsudox"},"clinicalData":[{"identifier":"center-on-health-equity-and-access","sortOrder":null,"children":[],"_id":"4ee49086-e720-4a65-883e-4efc24de53bb","name":"Center on Health Equity \u0026 Access"},{"sortOrder":null,"children":[],"_id":"topic_clinical","name":"Clinical","identifier":"clinical"},{"_id":"topic_healthcare-cost","name":"Health Care Cost","identifier":"healthcare-cost","sortOrder":null,"children":[]},{"_id":"topic_healthcare-delivery","name":"Health Care Delivery","identifier":"healthcare-delivery","sortOrder":null,"children":[]},{"_id":"topic_insurance","name":"Insurance","identifier":"insurance","sortOrder":null,"children":[]},{"_id":"topic_policy","name":"Policy","identifier":"policy","sortOrder":null,"children":[]},{"_id":"topic_technology","name":"Technology","identifier":"technology","sortOrder":null,"children":[]},{"children":[],"_id":"topic_value-based-care","name":"Value-Based Care","identifier":"value-based-care","sortOrder":null}],"seo_data":[],"recent_news":[{"authorMapping":{"_updatedAt":"2024-05-20T19:26:45Z","firstName":"Hayden","lastName":"Klein","_createdAt":"2021-07-07T19:05:23Z","_rev":"sgy4yN0CjmArmRDnE2KbUN","_id":"d4608bc5-b145-4495-9c67-41163578c9f2","displayName":"Hayden E. Klein","_type":"author","biography":[{"children":[{"_type":"span","marks":[],"text":"Hayden is an assistant editor for The American Journal of Managed Care® (AJMC®) and joined AJMC® in 2021, where she produces written and video content covering multiple disease states.","_key":"607fdc2dfcbb0"}],"_type":"block","style":"normal","_key":"038a30bd95f3","markDefs":[{"_type":"link","href":"https://www.linkedin.com/in/hayden-e-klein-40b8b1173/","_key":"b0bea7fd1873"}]},{"markDefs":[{"_key":"b0bea7fd1873","nofollow":true,"blank":true,"_type":"link","href":"https://www.linkedin.com/in/hayden-e-klein-40b8b1173/"}],"children":[{"_type":"span","marks":[],"text":"She has a BA in journalism \u0026 media studies from Rutgers University. You can connect with Hayden on ","_key":"3c55bddd8456"},{"_key":"607fdc2dfcbb1","_type":"span","marks":["b0bea7fd1873"],"text":"LinkedIn"},{"text":".","_key":"607fdc2dfcbb2","_type":"span","marks":[]}],"_type":"block","style":"normal","_key":"0c154c4abedd"}],"profileImage":{"_type":"mainImage","alt":"Hayden E. Klein","asset":{"_ref":"image-9a2a017c03e16e188b88d86afed2b268b4b00214-430x430-png","_type":"reference"}},"url":{"current":"hayden-e-klein","_type":"slug"}},"factCheckAuthorMapping":null,"contentCategory":{"_updatedAt":"2023-09-29T14:32:27Z","_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory","name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2"},"_id":"86d3362c-b948-469e-80be-ca1af7693cbe","title":"Viltolarsen Slows DMD Progression in Small Study","summary":"Further research is needed to determine how once-weekly viltolarsen can slow disease progression and preserve motor function in boys and young men with Duchenne muscular dystrophy (DMD).","url":{"current":"viltolarsen-slows-dmd-progression-in-small-study","_type":"slug"},"published":"2024-11-23T18:00:00.000Z","thumbnail":{"_type":"mainImage","alt":"Boy with DMD using walker | Image credit: Svitlana – stock.adobe.com","asset":{"_type":"reference","_ref":"image-7e20ff65b7abea493e84dace957fb80991ce7bb1-6048x4024-jpg"}}},{"_id":"9de436c7-b93c-4acd-82fc-20d1f27bec02","title":"Age-Related Disparities in Long-Term Outcomes for ER+, HER2– Breast Cancer","authorMapping":{"lastName":"Santoro","_rev":"sgy4yN0CjmArmRDnE2KiNm","profileImage":{"_type":"mainImage","alt":"Cameron Santoro","asset":{"_ref":"image-6ae51a61642a5ecba7cf4085fe97e68814e3c917-430x430-png","_type":"reference"}},"_updatedAt":"2024-05-20T19:28:22Z","firstName":"Cameron","displayName":"Cameron Santoro","_createdAt":"2023-11-22T18:35:06Z","_type":"author","_id":"232836b2-a7d6-4cdd-8d7e-65ab104eaf06","biography":[{"style":"normal","_key":"3da8fced8696","markDefs":[],"children":[{"_type":"span","marks":[],"text":"Cameron Santoro is an associate editor for ","_key":"93662c5c4cfd"},{"text":"The American Journal of Managed Care","_key":"213c257c1eca","_type":"span","marks":["em"]},{"_type":"span","marks":["superscript"],"text":"®","_key":"f546acb0aa91"},{"_type":"span","marks":[],"text":" (","_key":"acd931edd707"},{"_type":"span","marks":["em"],"text":"AJMC","_key":"843f7d4e787d"},{"_type":"span","marks":["superscript"],"text":"®","_key":"7c809e803edb"},{"_type":"span","marks":[],"text":"), AJMC.com, and The Center for Biosimilars","_key":"35b69a01dbbe"},{"_type":"span","marks":["superscript"],"text":"®","_key":"8ddca200bc46"},{"_type":"span","marks":[],"text":".","_key":"ba3cca6122e3"}],"_type":"block"}],"url":{"current":"cameron-santoro","_type":"slug"}},"factCheckAuthorMapping":null,"contentCategory":{"name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z","_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory"},"summary":"Younger women with estrogen receptor (ER)–positive, HER2-negative breast cancer have significantly worse long-term outcomes, including higher rates of recurrence and metastasis, compared with older women. ","thumbnail":{"_type":"mainImage","alt":"Young woman receiving breast screening | Image Credit: My Ocean studio - stock.adobe.com","caption":"Younger women with HR-positive, HER2-negative breast cancer have significantly worse long-term outcomes, including higher rates of recurrence and metastasis, compared with older women. | Image Credit: My Ocean studio - stock.adobe.com","asset":{"_ref":"image-f6dde86a347fe1814dcaa933db7ea64e27db3add-8995x5997-jpg","_type":"reference"}},"url":{"current":"age-related-disparities-in-long-term-outcomes-for-er-her2-breast-cancer","_type":"slug"},"published":"2024-11-23T17:30:00.000Z"},{"_id":"809dec58-4f3c-49a1-8c2b-53878dc5e0c3","url":{"current":"edentulism-may-heighten-sleep-apnea-risk","_type":"slug"},"published":"2024-11-23T15:00:00.000Z","authorMapping":{"_createdAt":"2020-05-05T10:50:04Z","_rev":"0TowddpnSMVYA5OKF42uAM","_type":"author","_id":"author_18c68a1fd690db471eba0e0da3b8e979","biography":[{"style":"normal","_key":"75ff381b2d42","markDefs":[{"_type":"link","href":"https://www.linkedin.com/in/jaredkalt/","_key":"30c8f5445624"}],"children":[{"_type":"span","marks":[],"text":"Jared is a freelance writer for The American Journal of Managed Care® (AJMC®), and previously worked as a senior editor for HCPLive® at MJH Life Sciences®.","_key":"e9f80bd7687c0"}],"_type":"block"},{"children":[{"marks":[],"text":"He has an MA from University of Sioux Falls. You can connect with Jared on ","_key":"95b8dd3e29db","_type":"span"},{"marks":["30c8f5445624"],"text":"LinkedIn","_key":"e9f80bd7687c1","_type":"span"},{"_type":"span","marks":[],"text":".","_key":"e9f80bd7687c2"}],"_type":"block","style":"normal","_key":"a90d9599d615","markDefs":[{"_type":"link","href":"https://www.linkedin.com/in/jaredkalt/","_key":"30c8f5445624","nofollow":true,"blank":true}]}],"_updatedAt":"2022-08-30T13:26:44Z","url":{"_type":"slug","current":"jared-kaltwasser"},"displayName":"Jared Kaltwasser"},"factCheckAuthorMapping":null,"title":"Edentulism May Heighten Sleep Apnea Risk","summary":"A systematic review has found a potential link between edentulism and sleep apnea risk, although the authors said differences in study designs prohibited a meta-analysis.","thumbnail":{"_type":"mainImage","alt":"Tooth loss | Image Credit: © valiantsin-stock.adobe.com","asset":{"_ref":"image-d8405a2a194a2c5f871d2c521ca31d0ec29d29bc-1200x738-jpg","_type":"reference"}},"contentCategory":{"_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z","_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory","name":"Articles"}},{"factCheckAuthorMapping":null,"contentCategory":{"_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory","name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z"},"_id":"1fdd2f09-9d9d-4679-8c5c-64fee40e632c","summary":"The new report is an attempt to provide comprehensive safety data on the rapidly changing treatment landscape for relapsed or refractory chronic lymphocytic leukemia (CLL).","url":{"current":"novel-relapsed-refractory-cll-therapies-have-similar-safety-profiles","_type":"slug"},"authorMapping":{"_id":"author_18c68a1fd690db471eba0e0da3b8e979","biography":[{"style":"normal","_key":"75ff381b2d42","markDefs":[{"_type":"link","href":"https://www.linkedin.com/in/jaredkalt/","_key":"30c8f5445624"}],"children":[{"_type":"span","marks":[],"text":"Jared is a freelance writer for The American Journal of Managed Care® (AJMC®), and previously worked as a senior editor for HCPLive® at MJH Life Sciences®.","_key":"e9f80bd7687c0"}],"_type":"block"},{"_key":"a90d9599d615","markDefs":[{"_type":"link","href":"https://www.linkedin.com/in/jaredkalt/","_key":"30c8f5445624","nofollow":true,"blank":true}],"children":[{"marks":[],"text":"He has an MA from University of Sioux Falls. You can connect with Jared on ","_key":"95b8dd3e29db","_type":"span"},{"marks":["30c8f5445624"],"text":"LinkedIn","_key":"e9f80bd7687c1","_type":"span"},{"_type":"span","marks":[],"text":".","_key":"e9f80bd7687c2"}],"_type":"block","style":"normal"}],"_updatedAt":"2022-08-30T13:26:44Z","url":{"_type":"slug","current":"jared-kaltwasser"},"displayName":"Jared Kaltwasser","_createdAt":"2020-05-05T10:50:04Z","_rev":"0TowddpnSMVYA5OKF42uAM","_type":"author"},"title":"Novel Relapsed/Refractory CLL Therapies Have Similar Safety Profiles","thumbnail":{"_type":"mainImage","alt":"Older woman taking out dose of pills from glass bottle | Image Credit: © fizkes - stock.adobe.com","asset":{"_ref":"image-b276506cb9fe42e52165074a6e038a4b99789dcb-5622x3622-jpg","_type":"reference"}},"published":"2024-11-23T13:16:00.000Z"}],"latest_publications":[{"issueGroup":{"_ref":"477f9888-ea5b-4621-bb40-41487563b322","_type":"reference"},"title":"To Improve Clinical Trial Equity in Multiple Myeloma, Just Ask","thumbnail":{"_type":"mainImage","asset":{"extension":"jpg","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/3e665a0c15a17fc3c7ade987a36f77617f865715-437x115.jpg","size":8393,"_createdAt":"2024-11-22T12:47:16Z","metadata":{"lqip":"data:image/jpeg;base64,/9j/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAAFABQDASIAAhEBAxEB/8QAFwABAAMAAAAAAAAAAAAAAAAAAAIFCP/EAB0QAAICAwADAAAAAAAAAAAAAAECAAMEERITITP/xAAVAQEBAAAAAAAAAAAAAAAAAAABAv/EABcRAQEBAQAAAAAAAAAAAAAAAAAxAQL/2gAMAwEAAhEDEQA/ANFmtqktPkY7IEjis1mQlfRHXvYiI7U8xcLjtr7OYiIKf//Z","dimensions":{"_type":"sanity.imageDimensions","width":437,"aspectRatio":3.8,"height":115},"isOpaque":true,"blurHash":"DARW3j9v?vR.IV~qWXM{ayof","_type":"sanity.imageMetadata","palette":{"darkVibrant":{"population":0.5,"background":"#15445f","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"},"lightMuted":{"title":"#000","population":1.36,"background":"#c5cdd0","_type":"sanity.imagePaletteSwatch","foreground":"#000"},"vibrant":{"population":0.07,"background":"#678db6","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"},"dominant":{"population":1.36,"background":"#c5cdd0","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#000"},"_type":"sanity.imagePalette","darkMuted":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.41,"background":"#383838"},"muted":{"background":"#60829c","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.66},"lightVibrant":{"background":"#a4daec","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#000","population":0.02}},"hasAlpha":false},"uploadId":"S6qsHDgdYFzzPaJkPMiq04qdRlFigqm8","path":"images/0vv8moc6/ajmc/3e665a0c15a17fc3c7ade987a36f77617f865715-437x115.jpg","_updatedAt":"2024-11-22T12:47:16Z","originalFilename":"CHEA LOGO.jpg","_type":"sanity.imageAsset","sha1hash":"3e665a0c15a17fc3c7ade987a36f77617f865715","assetId":"3e665a0c15a17fc3c7ade987a36f77617f865715","_rev":"qMZkEXqBAV3IRERLM7zYaX","mimeType":"image/jpeg","_id":"image-3e665a0c15a17fc3c7ade987a36f77617f865715-437x115-jpg"}},"url":"to-improve-clinical-trial-equity-in-multiple-myeloma-just-ask","published":"2024-11-22T12:37:00.000Z","authorDetails":[{"displayName":"Mary Caffrey","firstName":null,"lastName":null,"url":{"current":"mary-caffrey","_type":"slug"},"profileImage":null,"biography":[{"_key":"80606b0b2412","markDefs":[],"children":[{"text":"Mary Caffrey is the Executive Editor for The American Journal of Managed Care® (","_key":"9737335da1ed0","_type":"span","marks":[]},{"_type":"span","marks":["em"],"text":"AJMC","_key":"b8dda18bb0dc"},{"_type":"span","marks":[],"text":"®). She joined AJMC® in 2013 and is the primary staff editor for ","_key":"f56917041c08"},{"_type":"span","marks":["em"],"text":"Evidence-Based Oncology, ","_key":"8c710bb1d962"},{"_type":"span","marks":[],"text":"the multistakeholder publication that reaches 22,000+ oncology providers, policy makers and formulary decision makers. She is also part of the team that oversees speaker recruitment and panel preparations for ","_key":"1b94f48924f3"},{"_type":"span","marks":["em"],"text":"AJMC","_key":"3c5f9805f644"},{"_type":"span","marks":[],"text":"®'s premier annual oncology meeting, Patient-Centered Oncology Care®. For more than a decade, Mary has covered ASCO, ASH, ACC and other leading scientific meetings for ","_key":"d533ba55a862"},{"_type":"span","marks":["em"],"text":"AJMC","_key":"953d8c643cce"},{"_type":"span","marks":[],"text":" readers. ","_key":"182af2348b04"}],"_type":"block","style":"normal"},{"markDefs":[{"nofollow":true,"blank":true,"_type":"link","href":"https://www.linkedin.com/in/marykcaffrey/","_key":"4f88673cb2c4"}],"children":[{"text":"Mary has a BA in communications and philosophy from Loyola University New Orleans. You can connect with Mary on ","_key":"c2027cf5a357","_type":"span","marks":[]},{"_type":"span","marks":["4f88673cb2c4"],"text":"LinkedIn","_key":"9737335da1ed1"},{"marks":[],"text":".","_key":"9737335da1ed2","_type":"span"}],"_type":"block","style":"normal","_key":"a03d32973d6e"}],"showSocialShare":null}],"_id":"5877a6f2-9fdc-47af-8a5c-89e09960f92a","summary":null,"factCheckBy":[{"lastName":null,"url":{"current":"mary-caffrey","_type":"slug"},"profileImage":null,"biography":[{"_type":"block","style":"normal","_key":"80606b0b2412","markDefs":[],"children":[{"_type":"span","marks":[],"text":"Mary Caffrey is the Executive Editor for The American Journal of Managed Care® (","_key":"9737335da1ed0"},{"_key":"b8dda18bb0dc","_type":"span","marks":["em"],"text":"AJMC"},{"_type":"span","marks":[],"text":"®). She joined AJMC® in 2013 and is the primary staff editor for ","_key":"f56917041c08"},{"_type":"span","marks":["em"],"text":"Evidence-Based Oncology, ","_key":"8c710bb1d962"},{"_type":"span","marks":[],"text":"the multistakeholder publication that reaches 22,000+ oncology providers, policy makers and formulary decision makers. She is also part of the team that oversees speaker recruitment and panel preparations for ","_key":"1b94f48924f3"},{"text":"AJMC","_key":"3c5f9805f644","_type":"span","marks":["em"]},{"_type":"span","marks":[],"text":"®'s premier annual oncology meeting, Patient-Centered Oncology Care®. For more than a decade, Mary has covered ASCO, ASH, ACC and other leading scientific meetings for ","_key":"d533ba55a862"},{"text":"AJMC","_key":"953d8c643cce","_type":"span","marks":["em"]},{"_key":"182af2348b04","_type":"span","marks":[],"text":" readers. "}]},{"markDefs":[{"href":"https://www.linkedin.com/in/marykcaffrey/","_key":"4f88673cb2c4","nofollow":true,"blank":true,"_type":"link"}],"children":[{"_type":"span","marks":[],"text":"Mary has a BA in communications and philosophy from Loyola University New Orleans. You can connect with Mary on ","_key":"c2027cf5a357"},{"_type":"span","marks":["4f88673cb2c4"],"text":"LinkedIn","_key":"9737335da1ed1"},{"_type":"span","marks":[],"text":".","_key":"9737335da1ed2"}],"_type":"block","style":"normal","_key":"a03d32973d6e"}],"showSocialShare":null,"displayName":"Mary Caffrey","firstName":null}]},{"published":"2024-11-21T18:30:00.000Z","authorDetails":[{"profileImage":{"_type":"mainImage","alt":"Maggie L. Shaw","asset":{"_type":"reference","_ref":"image-7219c501186d8cbe6d25614b5b22645ea1c6fe2c-600x619-jpg"}},"biography":[{"_key":"643be033259e","markDefs":[],"children":[{"_key":"abc0e18a29ce0","_type":"span","marks":[],"text":"Maggie is an editor for The American Journal of Managed Care® (AJMC®) and produces written, video, and podcast content covering several disease states. She joined AJMC® in 2019, and has been with AJMC®’s parent company, MJH Life Sciences®, since 2014, when she started as a copy editor."}],"_type":"block","style":"normal"},{"children":[{"_type":"span","marks":[],"text":"She has a BA in English from Penn State University. You can connect with Maggie on ","_key":"8e1abe71bcd2"},{"_type":"span","marks":["159c764717fb"],"text":"LinkedIn","_key":"abc0e18a29ce1"},{"_key":"abc0e18a29ce2","_type":"span","marks":[],"text":"."}],"_type":"block","style":"normal","_key":"f4070c315fab","markDefs":[{"_type":"link","href":"https://www.linkedin.com/in/maggielshaw/","_key":"159c764717fb","nofollow":true,"blank":true}]}],"showSocialShare":null,"displayName":"Maggie L. Shaw","firstName":null,"lastName":null,"url":{"current":"maggie-l-shaw","_type":"slug"}}],"factCheckBy":[{"url":{"current":"maggie-l-shaw","_type":"slug"},"profileImage":{"asset":{"_ref":"image-7219c501186d8cbe6d25614b5b22645ea1c6fe2c-600x619-jpg","_type":"reference"},"_type":"mainImage","alt":"Maggie L. Shaw"},"biography":[{"_type":"block","style":"normal","_key":"643be033259e","markDefs":[],"children":[{"_type":"span","marks":[],"text":"Maggie is an editor for The American Journal of Managed Care® (AJMC®) and produces written, video, and podcast content covering several disease states. She joined AJMC® in 2019, and has been with AJMC®’s parent company, MJH Life Sciences®, since 2014, when she started as a copy editor.","_key":"abc0e18a29ce0"}]},{"markDefs":[{"_key":"159c764717fb","nofollow":true,"blank":true,"_type":"link","href":"https://www.linkedin.com/in/maggielshaw/"}],"children":[{"_type":"span","marks":[],"text":"She has a BA in English from Penn State University. You can connect with Maggie on ","_key":"8e1abe71bcd2"},{"marks":["159c764717fb"],"text":"LinkedIn","_key":"abc0e18a29ce1","_type":"span"},{"text":".","_key":"abc0e18a29ce2","_type":"span","marks":[]}],"_type":"block","style":"normal","_key":"f4070c315fab"}],"showSocialShare":null,"displayName":"Maggie L. Shaw","firstName":null,"lastName":null}],"issueGroup":{"_type":"reference","_ref":"477f9888-ea5b-4621-bb40-41487563b322"},"thumbnail":{"_type":"mainImage","asset":{"originalFilename":"NYU Lang Health.png","path":"images/0vv8moc6/ajmc/54f2a4431fd4ea73ec6c2ec625fd0d107129c22d-285x121.png","_updatedAt":"2024-11-21T18:37:58Z","_rev":"EbkpNMUbiIwDU1ASliP5Sw","_type":"sanity.imageAsset","size":3589,"_createdAt":"2024-11-21T18:37:58Z","extension":"png","metadata":{"_type":"sanity.imageMetadata","palette":{"dominant":{"background":"#510684","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":5.11},"_type":"sanity.imagePalette","darkMuted":{"foreground":"#fff","title":"#fff","population":1.1,"background":"#663881","_type":"sanity.imagePaletteSwatch"},"muted":{"background":"#7a5f8f","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.66},"lightVibrant":{"background":"#deb7ee","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#000","population":1.44},"darkVibrant":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":5.11,"background":"#510684"},"lightMuted":{"background":"#b6aac4","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":0.23},"vibrant":{"background":"#5a0696","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":3.6}},"hasAlpha":false,"lqip":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAABQAAAAICAIAAAB2/0i6AAAACXBIWXMAAAsTAAALEwEAmpwYAAABv0lEQVR4nCWQXW/SYACF+3P1wswbI4kx0cSYOXHGbcQbZM6tJCobgTL5GBW7AqWlxUDXDwqjlZaOlrbQAiPT9a0pnDwneXIuD7Ty7lR+wl+q3bomNUYirqrc5Na7AwAEIABhgg0BCIJwWHcdaDFdGddTTbB1ybmRHF20zcHMmyxXi7/+Px8A4PsArPHvgX/vbzwEAGhu33YJjUiJ5GmXzvSY834HVcSa+oc1raFrXE9Hgj0SQzTe0ngrlPViDGbQdLyofeNPIpXvL6tIlDrfo/MfmcqXDnEmUmmpGPuNvKWQKJV5Q2Z3yFyU+rFLI++aud1mJcFCuuR0LmQ03sZhjs72yLSEHV/VUwKREqswVzxo5T/QZ6+Io8doMoIhO1Qp1irGWoV9pnrCQd3aSGbGuuTYmucaS1NxBVxtZqVmRmLLinCpshdKJdH5+hxPbzeYXF8TLFOeGf2pNXShXkO/QpUBM54ormcuHX3eKcvIe/L0dT2/R/9KsIV9JvWievykknyG4TBna3PgB5vPIEfz2kX5Z7xdS/ICNlTaBpPrp7eJz1vlTw9LR1to/EHp8FEZforBEaxw0LrpOZurAQj+Ay9Ui31UdNnBAAAAAElFTkSuQmCC","dimensions":{"_type":"sanity.imageDimensions","width":285,"aspectRatio":2.355371900826446,"height":121},"isOpaque":true,"blurHash":"MQQ9ycah-:Rkx[~pM|D*%Lt7_2IVt6a{ay"},"_id":"image-54f2a4431fd4ea73ec6c2ec625fd0d107129c22d-285x121-png","uploadId":"TBdykeEPkoVIc4yGVg1aMDXZqoY4mmnp","sha1hash":"54f2a4431fd4ea73ec6c2ec625fd0d107129c22d","assetId":"54f2a4431fd4ea73ec6c2ec625fd0d107129c22d","mimeType":"image/png","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/54f2a4431fd4ea73ec6c2ec625fd0d107129c22d-285x121.png"}},"summary":"Coverage from the recent Institute for Value-Based Medicine event with NYU Langone Health.","url":"collaborating-for-cancer-care-equity-community-and-academic-insights","_id":"e122e007-e3bd-49b9-982a-29e287e95906","title":"Collaborating for Cancer Care Equity: Community and Academic Insights"},{"_id":"3ab0a249-35da-4929-895b-bc3bc50fe93c","issueGroup":{"_ref":"477f9888-ea5b-4621-bb40-41487563b322","_type":"reference"},"published":"2024-11-21T17:23:00.000Z","authorDetails":[{"displayName":"Cameron Santoro","firstName":"Cameron","lastName":"Santoro","url":{"current":"cameron-santoro","_type":"slug"},"profileImage":{"asset":{"_ref":"image-6ae51a61642a5ecba7cf4085fe97e68814e3c917-430x430-png","_type":"reference"},"_type":"mainImage","alt":"Cameron Santoro"},"biography":[{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"Cameron Santoro is an associate editor for ","_key":"93662c5c4cfd"},{"_type":"span","marks":["em"],"text":"The American Journal of Managed Care","_key":"213c257c1eca"},{"_type":"span","marks":["superscript"],"text":"®","_key":"f546acb0aa91"},{"marks":[],"text":" (","_key":"acd931edd707","_type":"span"},{"_type":"span","marks":["em"],"text":"AJMC","_key":"843f7d4e787d"},{"_key":"7c809e803edb","_type":"span","marks":["superscript"],"text":"®"},{"text":"), AJMC.com, and The Center for Biosimilars","_key":"35b69a01dbbe","_type":"span","marks":[]},{"_type":"span","marks":["superscript"],"text":"®","_key":"8ddca200bc46"},{"_type":"span","marks":[],"text":".","_key":"ba3cca6122e3"}],"_type":"block","style":"normal","_key":"3da8fced8696"}],"showSocialShare":null}],"factCheckBy":[{"displayName":"Cameron Santoro","firstName":"Cameron","lastName":"Santoro","url":{"current":"cameron-santoro","_type":"slug"},"profileImage":{"_type":"mainImage","alt":"Cameron Santoro","asset":{"_ref":"image-6ae51a61642a5ecba7cf4085fe97e68814e3c917-430x430-png","_type":"reference"}},"biography":[{"children":[{"marks":[],"text":"Cameron Santoro is an associate editor for ","_key":"93662c5c4cfd","_type":"span"},{"_type":"span","marks":["em"],"text":"The American Journal of Managed Care","_key":"213c257c1eca"},{"text":"®","_key":"f546acb0aa91","_type":"span","marks":["superscript"]},{"_key":"acd931edd707","_type":"span","marks":[],"text":" ("},{"_type":"span","marks":["em"],"text":"AJMC","_key":"843f7d4e787d"},{"_type":"span","marks":["superscript"],"text":"®","_key":"7c809e803edb"},{"_key":"35b69a01dbbe","_type":"span","marks":[],"text":"), AJMC.com, and The Center for Biosimilars"},{"text":"®","_key":"8ddca200bc46","_type":"span","marks":["superscript"]},{"text":".","_key":"ba3cca6122e3","_type":"span","marks":[]}],"_type":"block","style":"normal","_key":"3da8fced8696","markDefs":[]}],"showSocialShare":null}],"title":"Elevating Value in Cancer Care With Innovations, Accessibility, Equity","summary":"Coverage from the IVBM Regional event in Denver, Colorado.","thumbnail":{"asset":{"uploadId":"gJzaHcTHR9p1SOaC0U8krFjLzNeOH32L","_type":"sanity.imageAsset","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/c93bf646d31467af3bf1146ded1ddb1b32755d08-2022x645.png","_rev":"AGf4LvcO2r7q1La1cjaXrz","sha1hash":"c93bf646d31467af3bf1146ded1ddb1b32755d08","path":"images/0vv8moc6/ajmc/c93bf646d31467af3bf1146ded1ddb1b32755d08-2022x645.png","extension":"png","metadata":{"isOpaque":false,"blurHash":"D85Zzn4T?^H;oI.ADg%MM_j=","_type":"sanity.imageMetadata","palette":{"darkVibrant":{"foreground":"#fff","title":"#fff","population":0.04,"background":"#064487","_type":"sanity.imagePaletteSwatch"},"lightMuted":{"background":"#d5bec1","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":0.04},"vibrant":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":1.07,"background":"#18a3d3"},"dominant":{"background":"#18a3d3","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":1.07},"_type":"sanity.imagePalette","darkMuted":{"foreground":"#fff","title":"#fff","population":0.24,"background":"#28374c","_type":"sanity.imagePaletteSwatch"},"muted":{"title":"#fff","population":0.19,"background":"#61739a","_type":"sanity.imagePaletteSwatch","foreground":"#fff"},"lightVibrant":{"foreground":"#000","title":"#fff","population":0.01,"background":"#5ce4fc","_type":"sanity.imagePaletteSwatch"}},"hasAlpha":true,"lqip":"data:image/png;base64,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","dimensions":{"aspectRatio":3.1348837209302327,"height":645,"_type":"sanity.imageDimensions","width":2022}},"assetId":"c93bf646d31467af3bf1146ded1ddb1b32755d08","_createdAt":"2024-07-23T15:37:52Z","_id":"image-c93bf646d31467af3bf1146ded1ddb1b32755d08-2022x645-png","_updatedAt":"2024-07-23T15:37:52Z","mimeType":"image/png","size":266092,"originalFilename":"AJMC_Denver_Final 1.png"},"_type":"mainImage"},"url":"elevating-value-in-cancer-care-with-innovations-accessibility-equity"},{"summary":"Adults currently aging into Medicare utilized counseling and psychotherapy services at higher rates than those in prior cohorts at the same age.","thumbnail":{"_type":"mainImage","alt":"AJMC","asset":{"extension":"png","_rev":"hiKH9HIKxNVM35TxYdonKh","size":203185,"_id":"image-5421358c8f117ee86126333e135f08cf1e61ded6-778x382-png","originalFilename":"AJMC_logo_NEW.png","_type":"sanity.imageAsset","mimeType":"image/png","path":"images/0vv8moc6/ajmc/5421358c8f117ee86126333e135f08cf1e61ded6-778x382.png","assetId":"5421358c8f117ee86126333e135f08cf1e61ded6","_createdAt":"2023-07-11T20:45:56Z","_updatedAt":"2023-07-11T20:45:56Z","metadata":{"exif":{"PixelYDimension":382,"_type":"sanity.imageExifMetadata","PixelXDimension":778},"isOpaque":true,"blurHash":"MQRfnMfl?Ht7%LxvofofWBWC~pofE1t6Rj","_type":"sanity.imageMetadata","palette":{"darkMuted":{"background":"#37536a","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.71},"muted":{"title":"#fff","population":0.38,"background":"#628cad","_type":"sanity.imagePaletteSwatch","foreground":"#fff"},"lightVibrant":{"population":0.93,"background":"#cae1f2","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#000"},"darkVibrant":{"foreground":"#fff","title":"#fff","population":0.09,"background":"#044679","_type":"sanity.imagePaletteSwatch"},"lightMuted":{"title":"#fff","population":1.26,"background":"#9bb7cc","_type":"sanity.imagePaletteSwatch","foreground":"#000"},"vibrant":{"foreground":"#fff","title":"#fff","population":0.52,"background":"#18568d","_type":"sanity.imagePaletteSwatch"},"dominant":{"_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":1.26,"background":"#9bb7cc"},"_type":"sanity.imagePalette"},"hasAlpha":true,"lqip":"data:image/png;base64,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","dimensions":{"_type":"sanity.imageDimensions","width":778,"aspectRatio":2.0366492146596857,"height":382}},"uploadId":"HVdJn1r9v3RWlQCGbYP2dDQdFL6PajVT","sha1hash":"5421358c8f117ee86126333e135f08cf1e61ded6","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/5421358c8f117ee86126333e135f08cf1e61ded6-778x382.png"}},"url":"recent-cohorts-aging-into-medicare-use-more-counseling-and-psychotherapy-than-past-cohorts","published":"2024-11-14T14:00:00.000Z","authorDetails":[{"showSocialShare":null,"displayName":"Grace McCormack, PhD","firstName":"Grace","lastName":"McCormack","url":{"current":"grace-mccormack-phd","_type":"slug"},"profileImage":null,"biography":null},{"firstName":"Erin","lastName":"Duffy","url":{"current":"erin-l-duffy-phd-mph","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Erin L. Duffy, PhD, MPH"},{"biography":null,"showSocialShare":null,"displayName":"Adam Biener, PhD","firstName":"Adam","lastName":"Biener","url":{"current":"adam-biener-phd","_type":"slug"},"profileImage":null}],"_id":"f5657fbb-1a24-4a40-b7dd-55b0c5bd2234","issueGroup":{"_ref":"3b0140fe-ebe5-450c-b4e4-9f7b3e0f41d3","_type":"reference"},"title":"Recent Cohorts Aging Into Medicare Use More Counseling and Psychotherapy Than Past Cohorts","factCheckBy":[{"url":{"current":"grace-mccormack-phd","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Grace McCormack, PhD","firstName":"Grace","lastName":"McCormack"},{"lastName":"Duffy","url":{"current":"erin-l-duffy-phd-mph","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Erin L. Duffy, PhD, MPH","firstName":"Erin"},{"displayName":"Adam Biener, PhD","firstName":"Adam","lastName":"Biener","url":{"current":"adam-biener-phd","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null}]},{"issueGroup":{"_ref":"3b0140fe-ebe5-450c-b4e4-9f7b3e0f41d3","_type":"reference"},"published":"2024-11-13T14:00:00.000Z","authorDetails":[{"showSocialShare":null,"displayName":"Arthur S. Hong, MD, MPH","firstName":"Arthur","lastName":"Hong","url":{"current":"arthur-s-hong-md-mph","_type":"slug"},"profileImage":null,"biography":null},{"url":{"current":"beverly-kyalwazi-md","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Beverly Kyalwazi, MD","firstName":"Beverly","lastName":"Kyalwazi"},{"displayName":"Ethan A. Halm, MD, MPH, MBA","firstName":"Ethan","lastName":"Halm","url":{"current":"ethan-a-halm-md-mph-mba","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null},{"showSocialShare":null,"displayName":"D. Mark Courtney, MD, MSCI","firstName":"D.","lastName":"Courtney","url":{"_type":"slug","current":"d-mark-courtney-md-msci"},"profileImage":null,"biography":null},{"url":{"current":"john-w-sweetenham-md","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"John W. Sweetenham, MD","firstName":"John","lastName":"Sweetenham"},{"url":{"_type":"slug","current":"navid-sadeghi-md"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Navid Sadeghi, MD, MSPH","firstName":"Navid","lastName":"Sadeghi"},{"url":{"current":"john-v-cox-do-mba","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"John V. Cox, DO, MBA","firstName":"John","lastName":"Cox"},{"displayName":"Simon J. Craddock Lee, PhD, MPH","firstName":"Simon","lastName":"Craddock Lee","url":{"current":"simon-j-craddock-lee-phd-mph","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null}],"factCheckBy":[{"url":{"current":"arthur-s-hong-md-mph","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Arthur S. Hong, MD, MPH","firstName":"Arthur","lastName":"Hong"},{"biography":null,"showSocialShare":null,"displayName":"Beverly Kyalwazi, MD","firstName":"Beverly","lastName":"Kyalwazi","url":{"current":"beverly-kyalwazi-md","_type":"slug"},"profileImage":null},{"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Ethan A. Halm, MD, MPH, MBA","firstName":"Ethan","lastName":"Halm","url":{"current":"ethan-a-halm-md-mph-mba","_type":"slug"}},{"displayName":"D. Mark Courtney, MD, MSCI","firstName":"D.","lastName":"Courtney","url":{"current":"d-mark-courtney-md-msci","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null},{"url":{"_type":"slug","current":"john-w-sweetenham-md"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"John W. Sweetenham, MD","firstName":"John","lastName":"Sweetenham"},{"url":{"current":"navid-sadeghi-md","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Navid Sadeghi, MD, MSPH","firstName":"Navid","lastName":"Sadeghi"},{"lastName":"Cox","url":{"current":"john-v-cox-do-mba","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"John V. Cox, DO, MBA","firstName":"John"},{"firstName":"Simon","lastName":"Craddock Lee","url":{"current":"simon-j-craddock-lee-phd-mph","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Simon J. Craddock Lee, PhD, MPH"}],"_id":"d99dde01-66cf-4191-8bad-05d431132d9f","summary":"Care delivery innovations to help patients with cancer avoid emergency department visits are underused. The authors interviewed English- and Spanish-preferring patients at 2 diverse health systems to understand why.","thumbnail":{"_type":"mainImage","alt":"AJMC","asset":{"extension":"png","_rev":"hiKH9HIKxNVM35TxYdonKh","size":203185,"_id":"image-5421358c8f117ee86126333e135f08cf1e61ded6-778x382-png","originalFilename":"AJMC_logo_NEW.png","_type":"sanity.imageAsset","mimeType":"image/png","path":"images/0vv8moc6/ajmc/5421358c8f117ee86126333e135f08cf1e61ded6-778x382.png","assetId":"5421358c8f117ee86126333e135f08cf1e61ded6","_createdAt":"2023-07-11T20:45:56Z","_updatedAt":"2023-07-11T20:45:56Z","metadata":{"isOpaque":true,"blurHash":"MQRfnMfl?Ht7%LxvofofWBWC~pofE1t6Rj","_type":"sanity.imageMetadata","palette":{"lightVibrant":{"_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#000","population":0.93,"background":"#cae1f2"},"darkVibrant":{"foreground":"#fff","title":"#fff","population":0.09,"background":"#044679","_type":"sanity.imagePaletteSwatch"},"lightMuted":{"title":"#fff","population":1.26,"background":"#9bb7cc","_type":"sanity.imagePaletteSwatch","foreground":"#000"},"vibrant":{"title":"#fff","population":0.52,"background":"#18568d","_type":"sanity.imagePaletteSwatch","foreground":"#fff"},"dominant":{"background":"#9bb7cc","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":1.26},"_type":"sanity.imagePalette","darkMuted":{"background":"#37536a","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.71},"muted":{"background":"#628cad","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.38}},"hasAlpha":true,"lqip":"data:image/png;base64,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","dimensions":{"_type":"sanity.imageDimensions","width":778,"aspectRatio":2.0366492146596857,"height":382},"exif":{"PixelYDimension":382,"_type":"sanity.imageExifMetadata","PixelXDimension":778}},"uploadId":"HVdJn1r9v3RWlQCGbYP2dDQdFL6PajVT","sha1hash":"5421358c8f117ee86126333e135f08cf1e61ded6","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/5421358c8f117ee86126333e135f08cf1e61ded6-778x382.png"}},"url":"how-english--and-spanish-preferring-patients-with-cancer-decide-on-emergency-care","title":"How English- and Spanish-Preferring Patients With Cancer Decide on Emergency Care "},{"published":"2024-11-12T14:00:00.000Z","authorDetails":[{"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Sadiq Y. Patel, PhD, MS","firstName":"Sadiq","lastName":"Patel","url":{"current":"sadiq-y-patel-phd-ms","_type":"slug"}},{"displayName":"Aaron Baum, PhD","firstName":"Aaron","lastName":"Baum","url":{"current":"aaron-baum-phd","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null},{"displayName":"Sanjay Basu, MD, PhD","firstName":"Sanjay","lastName":"Basu","url":{"current":"sanjay-basu-md-phd","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null}],"issueGroup":{"_ref":"3b0140fe-ebe5-450c-b4e4-9f7b3e0f41d3","_type":"reference"},"summary":"Emergency department (ED) visits and hospitalizations for ambulatory care–sensitive conditions (ACSCs) among Medicaid patients constitute almost 40% of all ED visits and hospitalizations, with lower rates observed in areas with greater proximity to urgent care facilities and density of rural health clinics.","thumbnail":{"alt":"AJMC","asset":{"assetId":"5421358c8f117ee86126333e135f08cf1e61ded6","_createdAt":"2023-07-11T20:45:56Z","_updatedAt":"2023-07-11T20:45:56Z","metadata":{"dimensions":{"_type":"sanity.imageDimensions","width":778,"aspectRatio":2.0366492146596857,"height":382},"exif":{"PixelYDimension":382,"_type":"sanity.imageExifMetadata","PixelXDimension":778},"isOpaque":true,"blurHash":"MQRfnMfl?Ht7%LxvofofWBWC~pofE1t6Rj","_type":"sanity.imageMetadata","palette":{"darkMuted":{"background":"#37536a","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.71},"muted":{"population":0.38,"background":"#628cad","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"},"lightVibrant":{"title":"#000","population":0.93,"background":"#cae1f2","_type":"sanity.imagePaletteSwatch","foreground":"#000"},"darkVibrant":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.09,"background":"#044679"},"lightMuted":{"background":"#9bb7cc","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":1.26},"vibrant":{"title":"#fff","population":0.52,"background":"#18568d","_type":"sanity.imagePaletteSwatch","foreground":"#fff"},"dominant":{"population":1.26,"background":"#9bb7cc","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff"},"_type":"sanity.imagePalette"},"hasAlpha":true,"lqip":"data:image/png;base64,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"},"uploadId":"HVdJn1r9v3RWlQCGbYP2dDQdFL6PajVT","sha1hash":"5421358c8f117ee86126333e135f08cf1e61ded6","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/5421358c8f117ee86126333e135f08cf1e61ded6-778x382.png","extension":"png","_rev":"hiKH9HIKxNVM35TxYdonKh","size":203185,"_id":"image-5421358c8f117ee86126333e135f08cf1e61ded6-778x382-png","originalFilename":"AJMC_logo_NEW.png","_type":"sanity.imageAsset","mimeType":"image/png","path":"images/0vv8moc6/ajmc/5421358c8f117ee86126333e135f08cf1e61ded6-778x382.png"},"_type":"mainImage"},"url":"geographic-variations-and-facility-determinants-of-acute-care-utilization-and-spending-for-acscs","factCheckBy":[{"showSocialShare":null,"displayName":"Sadiq Y. Patel, PhD, MS","firstName":"Sadiq","lastName":"Patel","url":{"current":"sadiq-y-patel-phd-ms","_type":"slug"},"profileImage":null,"biography":null},{"displayName":"Aaron Baum, PhD","firstName":"Aaron","lastName":"Baum","url":{"current":"aaron-baum-phd","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null},{"displayName":"Sanjay Basu, MD, PhD","firstName":"Sanjay","lastName":"Basu","url":{"current":"sanjay-basu-md-phd","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null}],"_id":"404b320c-f480-4fc3-b080-8fa1dd562551","title":"Geographic Variations and Facility Determinants of Acute Care Utilization and Spending for ACSCs"},{"summary":null,"thumbnail":{"_type":"mainImage","alt":"Orange City ribbon-cutting | Image credit: FCS press release","caption":"Ribbon-cutting at new facility in Orange City for Florida Cancer Specialists \u0026 Research Institute in February 2024. | Image credit: FCS press release","asset":{"metadata":{"lqip":"data:image/jpeg;base64,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","dimensions":{"_type":"sanity.imageDimensions","width":1200,"aspectRatio":1.910828025477707,"height":628},"isOpaque":true,"blurHash":"MkL:AbR5tQRPo}~AV@kDi^ozx^oet7WBW=","_type":"sanity.imageMetadata","palette":{"darkMuted":{"foreground":"#fff","title":"#fff","population":2.59,"background":"#4c3827","_type":"sanity.imagePaletteSwatch"},"muted":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":7.44,"background":"#8e7b63"},"lightVibrant":{"background":"#f58d57","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":0.36},"darkVibrant":{"title":"#fff","population":0.28,"background":"#714918","_type":"sanity.imagePaletteSwatch","foreground":"#fff"},"lightMuted":{"_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":7.27,"background":"#c1a394"},"vibrant":{"background":"#e48c53","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":5.37},"dominant":{"population":7.44,"background":"#8e7b63","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"},"_type":"sanity.imagePalette"},"hasAlpha":false},"_type":"sanity.imageAsset","sha1hash":"4cc5fe49422965d25cd9df088a7f56d3a2de40b1","_createdAt":"2024-10-25T13:47:39Z","_id":"image-4cc5fe49422965d25cd9df088a7f56d3a2de40b1-1200x628-jpg","mimeType":"image/jpeg","path":"images/0vv8moc6/ajmc/4cc5fe49422965d25cd9df088a7f56d3a2de40b1-1200x628.jpg","originalFilename":"Orange-City-Ribbon-Cutting-022724.jpg","extension":"jpg","_rev":"l8hWsBDY1XE7uXNKgKoAse","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/4cc5fe49422965d25cd9df088a7f56d3a2de40b1-1200x628.jpg","size":206688,"uploadId":"i9vAHOJP6REIOEUWNlG2EiJ2k2uzm3nO","assetId":"4cc5fe49422965d25cd9df088a7f56d3a2de40b1","_updatedAt":"2024-10-25T13:47:39Z"}},"url":"beyond-mckesson-and-florida-cancer-specialists-deals-are-reshaping-community-oncology","published":"2024-10-25T13:04:00.000Z","authorDetails":[{"displayName":"Mary Caffrey","firstName":null,"lastName":null,"url":{"current":"mary-caffrey","_type":"slug"},"profileImage":null,"biography":[{"style":"normal","_key":"80606b0b2412","markDefs":[],"children":[{"text":"Mary Caffrey is the Executive Editor for The American Journal of Managed Care® (","_key":"9737335da1ed0","_type":"span","marks":[]},{"_type":"span","marks":["em"],"text":"AJMC","_key":"b8dda18bb0dc"},{"_type":"span","marks":[],"text":"®). She joined AJMC® in 2013 and is the primary staff editor for ","_key":"f56917041c08"},{"_type":"span","marks":["em"],"text":"Evidence-Based Oncology, ","_key":"8c710bb1d962"},{"_type":"span","marks":[],"text":"the multistakeholder publication that reaches 22,000+ oncology providers, policy makers and formulary decision makers. She is also part of the team that oversees speaker recruitment and panel preparations for ","_key":"1b94f48924f3"},{"_type":"span","marks":["em"],"text":"AJMC","_key":"3c5f9805f644"},{"_type":"span","marks":[],"text":"®'s premier annual oncology meeting, Patient-Centered Oncology Care®. For more than a decade, Mary has covered ASCO, ASH, ACC and other leading scientific meetings for ","_key":"d533ba55a862"},{"_type":"span","marks":["em"],"text":"AJMC","_key":"953d8c643cce"},{"_type":"span","marks":[],"text":" readers. ","_key":"182af2348b04"}],"_type":"block"},{"style":"normal","_key":"a03d32973d6e","markDefs":[{"_key":"4f88673cb2c4","nofollow":true,"blank":true,"_type":"link","href":"https://www.linkedin.com/in/marykcaffrey/"}],"children":[{"text":"Mary has a BA in communications and philosophy from Loyola University New Orleans. You can connect with Mary on ","_key":"c2027cf5a357","_type":"span","marks":[]},{"_type":"span","marks":["4f88673cb2c4"],"text":"LinkedIn","_key":"9737335da1ed1"},{"marks":[],"text":".","_key":"9737335da1ed2","_type":"span"}],"_type":"block"}],"showSocialShare":null}],"factCheckBy":[{"url":{"current":"mary-caffrey","_type":"slug"},"profileImage":null,"biography":[{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"Mary Caffrey is the Executive Editor for The American Journal of Managed Care® (","_key":"9737335da1ed0"},{"_key":"b8dda18bb0dc","_type":"span","marks":["em"],"text":"AJMC"},{"_type":"span","marks":[],"text":"®). She joined AJMC® in 2013 and is the primary staff editor for ","_key":"f56917041c08"},{"_type":"span","marks":["em"],"text":"Evidence-Based Oncology, ","_key":"8c710bb1d962"},{"_type":"span","marks":[],"text":"the multistakeholder publication that reaches 22,000+ oncology providers, policy makers and formulary decision makers. She is also part of the team that oversees speaker recruitment and panel preparations for ","_key":"1b94f48924f3"},{"text":"AJMC","_key":"3c5f9805f644","_type":"span","marks":["em"]},{"_type":"span","marks":[],"text":"®'s premier annual oncology meeting, Patient-Centered Oncology Care®. For more than a decade, Mary has covered ASCO, ASH, ACC and other leading scientific meetings for ","_key":"d533ba55a862"},{"text":"AJMC","_key":"953d8c643cce","_type":"span","marks":["em"]},{"_key":"182af2348b04","_type":"span","marks":[],"text":" readers. "}],"_type":"block","style":"normal","_key":"80606b0b2412"},{"_type":"block","style":"normal","_key":"a03d32973d6e","markDefs":[{"_key":"4f88673cb2c4","nofollow":true,"blank":true,"_type":"link","href":"https://www.linkedin.com/in/marykcaffrey/"}],"children":[{"_type":"span","marks":[],"text":"Mary has a BA in communications and philosophy from Loyola University New Orleans. You can connect with Mary on ","_key":"c2027cf5a357"},{"_type":"span","marks":["4f88673cb2c4"],"text":"LinkedIn","_key":"9737335da1ed1"},{"_type":"span","marks":[],"text":".","_key":"9737335da1ed2"}]}],"showSocialShare":null,"displayName":"Mary Caffrey","firstName":null,"lastName":null}],"issueGroup":{"_type":"reference","_ref":"f3dd603a-37be-46c5-a0ed-79c2e9f9a55d"},"title":"Beyond McKesson and Florida Cancer Specialists, Deals Are Reshaping Community Oncology ","_id":"f46ba78f-9e25-4566-a21d-7f2d8013f43b"},{"title":"Accountable Care Organizations and HPV Vaccine Uptake: A Multilevel Analysis","summary":"The authors evaluated whether adolescents receiving care at accountable care organizations (ACOs) vs non-ACOs were more likely to initiate and complete the human papillomavirus (HPV) vaccination series.","url":"accountable-care-organizations-and-hpv-vaccine-uptake-a-multilevel-analysis","_id":"444a4315-6531-40e0-845b-418d00ed04bb","thumbnail":{"asset":{"mimeType":"image/png","path":"images/0vv8moc6/ajmc/5421358c8f117ee86126333e135f08cf1e61ded6-778x382.png","_type":"sanity.imageAsset","_createdAt":"2023-07-11T20:45:56Z","_updatedAt":"2023-07-11T20:45:56Z","assetId":"5421358c8f117ee86126333e135f08cf1e61ded6","uploadId":"HVdJn1r9v3RWlQCGbYP2dDQdFL6PajVT","sha1hash":"5421358c8f117ee86126333e135f08cf1e61ded6","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/5421358c8f117ee86126333e135f08cf1e61ded6-778x382.png","metadata":{"palette":{"darkMuted":{"background":"#37536a","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.71},"muted":{"foreground":"#fff","title":"#fff","population":0.38,"background":"#628cad","_type":"sanity.imagePaletteSwatch"},"lightVibrant":{"foreground":"#000","title":"#000","population":0.93,"background":"#cae1f2","_type":"sanity.imagePaletteSwatch"},"darkVibrant":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.09,"background":"#044679"},"lightMuted":{"foreground":"#000","title":"#fff","population":1.26,"background":"#9bb7cc","_type":"sanity.imagePaletteSwatch"},"vibrant":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.52,"background":"#18568d"},"dominant":{"background":"#9bb7cc","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":1.26},"_type":"sanity.imagePalette"},"hasAlpha":true,"lqip":"data:image/png;base64,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","dimensions":{"_type":"sanity.imageDimensions","width":778,"aspectRatio":2.0366492146596857,"height":382},"exif":{"PixelYDimension":382,"_type":"sanity.imageExifMetadata","PixelXDimension":778},"isOpaque":true,"blurHash":"MQRfnMfl?Ht7%LxvofofWBWC~pofE1t6Rj","_type":"sanity.imageMetadata"},"_rev":"hiKH9HIKxNVM35TxYdonKh","size":203185,"_id":"image-5421358c8f117ee86126333e135f08cf1e61ded6-778x382-png","originalFilename":"AJMC_logo_NEW.png","extension":"png"},"_type":"mainImage"},"published":"2024-10-24T18:00:00.000Z","authorDetails":[{"firstName":"Eileen","lastName":"Carter","url":{"current":"eileen-j-carter-phd-rn","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Eileen J. Carter, PhD, RN"},{"showSocialShare":null,"displayName":"Yuen Tsz Abby Lau, PhD","firstName":"Yuen Tsz","lastName":"Lau","url":{"current":"yuen-tsz-abby-lau-phd","_type":"slug"},"profileImage":null,"biography":null},{"showSocialShare":null,"displayName":"Laurel Buchanan, MA","firstName":"Laurel","lastName":"Buchanan","url":{"current":"laurel-buchanan-ma","_type":"slug"},"profileImage":null,"biography":null},{"displayName":"David M. Krol, MD, MPH","firstName":"David","lastName":"Krol","url":{"current":"david-m-krol-md-mph","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null},{"showSocialShare":null,"displayName":"Jun Yan, PhD","firstName":"Jun","lastName":"Yan","url":{"current":"jun-yan-phd","_type":"slug"},"profileImage":null,"biography":null},{"firstName":"Robert","lastName":"Aseltine","url":{"current":"robert-h-aseltine-jr-phd","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Robert H. Aseltine Jr, PhD"}],"factCheckBy":[{"displayName":"Eileen J. Carter, PhD, RN","firstName":"Eileen","lastName":"Carter","url":{"current":"eileen-j-carter-phd-rn","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null},{"lastName":"Lau","url":{"current":"yuen-tsz-abby-lau-phd","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Yuen Tsz Abby Lau, PhD","firstName":"Yuen Tsz"},{"lastName":"Buchanan","url":{"current":"laurel-buchanan-ma","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Laurel Buchanan, MA","firstName":"Laurel"},{"displayName":"David M. Krol, MD, MPH","firstName":"David","lastName":"Krol","url":{"current":"david-m-krol-md-mph","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null},{"firstName":"Jun","lastName":"Yan","url":{"current":"jun-yan-phd","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Jun Yan, PhD"},{"firstName":"Robert","lastName":"Aseltine","url":{"current":"robert-h-aseltine-jr-phd","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Robert H. Aseltine Jr, PhD"}],"issueGroup":{"_ref":"f9450ef8-d89e-4aaa-9fac-2b11c3a068fb","_type":"reference"}},{"title":"Racial/Ethnic Disparities in Cost-Related Barriers to Care Among Near-Poor Beneficiaries in Medicare Advantage vs Traditional Medicare","summary":"Among near-poor Black and Hispanic individuals, Medicare Advantage was associated with increased vision care and some, although not uniform, reductions in access disparities vs traditional Medicare.","url":"racial-ethnic-disparities-in-cost-related-barriers-to-care-among-near-poor-beneficiaries-in-medicare-advantage-vs-traditional-medicare","published":"2024-10-23T14:00:11.540Z","_id":"c797bf68-6f9e-4d02-9336-14c1800b8a24","issueGroup":{"_ref":"f9450ef8-d89e-4aaa-9fac-2b11c3a068fb","_type":"reference"},"thumbnail":{"_type":"mainImage","alt":"AJMC","asset":{"assetId":"5421358c8f117ee86126333e135f08cf1e61ded6","_createdAt":"2023-07-11T20:45:56Z","_updatedAt":"2023-07-11T20:45:56Z","metadata":{"palette":{"vibrant":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.52,"background":"#18568d"},"dominant":{"background":"#9bb7cc","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":1.26},"_type":"sanity.imagePalette","darkMuted":{"background":"#37536a","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.71},"muted":{"background":"#628cad","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.38},"lightVibrant":{"background":"#cae1f2","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#000","population":0.93},"darkVibrant":{"foreground":"#fff","title":"#fff","population":0.09,"background":"#044679","_type":"sanity.imagePaletteSwatch"},"lightMuted":{"background":"#9bb7cc","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":1.26}},"hasAlpha":true,"lqip":"data:image/png;base64,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","dimensions":{"_type":"sanity.imageDimensions","width":778,"aspectRatio":2.0366492146596857,"height":382},"exif":{"PixelYDimension":382,"_type":"sanity.imageExifMetadata","PixelXDimension":778},"isOpaque":true,"blurHash":"MQRfnMfl?Ht7%LxvofofWBWC~pofE1t6Rj","_type":"sanity.imageMetadata"},"uploadId":"HVdJn1r9v3RWlQCGbYP2dDQdFL6PajVT","sha1hash":"5421358c8f117ee86126333e135f08cf1e61ded6","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/5421358c8f117ee86126333e135f08cf1e61ded6-778x382.png","extension":"png","_rev":"hiKH9HIKxNVM35TxYdonKh","size":203185,"_id":"image-5421358c8f117ee86126333e135f08cf1e61ded6-778x382-png","originalFilename":"AJMC_logo_NEW.png","_type":"sanity.imageAsset","mimeType":"image/png","path":"images/0vv8moc6/ajmc/5421358c8f117ee86126333e135f08cf1e61ded6-778x382.png"}},"authorDetails":[{"firstName":"Alexandra","lastName":"Hames","url":{"current":"alexandra-g-hames-phd","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Alexandra G. Hames, PhD"},{"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Renuka Tipirneni, MD, MSc","firstName":"Renuka","lastName":"Tipirneni","url":{"current":"renuka-tipirneni-md-msc","_type":"slug"}},{"showSocialShare":null,"displayName":"Galen E. Switzer, PhD","firstName":"Galen","lastName":"Switzer","url":{"current":"galen-e-switzer-phd","_type":"slug"},"profileImage":null,"biography":null},{"biography":null,"showSocialShare":null,"displayName":"John Z. Ayanian, MD, MPP","firstName":"John","lastName":"Ayanian","url":{"current":"john-z-ayanian-md-mpp","_type":"slug"},"profileImage":null},{"showSocialShare":null,"displayName":"Jeffrey T. Kullgren, MD, MS, MPH","firstName":"Jeffrey","lastName":"Kullgren","url":{"_type":"slug","current":"jeffrey-t-kullgren-md-ms-mph"},"profileImage":null,"biography":null},{"biography":null,"showSocialShare":null,"displayName":"Erica Solway, PhD, MPH, MSW","firstName":"Erica","lastName":"Solway","url":{"current":"erica-solway-phd-mph-msw","_type":"slug"},"profileImage":null},{"displayName":"Eric T. Roberts, PhD","firstName":"Eric","lastName":"Roberts","url":{"current":"eric-t-roberts-phd","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null}],"factCheckBy":[{"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Alexandra G. Hames, PhD","firstName":"Alexandra","lastName":"Hames","url":{"current":"alexandra-g-hames-phd","_type":"slug"}},{"biography":null,"showSocialShare":null,"displayName":"Renuka Tipirneni, MD, MSc","firstName":"Renuka","lastName":"Tipirneni","url":{"current":"renuka-tipirneni-md-msc","_type":"slug"},"profileImage":null},{"displayName":"Galen E. Switzer, PhD","firstName":"Galen","lastName":"Switzer","url":{"current":"galen-e-switzer-phd","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null},{"biography":null,"showSocialShare":null,"displayName":"John Z. Ayanian, MD, MPP","firstName":"John","lastName":"Ayanian","url":{"current":"john-z-ayanian-md-mpp","_type":"slug"},"profileImage":null},{"lastName":"Kullgren","url":{"current":"jeffrey-t-kullgren-md-ms-mph","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Jeffrey T. Kullgren, MD, MS, MPH","firstName":"Jeffrey"},{"biography":null,"showSocialShare":null,"displayName":"Erica Solway, PhD, MPH, MSW","firstName":"Erica","lastName":"Solway","url":{"current":"erica-solway-phd-mph-msw","_type":"slug"},"profileImage":null},{"url":{"current":"eric-t-roberts-phd","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Eric T. Roberts, PhD","firstName":"Eric","lastName":"Roberts"}]},{"url":"hospital-stays-and-probable-dementia-as-predictors-of-relocation-to-long-term-care-facilities","published":"2024-10-22T13:00:00.000Z","summary":"This article explores late-life relocations in patients with dementia, hospital stays, and their implications for health care policy, geriatric care, and future research priorities.","thumbnail":{"_type":"mainImage","alt":"AJMC","asset":{"_type":"sanity.imageAsset","mimeType":"image/png","path":"images/0vv8moc6/ajmc/5421358c8f117ee86126333e135f08cf1e61ded6-778x382.png","assetId":"5421358c8f117ee86126333e135f08cf1e61ded6","_createdAt":"2023-07-11T20:45:56Z","_updatedAt":"2023-07-11T20:45:56Z","metadata":{"lqip":"data:image/png;base64,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","dimensions":{"_type":"sanity.imageDimensions","width":778,"aspectRatio":2.0366492146596857,"height":382},"exif":{"PixelYDimension":382,"_type":"sanity.imageExifMetadata","PixelXDimension":778},"isOpaque":true,"blurHash":"MQRfnMfl?Ht7%LxvofofWBWC~pofE1t6Rj","_type":"sanity.imageMetadata","palette":{"darkMuted":{"background":"#37536a","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.71},"muted":{"background":"#628cad","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.38},"lightVibrant":{"foreground":"#000","title":"#000","population":0.93,"background":"#cae1f2","_type":"sanity.imagePaletteSwatch"},"darkVibrant":{"population":0.09,"background":"#044679","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"},"lightMuted":{"foreground":"#000","title":"#fff","population":1.26,"background":"#9bb7cc","_type":"sanity.imagePaletteSwatch"},"vibrant":{"foreground":"#fff","title":"#fff","population":0.52,"background":"#18568d","_type":"sanity.imagePaletteSwatch"},"dominant":{"foreground":"#000","title":"#fff","population":1.26,"background":"#9bb7cc","_type":"sanity.imagePaletteSwatch"},"_type":"sanity.imagePalette"},"hasAlpha":true},"uploadId":"HVdJn1r9v3RWlQCGbYP2dDQdFL6PajVT","sha1hash":"5421358c8f117ee86126333e135f08cf1e61ded6","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/5421358c8f117ee86126333e135f08cf1e61ded6-778x382.png","extension":"png","_rev":"hiKH9HIKxNVM35TxYdonKh","size":203185,"_id":"image-5421358c8f117ee86126333e135f08cf1e61ded6-778x382-png","originalFilename":"AJMC_logo_NEW.png"}},"title":"Hospital Stays and Probable Dementia as Predictors of Relocation to Long-Term Care Facilities","authorDetails":[{"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Reza Amini, PhD, MD, MPH","firstName":"Reza","lastName":"Amini","url":{"current":"reza-amini-phd-md-mph","_type":"slug"}},{"lastName":"Sidhu","url":{"current":"azmat-sidhu-mph","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Azmat Sidhu, MPH","firstName":"Azmat"}],"factCheckBy":[{"displayName":"Reza Amini, PhD, MD, MPH","firstName":"Reza","lastName":"Amini","url":{"current":"reza-amini-phd-md-mph","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null},{"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Azmat Sidhu, MPH","firstName":"Azmat","lastName":"Sidhu","url":{"current":"azmat-sidhu-mph","_type":"slug"}}],"_id":"0f3eca76-cd72-4e5c-b4bc-cdc6fe1cea34","issueGroup":{"_ref":"f9450ef8-d89e-4aaa-9fac-2b11c3a068fb","_type":"reference"}},{"issueGroup":{"_type":"reference","_ref":"f3dd603a-37be-46c5-a0ed-79c2e9f9a55d"},"title":"The Daily Balancing Act of Value-Based Cancer Care","summary":null,"url":"the-daily-balancing-act-of-value-based-cancer-care","published":"2024-10-14T20:00:00.000Z","authorDetails":[{"url":{"current":"laura-joszt","_type":"slug"},"profileImage":{"_type":"mainImage","alt":"Laura Joszt headshot","asset":{"_ref":"image-93ea362164e769dfd84dca31a8b2670a1dd9092b-512x512-jpg","_type":"reference"}},"biography":[{"markDefs":[{"_type":"link","href":"https://www.linkedin.com/in/laura-joszt-05ba7116/","_key":"f77b28536a8d"},{"href":"https://twitter.com/joszt","_key":"c419f18a7ffe","_type":"link"}],"children":[{"marks":[],"text":"Laura is the vice president of content for The American Journal of Managed Care® (AJMC®) and all its brands, including The American Journal of Accountable Care®, Evidence-Based Oncology™, and The Center for Biosimilars®. She has been working on AJMC® since 2014 and has been with AJMC®’s parent company, MJH Life Sciences®, since 2011.","_key":"67a67d3764f00","_type":"span"}],"_type":"block","style":"normal","_key":"4a950aea97b3"},{"_type":"block","style":"normal","_key":"b28d8058b3d8","markDefs":[{"nofollow":true,"blank":true,"_type":"link","href":"https://www.linkedin.com/in/laura-joszt-05ba7116/","_key":"f77b28536a8d"},{"nofollow":true,"blank":true,"_type":"link","href":"https://twitter.com/joszt","_key":"c419f18a7ffe"}],"children":[{"_key":"48d199d8ecd5","_type":"span","marks":[],"text":"She has an MA in business and economic reporting from New York University. You can connect with Laura on "},{"_type":"span","marks":["f77b28536a8d"],"text":"LinkedIn","_key":"67a67d3764f01"},{"_type":"span","marks":[],"text":" or ","_key":"67a67d3764f02"},{"_type":"span","marks":["c419f18a7ffe"],"text":"Twitter","_key":"67a67d3764f03"},{"_type":"span","marks":[],"text":".","_key":"67a67d3764f04"}]}],"showSocialShare":true,"displayName":"Laura Joszt, MA","firstName":"Laura","lastName":"Joszt"}],"factCheckBy":[{"lastName":"Joszt","url":{"current":"laura-joszt","_type":"slug"},"profileImage":{"alt":"Laura Joszt headshot","asset":{"_ref":"image-93ea362164e769dfd84dca31a8b2670a1dd9092b-512x512-jpg","_type":"reference"},"_type":"mainImage"},"biography":[{"markDefs":[{"_type":"link","href":"https://www.linkedin.com/in/laura-joszt-05ba7116/","_key":"f77b28536a8d"},{"_type":"link","href":"https://twitter.com/joszt","_key":"c419f18a7ffe"}],"children":[{"marks":[],"text":"Laura is the vice president of content for The American Journal of Managed Care® (AJMC®) and all its brands, including The American Journal of Accountable Care®, Evidence-Based Oncology™, and The Center for Biosimilars®. She has been working on AJMC® since 2014 and has been with AJMC®’s parent company, MJH Life Sciences®, since 2011.","_key":"67a67d3764f00","_type":"span"}],"_type":"block","style":"normal","_key":"4a950aea97b3"},{"_type":"block","style":"normal","_key":"b28d8058b3d8","markDefs":[{"href":"https://www.linkedin.com/in/laura-joszt-05ba7116/","_key":"f77b28536a8d","nofollow":true,"blank":true,"_type":"link"},{"blank":true,"_type":"link","href":"https://twitter.com/joszt","_key":"c419f18a7ffe","nofollow":true}],"children":[{"_key":"48d199d8ecd5","_type":"span","marks":[],"text":"She has an MA in business and economic reporting from New York University. You can connect with Laura on "},{"_type":"span","marks":["f77b28536a8d"],"text":"LinkedIn","_key":"67a67d3764f01"},{"marks":[],"text":" or ","_key":"67a67d3764f02","_type":"span"},{"_type":"span","marks":["c419f18a7ffe"],"text":"Twitter","_key":"67a67d3764f03"},{"_type":"span","marks":[],"text":".","_key":"67a67d3764f04"}]}],"showSocialShare":true,"displayName":"Laura Joszt, MA","firstName":"Laura"}],"_id":"2fe4c86e-9756-4ef8-ab38-411834bb1a83","thumbnail":{"_type":"mainImage","alt":"MinnOncology logo | Image: Minnesota Oncology","caption":"MinnOncology logo | Image: Minnesota Oncology","asset":{"_updatedAt":"2024-10-14T16:43:33Z","metadata":{"dimensions":{"_type":"sanity.imageDimensions","width":540,"aspectRatio":2.297872340425532,"height":235},"isOpaque":true,"blurHash":"MFS6V%t8~Vxu9G^+j[x]j[D*%gofsooft6","_type":"sanity.imageMetadata","palette":{"vibrant":{"background":"#0bb6ce","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.2},"dominant":{"foreground":"#fff","title":"#fff","population":0.47,"background":"#3f483a","_type":"sanity.imagePaletteSwatch"},"_type":"sanity.imagePalette","darkMuted":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.47,"background":"#3f483a"},"muted":{"foreground":"#fff","title":"#fff","population":0.11,"background":"#8e9559","_type":"sanity.imagePaletteSwatch"},"lightVibrant":{"population":0.38,"background":"#9be8ee","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#000"},"darkVibrant":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.21,"background":"#24475d"},"lightMuted":{"_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#000","population":0.1,"background":"#ccd3a1"}},"hasAlpha":false,"lqip":"data:image/jpeg;base64,/9j/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAAJABQDASIAAhEBAxEB/8QAGAAAAwEBAAAAAAAAAAAAAAAAAAQFAwj/xAAhEAABBAEEAwEAAAAAAAAAAAACAAEDBBEFITFxFDNDkf/EABUBAQEAAAAAAAAAAAAAAAAAAAID/8QAFxEAAwEAAAAAAAAAAAAAAAAAAAIRAf/aAAwDAQACEQMRAD8A6ee3kXzFILvtuym6MFmnJY8qUpmkLIYbhlR1H1D2lR5DtPFuEmeNB9rGfmf4hbIQKn//2Q=="},"path":"images/0vv8moc6/ajmc/7d70f8513adc70c28ce0e147ba594bb572d73064-540x235.jpg","size":11001,"assetId":"7d70f8513adc70c28ce0e147ba594bb572d73064","_createdAt":"2024-10-14T16:43:33Z","_id":"image-7d70f8513adc70c28ce0e147ba594bb572d73064-540x235-jpg","originalFilename":"minnesota-oncology.jpg","uploadId":"KFZplqb0QKaISRQVulrrZEj0ohzt8bwt","_type":"sanity.imageAsset","mimeType":"image/jpeg","sha1hash":"7d70f8513adc70c28ce0e147ba594bb572d73064","extension":"jpg","_rev":"KLVqzQL7KTVccOrMxma2pU","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/7d70f8513adc70c28ce0e147ba594bb572d73064-540x235.jpg"}}},{"title":"Transforming Value-Based Oncology Care in an Evolving Therapeutic Landscape","summary":null,"thumbnail":{"_type":"mainImage","asset":{"_type":"sanity.imageAsset","size":7531,"_createdAt":"2024-10-14T12:53:32Z","_id":"image-b3c196af748f73352b08b68beb6bd7d1b1becb97-310x163-jpg","extension":"jpg","uploadId":"Cn0HwxWFv0Ec8KIymIMyyzBtesHXyLzB","_rev":"tCpUdDwaYfiJObLAq3Mq1j","metadata":{"dimensions":{"width":310,"aspectRatio":1.901840490797546,"height":163,"_type":"sanity.imageDimensions"},"isOpaque":true,"blurHash":"MTRfnKxuWCkCWCt7RjjZoejZ~poJoJjsoK","_type":"sanity.imageMetadata","palette":{"lightVibrant":{"background":"#96e0f1","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#000","population":0.1},"darkVibrant":{"background":"#045ca4","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0},"lightMuted":{"background":"#caa7ae","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":0.17},"vibrant":{"foreground":"#fff","title":"#fff","population":0.03,"background":"#db1b41","_type":"sanity.imagePaletteSwatch"},"dominant":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.2,"background":"#32424f"},"_type":"sanity.imagePalette","darkMuted":{"foreground":"#fff","title":"#fff","population":0.2,"background":"#32424f","_type":"sanity.imagePaletteSwatch"},"muted":{"population":0.16,"background":"#886d76","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"}},"hasAlpha":false,"lqip":"data:image/jpeg;base64,/9j/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAALABQDASIAAhEBAxEB/8QAGAAAAwEBAAAAAAAAAAAAAAAAAAMGBQj/xAAhEAACAgICAQUAAAAAAAAAAAABAgADBREEEhRBUVNhkf/EABUBAQEAAAAAAAAAAAAAAAAAAAAB/8QAFxEBAQEBAAAAAAAAAAAAAAAAABEhQf/aAAwDAQACEQMRAD8A6FoyOUbirYlIcuOwDKQR9GNGSyCjVlNQfW9bm/oRVlFTv2etS3uRLib1OXZjKK+q6aCuvUwlB4nH+FPyEUj/2Q=="},"mimeType":"image/jpeg","sha1hash":"b3c196af748f73352b08b68beb6bd7d1b1becb97","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/b3c196af748f73352b08b68beb6bd7d1b1becb97-310x163.jpg","path":"images/0vv8moc6/ajmc/b3c196af748f73352b08b68beb6bd7d1b1becb97-310x163.jpg","assetId":"b3c196af748f73352b08b68beb6bd7d1b1becb97","_updatedAt":"2024-10-14T12:53:32Z","originalFilename":"fcs logo.jpg"}},"url":"transforming-value-based-oncology-care-in-an-evolving-therapeutic-landscape","published":"2024-10-14T18:00:00.000Z","authorDetails":[{"url":{"current":"rose-mcnulty","_type":"slug"},"profileImage":{"_type":"mainImage","alt":"Rose McNulty","asset":{"_ref":"image-8445b436ab605560bc20c7e9c6f4f60912e914df-430x430-png","_type":"reference"}},"biography":[{"_type":"block","style":"normal","_key":"3a2b873558e3","markDefs":[],"children":[{"marks":[],"text":"Rose is an associate editorial director at ","_key":"123612bd9b2b0","_type":"span"},{"_key":"2cd28f20d2b9","_type":"span","marks":["em"],"text":"The American Journal of Managed Care"},{"_type":"span","marks":["superscript"],"text":"®","_key":"032c8e723210"},{"marks":[],"text":" (","_key":"e2d5625eae03","_type":"span"},{"_key":"3af109dc927a","_type":"span","marks":["em"],"text":"AJMC"},{"_type":"span","marks":["superscript"],"text":"®","_key":"1903cd426eb6"},{"_key":"688f269c2ad0","_type":"span","marks":[],"text":")."}]},{"children":[{"_type":"span","marks":[],"text":"She has a BA in journalism \u0026 media studies and Spanish from Rutgers University. You can connect with Rose on ","_key":"3abc796e3805"},{"text":"LinkedIn","_key":"123612bd9b2b1","_type":"span","marks":["a1a427c7e90e"]},{"_type":"span","marks":[],"text":".","_key":"123612bd9b2b2"}],"_type":"block","style":"normal","_key":"3a18842aed2b","markDefs":[{"href":"https://www.linkedin.com/in/rose-mcnulty-652a09126/","_key":"a1a427c7e90e","nofollow":true,"blank":true,"_type":"link"}]}],"showSocialShare":null,"displayName":"Rose McNulty","firstName":"Rose","lastName":"McNulty"}],"factCheckBy":[{"firstName":"Rose","lastName":"McNulty","url":{"current":"rose-mcnulty","_type":"slug"},"profileImage":{"_type":"mainImage","alt":"Rose McNulty","asset":{"_ref":"image-8445b436ab605560bc20c7e9c6f4f60912e914df-430x430-png","_type":"reference"}},"biography":[{"children":[{"_type":"span","marks":[],"text":"Rose is an associate editorial director at ","_key":"123612bd9b2b0"},{"text":"The American Journal of Managed Care","_key":"2cd28f20d2b9","_type":"span","marks":["em"]},{"_type":"span","marks":["superscript"],"text":"®","_key":"032c8e723210"},{"marks":[],"text":" (","_key":"e2d5625eae03","_type":"span"},{"_type":"span","marks":["em"],"text":"AJMC","_key":"3af109dc927a"},{"_type":"span","marks":["superscript"],"text":"®","_key":"1903cd426eb6"},{"_type":"span","marks":[],"text":").","_key":"688f269c2ad0"}],"_type":"block","style":"normal","_key":"3a2b873558e3","markDefs":[]},{"_type":"block","style":"normal","_key":"3a18842aed2b","markDefs":[{"_key":"a1a427c7e90e","nofollow":true,"blank":true,"_type":"link","href":"https://www.linkedin.com/in/rose-mcnulty-652a09126/"}],"children":[{"text":"She has a BA in journalism \u0026 media studies and Spanish from Rutgers University. You can connect with Rose on ","_key":"3abc796e3805","_type":"span","marks":[]},{"marks":["a1a427c7e90e"],"text":"LinkedIn","_key":"123612bd9b2b1","_type":"span"},{"_type":"span","marks":[],"text":".","_key":"123612bd9b2b2"}]}],"showSocialShare":null,"displayName":"Rose McNulty"}],"_id":"ac700a43-4c32-49dd-81d3-c17f7eb1b5c2","issueGroup":{"_ref":"f3dd603a-37be-46c5-a0ed-79c2e9f9a55d","_type":"reference"}},{"_id":"d8777579-53e5-4e4f-a977-0e8f0c366418","issueGroup":{"_ref":"b8e3b82c-0452-4c4b-8ec4-c441a3a5bfb8","_type":"reference"},"summary":"The authors examine how insurer and patient out-of-pocket payments for advanced prostate cancer differ by drug and health plan type and describe the relationship between these payments and utilization.","thumbnail":{"_type":"mainImage","alt":"AJMC","asset":{"assetId":"5421358c8f117ee86126333e135f08cf1e61ded6","_createdAt":"2023-07-11T20:45:56Z","_updatedAt":"2023-07-11T20:45:56Z","metadata":{"dimensions":{"_type":"sanity.imageDimensions","width":778,"aspectRatio":2.0366492146596857,"height":382},"exif":{"PixelYDimension":382,"_type":"sanity.imageExifMetadata","PixelXDimension":778},"isOpaque":true,"blurHash":"MQRfnMfl?Ht7%LxvofofWBWC~pofE1t6Rj","_type":"sanity.imageMetadata","palette":{"darkMuted":{"title":"#fff","population":0.71,"background":"#37536a","_type":"sanity.imagePaletteSwatch","foreground":"#fff"},"muted":{"background":"#628cad","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.38},"lightVibrant":{"foreground":"#000","title":"#000","population":0.93,"background":"#cae1f2","_type":"sanity.imagePaletteSwatch"},"darkVibrant":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.09,"background":"#044679"},"lightMuted":{"foreground":"#000","title":"#fff","population":1.26,"background":"#9bb7cc","_type":"sanity.imagePaletteSwatch"},"vibrant":{"title":"#fff","population":0.52,"background":"#18568d","_type":"sanity.imagePaletteSwatch","foreground":"#fff"},"dominant":{"population":1.26,"background":"#9bb7cc","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff"},"_type":"sanity.imagePalette"},"hasAlpha":true,"lqip":"data:image/png;base64,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"},"uploadId":"HVdJn1r9v3RWlQCGbYP2dDQdFL6PajVT","sha1hash":"5421358c8f117ee86126333e135f08cf1e61ded6","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/5421358c8f117ee86126333e135f08cf1e61ded6-778x382.png","extension":"png","_rev":"hiKH9HIKxNVM35TxYdonKh","size":203185,"_id":"image-5421358c8f117ee86126333e135f08cf1e61ded6-778x382-png","originalFilename":"AJMC_logo_NEW.png","_type":"sanity.imageAsset","mimeType":"image/png","path":"images/0vv8moc6/ajmc/5421358c8f117ee86126333e135f08cf1e61ded6-778x382.png"}},"published":"2024-09-20T13:00:00.000Z","factCheckBy":[{"lastName":"Kaye","url":{"current":"deborah-r-kaye-md-ms","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Deborah R. Kaye, MD, MS","firstName":"Deborah"},{"biography":null,"showSocialShare":null,"displayName":"Hui-Jie Lee, PhD","firstName":"Hui-Jie","lastName":"Lee","url":{"current":"hui-jie-lee-phd","_type":"slug"},"profileImage":null},{"displayName":"Alexander Gordee, MA","firstName":"Alexander","lastName":"Gordee","url":{"_type":"slug","current":"alexander-gordee-ma"},"profileImage":null,"biography":null,"showSocialShare":null},{"firstName":"Daniel","lastName":"George","url":{"current":"daniel-j-george-md","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Daniel J. George, MD"},{"showSocialShare":null,"displayName":"Charles D. Scales Jr, MD, MSHS","firstName":"Charles","lastName":"Scales","url":{"current":"charles-d-scales-jr-md-mshs","_type":"slug"},"profileImage":null,"biography":null},{"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Peter A. Ubel, MD","firstName":"Peter","lastName":"Ubel","url":{"current":"peter-a-ubel-md","_type":"slug"}},{"url":{"current":"m-kate-bundorf-phd-mba-mph","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"M. Kate Bundorf, PhD, MBA, MPH","firstName":"M.","lastName":"Bundorf"}],"title":"Systemic Treatments for Advanced Prostate Cancer: Relationship Between Health Insurance Plan and Treatment Costs","url":"systemic-treatments-for-advanced-prostate-cancer-relationship-between-health-insurance-plan-and-treatment-costs","authorDetails":[{"lastName":"Kaye","url":{"current":"deborah-r-kaye-md-ms","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Deborah R. Kaye, MD, MS","firstName":"Deborah"},{"showSocialShare":null,"displayName":"Hui-Jie Lee, PhD","firstName":"Hui-Jie","lastName":"Lee","url":{"current":"hui-jie-lee-phd","_type":"slug"},"profileImage":null,"biography":null},{"displayName":"Alexander Gordee, MA","firstName":"Alexander","lastName":"Gordee","url":{"current":"alexander-gordee-ma","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null},{"url":{"current":"daniel-j-george-md","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Daniel J. George, MD","firstName":"Daniel","lastName":"George"},{"displayName":"Charles D. Scales Jr, MD, MSHS","firstName":"Charles","lastName":"Scales","url":{"current":"charles-d-scales-jr-md-mshs","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null},{"lastName":"Ubel","url":{"current":"peter-a-ubel-md","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Peter A. Ubel, MD","firstName":"Peter"},{"url":{"current":"m-kate-bundorf-phd-mba-mph","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"M. Kate Bundorf, PhD, MBA, MPH","firstName":"M.","lastName":"Bundorf"}]},{"_id":"caac8d8b-f8a3-4614-8abe-abe358cfa806","thumbnail":{"_type":"mainImage","alt":"AJMC","asset":{"mimeType":"image/png","path":"images/0vv8moc6/ajmc/5421358c8f117ee86126333e135f08cf1e61ded6-778x382.png","_type":"sanity.imageAsset","_createdAt":"2023-07-11T20:45:56Z","_updatedAt":"2023-07-11T20:45:56Z","assetId":"5421358c8f117ee86126333e135f08cf1e61ded6","uploadId":"HVdJn1r9v3RWlQCGbYP2dDQdFL6PajVT","sha1hash":"5421358c8f117ee86126333e135f08cf1e61ded6","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/5421358c8f117ee86126333e135f08cf1e61ded6-778x382.png","metadata":{"lqip":"data:image/png;base64,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","dimensions":{"_type":"sanity.imageDimensions","width":778,"aspectRatio":2.0366492146596857,"height":382},"exif":{"PixelYDimension":382,"_type":"sanity.imageExifMetadata","PixelXDimension":778},"isOpaque":true,"blurHash":"MQRfnMfl?Ht7%LxvofofWBWC~pofE1t6Rj","_type":"sanity.imageMetadata","palette":{"lightMuted":{"foreground":"#000","title":"#fff","population":1.26,"background":"#9bb7cc","_type":"sanity.imagePaletteSwatch"},"vibrant":{"foreground":"#fff","title":"#fff","population":0.52,"background":"#18568d","_type":"sanity.imagePaletteSwatch"},"dominant":{"_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":1.26,"background":"#9bb7cc"},"_type":"sanity.imagePalette","darkMuted":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.71,"background":"#37536a"},"muted":{"background":"#628cad","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.38},"lightVibrant":{"background":"#cae1f2","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#000","population":0.93},"darkVibrant":{"foreground":"#fff","title":"#fff","population":0.09,"background":"#044679","_type":"sanity.imagePaletteSwatch"}},"hasAlpha":true},"_rev":"hiKH9HIKxNVM35TxYdonKh","size":203185,"_id":"image-5421358c8f117ee86126333e135f08cf1e61ded6-778x382-png","originalFilename":"AJMC_logo_NEW.png","extension":"png"}},"issueGroup":{"_ref":"b8e3b82c-0452-4c4b-8ec4-c441a3a5bfb8","_type":"reference"},"title":"Care Transition Management and Patient Outcomes in Hospitalized Medicare Beneficiaries","summary":"Hospital care transition activity facilitates uptake of Medicare-reimbursed transitional care management, which is associated with lower spending and better patient outcomes.","url":"care-transition-management-and-patient-outcomes-in-hospitalized-medicare-beneficiaries","published":"2024-09-19T13:00:00.000Z","authorDetails":[{"lastName":"Ouayogodé","url":{"current":"marietou-h-ouayogode-phd","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Mariétou H. Ouayogodé, PhD","firstName":"Mariétou"},{"lastName":"Hardy","url":{"current":"brianna-hardy-bs","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Brianna Hardy, BS","firstName":"Brianna"},{"displayName":"John Mullahy, PhD","firstName":"John","lastName":"Mullahy","url":{"current":"john-mullahy-phd","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null},{"displayName":"Maureen A. Smith, MD, PhD, MPH","firstName":"Maureen","lastName":"Smith","url":{"current":"maureen-a-smith-md-phd-mph","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null},{"url":{"current":"ellen-meara-phd","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Ellen Meara, PhD","firstName":"Ellen","lastName":"Meara"}],"factCheckBy":[{"biography":null,"showSocialShare":null,"displayName":"Mariétou H. Ouayogodé, PhD","firstName":"Mariétou","lastName":"Ouayogodé","url":{"current":"marietou-h-ouayogode-phd","_type":"slug"},"profileImage":null},{"showSocialShare":null,"displayName":"Brianna Hardy, BS","firstName":"Brianna","lastName":"Hardy","url":{"current":"brianna-hardy-bs","_type":"slug"},"profileImage":null,"biography":null},{"firstName":"John","lastName":"Mullahy","url":{"_type":"slug","current":"john-mullahy-phd"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"John Mullahy, PhD"},{"displayName":"Maureen A. Smith, MD, PhD, MPH","firstName":"Maureen","lastName":"Smith","url":{"current":"maureen-a-smith-md-phd-mph","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null},{"biography":null,"showSocialShare":null,"displayName":"Ellen Meara, PhD","firstName":"Ellen","lastName":"Meara","url":{"_type":"slug","current":"ellen-meara-phd"},"profileImage":null}]},{"summary":"This article supports the use of the chronic obstructive pulmonary disease (COPD) treatment ratio as a surrogate marker of COPD exacerbation risk for quality measurement purposes.","thumbnail":{"asset":{"_type":"sanity.imageAsset","mimeType":"image/png","path":"images/0vv8moc6/ajmc/5421358c8f117ee86126333e135f08cf1e61ded6-778x382.png","assetId":"5421358c8f117ee86126333e135f08cf1e61ded6","_createdAt":"2023-07-11T20:45:56Z","_updatedAt":"2023-07-11T20:45:56Z","metadata":{"exif":{"PixelYDimension":382,"_type":"sanity.imageExifMetadata","PixelXDimension":778},"isOpaque":true,"blurHash":"MQRfnMfl?Ht7%LxvofofWBWC~pofE1t6Rj","_type":"sanity.imageMetadata","palette":{"lightMuted":{"title":"#fff","population":1.26,"background":"#9bb7cc","_type":"sanity.imagePaletteSwatch","foreground":"#000"},"vibrant":{"background":"#18568d","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.52},"dominant":{"title":"#fff","population":1.26,"background":"#9bb7cc","_type":"sanity.imagePaletteSwatch","foreground":"#000"},"_type":"sanity.imagePalette","darkMuted":{"background":"#37536a","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.71},"muted":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.38,"background":"#628cad"},"lightVibrant":{"population":0.93,"background":"#cae1f2","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#000"},"darkVibrant":{"population":0.09,"background":"#044679","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"}},"hasAlpha":true,"lqip":"data:image/png;base64,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","dimensions":{"_type":"sanity.imageDimensions","width":778,"aspectRatio":2.0366492146596857,"height":382}},"uploadId":"HVdJn1r9v3RWlQCGbYP2dDQdFL6PajVT","sha1hash":"5421358c8f117ee86126333e135f08cf1e61ded6","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/5421358c8f117ee86126333e135f08cf1e61ded6-778x382.png","extension":"png","_rev":"hiKH9HIKxNVM35TxYdonKh","size":203185,"_id":"image-5421358c8f117ee86126333e135f08cf1e61ded6-778x382-png","originalFilename":"AJMC_logo_NEW.png"},"_type":"mainImage","alt":"AJMC"},"published":"2024-09-18T16:00:00.000Z","_id":"53f2a80a-ab08-4863-9f67-14a3c7903a0d","issueGroup":{"_type":"reference","_ref":"b8e3b82c-0452-4c4b-8ec4-c441a3a5bfb8"},"title":"COPD Treatment Ratio: A Measure for Improving COPD Population Health","url":"copd-treatment-ratio-a-measure-for-improving-copd-population-health","authorDetails":[{"showSocialShare":null,"displayName":"Megha A. Parikh, PhD, MS","firstName":"Megha","lastName":"Parikh","url":{"current":"megha-a-parikh-phd-ms","_type":"slug"},"profileImage":null,"biography":null},{"displayName":"Sabree C. Burbage, PharmD, MPH","firstName":"Sabree","lastName":"Burbage","url":{"current":"sabree-c-burbage-pharmd-mph","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null},{"showSocialShare":null,"displayName":"Meghan H. Gabriel, PhD","firstName":"Meghan","lastName":"Gabriel","url":{"current":"meghan-h-gabriel-phd","_type":"slug"},"profileImage":null,"biography":null},{"url":{"_type":"slug","current":"ben-e-shirley-bsph"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Ben E. Shirley, BSPH","firstName":"Ben","lastName":"Shirley"},{"displayName":"Patrick J. Campbell, PharmD, PhD","firstName":"Patrick","lastName":"Campbell","url":{"current":"patrick-j-campbell-pharmd-phd","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null}],"factCheckBy":[{"showSocialShare":null,"displayName":"Megha A. Parikh, PhD, MS","firstName":"Megha","lastName":"Parikh","url":{"current":"megha-a-parikh-phd-ms","_type":"slug"},"profileImage":null,"biography":null},{"displayName":"Sabree C. Burbage, PharmD, MPH","firstName":"Sabree","lastName":"Burbage","url":{"current":"sabree-c-burbage-pharmd-mph","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null},{"biography":null,"showSocialShare":null,"displayName":"Meghan H. Gabriel, PhD","firstName":"Meghan","lastName":"Gabriel","url":{"current":"meghan-h-gabriel-phd","_type":"slug"},"profileImage":null},{"biography":null,"showSocialShare":null,"displayName":"Ben E. Shirley, BSPH","firstName":"Ben","lastName":"Shirley","url":{"current":"ben-e-shirley-bsph","_type":"slug"},"profileImage":null},{"displayName":"Patrick J. Campbell, PharmD, PhD","firstName":"Patrick","lastName":"Campbell","url":{"current":"patrick-j-campbell-pharmd-phd","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null}]},{"factCheckBy":[{"showSocialShare":null,"displayName":"Mary K. Caffrey","firstName":null,"lastName":null,"url":{"current":"mary-k-caffrey","_type":"slug"},"profileImage":{"_type":"mainImage","alt":"Mary K. Caffrey","asset":{"_ref":"image-ed06a2c91900970a850116ba649d9f9b4a954ca5-430x430-png","_type":"reference"},"default":false},"biography":null}],"_id":"04159ba8-44f9-40b5-b25f-0ae627881e39","issueGroup":{"_ref":"73c988a3-a73b-49fa-af49-dce7e755e713","_type":"reference"},"summary":"An IVBM event cohosted by The American Journal of Managed Care focused on Healthy State, a multiyear, multistakeholder commitment to moving Louisiana ahead in America’s Health Rankings.","published":"2024-09-16T16:31:55.211Z","authorDetails":[{"displayName":"Mary K. Caffrey","firstName":null,"lastName":null,"url":{"current":"mary-k-caffrey","_type":"slug"},"profileImage":{"default":false,"_type":"mainImage","alt":"Mary K. Caffrey","asset":{"_ref":"image-ed06a2c91900970a850116ba649d9f9b4a954ca5-430x430-png","_type":"reference"}},"biography":null,"showSocialShare":null}],"title":"Healthy State: Practicing What They Preach in Louisiana","thumbnail":{"_type":"mainImage","alt":"New Orleans Bourbon Street | Image Credit: © f11photo - stock.adobe.com","asset":{"description":null,"mimeType":"image/jpeg","sha1hash":"29b0fbb8f7b48c24276a1a8a300c1168e50e8707","path":"images/0vv8moc6/ajmc/29b0fbb8f7b48c24276a1a8a300c1168e50e8707-2800x1867.jpg","_id":"image-29b0fbb8f7b48c24276a1a8a300c1168e50e8707-2800x1867-jpg","_type":"sanity.imageAsset","uploadId":"kH1bS8OTS7iWFNmOt3qixxFUDmuSmj11","size":4265557,"extension":"jpg","title":null,"url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/29b0fbb8f7b48c24276a1a8a300c1168e50e8707-2800x1867.jpg","opt":{"media":{"tags":null}},"assetId":"29b0fbb8f7b48c24276a1a8a300c1168e50e8707","originalFilename":"New Orleans Bourbon Street - f11photo - AdobeStock_169182961.jpeg","_rev":"LtkInV1jlQdtEIFjVqjDMg","altText":null,"_createdAt":"2024-08-28T16:07:24Z","_updatedAt":"2024-08-28T16:07:46Z","metadata":{"_type":"sanity.imageMetadata","palette":{"lightVibrant":{"title":"#000","population":6.13,"background":"#f6d770","_type":"sanity.imagePaletteSwatch","foreground":"#000"},"darkVibrant":{"background":"#935917","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":6.13},"lightMuted":{"foreground":"#000","title":"#fff","population":0.06,"background":"#b6a9cd","_type":"sanity.imagePaletteSwatch"},"vibrant":{"background":"#efa11f","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":5.95},"dominant":{"background":"#f6d770","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#000","population":6.13},"_type":"sanity.imagePalette","darkMuted":{"title":"#fff","population":2.99,"background":"#2e3d58","_type":"sanity.imagePaletteSwatch","foreground":"#fff"},"muted":{"title":"#fff","population":5.22,"background":"#976e64","_type":"sanity.imagePaletteSwatch","foreground":"#fff"}},"hasAlpha":false,"lqip":"data:image/jpeg;base64,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","dimensions":{"_type":"sanity.imageDimensions","width":2800,"aspectRatio":1.4997321906802357,"height":1867},"exif":{"ExposureTime":2,"Saturation":2,"MaxApertureValue":4,"ShutterSpeedValue":-1,"PixelYDimension":1867,"PixelXDimension":2800,"LensModel":"16-35mm F4 G SSM OSS","FocalLengthIn35mmFormat":42,"ExposureProgram":1,"CustomRendered":0,"DateTimeDigitized":null,"ISO":100,"MeteringMode":5,"ColorSpace":1,"BrightnessValue":-0.89296875,"SceneCaptureType":0,"_type":"sanity.imageExifMetadata","FocalPlaneYResolution":2164.4328018223237,"FocalPlaneResolutionUnit":3,"DigitalZoomRatio":1,"DateTimeOriginal":"2016-11-15T06:32:19.000Z","LensSpecification":[16,35,4,4],"Sharpness":0,"ExposureMode":1,"RecommendedExposureIndex":100,"Contrast":0,"FocalPlaneXResolution":2164.4328018223237,"FocalLength":28,"ApertureValue":4.970853658536585,"ExposureBiasValue":0,"WhiteBalance":0,"SensitivityType":2,"FNumber":5.6,"LightSource":0},"isOpaque":true,"blurHash":"VLKJoRB?^vPDoi765Ev|$*$x~W-poztRR-%#x]SxNyt7"}}},"url":"healthy-state-practicing-what-they-preach-in-louisiana"},{"_id":"2a95bae0-0c9f-4bc1-8e7d-3602ac803646","thumbnail":{"_type":"mainImage","alt":"Denver Colorado | Image Credit: © f11photo - stock.adobe.com","asset":{"_rev":"WVB52uR738qojYGNKmrerb","mimeType":"image/jpeg","assetId":"c2b2ded664a1fbdc0483dd96d0b7deae84831a7b","_id":"image-c2b2ded664a1fbdc0483dd96d0b7deae84831a7b-1200x700-jpg","originalFilename":"Denver Colorado - f11photo - stock.adobe.com.jpeg","uploadId":"H7WTao1JKvhWv1JBicLCJENbGPV6jpQH","sha1hash":"c2b2ded664a1fbdc0483dd96d0b7deae84831a7b","extension":"jpg","_type":"sanity.imageAsset","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/c2b2ded664a1fbdc0483dd96d0b7deae84831a7b-1200x700.jpg","path":"images/0vv8moc6/ajmc/c2b2ded664a1fbdc0483dd96d0b7deae84831a7b-1200x700.jpg","metadata":{"blurHash":"MjHx1~IoS$S4oL%QRijZWrbH9vocWAoffP","_type":"sanity.imageMetadata","palette":{"dominant":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":6.64,"background":"#4f4e2c"},"_type":"sanity.imagePalette","darkMuted":{"background":"#4f4e2c","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":6.64},"muted":{"background":"#50659b","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":4.67},"lightVibrant":{"population":0.31,"background":"#e9cf8d","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#000"},"darkVibrant":{"foreground":"#fff","title":"#fff","population":0.56,"background":"#544d07","_type":"sanity.imagePaletteSwatch"},"lightMuted":{"background":"#a2a7c8","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":2.17},"vibrant":{"background":"#ca762d","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":1.42}},"hasAlpha":false,"lqip":"data:image/jpeg;base64,/9j/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAAMABQDASIAAhEBAxEB/8QAGAAAAgMAAAAAAAAAAAAAAAAAAAcCBAX/xAAfEAACAgICAwEAAAAAAAAAAAABAgADBBEGEiExYQX/xAAWAQEBAQAAAAAAAAAAAAAAAAACAwT/xAAdEQABBAIDAAAAAAAAAAAAAAADAAECEQQxBRJB/9oADAMBAAIRAxEAPwCeBhfnUkd7arNe+reptUZ/HVcV2voiKx8m2mtTWQCfgly3NtZEdhWWHgHqJI3InaVstA4C6aTkqyOIJWvfKRSRvREImxc7gMx8n5CBs83qLxhel//Z","dimensions":{"_type":"sanity.imageDimensions","width":1200,"aspectRatio":1.7142857142857142,"height":700},"exif":{"ColorSpace":1,"PixelXDimension":1200,"PixelYDimension":700,"_type":"sanity.imageExifMetadata","DateTimeDigitized":"2014-09-12T07:37:33.000Z"},"isOpaque":true},"size":584915,"_createdAt":"2024-09-13T18:14:54Z","_updatedAt":"2024-09-13T18:14:54Z"}},"published":"2024-09-16T16:31:18.436Z","authorDetails":[{"profileImage":{"_type":"mainImage","alt":"Christina Mattina","asset":{"_type":"reference","_ref":"image-6304e08858dcb7b689cd8fa5703c926a96ecdb48-512x492-jpg"}},"biography":[{"style":"normal","_key":"9271b97a8f45","markDefs":[],"children":[{"_type":"span","marks":[],"text":"Christina is the associate editorial director of ","_key":"ffac76b64934"},{"_type":"span","marks":["em"],"text":"The American Journal of Managed Care","_key":"4eac35f29678"},{"_type":"span","marks":["superscript"],"text":"®","_key":"b16316585120"},{"_type":"span","marks":[],"text":" (","_key":"ed200dc9139a"},{"_key":"b773bee92455","_type":"span","marks":["em"],"text":"AJMC"},{"_key":"1f9bb13b24fa","_type":"span","marks":["superscript"],"text":"®"},{"_type":"span","marks":[],"text":") and ","_key":"b9461d308bc8"},{"marks":["em"],"text":"The American Journal of Accountable Care","_key":"f235dc7df490","_type":"span"},{"text":"®","_key":"14118ee858d3","_type":"span","marks":["superscript"]},{"marks":[],"text":" (","_key":"a25757970c62","_type":"span"},{"marks":["em"],"text":"AJAC","_key":"6353c3a02e0f","_type":"span"},{"text":"), and joined ","_key":"7f777b20be12","_type":"span","marks":[]},{"_type":"span","marks":["em"],"text":"AJMC","_key":"682a0f2ea0d4"},{"_type":"span","marks":[],"text":" in 2016. She oversees the publication of the print journals, from manuscript submission to publication, and works with the editors in chief and editorial boards to promote the journals.","_key":"8b1f00d70d7f"}],"_type":"block"},{"markDefs":[{"nofollow":true,"blank":true,"_type":"link","href":"https://www.linkedin.com/in/christinamattina/","_key":"c281c6aba22d"}],"children":[{"text":"She has a BS in public health from Rutgers University. You can connect with Christina on ","_key":"6d8dca7834cc","_type":"span","marks":[]},{"_key":"e23534b48658","_type":"span","marks":["c281c6aba22d"],"text":"LinkedIn"},{"_key":"83d100c64d0e","_type":"span","marks":[],"text":"."}],"_type":"block","style":"normal","_key":"a90d7ab4c801"}],"showSocialShare":null,"displayName":"Christina Mattina","firstName":"Christina","lastName":"Mattina","url":{"current":"christina-mattina","_type":"slug"}}],"issueGroup":{"_ref":"73c988a3-a73b-49fa-af49-dce7e755e713","_type":"reference"},"title":"Institute for Value-Based Medicine®: Multifaceted Approach Can Help Patients Benefit From the Expanded Lipid-Lowering Toolbox","summary":"Clinicians, researchers, and payer experts convened in Aurora, Colorado, on August 13, 2024, for discussions on ensuring that the recent advancements in lipid management are making their way to patients.","url":"multifaceted-approach-can-help-patients-benefit-from-the-expanded-lipid-lowering-toolbox","factCheckBy":[{"firstName":"Christina","lastName":"Mattina","url":{"current":"christina-mattina","_type":"slug"},"profileImage":{"_type":"mainImage","alt":"Christina Mattina","asset":{"_ref":"image-6304e08858dcb7b689cd8fa5703c926a96ecdb48-512x492-jpg","_type":"reference"}},"biography":[{"_key":"9271b97a8f45","markDefs":[],"children":[{"text":"Christina is the associate editorial director of ","_key":"ffac76b64934","_type":"span","marks":[]},{"_key":"4eac35f29678","_type":"span","marks":["em"],"text":"The American Journal of Managed Care"},{"text":"®","_key":"b16316585120","_type":"span","marks":["superscript"]},{"_type":"span","marks":[],"text":" (","_key":"ed200dc9139a"},{"_key":"b773bee92455","_type":"span","marks":["em"],"text":"AJMC"},{"_type":"span","marks":["superscript"],"text":"®","_key":"1f9bb13b24fa"},{"_type":"span","marks":[],"text":") and ","_key":"b9461d308bc8"},{"_key":"f235dc7df490","_type":"span","marks":["em"],"text":"The American Journal of Accountable Care"},{"_type":"span","marks":["superscript"],"text":"®","_key":"14118ee858d3"},{"_type":"span","marks":[],"text":" (","_key":"a25757970c62"},{"_type":"span","marks":["em"],"text":"AJAC","_key":"6353c3a02e0f"},{"text":"), and joined ","_key":"7f777b20be12","_type":"span","marks":[]},{"_type":"span","marks":["em"],"text":"AJMC","_key":"682a0f2ea0d4"},{"_type":"span","marks":[],"text":" in 2016. She oversees the publication of the print journals, from manuscript submission to publication, and works with the editors in chief and editorial boards to promote the journals.","_key":"8b1f00d70d7f"}],"_type":"block","style":"normal"},{"style":"normal","_key":"a90d7ab4c801","markDefs":[{"nofollow":true,"blank":true,"_type":"link","href":"https://www.linkedin.com/in/christinamattina/","_key":"c281c6aba22d"}],"children":[{"marks":[],"text":"She has a BS in public health from Rutgers University. You can connect with Christina on ","_key":"6d8dca7834cc","_type":"span"},{"_type":"span","marks":["c281c6aba22d"],"text":"LinkedIn","_key":"e23534b48658"},{"_type":"span","marks":[],"text":".","_key":"83d100c64d0e"}],"_type":"block"}],"showSocialShare":null,"displayName":"Christina Mattina"}]},{"title":"Telehealth Insights From an Integrated Care System","summary":"Experiences from a large, integrated, value-based health system suggest that telehealth can be an effective care delivery approach. Public policies can improve telehealth access and care.","url":"telehealth-insights-from-an-integrated-care-system","published":"2024-09-16T16:29:41.215Z","factCheckBy":[{"showSocialShare":null,"displayName":"Rebecca Flournoy, MPH","firstName":"Rebecca","lastName":"Flournoy","url":{"current":"rebecca-flournoy-mph","_type":"slug"},"profileImage":null,"biography":null},{"url":{"current":"reema-shah-mph","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Reema Shah, MPH","firstName":"Reema","lastName":"Shah"},{"displayName":"Elizabeth Moisan, MS","firstName":"Elizabeth","lastName":"Moisan","url":{"current":"elizabeth-moisan-ms","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null},{"firstName":"Cecilia","lastName":"Oregón","url":{"current":"cecilia-oreg-n-mpp-mph","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Cecilia Oregón, MPP, MPH"}],"_id":"336a74f6-937d-40c6-a94c-b14c26f025f6","issueGroup":{"_ref":"73c988a3-a73b-49fa-af49-dce7e755e713","_type":"reference"},"thumbnail":{"alt":"telemedicine | Image Credit: © rh2010 - stock.adobe.com","asset":{"extension":"jpg","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/aa55cba013e542363db5e3021a7d049b005c0d44-7360x4912.jpg","path":"images/0vv8moc6/ajmc/aa55cba013e542363db5e3021a7d049b005c0d44-7360x4912.jpg","assetId":"aa55cba013e542363db5e3021a7d049b005c0d44","_id":"image-aa55cba013e542363db5e3021a7d049b005c0d44-7360x4912-jpg","sha1hash":"aa55cba013e542363db5e3021a7d049b005c0d44","size":10640408,"originalFilename":"telemedicine - rh2010.jpeg","metadata":{"palette":{"lightVibrant":{"_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#000","population":0.05,"background":"#e7d1c6"},"darkVibrant":{"background":"#493a1a","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":6.07},"lightMuted":{"_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":6.95,"background":"#bbbcbe"},"vibrant":{"background":"#ba825c","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.01},"dominant":{"_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":6.95,"background":"#bbbcbe"},"_type":"sanity.imagePalette","darkMuted":{"foreground":"#fff","title":"#fff","population":6.82,"background":"#61553c","_type":"sanity.imagePaletteSwatch"},"muted":{"background":"#b4745c","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0}},"hasAlpha":false,"lqip":"data:image/jpeg;base64,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","dimensions":{"_type":"sanity.imageDimensions","width":7360,"aspectRatio":1.498371335504886,"height":4912},"isOpaque":true,"blurHash":"VEDl=,D%4n?c-;_N%M-pD%xvM{-;_3DiWBt7xax]t7M{","_type":"sanity.imageMetadata"},"uploadId":"ueKegQc9OLg07IP1riXXhgBAywYfiVMU","_rev":"yLkPQ1Yunv4gUqVh5QBQaa","_type":"sanity.imageAsset","mimeType":"image/jpeg","_createdAt":"2023-12-05T16:28:07Z","_updatedAt":"2023-12-05T16:28:07Z"},"_type":"mainImage"},"authorDetails":[{"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Rebecca Flournoy, MPH","firstName":"Rebecca","lastName":"Flournoy","url":{"current":"rebecca-flournoy-mph","_type":"slug"}},{"biography":null,"showSocialShare":null,"displayName":"Reema Shah, MPH","firstName":"Reema","lastName":"Shah","url":{"current":"reema-shah-mph","_type":"slug"},"profileImage":null},{"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Elizabeth Moisan, MS","firstName":"Elizabeth","lastName":"Moisan","url":{"_type":"slug","current":"elizabeth-moisan-ms"}},{"lastName":"Oregón","url":{"current":"cecilia-oreg-n-mpp-mph","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Cecilia Oregón, MPP, MPH","firstName":"Cecilia"}]},{"issueGroup":{"_ref":"8f469cb0-5c36-4eaf-ab0e-2a34a0c7bf53","_type":"reference"},"title":"Building a Virtual Model for Care After Cancer","summary":null,"url":"building-a-virtual-model-for-care-after-cancer","published":"2024-08-19T16:19:00.000Z","authorDetails":[{"firstName":null,"lastName":null,"url":{"current":"mary-caffrey","_type":"slug"},"profileImage":null,"biography":[{"children":[{"text":"Mary Caffrey is the Executive Editor for The American Journal of Managed Care® (","_key":"9737335da1ed0","_type":"span","marks":[]},{"_type":"span","marks":["em"],"text":"AJMC","_key":"b8dda18bb0dc"},{"_type":"span","marks":[],"text":"®). She joined AJMC® in 2013 and is the primary staff editor for ","_key":"f56917041c08"},{"_type":"span","marks":["em"],"text":"Evidence-Based Oncology, ","_key":"8c710bb1d962"},{"_type":"span","marks":[],"text":"the multistakeholder publication that reaches 22,000+ oncology providers, policy makers and formulary decision makers. She is also part of the team that oversees speaker recruitment and panel preparations for ","_key":"1b94f48924f3"},{"_type":"span","marks":["em"],"text":"AJMC","_key":"3c5f9805f644"},{"_type":"span","marks":[],"text":"®'s premier annual oncology meeting, Patient-Centered Oncology Care®. For more than a decade, Mary has covered ASCO, ASH, ACC and other leading scientific meetings for ","_key":"d533ba55a862"},{"_type":"span","marks":["em"],"text":"AJMC","_key":"953d8c643cce"},{"_type":"span","marks":[],"text":" readers. ","_key":"182af2348b04"}],"_type":"block","style":"normal","_key":"80606b0b2412","markDefs":[]},{"style":"normal","_key":"a03d32973d6e","markDefs":[{"nofollow":true,"blank":true,"_type":"link","href":"https://www.linkedin.com/in/marykcaffrey/","_key":"4f88673cb2c4"}],"children":[{"text":"Mary has a BA in communications and philosophy from Loyola University New Orleans. You can connect with Mary on ","_key":"c2027cf5a357","_type":"span","marks":[]},{"_type":"span","marks":["4f88673cb2c4"],"text":"LinkedIn","_key":"9737335da1ed1"},{"marks":[],"text":".","_key":"9737335da1ed2","_type":"span"}],"_type":"block"}],"showSocialShare":null,"displayName":"Mary Caffrey"}],"_id":"f8b60efe-f6db-4fc2-a830-b561053d4e91","thumbnail":{"_type":"mainImage","alt":"Nurse offering virtual visit | Image credit: Pexels/ Tima Miroshnichenko","caption":"Nurse offering virtual visit | Image credit: Pexels/ Tima Miroshnichenko","asset":{"originalFilename":"telemedicine.jpeg","mimeType":"image/jpeg","sha1hash":"ff16c42fb864c9e25a3c3f95ebe8c2519c41fc88","path":"images/0vv8moc6/ajmc/ff16c42fb864c9e25a3c3f95ebe8c2519c41fc88-5928x3952.jpg","size":1146957,"_createdAt":"2024-08-19T18:07:41Z","_updatedAt":"2024-08-19T18:07:41Z","extension":"jpg","_rev":"wjCpg6dpTOIsmpmsT5C0z0","_type":"sanity.imageAsset","_id":"image-ff16c42fb864c9e25a3c3f95ebe8c2519c41fc88-5928x3952-jpg","uploadId":"2MwogAhJjfoY4HPFZ5xFzgjlENqac6KT","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/ff16c42fb864c9e25a3c3f95ebe8c2519c41fc88-5928x3952.jpg","assetId":"ff16c42fb864c9e25a3c3f95ebe8c2519c41fc88","metadata":{"lqip":"data:image/jpeg;base64,/9j/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAANABQDASIAAhEBAxEB/8QAGAAAAwEBAAAAAAAAAAAAAAAAAAYHAgT/xAAlEAABAwMDAwUAAAAAAAAAAAADAQIEAAURBhIhBxQWMTJCUXH/xAAVAQEBAAAAAAAAAAAAAAAAAAADBP/EABgRAQADAQAAAAAAAAAAAAAAAAAREyIS/9oADAMBAAIRAxEAPwCp9wbuoqPKj2lzxjFYssed5BLeSQQkdUXAl9rfypf1Bv08UWIYRdjmO2ps4ru6Q6onlucgZ3qVpGfJ2cL90N2+SVZk73udqkdzMy1RBviIqbHOVMrRTOo3Nwm9V4z6UVWmf//Z","dimensions":{"_type":"sanity.imageDimensions","width":5928,"aspectRatio":1.5,"height":3952},"isOpaque":true,"blurHash":"VLLXb^Dh.9?bD%_4%gIUM_jZD%NG%MR*bb?cR*flo#t8","_type":"sanity.imageMetadata","palette":{"lightMuted":{"_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":2.7,"background":"#c4b7a8"},"vibrant":{"background":"#bc8e62","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":0.01},"dominant":{"title":"#fff","population":7.7,"background":"#3e321f","_type":"sanity.imagePaletteSwatch","foreground":"#fff"},"_type":"sanity.imagePalette","darkMuted":{"foreground":"#fff","title":"#fff","population":7.7,"background":"#3e321f","_type":"sanity.imagePaletteSwatch"},"muted":{"background":"#945c5c","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.01},"lightVibrant":{"population":0,"background":"#d7bca2","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff"},"darkVibrant":{"population":6.19,"background":"#6e5434","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"}},"hasAlpha":false}}},"factCheckBy":[{"displayName":"Mary Caffrey","firstName":null,"lastName":null,"url":{"current":"mary-caffrey","_type":"slug"},"profileImage":null,"biography":[{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"Mary Caffrey is the Executive Editor for The American Journal of Managed Care® (","_key":"9737335da1ed0"},{"_key":"b8dda18bb0dc","_type":"span","marks":["em"],"text":"AJMC"},{"_type":"span","marks":[],"text":"®). She joined AJMC® in 2013 and is the primary staff editor for ","_key":"f56917041c08"},{"_type":"span","marks":["em"],"text":"Evidence-Based Oncology, ","_key":"8c710bb1d962"},{"_type":"span","marks":[],"text":"the multistakeholder publication that reaches 22,000+ oncology providers, policy makers and formulary decision makers. She is also part of the team that oversees speaker recruitment and panel preparations for ","_key":"1b94f48924f3"},{"text":"AJMC","_key":"3c5f9805f644","_type":"span","marks":["em"]},{"_type":"span","marks":[],"text":"®'s premier annual oncology meeting, Patient-Centered Oncology Care®. For more than a decade, Mary has covered ASCO, ASH, ACC and other leading scientific meetings for ","_key":"d533ba55a862"},{"text":"AJMC","_key":"953d8c643cce","_type":"span","marks":["em"]},{"_key":"182af2348b04","_type":"span","marks":[],"text":" readers. "}],"_type":"block","style":"normal","_key":"80606b0b2412"},{"_type":"block","style":"normal","_key":"a03d32973d6e","markDefs":[{"_key":"4f88673cb2c4","nofollow":true,"blank":true,"_type":"link","href":"https://www.linkedin.com/in/marykcaffrey/"}],"children":[{"_type":"span","marks":[],"text":"Mary has a BA in communications and philosophy from Loyola University New Orleans. You can connect with Mary on ","_key":"c2027cf5a357"},{"_type":"span","marks":["4f88673cb2c4"],"text":"LinkedIn","_key":"9737335da1ed1"},{"_type":"span","marks":[],"text":".","_key":"9737335da1ed2"}]}],"showSocialShare":null}]},{"issueGroup":{"_ref":"8f469cb0-5c36-4eaf-ab0e-2a34a0c7bf53","_type":"reference"},"title":"Revised EOM Offers More Favorable Opportunities for Community Practices, Experts Say","thumbnail":{"asset":{"path":"images/0vv8moc6/ajmc/17ee076fc9d3da91dfa9c86f1e4048fa882b29eb-602x602.png","_createdAt":"2024-05-21T20:44:39Z","metadata":{"_type":"sanity.imageMetadata","palette":{"vibrant":{"background":"#e31934","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":19.15},"dominant":{"background":"#143c8c","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":19.23},"_type":"sanity.imagePalette","darkMuted":{"background":"#293653","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":1.07},"muted":{"title":"#fff","population":0.42,"background":"#54719f","_type":"sanity.imagePaletteSwatch","foreground":"#fff"},"lightVibrant":{"background":"#fa84a0","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":0.07},"darkVibrant":{"title":"#fff","population":19.23,"background":"#143c8c","_type":"sanity.imagePaletteSwatch","foreground":"#fff"},"lightMuted":{"title":"#fff","population":3.12,"background":"#a0acc0","_type":"sanity.imagePaletteSwatch","foreground":"#000"}},"hasAlpha":true,"lqip":"data:image/png;base64,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","dimensions":{"aspectRatio":1,"height":602,"_type":"sanity.imageDimensions","width":602},"isOpaque":false,"blurHash":"eBK9_:sp2@XSI8jGkWWUMdjb1HWV_#VsQmR+rrRPt,t7ptj@HXbF6-"},"_rev":"sgy4yN0CjmArmRDnE4d79D","sha1hash":"17ee076fc9d3da91dfa9c86f1e4048fa882b29eb","size":89027,"assetId":"17ee076fc9d3da91dfa9c86f1e4048fa882b29eb","_id":"image-17ee076fc9d3da91dfa9c86f1e4048fa882b29eb-602x602-png","originalFilename":"COA_seal_2019-4C.png","extension":"png","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/17ee076fc9d3da91dfa9c86f1e4048fa882b29eb-602x602.png","_updatedAt":"2024-05-21T20:44:39Z","_type":"sanity.imageAsset","mimeType":"image/png","uploadId":"55Ghe83hpIc18afc6jZj9tvxmCfNsnZ7"},"_type":"mainImage","alt":"COA seal | Image : COA"},"url":"revised-eom-offers-more-favorable-opportunities-for-community-practices-experts-say","published":"2024-08-16T17:21:00.000Z","_id":"eaa4797e-cc0e-4b10-b3c5-169ea3739552","summary":null,"authorDetails":[{"url":{"current":"mary-caffrey","_type":"slug"},"profileImage":null,"biography":[{"_type":"block","style":"normal","_key":"80606b0b2412","markDefs":[],"children":[{"text":"Mary Caffrey is the Executive Editor for The American Journal of Managed Care® (","_key":"9737335da1ed0","_type":"span","marks":[]},{"_type":"span","marks":["em"],"text":"AJMC","_key":"b8dda18bb0dc"},{"_type":"span","marks":[],"text":"®). She joined AJMC® in 2013 and is the primary staff editor for ","_key":"f56917041c08"},{"_type":"span","marks":["em"],"text":"Evidence-Based Oncology, ","_key":"8c710bb1d962"},{"_type":"span","marks":[],"text":"the multistakeholder publication that reaches 22,000+ oncology providers, policy makers and formulary decision makers. She is also part of the team that oversees speaker recruitment and panel preparations for ","_key":"1b94f48924f3"},{"_type":"span","marks":["em"],"text":"AJMC","_key":"3c5f9805f644"},{"_type":"span","marks":[],"text":"®'s premier annual oncology meeting, Patient-Centered Oncology Care®. For more than a decade, Mary has covered ASCO, ASH, ACC and other leading scientific meetings for ","_key":"d533ba55a862"},{"_type":"span","marks":["em"],"text":"AJMC","_key":"953d8c643cce"},{"_type":"span","marks":[],"text":" readers. ","_key":"182af2348b04"}]},{"children":[{"text":"Mary has a BA in communications and philosophy from Loyola University New Orleans. You can connect with Mary on ","_key":"c2027cf5a357","_type":"span","marks":[]},{"_type":"span","marks":["4f88673cb2c4"],"text":"LinkedIn","_key":"9737335da1ed1"},{"marks":[],"text":".","_key":"9737335da1ed2","_type":"span"}],"_type":"block","style":"normal","_key":"a03d32973d6e","markDefs":[{"_type":"link","href":"https://www.linkedin.com/in/marykcaffrey/","_key":"4f88673cb2c4","nofollow":true,"blank":true}]}],"showSocialShare":null,"displayName":"Mary Caffrey","firstName":null,"lastName":null}],"factCheckBy":[{"firstName":null,"lastName":null,"url":{"current":"mary-caffrey","_type":"slug"},"profileImage":null,"biography":[{"children":[{"_type":"span","marks":[],"text":"Mary Caffrey is the Executive Editor for The American Journal of Managed Care® (","_key":"9737335da1ed0"},{"_key":"b8dda18bb0dc","_type":"span","marks":["em"],"text":"AJMC"},{"_type":"span","marks":[],"text":"®). She joined AJMC® in 2013 and is the primary staff editor for ","_key":"f56917041c08"},{"_type":"span","marks":["em"],"text":"Evidence-Based Oncology, ","_key":"8c710bb1d962"},{"_type":"span","marks":[],"text":"the multistakeholder publication that reaches 22,000+ oncology providers, policy makers and formulary decision makers. She is also part of the team that oversees speaker recruitment and panel preparations for ","_key":"1b94f48924f3"},{"text":"AJMC","_key":"3c5f9805f644","_type":"span","marks":["em"]},{"_type":"span","marks":[],"text":"®'s premier annual oncology meeting, Patient-Centered Oncology Care®. For more than a decade, Mary has covered ASCO, ASH, ACC and other leading scientific meetings for ","_key":"d533ba55a862"},{"text":"AJMC","_key":"953d8c643cce","_type":"span","marks":["em"]},{"_key":"182af2348b04","_type":"span","marks":[],"text":" readers. "}],"_type":"block","style":"normal","_key":"80606b0b2412","markDefs":[]},{"markDefs":[{"_key":"4f88673cb2c4","nofollow":true,"blank":true,"_type":"link","href":"https://www.linkedin.com/in/marykcaffrey/"}],"children":[{"_type":"span","marks":[],"text":"Mary has a BA in communications and philosophy from Loyola University New Orleans. You can connect with Mary on ","_key":"c2027cf5a357"},{"_type":"span","marks":["4f88673cb2c4"],"text":"LinkedIn","_key":"9737335da1ed1"},{"_type":"span","marks":[],"text":".","_key":"9737335da1ed2"}],"_type":"block","style":"normal","_key":"a03d32973d6e"}],"showSocialShare":null,"displayName":"Mary Caffrey"}]},{"_id":"77701ccb-39e1-4b49-ac6b-b5aa65801a00","title":"Collaborative Innovation: Flatiron Health and Canopy Partner to Streamline Continuous Care for Oncology Practices","summary":null,"authorDetails":[{"displayName":"Lavi Kwiatkowsky","firstName":"lavi","lastName":"Kwiatkowsky","url":{"current":"lavi-kwiatkowsky","_type":"slug"},"profileImage":null,"biography":[{"style":"normal","_key":"4839ffeb2829","markDefs":[],"children":[{"_type":"span","marks":[],"text":"Lavi Kwiatkowsky is the founder and CEO of Canopy.","_key":"33c855f42e2b0"}],"_type":"block"}],"showSocialShare":null},{"showSocialShare":null,"displayName":"Geoff Calkins","firstName":"Geoff","lastName":"Calkins","url":{"current":"geoff-calkins","_type":"slug"},"profileImage":null,"biography":null}],"factCheckBy":[{"displayName":"Lavi Kwiatkowsky","firstName":"lavi","lastName":"Kwiatkowsky","url":{"current":"lavi-kwiatkowsky","_type":"slug"},"profileImage":null,"biography":[{"children":[{"_type":"span","marks":[],"text":"Lavi Kwiatkowsky is the founder and CEO of Canopy.","_key":"33c855f42e2b0"}],"_type":"block","style":"normal","_key":"4839ffeb2829","markDefs":[]}],"showSocialShare":null},{"firstName":"Geoff","lastName":"Calkins","url":{"current":"geoff-calkins","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Geoff Calkins"}],"issueGroup":{"_type":"reference","_ref":"8f469cb0-5c36-4eaf-ab0e-2a34a0c7bf53"},"thumbnail":{"caption":"Flatiron + Canopy logo | Image: Canopy","asset":{"_createdAt":"2024-08-16T11:54:45Z","extension":"png","originalFilename":"flatiron canopy.png","_updatedAt":"2024-08-16T11:54:45Z","_rev":"EDJmlW7GHoHEwq10zl3D3G","sha1hash":"48b05b74a043a14725208c64dc5511c83f873960","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/48b05b74a043a14725208c64dc5511c83f873960-2048x738.png","path":"images/0vv8moc6/ajmc/48b05b74a043a14725208c64dc5511c83f873960-2048x738.png","assetId":"48b05b74a043a14725208c64dc5511c83f873960","_id":"image-48b05b74a043a14725208c64dc5511c83f873960-2048x738-png","metadata":{"_type":"sanity.imageMetadata","palette":{"_type":"sanity.imagePalette","darkMuted":{"population":0.44,"background":"#465281","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"},"muted":{"foreground":"#fff","title":"#fff","population":0.1,"background":"#5e599d","_type":"sanity.imagePaletteSwatch"},"lightVibrant":{"foreground":"#000","title":"#000","population":0.03,"background":"#d5d4fc","_type":"sanity.imagePaletteSwatch"},"darkVibrant":{"foreground":"#fff","title":"#fff","population":0.01,"background":"#041c71","_type":"sanity.imagePaletteSwatch"},"lightMuted":{"population":0.58,"background":"#a4afd8","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff"},"vibrant":{"background":"#1c2c84","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":42.73},"dominant":{"population":42.73,"background":"#1c2c84","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"}},"hasAlpha":true,"lqip":"data:image/png;base64,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","dimensions":{"aspectRatio":2.7750677506775068,"height":738,"_type":"sanity.imageDimensions","width":2048},"isOpaque":true,"blurHash":"D47nu1xU%Lx^4n?dxtt7ofM{"},"uploadId":"3ct5wI5akdtTDeBzgjxMzDWJAYaAnmYK","_type":"sanity.imageAsset","mimeType":"image/png","size":930539},"_type":"mainImage","alt":"Flatiron + Canopy logo | Image: Canopy"},"url":"collaborative-innovation-flatiron-health-and-canopy-partner-to-streamline-continuous-care-for-oncology-practices","published":"2024-08-16T11:30:00.000Z"},{"url":"cardiometabolic-interventions-focus-on-accessibility-evidence-based-medicine","published":"2024-06-14T13:00:00.000Z","factCheckBy":[{"showSocialShare":null,"displayName":"Giuliana Grossi","firstName":null,"lastName":null,"url":{"current":"giuliana-grossi","_type":"slug"},"profileImage":{"_type":"mainImage","alt":"Giuliana Grossi","asset":{"_ref":"image-5dc1da24786c43a7f87e4ea0a7ae3880e6cee39f-430x430-png","_type":"reference"}},"biography":null}],"summary":"At an Institute for Value-Based Medicine® (IVBM) event cohosted by The American Journal of Managed Care® and Sutter Health, experts illuminated the current state of cardiometabolic health care and offered a glimpse into the future.","thumbnail":{"_type":"mainImage","alt":"San Francisco's Golden Gate Bridge | Image Credit: © phitha - stock.adobe.com","asset":{"_type":"sanity.imageAsset","_id":"image-1f3095024fd984fa3a60b43c4cf33663635bcaf7-1200x800-jpg","originalFilename":"San Francisco Golden Gate Bridge - phitha - stock.adobe.com.jpeg","extension":"jpg","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/1f3095024fd984fa3a60b43c4cf33663635bcaf7-1200x800.jpg","size":416089,"_createdAt":"2024-06-07T15:30:01Z","assetId":"1f3095024fd984fa3a60b43c4cf33663635bcaf7","metadata":{"blurHash":"VuJ@2qs:WCjYbb}%soahbIjs-:R*WBoJW:I.W=WEoLj[","_type":"sanity.imageMetadata","palette":{"darkMuted":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":7.93,"background":"#2e3250"},"muted":{"title":"#fff","population":0.47,"background":"#9c5c58","_type":"sanity.imagePaletteSwatch","foreground":"#fff"},"lightVibrant":{"background":"#fbe182","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#000","population":4.62},"darkVibrant":{"foreground":"#fff","title":"#fff","population":3.69,"background":"#6f2c2a","_type":"sanity.imagePaletteSwatch"},"lightMuted":{"foreground":"#000","title":"#fff","population":8.5,"background":"#9099c0","_type":"sanity.imagePaletteSwatch"},"vibrant":{"background":"#f2a973","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":7.2},"dominant":{"title":"#fff","population":8.5,"background":"#9099c0","_type":"sanity.imagePaletteSwatch","foreground":"#000"},"_type":"sanity.imagePalette"},"hasAlpha":false,"lqip":"data:image/jpeg;base64,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","dimensions":{"_type":"sanity.imageDimensions","width":1200,"aspectRatio":1.5,"height":800},"exif":{"ExposureBiasValue":0,"ApertureValue":6.9188632619439865,"ExposureProgram":3,"FocalPlaneXResolution":2164.4328018223237,"ShutterSpeedValue":-1.6780719083366258,"ExposureMode":0,"PixelYDimension":800,"WhiteBalance":1,"SceneCaptureType":0,"Sharpness":0,"ISO":200,"DateTimeOriginal":"2016-06-04T04:25:41.000Z","LightSource":14,"FocalPlaneResolutionUnit":3,"Contrast":0,"MaxApertureValue":4.970853658536585,"BrightnessValue":-0.44765625,"Saturation":0,"CustomRendered":0,"ColorSpace":1,"MeteringMode":5,"LensSpecification":[70,300,4.5,5.6],"ExposureTime":3.2,"FNumber":11,"FocalLength":220,"PixelXDimension":1200,"RecommendedExposureIndex":200,"SensitivityType":2,"DigitalZoomRatio":1,"DateTimeDigitized":"2016-06-04T04:25:41.000Z","LensModel":"FE 70-300mm F4.5-5.6 G OSS","FocalLengthIn35mmFormat":220,"_type":"sanity.imageExifMetadata","FocalPlaneYResolution":2164.4328018223237},"isOpaque":true},"uploadId":"O5nnIZFuz4knEBd9QmteN8nCCmR8xh2K","_rev":"SWZtARO2mf3vRstToueLld","mimeType":"image/jpeg","path":"images/0vv8moc6/ajmc/1f3095024fd984fa3a60b43c4cf33663635bcaf7-1200x800.jpg","sha1hash":"1f3095024fd984fa3a60b43c4cf33663635bcaf7","_updatedAt":"2024-06-07T15:30:01Z"}},"title":"Cardiometabolic Interventions Focus on Accessibility, Evidence-Based Medicine","authorDetails":[{"profileImage":{"_type":"mainImage","alt":"Giuliana Grossi","asset":{"_ref":"image-5dc1da24786c43a7f87e4ea0a7ae3880e6cee39f-430x430-png","_type":"reference"}},"biography":null,"showSocialShare":null,"displayName":"Giuliana Grossi","firstName":null,"lastName":null,"url":{"current":"giuliana-grossi","_type":"slug"}}],"_id":"1472df1f-ab77-4b68-8ced-12ff81256022","issueGroup":{"_ref":"c6747bef-322f-4aa5-bf20-1af9d678cde0","_type":"reference"}},{"title":"Experts Highlight How GLP-1s Have Revolutionized Management of T2D and Obesity ","published":"2024-06-13T19:00:00.000Z","authorDetails":[{"profileImage":{"_type":"mainImage","alt":"Laura Joszt headshot","asset":{"_ref":"image-93ea362164e769dfd84dca31a8b2670a1dd9092b-512x512-jpg","_type":"reference"}},"biography":[{"_type":"block","style":"normal","_key":"4a950aea97b3","markDefs":[{"_type":"link","href":"https://www.linkedin.com/in/laura-joszt-05ba7116/","_key":"f77b28536a8d"},{"href":"https://twitter.com/joszt","_key":"c419f18a7ffe","_type":"link"}],"children":[{"marks":[],"text":"Laura is the vice president of content for The American Journal of Managed Care® (AJMC®) and all its brands, including The American Journal of Accountable Care®, Evidence-Based Oncology™, and The Center for Biosimilars®. She has been working on AJMC® since 2014 and has been with AJMC®’s parent company, MJH Life Sciences®, since 2011.","_key":"67a67d3764f00","_type":"span"}]},{"markDefs":[{"nofollow":true,"blank":true,"_type":"link","href":"https://www.linkedin.com/in/laura-joszt-05ba7116/","_key":"f77b28536a8d"},{"nofollow":true,"blank":true,"_type":"link","href":"https://twitter.com/joszt","_key":"c419f18a7ffe"}],"children":[{"_key":"48d199d8ecd5","_type":"span","marks":[],"text":"She has an MA in business and economic reporting from New York University. You can connect with Laura on "},{"_type":"span","marks":["f77b28536a8d"],"text":"LinkedIn","_key":"67a67d3764f01"},{"_type":"span","marks":[],"text":" or ","_key":"67a67d3764f02"},{"_type":"span","marks":["c419f18a7ffe"],"text":"Twitter","_key":"67a67d3764f03"},{"_type":"span","marks":[],"text":".","_key":"67a67d3764f04"}],"_type":"block","style":"normal","_key":"b28d8058b3d8"}],"showSocialShare":true,"displayName":"Laura Joszt, MA","firstName":"Laura","lastName":"Joszt","url":{"current":"laura-joszt","_type":"slug"}}],"factCheckBy":[{"firstName":"Laura","lastName":"Joszt","url":{"current":"laura-joszt","_type":"slug"},"profileImage":{"alt":"Laura Joszt headshot","asset":{"_ref":"image-93ea362164e769dfd84dca31a8b2670a1dd9092b-512x512-jpg","_type":"reference"},"_type":"mainImage"},"biography":[{"markDefs":[{"_type":"link","href":"https://www.linkedin.com/in/laura-joszt-05ba7116/","_key":"f77b28536a8d"},{"_type":"link","href":"https://twitter.com/joszt","_key":"c419f18a7ffe"}],"children":[{"marks":[],"text":"Laura is the vice president of content for The American Journal of Managed Care® (AJMC®) and all its brands, including The American Journal of Accountable Care®, Evidence-Based Oncology™, and The Center for Biosimilars®. She has been working on AJMC® since 2014 and has been with AJMC®’s parent company, MJH Life Sciences®, since 2011.","_key":"67a67d3764f00","_type":"span"}],"_type":"block","style":"normal","_key":"4a950aea97b3"},{"style":"normal","_key":"b28d8058b3d8","markDefs":[{"_key":"f77b28536a8d","nofollow":true,"blank":true,"_type":"link","href":"https://www.linkedin.com/in/laura-joszt-05ba7116/"},{"nofollow":true,"blank":true,"_type":"link","href":"https://twitter.com/joszt","_key":"c419f18a7ffe"}],"children":[{"_key":"48d199d8ecd5","_type":"span","marks":[],"text":"She has an MA in business and economic reporting from New York University. You can connect with Laura on "},{"_type":"span","marks":["f77b28536a8d"],"text":"LinkedIn","_key":"67a67d3764f01"},{"marks":[],"text":" or ","_key":"67a67d3764f02","_type":"span"},{"_type":"span","marks":["c419f18a7ffe"],"text":"Twitter","_key":"67a67d3764f03"},{"_type":"span","marks":[],"text":".","_key":"67a67d3764f04"}],"_type":"block"}],"showSocialShare":true,"displayName":"Laura Joszt, MA"}],"_id":"4d553701-915f-4873-8b9f-4f53893d6561","issueGroup":{"_ref":"c6747bef-322f-4aa5-bf20-1af9d678cde0","_type":"reference"},"summary":"The number of Americans with type 2 diabetes and/or obesity is rising, and the entry of therapies such as glucagon-like peptide-1 (GLP-1) receptor agonists has been revolutionary.","thumbnail":{"_type":"mainImage","alt":"Cleveland Ohio | Image Credit: © Ai - stock.adobe.com.jpeg","asset":{"_rev":"FTf7O3KU2GxuMy4tElpSB4","originalFilename":"Cleveland Ohio - Ai - stock.adobe.com.jpeg","metadata":{"dimensions":{"width":1200,"aspectRatio":1.5,"height":800,"_type":"sanity.imageDimensions"},"exif":{"MeteringMode":5,"FNumber":20,"ExposureProgram":3,"Saturation":1,"LensSpecification":[18,55,2.8,4],"ExposureMode":0,"LensSerialNumber":"48A03748","PixelXDimension":1200,"FocalPlaneResolutionUnit":3,"SubjectDistanceRange":0,"FocalPlaneYResolution":2083.4231274638632,"DateTimeOriginal":"2016-07-24T18:28:07.000Z","ISO":500,"FocalPlaneXResolution":2083.4231274638632,"LightSource":11,"PixelYDimension":800,"ShutterSpeedValue":3.584962502403692,"ExposureTime":0.08333333333333333,"Sharpness":0,"ColorSpace":1,"LensModel":"XF18-55mmF2.8-4 R LM OIS","BrightnessValue":5.84,"CustomRendered":0,"WhiteBalance":1,"_type":"sanity.imageExifMetadata","SensitivityType":1,"SensingMethod":2,"ApertureValue":8.643856143856144,"ExposureBiasValue":0.33,"LensMake":"FUJIFILM","FocalLengthIn35mmFormat":27,"MaxApertureValue":2.9708536585365852,"FocalLength":18,"SceneCaptureType":0,"DateTimeDigitized":"2016-07-24T00:00:00.000Z"},"isOpaque":true,"blurHash":"VwHx:8$xRit5WA_4$~jEaej[T1oMWEa}axENR-f6bIWC","_type":"sanity.imageMetadata","palette":{"vibrant":{"population":5.13,"background":"#0d90d3","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"},"dominant":{"background":"#677397","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":6.22},"_type":"sanity.imagePalette","darkMuted":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":2.79,"background":"#30384f"},"muted":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":6.22,"background":"#677397"},"lightVibrant":{"title":"#000","population":2.52,"background":"#efc989","_type":"sanity.imagePaletteSwatch","foreground":"#000"},"darkVibrant":{"background":"#043484","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0},"lightMuted":{"foreground":"#000","title":"#fff","population":2.56,"background":"#8897be","_type":"sanity.imagePaletteSwatch"}},"hasAlpha":false,"lqip":"data:image/jpeg;base64,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"},"extension":"jpg","sha1hash":"264df279db594adda69bc3737a08c6773f27a6ef","size":501001,"_updatedAt":"2024-06-07T15:42:37Z","uploadId":"gcL2RcGUNOwVnVWGsh0ao9mQiEvDHrKK","_type":"sanity.imageAsset","mimeType":"image/jpeg","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/264df279db594adda69bc3737a08c6773f27a6ef-1200x800.jpg","path":"images/0vv8moc6/ajmc/264df279db594adda69bc3737a08c6773f27a6ef-1200x800.jpg","assetId":"264df279db594adda69bc3737a08c6773f27a6ef","_createdAt":"2024-06-07T15:42:37Z","_id":"image-264df279db594adda69bc3737a08c6773f27a6ef-1200x800-jpg"}},"url":"experts-highlight-how-glp-1s-have-revolutionized-management-of-t2d-and-obesity"},{"authorDetails":[{"firstName":"Dennis","lastName":"Holmes","url":{"current":"dennis-r-holmes-md","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Dennis R. Holmes, MD"},{"url":{"current":"steven-d-evans-md","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Steven D. Evans, MD","firstName":"Steven","lastName":"Evans"},{"lastName":"Fisher","url":{"current":"warren-fisher-do","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Warren Fisher, DO","firstName":"Warren"},{"showSocialShare":null,"displayName":"Darren Wheeler, MD","firstName":"Darren","lastName":"Wheeler","url":{"current":"darren-wheeler-md","_type":"slug"},"profileImage":null,"biography":null},{"displayName":"Riya Pulicharam, MD, CPI","firstName":"Riya","lastName":"Pulicharam","url":{"current":"riya-pulicharam-md-cpi","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null}],"thumbnail":{"alt":"Medical technology and digital health network concept | Image Credit: © ipopba - stock.adobe.com","asset":{"metadata":{"lqip":"data:image/jpeg;base64,/9j/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAANABQDASIAAhEBAxEB/8QAFwAAAwEAAAAAAAAAAAAAAAAAAAUHBv/EACIQAAICAQQCAwEAAAAAAAAAAAECAwQABQYREiExIiNCUf/EABYBAQEBAAAAAAAAAAAAAAAAAAUDBP/EABsRAAICAwEAAAAAAAAAAAAAAAACAREDIVEx/9oADAMBAAIRAxEAPwCshFEbMydlXyOBivWAwoLclAjqBvtP6C/3NC1wQN0SFfI94rv6WNy6fZqzTyV4SCGEXs4gjVOwrKkstL6LKm3tEvVYrUEvMcq9h1bxhk21apY27dbTal+doIh8eTxhmip6SqOH/9k=","dimensions":{"_type":"sanity.imageDimensions","width":1280,"aspectRatio":1.6,"height":800},"isOpaque":true,"blurHash":"VKJ01o~pIBTJo#K6MxxuRjs:R6xuNGxuRORi-;IUSexb","_type":"sanity.imageMetadata","palette":{"_type":"sanity.imagePalette","darkMuted":{"title":"#fff","population":0.14,"background":"#655176","_type":"sanity.imagePaletteSwatch","foreground":"#fff"},"muted":{"population":7.54,"background":"#629eb9","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"},"lightVibrant":{"title":"#000","population":3.38,"background":"#badff5","_type":"sanity.imagePaletteSwatch","foreground":"#000"},"darkVibrant":{"title":"#fff","population":8.47,"background":"#205a7b","_type":"sanity.imagePaletteSwatch","foreground":"#fff"},"lightMuted":{"foreground":"#000","title":"#fff","population":4.58,"background":"#a4c2d3","_type":"sanity.imagePaletteSwatch"},"vibrant":{"background":"#2bc4d6","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":1.22},"dominant":{"background":"#205a7b","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":8.47}},"hasAlpha":false},"size":323017,"_id":"image-1e602bba35858bd62230432132517d1d42061e3d-1280x800-jpg","uploadId":"hTRTLrPbL2uAPSQkjvmAG41W4tGru8UX","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/1e602bba35858bd62230432132517d1d42061e3d-1280x800.jpg","assetId":"1e602bba35858bd62230432132517d1d42061e3d","originalFilename":"Medicine doctor hold icon health and electronic medical record on interface. Digital healthcare and network connection on hologram virtual screen, insurance. medical technology and network concept - ipopba - stock.adobe.com.jpeg","extension":"jpg","path":"images/0vv8moc6/ajmc/1e602bba35858bd62230432132517d1d42061e3d-1280x800.jpg","_createdAt":"2023-09-25T20:33:46Z","_rev":"pEhoUqandJkxjPidorVwRV","_type":"sanity.imageAsset","mimeType":"image/jpeg","sha1hash":"1e602bba35858bd62230432132517d1d42061e3d","_updatedAt":"2023-09-25T20:33:46Z"},"_type":"mainImage"},"issueGroup":{"_type":"reference","_ref":"c6747bef-322f-4aa5-bf20-1af9d678cde0"},"title":"Reducing Delays in Breast Cancer Care Using an Innovative Digital Health Platform","summary":"The use of a novel digital health platform achieved a 55% reduction in time to treatment among women with a new diagnosis of breast cancer.","url":"reducing-delays-in-breast-cancer-care-using-an-innovative-digital-health-platform","published":"2024-06-13T13:00:00.000Z","factCheckBy":[{"biography":null,"showSocialShare":null,"displayName":"Dennis R. Holmes, MD","firstName":"Dennis","lastName":"Holmes","url":{"current":"dennis-r-holmes-md","_type":"slug"},"profileImage":null},{"firstName":"Steven","lastName":"Evans","url":{"current":"steven-d-evans-md","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null,"displayName":"Steven D. Evans, MD"},{"displayName":"Warren Fisher, DO","firstName":"Warren","lastName":"Fisher","url":{"current":"warren-fisher-do","_type":"slug"},"profileImage":null,"biography":null,"showSocialShare":null},{"showSocialShare":null,"displayName":"Darren Wheeler, MD","firstName":"Darren","lastName":"Wheeler","url":{"current":"darren-wheeler-md","_type":"slug"},"profileImage":null,"biography":null},{"biography":null,"showSocialShare":null,"displayName":"Riya Pulicharam, MD, CPI","firstName":"Riya","lastName":"Pulicharam","url":{"current":"riya-pulicharam-md-cpi","_type":"slug"},"profileImage":null}],"_id":"e881417a-9e64-48ca-9b72-7daafa2dd9c4"}],"isLiveSite":true,"host":"www.ajmc.com","settings":{"title":"AJMC","networkID":"4688","adUnit":"ajmc.com","liveDomain":"www.ajmc.com","publicationName":"AJMC","logo":"/ajmc_logo_inverted.png","white_logo":"/ajmc_logo_inverted.png","logoHeight":"50px","enableEdgeCache":true,"sMaxAge":300,"staleWhileRevalidate":359,"clinicalTopicTopLatestNews":true,"megaMenuTaxName":"topic","megaMenuChildren":true,"sharingImageUrl":"https://s3.amazonaws.com/mjhlifesciences.com/sitelogos/AJMC_1200x637.png","twitterHandle":"@AJMC_Journal","publicationMapping":"publications","useNewSubNavMegaMenu":true,"redesignDetail":true,"redesignSAP":true,"useNewFooter":true,"newFooterLogos":[{"img":"/CHA_Logo.png","alt":"CH Logo","mobileWidth":"158px","mobileHeight":"42px","link":"/topic/center-on-health-equity-and-access","target":"_self"},{"img":"/CB.png","alt":"Center for Biosimilars Logo","mobileWidth":"170px","mobileHeight":"42px","link":"https://www.centerforbiosimilars.com/","target":"_blank"}],"useV3Components":true,"useAuthorRedesign":true,"navigationOptions":{"version":"2","variant":"4","customSpecialtyText":"Speciality Area"},"gateEnabled":"modal"},"homepage_creative_layout":{"creativeLayout":null}},"targeting":{"content_placement":["compendium/nhl"],"document_url":["compendium/nhl"],"document_group":[],"rootDocumentGroup":[],"hostname":"www.ajmc.com"},"statusCode":200,"data":{"page":{"taxonomy":{"_updatedAt":"2024-04-09T09:14:18Z","identifier":"compendium","_createdAt":"2020-03-30T18:16:46Z","_rev":"oruil6rlosjyltJbhrNMGF","_type":"taxonomy","name":"Compendium","_id":"297fa3d1-5216-46eb-bf51-66c5f77c3c8a","isMainTopic":true,"pixelTrackingCode":null},"contentCategory":null,"styling":{"imageControl":{"_type":"imageControl","showImage":true,"thumbnailRadius":{"topRight":"0rem","bottomLeft":"0rem","bottomRight":"0rem","topLeft":"0rem"}},"divider":{"_type":"divider","dividerSize":1},"titleOptions":{"_type":"titleOptions","titleSize":"1rem"},"useDefaultLayout":true,"border":{"borderType":"lines","borderRadius":{"bottomLeft":"0rem","bottomRight":"0rem","topLeft":"0rem","topRight":"0rem"},"_type":"border","borderSize":0},"contentControl":{"showSummary":true,"_type":"contentControl","showPublished":true,"readMore":true,"showAuthor":true}},"gateCode":null,"creativeLayoutLatestNews":null,"url":{"current":"/compendium","_type":"slug"},"articleDetailConfig":{"enableSegmentRecommend":true,"brightcoveAccountID":"10203567001","disqusShortName":"www-ajmc-com","downloadCitation":true,"shareOptions":{"SocialIconSize":32,"twitterSiteName":"@AJMC_Journal","hidePinterest":false,"shareSubject":"Check out this article!","twitterHandle":"AJMC","siteName":"ajmc","hideFacebook":false},"brightcovePlayerID":"pbDmfQhRw","drupalleadBaseURL":"https://drupalleads.mjh.group/injectablewebform/output/","issueMapping":"/publications"},"theme":"default","creativeLayout":null,"filterRequired":false,"docGroup":null,"labelRequired":false,"orderDesc":null,"creativeLayoutDetail":null,"externalLinks":null,"relatedMegaMenu":null,"pages":null,"disableEpisode":null,"intro":null,"linkedPage":null,"filters":null,"fixIdentifier":null,"pageSliders":null,"pageType":"Clinical Topic","content":null,"franchise":null,"cmeConfig":null,"searchConfig":{"baseUrl":"/view/"},"videoPlayerConfig":null,"excludeFromSitemap":false,"contentCategories":null,"hasSubCategory":false,"label":null,"featureContent":null,"title":"Compendium","parent":null,"isDsoGated":null,"useV3":true,"identifier":null,"archived":false},"pageData":{"totalCount":84,"pageSize":30,"pageNumber":1,"data":[{"thumbnail":{"_type":"mainImage","alt":"Lymphoma diagnosis | Image Credit: © Vitalii Vodolazskyi - stock.adobe.com","asset":{"_ref":"image-241bc75607121b543e32cbafca5a25a1e956e30f-1200x724-jpg","_type":"reference"}},"summary":"Danish patients who were diagnosed with certain lymphomas and other B-cell malignancies demonstrated increased antimicrobial use for at least a decade before their diagnosis.","published":"2024-09-13T13:14:00.000Z","updatedOn":null,"authors":[{"displayName":"Nameera Temkar, MD","url":"nameera-temkar-md"}],"factCheckAuthors":null,"_id":"81253503-cbea-4f13-8380-68b2ea9482c9","title":"Patients With B-Cell Cancers Have History of Increased Antimicrobial Use","url":"patients-with-b-cell-cancers-have-history-of-increased-antimicrobial-use","contentCategory":{"_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory","name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z"}},{"thumbnail":{"asset":{"_ref":"image-1ba373f5a004b284e540407fa01abbcee009de21-3265x1837-jpg","_type":"reference"},"_type":"mainImage","alt":"Recombinant Hirudin shows promise in the treament of DLBCL | image credit: David A Litman - stock.adobe.com","caption":"Recombinant Hirudin shows promise in the treament of DLBCL | image credit: David A Litman - stock.adobe.com"},"published":"2024-09-05T13:05:00.000Z","authors":[{"displayName":"Karen Jacobson-Sive","url":"karen-jacobson-sive"}],"factCheckAuthors":null,"contentCategory":{"name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z","_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory"},"_id":"acfb13f6-885c-4604-ad23-0e7639a69684","title":"Recombinant Hirudin May Help Treat Diffuse Large B-Cell Lymphoma  ","url":"recombinant-hirudin-may-help-treat-diffuse-large-b-cell-lymphoma","summary":"Recombinant Hirudin (rH) inhibited the polarization of M2-type macrophages and protease-activated receptor-1 (PAR-1) in diffuse large B-cell lymphoma (DLBCL). ","updatedOn":null},{"published":"2024-08-30T18:48:36.340Z","updatedOn":null,"contentCategory":{"_type":"contentCategory","name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z","_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh"},"title":"Dr Jason Romancik on Novel Lymphoma Therapies, Increasing Costs of Care","url":"dr-jason-romancik-on-novel-lymphoma-therapies-increasing-costs-of-care","summary":"Jason Romancik, MD, a board-certified hematologist at Emory Winship Cancer Institute, discusses the current treatment landscape in aggressive lymphoma and drivers of high care costs. ","authors":[{"displayName":"Rose McNulty","url":"rose-mcnulty"}],"factCheckAuthors":null,"_id":"0e9646ea-4cce-4fc5-bae4-91eaca11ca2b","thumbnail":{"_type":"mainImage","alt":"Dr Jason Romancik, Emory Winship Cancer Institute","caption":"Dr Jason Romancik, Emory Winship Cancer Institute","asset":{"_ref":"image-cda142b257d0655a16c489985cf85b380e8e7d91-665x372-png","_type":"reference"}}},{"thumbnail":{"_type":"mainImage","alt":"Cancerous cells | image credit: Dr_Microbe - stock.adobe.com","caption":"Cancerous cells | image credit: Dr_Microbe - stock.adobe.com","asset":{"_ref":"image-abdffcc1d1893ce84e07f271631073945bd321a2-6336x4224-jpg","_type":"reference"}},"published":"2024-08-26T13:28:00.000Z","contentCategory":{"_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory","name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z"},"title":"Multiplex Spatial Analysis Highlights Mechanisms of Refractory cHL ","url":"multiplex-spatial-analysis-highlights-mechanisms-of-refractory-chl","summary":"Improvements in multiplex immunofluorescence and spatial analysis have enabled a better understanding of the ways classical Hodgkin lymphoma evades the immune system. ","updatedOn":null,"authors":[{"displayName":"Jared Kaltwasser","url":"jared-kaltwasser"}],"factCheckAuthors":null,"_id":"eb621c06-35cb-4d80-8f7a-cb7beefc1840"},{"url":"phase-3-trial-of-tafasitamab-in-follicular-lymphoma-meets-primary-end-point","summary":"The phase 3 inMIND trial evaluating tafasitamab in combination with lenalidomide and rituximab in relapsed or refractory follicular lymphoma showed promising progression-free survival findings, according to topline results.","contentCategory":{"_updatedAt":"2023-09-29T14:32:27Z","_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory","name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2"},"authors":[{"displayName":"Jordyn Sava","url":"jordyn-sava"}],"factCheckAuthors":null,"_id":"6900c270-b7ba-41b2-ae84-f3ea5ffb4140","title":"Phase 3 Trial of Tafasitamab in Follicular Lymphoma Meets Primary End Point","thumbnail":{"_type":"mainImage","alt":"Full results from the inMIND trial of of lenalidomide and rituximab with or without tafasitamab in lymphoma are expected to be submitted for presentation at an upcoming medical meeting. | Image credit: airdone - stock.adobe.com","caption":"Full results from the inMIND trial of of lenalidomide and rituximab with or without tafasitamab in lymphoma are expected to be submitted for presentation at an upcoming medical meeting. | Image credit: airdone - stock.adobe.com","asset":{"_ref":"image-9834a2d3a21450debd7c29165ab12a131d9d1eff-1280x848-jpg","_type":"reference"}},"published":"2024-08-21T19:02:04.291Z","updatedOn":null},{"thumbnail":{"_type":"mainImage","alt":"Cytokine release concept | image credit: Bijac - stock.adobe.com","caption":"Cytokine release concept | image credit: Bijac - stock.adobe.com","asset":{"_ref":"image-cabd8bc05398941e25b517f3128c29223f4a0f94-5824x3264-jpg","_type":"reference"}},"published":"2024-08-16T15:25:00.000Z","authors":[{"displayName":"Kimberly Rath, PharmD","url":"kimberly-rath-pharmd"}],"_id":"9dd6aa44-bef7-4238-87de-99518feb2772","title":"Cytokine Release Syndrome in CAR T-Cell Therapy: A Common Yet Controllable Complication in DLBCL ","url":"cytokine-release-syndrome-in-car-t--cell-therapy-a-common-yet-controllable-complication-in-dlbcl","summary":"CAR T-cell therapy results in a high incidence of cytokine release syndrome, but it is manageable in most cases. ","updatedOn":null,"contentCategory":{"_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory","name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z"},"factCheckAuthors":null},{"factCheckAuthors":null,"_id":"bd261dbd-2bc0-4ee5-b30c-ad879d7a6b9c","url":"advancements-in-r-r-lymphoma-bispecific-antibodies-in-focus","thumbnail":{"alt":"Anna Sureda, MD, PhD","asset":{"_ref":"image-0921f83c5cd84e16b5d9d18e84aac24e2617f185-1200x738-png","_type":"reference"},"_type":"mainImage"},"published":"2024-08-10T12:00:00.000Z","authors":[{"displayName":"Brooke McCormick","url":"brooke-mccormick"},{"displayName":"Maggie L. Shaw","url":"maggie-l-shaw"}],"title":"Advancements in R/R Lymphoma: Bispecific Antibodies in Focus","summary":"In part 1 of our interview with Anna Sureda, MD, PhD, president of the European Group for Blood and Marrow Transplantation, she summarized the current treatment landscape for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) and follicular lymphoma (FL). ","updatedOn":null,"contentCategory":{"_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory","name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z"}},{"title":"Scant Infection Data for Patients With R/R MM, NHL Treated With BsAbs ","updatedOn":null,"contentCategory":{"_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory","name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z","_createdAt":"2020-04-03T20:03:53Z"},"factCheckAuthors":null,"_id":"1140efde-a257-4f98-b79a-dc5269654a14","url":"scant-infection-data-for-patients-with-r-r-mm-nhl-treated-with-bsabs","thumbnail":{"_type":"mainImage","alt":"The current lack of comprehensive data reflects an urgent need for more robust data and reporting with regard to BsAbs in R/R non-Hodgkin lymphoma and multiple myeloma. | Image credit: Vitalii Vodolazskyi - stock.adobe.com","caption":"The current lack of comprehensive data reflects an urgent need for more robust data and reporting with regard to BsAbs in R/R non-Hodgkin lymphoma and multiple myeloma. | Image credit: Vitalii Vodolazskyi - stock.adobe.com","asset":{"_ref":"image-14565e78f839b82f71b7c7b220c5d33d373e67b2-1200x724-jpg","_type":"reference"}},"summary":"Better reporting is needed to create better guidelines for tracking infection risk in patients with relapsed or refractory non-Hodgkin lymphoma or multiple myeloma, investigators concluded. ","published":"2024-08-08T21:33:01.473Z","authors":[{"displayName":"Jared Kaltwasser","url":"jared-kaltwasser"}]},{"title":"Accurately Capturing Experiences of Patients With NHL","url":"accurately-capturing-experiences-of-patients-with-nhl","thumbnail":{"_type":"mainImage","alt":"doc interviewing patient | Image Credit: ChasingMagic/peopleimages.com-stock.adobe.com","asset":{"_type":"reference","_ref":"image-80a8f95e0313817a4704e7987cf07f82a83f8662-1200x738-jpg"}},"summary":"Investigators wanted to know how well the NFlymSI-18 assessment was able to assess patient-reported outcomes in people with indolent B-cell non-Hodgkin lymphoma (NHL).","_id":"a59d9c92-d6bd-452c-adbd-cce6aef161af","published":"2024-08-01T19:15:28.791Z","updatedOn":null,"contentCategory":{"_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z","_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory","name":"Articles"},"authors":[{"displayName":"Jared Kaltwasser","url":"jared-kaltwasser"}],"factCheckAuthors":null},{"_id":"ac93892b-40c7-411c-9e62-3ff8ab0acc75","title":"FDA Approval of Epcoritamab Offers New Hope for R/R Follicular Lymphoma Treatment","contentCategory":{"_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory","name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z"},"factCheckAuthors":null,"url":"fda-approval-of-epcoritamab-offers-new-hope-for-r-r-follicular-lymphoma-treatment","thumbnail":{"alt":"Yasmin H. Karimi, MD","asset":{"_ref":"image-8a4011123b4f413b2b54850ba3133172cd35061b-2879x1612-png","_type":"reference"},"_type":"mainImage"},"summary":"“It's nice to have another option that we can discuss with patients,” said Yasmin H. Karimi, MD, University of Michigan, about epcoritamab’s label expansion for difficult-to-treat relapsed/refractory (R/R) follicular lymphoma.","published":"2024-07-25T20:32:35.648Z","updatedOn":null,"authors":[{"displayName":"Hayden E. Klein","url":"hayden-e-klein"}]},{"summary":"New Jersey Governor Phil Murphy joined BeiGene CEO John Oyler and about 300 guests to open the facility, located in Hopewell, New Jersey. A version of this article appeared in the August issue of Evidence-Based Oncology.","contentCategory":{"name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z","_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory"},"authors":[{"displayName":"Mary Caffrey","url":"mary-caffrey"}],"_id":"83a690f5-7255-4f4f-ab05-b0b034cd9ff3","title":"BeiGene Opens $800M Flagship US Facility in New Jersey","published":"2024-07-23T21:20:00.000Z","updatedOn":null,"factCheckAuthors":null,"url":"beigene-opens-800m-flagship-us-facility-in-new-jersey","thumbnail":{"caption":"BeiGene opened an $800 million manufacturing facliity in Hopewell, New Jersey on July 23. | Image credit: BeiGene","asset":{"_ref":"image-332dd5dc31b4059b008ece9c602d639f4e72d617-480x320-jpg","_type":"reference"},"_type":"mainImage","alt":"BeiGene Hopewell facility | Image credit: BeiGene"}},{"updatedOn":null,"contentCategory":{"_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z","_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory","name":"Articles"},"authors":[{"displayName":"Gayle Turim Dickstein","url":"gayle-turim-dickstein"}],"factCheckAuthors":null,"_id":"7be19232-96d5-4f38-bea1-8bcd8ee701c9","title":"In LBCL, Barriers to CAR T Remain: SDOH and More","url":"in-lbcl-barriers-to-car-t-remain-sdoh-and-more","thumbnail":{"_type":"mainImage","alt":"CAR T | Image Credit: Christoph Burgstedt-stock.adobe.com","asset":{"_ref":"image-8221a6bc7f23de994c5e2045cd76cd6eb0bb6393-1200x738-jpg","_type":"reference"}},"summary":"The social determinants of health (SDOH) that need to be tackled most urgently when it comes to which patients with large B-cell lymphoma (LBCL) do and do not receive chimeric antigen receptor T-cell therapy (CAR T) are age, sex, income, and race/ethnicity.","published":"2024-07-23T12:00:00.000Z"},{"published":"2024-07-16T12:00:00.000Z","contentCategory":{"_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory","name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z"},"_id":"3c102c6d-a8c2-467c-8668-df81cf08197e","title":"The Importance of Treatment Sequencing in Mantle Cell Lymphoma","url":"the-importance-of-treatment-sequencing-in-mantle-cell-lymphoma","thumbnail":{"_type":"mainImage","alt":"Tycel Phillips, MD, City of Hope","asset":{"_ref":"image-63e5891e9acccbc13ee44b62a86d8faf5af8fb5b-1200x724-jpg","_type":"reference"}},"summary":"We recently spoke with Tycel Phillips, MD, associate professor, Division of Lymphoma, Department of Hematology \u0026 Hematopoietic Cell Transplantation, City of Hope, about his team’s interim analysis of their dose-escalation study of glofitamab against relapsed/refractory B-cell non-Hodgkin lymphoma.","updatedOn":null,"authors":[{"displayName":"Mary Caffrey","url":"mary-caffrey"},{"displayName":"Maggie L. Shaw","url":"maggie-l-shaw"}],"factCheckAuthors":null},{"_id":"b4f260c0-e28a-41ed-8fba-2ec65bf37f28","url":"da-epoch-rituximab-successfully-treating-pmbcl-in-a-transgender-woman","title":"DA-EPOCH-Rituximab: Successfully Treating PMBCL in a Transgender Woman","thumbnail":{"asset":{"_ref":"image-241bc75607121b543e32cbafca5a25a1e956e30f-1200x724-jpg","_type":"reference"},"_type":"mainImage","alt":"Lymphoma diagnosis | Image Credit: © Vitalii Vodolazskyi - stock.adobe.com"},"summary":"A case study describes the disparate factors that played into the chemotherapy and other treatment decisions made by a team in Japan when addressing their patient’s primary mediastinal large B-cell lymphoma (PMBCL).","published":"2024-07-10T16:50:59.162Z","updatedOn":null,"contentCategory":{"_updatedAt":"2023-09-29T14:32:27Z","_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory","name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2"},"authors":[{"displayName":"Gayle Turim Dickstein","url":"gayle-turim-dickstein"}],"factCheckAuthors":null},{"title":"Late Effects of CAR T-Cell Therapy in Lymphoma","thumbnail":{"_type":"mainImage","alt":"CART and gene therapy | Image Credit: ArtemisDiana-stock.adobe.com","asset":{"_ref":"image-60a762ddea051a34205a8876249e3f8028aa5e74-1200x728-jpg","_type":"reference"}},"published":"2024-07-09T11:07:00.000Z","updatedOn":null,"contentCategory":{"_type":"contentCategory","name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z","_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh"},"_id":"df81b23c-bb42-4518-bd09-3877b43f1377","summary":"In this new analysis, investigators review the late adverse events associated with anti-CD19 chimeric antigen receptor (CAR) T-cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma.","authors":[{"displayName":"Kimberly Rath, PharmD","url":"kimberly-rath-pharmd"}],"factCheckAuthors":null,"url":"late-effects-of-car-t-cell-therapy-in-lymphoma"},{"_id":"bbb72c04-7296-4ca1-8fed-3a7ff490d7fe","published":"2024-07-06T19:11:00.000Z","updatedOn":null,"authors":[{"displayName":"Karen Jacobson-Sive","url":"karen-jacobson-sive"}],"contentCategory":{"name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z","_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory"},"factCheckAuthors":null,"title":"Study to Quantify Non-Hodgkin Lymphoma Risk in HIV","url":"study-to-quantify-non-hodgkin-lymphoma-risk-in-hiv","thumbnail":{"_type":"mainImage","alt":"non-Hodgkin lymphoma | Image Credit: MQ-Illustrations-stock.adobe.com","asset":{"_ref":"image-010ed192a482703b2eb80f0fcb19407b06ab504b-1200x728-jpg","_type":"reference"}},"summary":"This meta-analysis study will estimate the global and regional burden of HIV-associated non-Hodgkin lymphoma to aid the development of prevention and control strategies."},{"contentCategory":{"_updatedAt":"2023-09-29T14:32:27Z","_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory","name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2"},"factCheckAuthors":null,"title":"ViPOR: Novel Targeted Therapy Combination Shows Potential in Relapsed DLBCL ","url":"vipor-novel-targeted-therapy-combination-shows-potential-in-relapsed-dlbcl","published":"2024-07-01T13:43:41.121Z","updatedOn":null,"authors":[{"displayName":"Gayle Turim Dickstein","url":"gayle-turim-dickstein"}],"_id":"53378ff2-ec05-41ca-80fe-58438b5346fe","thumbnail":{"_type":"mainImage","alt":"DLBCL | Image Credit: Image Credit: laszlo-stock.adobe.com","asset":{"_ref":"image-55e878efc551f05bedbb6f72d799e5d1d9c6ac11-1200x728-jpg","_type":"reference"}},"summary":"The 5 agents in ViPOR—including venetoclax and lenalidomide—worked better together in a phase 1b/2 trial than they previously have, individually, in treating patients with certain diffuse large B-cell lymphoma (DLBCL) subtypes. "},{"url":"epcoritamab-gets-label-expansion-for-difficult-to-treat-r-r-follicular-lymphoma","summary":"The FDA approved epcoritamab-bysp to treat adults with relapsed or refractory (R/R) follicular lymphoma after 2 or more lines of systemic therapy.","updatedOn":null,"authors":[{"displayName":"Hayden E. Klein","url":"hayden-e-klein"}],"factCheckAuthors":null,"_id":"22294d62-da59-458b-942b-ca8e6892d15d","title":"Epcoritamab Gets Label Expansion for Difficult-to-Treat R/R Follicular Lymphoma","thumbnail":{"hotspot":{"_type":"sanity.imageHotspot","width":1,"x":0.5,"y":0.49713378906250005,"height":0.750087890625},"_type":"mainImage","alt":"FDA approved | Image credit: ArtEternal – stock.adobe.com","asset":{"_ref":"image-2ca0e3cfdd22a31e0ffd78c9ba3b7bc976f74890-3873x3873-jpg","_type":"reference"},"crop":{"top":0.12208984375000004,"left":0,"bottom":0.12782226562499988,"_type":"sanity.imageCrop","right":0}},"published":"2024-06-27T01:07:09.492Z","contentCategory":{"name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z","_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory"}},{"contentCategory":{"_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory","name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z"},"_id":"920cad50-1a2b-4bd4-9e0f-6024dd091d9d","summary":"With its recent approvals around the world to treat newly diagnosed and relapsed/refractory diffuse large B-cell lymphoma (DLBCL), the antibody-drug conjugate polatuzumab vedotin is changing regimens for current and future patients, with manageable adverse effects.","updatedOn":null,"published":"2024-06-17T14:26:00.037Z","authors":[{"displayName":"Gayle Turim Dickstein","url":"gayle-turim-dickstein"}],"factCheckAuthors":null,"title":"Polatuzumab Vedotin: Review Spotlights Its Use, Promise in DLBCL","url":"polatuzumab-vedotin-review-spotlights-its-use-promise-in-dlbcl","thumbnail":{"_type":"mainImage","alt":"microscopic image of DLBCL | Image Credit: David A Litman-stock.adobe.com","asset":{"_ref":"image-d636e0b1d802d3df3660c9e263f854084e129057-1200x628-jpg","_type":"reference"}}},{"_id":"2a32966c-00f2-412c-952a-2b9ca26b8f04","url":"dr-catherine-diefenbach-on-the-evolving-dlbcl-treatment-landscape","summary":"Catherine Diefenbach, MD, an American Society of Hematology expert and director of the Clinical Lymphoma Program at NYU Langone's Perlmutter Cancer Center, discussed the evolving state of diffuse large B-cell lymphoma (DLBCL) therapeutics and exciting areas of research.","contentCategory":{"_type":"contentCategory","name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z","_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh"},"authors":[{"displayName":"Rose McNulty","url":"rose-mcnulty"}],"factCheckAuthors":null,"title":"Dr Catherine Diefenbach on the Evolving DLBCL Treatment Landscape","thumbnail":{"asset":{"_ref":"image-1e602bba35858bd62230432132517d1d42061e3d-1280x800-jpg","_type":"reference"},"_type":"mainImage","alt":"Medical technology | Image credit: ipopba - stock.adobe.com","caption":"Medical technology | Image credit: ipopba - stock.adobe.com"},"published":"2024-06-14T18:45:21.706Z","updatedOn":null},{"_id":"48667fba-a05b-4b82-8d52-d3344d545c83","title":"Case Reports: Managing DLBCL Associated With Papillary Thyroid Carcinoma ","url":"case-reports-managing-dlbcl-associated-with-papillary-thyroid-carcinoma","summary":"Case reports and systematic review found the combination of surgery, chemotherapy, and radiotherapy can effectively manage diffuse large B-cell lymphoma (DLBCL) associated with papillary thyroid carcinoma. ","authors":[{"displayName":"Kimberly Rath, PharmD","url":"kimberly-rath-pharmd"}],"thumbnail":{"_type":"mainImage","asset":{"_ref":"image-be86ef6bccb9979df807ed51615e693b9e4a0a89-1200x800-jpg","_type":"reference"}},"published":"2024-06-12T13:17:00.000Z","updatedOn":null,"contentCategory":{"_type":"contentCategory","name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z","_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh"},"factCheckAuthors":null},{"title":"Obinutuzumab and Radiation Combo Shows Promise for Refractory DLBCL","thumbnail":{"_type":"mainImage","alt":"Stethoscope chart graph data | Image Credit: © amazing studio - stock.adobe.com","asset":{"_ref":"image-e825022f10d04a8c8b873d06455d4327ec5a3449-1200x800-jpg","_type":"reference"}},"summary":"A small retrospective study found that combining obinutuzumab with radiation therapy may offer a viable and well-tolerated treatment option for patients with refractory diffuse large B-cell lymphoma (DLBCL). ","contentCategory":{"_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z","_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory","name":"Articles"},"authors":[{"displayName":"Kimberly Rath, PharmD","url":"kimberly-rath-pharmd"}],"_id":"dfb7a138-d1ed-4b73-b234-75128c2e5b1e","url":"obinutuzumab-and-radiation-combo-shows-promise-for-refractory-dlbcl","published":"2024-06-07T14:01:52.148Z","updatedOn":null,"factCheckAuthors":null},{"_id":"353edf77-f7f0-4151-9f27-a59a0ac13109","title":"How the Tumor Microenvironment Affects DLBCL Prognosis, Treatment ","thumbnail":{"_type":"mainImage","alt":"dlbcl | Image Credit: laszlo-stock.adobe.com","asset":{"_ref":"image-be86ef6bccb9979df807ed51615e693b9e4a0a89-1200x800-jpg","_type":"reference"}},"summary":"Further acknowledgement and study of the tumor microenvironment in diffuse large B-cell lymphoma (DLBCL) could eventually result in much more personalized—and effective—treatments.\n","factCheckAuthors":null,"url":"how-the-tumor-microenvironment-affects-dlbcl-prognosis-treatment","published":"2024-06-03T15:36:31.589Z","updatedOn":null,"contentCategory":{"_updatedAt":"2023-09-29T14:32:27Z","_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory","name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2"},"authors":[{"displayName":"Gayle Turim Dickstein","url":"gayle-turim-dickstein"}]},{"title":"Key Features of Rare Fibrin-Assisted Diffuse Large B-Cell Lymphoma","url":"key-features-of-rare-fibrin-assisted-diffuse-large-b-cell-lymphoma","thumbnail":{"_type":"mainImage","alt":"Lymphoma word block image | Image Credit: © airdone - stock.adobe.com","asset":{"_type":"reference","_ref":"image-14565e78f839b82f71b7c7b220c5d33d373e67b2-1200x724-jpg"}},"authors":[{"displayName":"Kimberly Rath, PharmD","url":"kimberly-rath-pharmd"}],"contentCategory":{"_type":"contentCategory","name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z","_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh"},"factCheckAuthors":null,"_id":"9edeb4cb-89cc-47ee-ae3d-059f92a6aab9","summary":"A case study details the cytological and histological features of fibrin-assisted diffuse large B-cell lymphoma in a patient with no clinical symptoms, highlighting the diagnostic challenges of this condition.","published":"2024-05-27T12:10:00.000Z","updatedOn":null},{"summary":"Prophylactic intravenous immunoglobulin reduces COVID-19 infection rates in older patients with DLBCL with hypogammaglobulinemia undergoing reduced-intensity R-CHOP therapy.","updatedOn":null,"contentCategory":{"_type":"contentCategory","name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z","_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh"},"authors":[{"displayName":"Kimberly Rath, PharmD","url":"kimberly-rath-pharmd"}],"factCheckAuthors":null,"_id":"10ccbb70-860b-4275-979e-d995afcf2ec1","url":"ivig-shows-promise-in-protecting-older-patients-with-lymphoma-from-covid-19","thumbnail":{"_type":"mainImage","alt":"Nurse holding older woman's hands | Image Credit: © Cecilie Arcurs/peopleimages.com - stock.adobe.com","asset":{"_ref":"image-9ae4cccd2425a595c476ba177f37bd90492eb355-1200x801-jpg","_type":"reference"}},"published":"2024-05-24T14:06:00.000Z","title":"IVIG Shows Promise in Protecting Older Patients With Lymphoma From COVID-19"},{"updatedOn":null,"contentCategory":{"_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z","_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory","name":"Articles"},"authors":[{"displayName":"Gayle Turim Dickstein","url":"gayle-turim-dickstein"}],"factCheckAuthors":null,"title":"Patient/Physician Teamwork: Treating a Rare Oral Presentation of DLBCL","url":"patient-physician-teamwork-treating-a-rare-oral-presentation-of-dlbcl","published":"2024-05-16T17:09:11.768Z","_id":"08c6a4ca-5219-4d87-a657-52a687c0f79c","thumbnail":{"_type":"mainImage","alt":"Photomicrograph of a diffuse large B-cell lymphoma | Image Credit: ©DavidALitman - stock.adobe.com","asset":{"_ref":"image-05a0a6fe2181863bf5f8b0c2d961e10600eb4aef-1200x724-jpg","_type":"reference"}},"summary":"A very unusual case of lip-based diffuse large B-cell lymphoma (DLBCL) was treated successfully thanks to prompt diagnosis and chemotherapy treatments. "},{"_id":"a39a0ba5-8e00-4da0-9796-01948f19b6db","url":"study-care-costs-for-r-r-dlbcl-increase-with-each-line-of-therapy","thumbnail":{"caption":"Health costs | Image credit: utah51 - stock.adobe.com","asset":{"_ref":"image-5903e177f109160ec92a1fda6341609ca4dc7154-1280x789-jpg","_type":"reference"},"default":false,"_type":"mainImage","alt":"Health costs | Image credit: utah51 - stock.adobe.com"},"published":"2024-05-08T19:19:05.423Z","updatedOn":null,"factCheckAuthors":null,"title":"Study: Care Costs for R/R DLBCL Increase With Each Line of Therapy","summary":"New therapies are helping patients, but are also driving up overall costs of care.","contentCategory":{"_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory","name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z"},"authors":[{"displayName":"Jared Kaltwasser","url":"jared-kaltwasser"}]},{"summary":"Although histological transformation to diffuse large B-cell lymphoma (DLBCL) remains a common complication of follicular lymphoma, patient survival has increased significantly since the introduction of rituximab about 2 decades ago.","published":"2024-05-02T19:34:25.760Z","factCheckAuthors":null,"updatedOn":null,"contentCategory":{"_updatedAt":"2023-09-29T14:32:27Z","_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory","name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2"},"authors":[{"displayName":"Gayle Turim Dickstein","url":"gayle-turim-dickstein"}],"_id":"4e85a06a-7680-440b-b65a-2897529e829b","title":"Much-Improved Outcomes for Follicular Lymphoma Transformed to DLBCL in the Rituximab Era, Study Finds","url":"much-improved-outcomes-for-follicular-lymphoma-transformed-to-dlbcl-in-the-rituximab-era-study-finds","thumbnail":{"_type":"mainImage","alt":"Lymphoma graphic | Image Credit: © MP Studion - stock.adobe.com","asset":{"_ref":"image-52e57b002a8ee4f36d0e991c03bd3f660fe2c87c-1200x724-jpg","_type":"reference"}}},{"thumbnail":{"asset":{"_type":"reference","_ref":"image-20d163c7d750e5b10e32a841db89b682efaaabf4-1200x724-jpg"},"_type":"mainImage","alt":"IV chemotherapy | Image Credit: Aidman - stock.adobe.com"},"summary":"Population pharmacokinetic and exposure-response analyses revealed a favorable benefit-risk profilane for the treatment combination of polatuzumab vedotin and rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP). ","updatedOn":null,"contentCategory":{"_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory","name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z","_createdAt":"2020-04-03T20:03:53Z"},"authors":[{"displayName":"Luke Halpern","url":"luke-halpern"}],"factCheckAuthors":null,"_id":"ef36dfaf-e169-4569-b957-58d88762a8c5","url":"polatuzumab-vedotin-and-r-chp-appropriate-for-untreated-dlbcl","title":"Polatuzumab Vedotin and R-CHP Appropriate for Untreated DLBCL ","published":"2024-04-24T13:49:59.424Z"},{"summary":"A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.\n","published":"2024-04-18T23:00:12.496Z","authors":[{"displayName":"Kimberly Rath, PharmD","url":"kimberly-rath-pharmd"}],"thumbnail":{"asset":{"_ref":"image-bb6bc65988ebb2feb7711ac168d6dd6e58c3eb51-1200x724-jpg","_type":"reference"},"_type":"mainImage","alt":"Doctors discussing a case | Image Credit: DelmaineDonson - stock.adobe.com"},"updatedOn":null,"contentCategory":{"name":"Articles","_id":"3f4b3ced-7c9d-4fc4-967f-fe993087cce2","_updatedAt":"2023-09-29T14:32:27Z","_createdAt":"2020-04-03T20:03:53Z","_rev":"Q2ZL7ihdIB33NiMMcGccmh","_type":"contentCategory"},"factCheckAuthors":null,"_id":"b418c231-e9cf-4a0b-a69e-3ceb75365934","title":"Real-World Study Reveals Key Insights Into DLBCL Treatment Patterns, Outcomes","url":"real-world-study-reveals-key-insights-into-dlbcl-treatment-patterns-outcomes"}],"targeting":{"content_placement":["compendium/nhl"],"document_url":["compendium/nhl"],"document_group":[],"rootDocumentGroup":[],"hostname":"www.ajmc.com"},"currentTopic":{"thumbnail":null,"url":"nhl","ptceKeywordMapping":null,"parent":{"_id":"297fa3d1-5216-46eb-bf51-66c5f77c3c8a","name":"Compendium","url":"compendium","parent":null},"name":"Non-Hodgkin Lymphoma (NHL) ","summary":null,"cmeType":"per","perKeywordMapping":["Hematologic Cancer","Health Equity Diversity \u0026 Inclusion"],"pixelTrackingCode":null,"_id":"8bbafbf9-c0ab-4a9b-9def-f0fbe182c451"},"filterData":[],"relatedTopics":null,"podcastsData":[],"videoSeriesData":[],"videoNonSeriesData":[{"_rev":"t9bgi0ApU0zpu1ycNK04ZM","source":null,"_type":"article","is_visible":true,"ExcludeFromPubMedXML":false,"url":{"current":"dr-anna-sureda-on-the-evolving-treatment-landscape-for-relapsed-refractory-dlbcl-follicular-lymphoma","_type":"slug"},"_createdAt":"2024-07-12T14:11:46Z","documentGroupMapping":[{"_key":"2d600d177cef","_ref":"c8290b53-9d62-43a0-8676-937e2332b940","_type":"reference"}],"articleType":"Commentary","updatedOn":null,"taxonomyMapping":[{"name":"Clinical","summary":[{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"The ","_key":"e80c79954e08"},{"_type":"span","marks":["em"],"text":"AJMC","_key":"a8e0f75c5d05"},{"_type":"span","marks":["superscript"],"text":"®","_key":"f7d4dddf7edd"},{"_type":"span","marks":[],"text":" clinical page includes all the published content across AJMC.com, ","_key":"0f03d46e3b3a"},{"_type":"span","marks":["em"],"text":"The American Journal of Managed Care","_key":"cc409f2da7da"},{"_key":"2babb3e59bb3","_type":"span","marks":["superscript"],"text":"®"},{"_type":"span","marks":[],"text":" and ","_key":"d86a5bb12052"},{"marks":["em"],"text":"Evidence-Based Oncology","_key":"40b2eaba6c17","_type":"span"},{"_key":"b59bef533cdf","_type":"span","marks":[],"text":"™ on a variety of specialties, including dermatology, cardiology, oncology, and rheumatology."}],"_type":"block","style":"normal","_key":"dd8ad578cd0b"}],"identifier":"clinical","parent":{"_ref":"15012229-f713-4f0a-8f82-7667530bb382","_type":"reference"},"_id":"topic_clinical","_updatedAt":"2022-02-18T12:13:55Z","_createdAt":"2020-05-04T23:46:13Z","_rev":"HexDiduX8d6Nqnq1ECriVF","_type":"taxonomy"},{"name":"News","_id":"39be7351-bd4c-4e98-82b3-0d675ae4671b","_updatedAt":"2022-01-19T10:20:16Z","identifier":"news","_createdAt":"2020-03-30T18:05:45Z","_rev":"OU32WOWh4YetHW0RkWbkso","_type":"taxonomy"},{"perKeywordMapping":["Hematologic Cancer","Health Equity Diversity \u0026 Inclusion"],"_createdAt":"2023-02-28T21:39:54Z","_rev":"rmdpbbz4U7GL9ExaGp97i6","usedForRecommendations":false,"_updatedAt":"2024-06-25T17:42:29Z","identifier":"nhl","cmeType":"per","_type":"taxonomy","name":"Non-Hodgkin Lymphoma (NHL) ","_id":"8bbafbf9-c0ab-4a9b-9def-f0fbe182c451","parent":{"_type":"reference","_ref":"297fa3d1-5216-46eb-bf51-66c5f77c3c8a"}}],"title":"Dr Anna Sureda on the Evolving Treatment Landscape for Relapsed/Refractory DLBCL, Follicular Lymphoma","authorMapping":[{"displayName":"Brooke McCormick","_rev":"m9zO7fOEUWAduYt5irO78Q","_type":"author","_id":"00af9d05-a2c4-4451-a6d1-0e28b08cbb65","profileImage":{"asset":{"_ref":"image-1fe4e81696463cdd9c1d6b62a2e47c2228d7df99-430x430-png","_type":"reference"},"_type":"mainImage","alt":"Brooke McCormick"},"url":{"current":"brooke-mccormick","_type":"slug"},"lastName":"McCormick","_createdAt":"2023-06-21T17:59:19Z","biography":[{"style":"normal","_key":"936ecf4b7f0c","markDefs":[],"children":[{"_key":"8d68730a8da0","_type":"span","marks":[],"text":"Brooke is an assistant editor for "},{"_type":"span","marks":["em"],"text":"The American Journal of Managed Care","_key":"730c46c984c9"},{"marks":[],"text":"® (","_key":"0b218fbaa571","_type":"span"},{"text":"AJMC","_key":"b1b5b3d9cff0","_type":"span","marks":["em"]},{"marks":[],"text":"®). She joined ","_key":"7de919198f04","_type":"span"},{"marks":["em"],"text":"AJMC","_key":"f31a60d737e2","_type":"span"},{"_type":"span","marks":[],"text":" in 2023, where she produces written content covering multiple disease states.","_key":"df11193684f8"}],"_type":"block"},{"_key":"9af540ce04de","markDefs":[],"children":[{"text":"","_key":"5731fbb8e0ae","_type":"span","marks":[]}],"_type":"block","style":"normal"},{"children":[{"_key":"bb68b5e8ee83","_type":"span","marks":[],"text":"She has a BA in journalism from Seton Hall University. You can connect with Brooke on "},{"_type":"span","marks":["80a1c1a9d7cd"],"text":"LinkedIn","_key":"4bb222fe2840"},{"_type":"span","marks":[],"text":".","_key":"c87621477700"}],"_type":"block","style":"normal","_key":"98aee68dab9d","markDefs":[{"href":"https://www.linkedin.com/in/brooke-mccormick-1a254b1b6/","_key":"80a1c1a9d7cd","nofollow":true,"blank":true,"_type":"link"}]}],"_updatedAt":"2024-05-20T19:29:20Z","firstName":"Brooke"}],"_id":"b1ad04e3-ae10-4cbc-a7f1-7924befc915f","_updatedAt":"2024-07-12T18:16:18Z","summary":"Anna Sureda, MD, PhD, of the Catalan Institute of Oncology, discusses the evolving treatment landscape for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma. ","contentCategory":{"_id":"ee14ccb3-3542-4414-9046-927be1198c76","_updatedAt":"2020-04-03T20:03:44Z","_createdAt":"2020-04-03T20:03:44Z","_rev":"Yw6MEKZDMdk6hC2JCPjfiB","_type":"contentCategory","name":"Videos"},"link":"/view/dr-anna-sureda-on-the-evolving-treatment-landscape-for-relapsed-refractory-dlbcl-follicular-lymphoma","factCheckAuthorMapping":null,"seoTag":["dr anna sureda","DLBCL","follicular lymphoma","EHA"],"thumbnail":{"asset":{"_rev":"PVzYy8erIP67fVJ7CHusSP","assetId":"7cbfb6054c666afc203e8f14d149579ef87dc41d","_updatedAt":"2024-07-12T18:03:20Z","metadata":{"dimensions":{"_type":"sanity.imageDimensions","width":2786,"aspectRatio":1.7745222929936306,"height":1570},"isOpaque":true,"blurHash":"MAI#6{0q02~o00;HIo^%Mw_2ov^$w^IXo}","_type":"sanity.imageMetadata","palette":{"muted":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":2.35,"background":"#a2785d"},"lightVibrant":{"title":"#fff","population":1.46,"background":"#e2b186","_type":"sanity.imagePaletteSwatch","foreground":"#000"},"darkVibrant":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":4.13,"background":"#5d3d28"},"lightMuted":{"title":"#fff","population":4.87,"background":"#c2b79d","_type":"sanity.imagePaletteSwatch","foreground":"#000"},"vibrant":{"population":5.29,"background":"#c7a570","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff"},"dominant":{"background":"#695638","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":5.56},"_type":"sanity.imagePalette","darkMuted":{"foreground":"#fff","title":"#fff","population":5.56,"background":"#695638","_type":"sanity.imagePaletteSwatch"}},"hasAlpha":true,"lqip":"data:image/png;base64,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"},"uploadId":"taSjIKFpN0x9mdVmi2K759mQIjYtrLvI","mimeType":"image/png","sha1hash":"7cbfb6054c666afc203e8f14d149579ef87dc41d","path":"images/0vv8moc6/ajmc/7cbfb6054c666afc203e8f14d149579ef87dc41d-2786x1570.png","size":4191058,"_type":"sanity.imageAsset","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/7cbfb6054c666afc203e8f14d149579ef87dc41d-2786x1570.png","_createdAt":"2024-07-12T18:03:20Z","_id":"image-7cbfb6054c666afc203e8f14d149579ef87dc41d-2786x1570-png","originalFilename":"Screenshot 2024-07-12 at 1.57.28 PM.png","extension":"png"}},"published":"2024-07-13T13:00:00.000Z","body":[{"videoID":"6357754499112","disableAutoPlayVideo":false,"source":"brightcove","_key":"64fd3402a5e5","videoObject":{"thumbnail":{"asset":{"_ref":"image-7cbfb6054c666afc203e8f14d149579ef87dc41d-2786x1570-png","_type":"reference"},"_type":"image"},"videoDuration":"PT4M39S","videoDescription":"dr anna sureda, DLBCL, follicular lymphoma, treatment","_type":"videoDetails","videoTitle":"Dr Anna Sureda on the Evolving Treatment Landscape for Relapsed/Refractory DLBCL, Follicular Lymphoma"},"_type":"video"},{"children":[{"_type":"span","marks":[],"text":"Anna Sureda, MD, PhD, president of the European Group for Blood and Marrow Transplantation (EMBT), head of the clinical hematology department at the Catalan Institute of Oncology, explains how the treatment landscape for relapsed/refractory","_key":"3f8061e0deab"},{"_type":"span","marks":["d049e33dbb9b"],"text":" diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma","_key":"3c91e99e4c34"},{"_key":"cd405255327d","_type":"span","marks":[],"text":" has evolved significantly, with chimeric antigen receptor (CAR) T-cells, bispecific monoclonal antibodies, and other novel therapies now offering promising options beyond traditional chemotherapy and stem cell transplantation."}],"_type":"block","style":"normal","_key":"79fc3b7eaa2c","markDefs":[{"nofollow":false,"blank":true,"_type":"link","href":"https://www.ajmc.com/compendium/nhl","_key":"d049e33dbb9b"}]},{"_type":"block","style":"normal","_key":"bf37c05661e0","markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"bfe86c4b3557"}]},{"_type":"block","style":"normal","_key":"6f9083cfa6bb","markDefs":[{"nofollow":false,"blank":true,"_type":"link","href":"https://www.ajmc.com/conference/eha","_key":"fb4a480c647e"}],"children":[{"_key":"bc084695d7a3","_type":"span","marks":[],"text":"She expanded upon this topic last month at the "},{"_type":"span","marks":["fb4a480c647e"],"text":"European Hematology Association (EHA) 2024 Congress","_key":"123c729af11e"},{"_type":"span","marks":[],"text":" during the sessions \"New Frontiers in Relapsed/Refractory B Cell Lymphomas: Current and Future Roles for Bispecific T Cell Engagers (TCE)\" and \"Pursuing New Heights in Lymphoma Care With Bispecific Antibodies.\"","_key":"e45dd3d1883b"}]},{"_type":"block","style":"normal","_key":"e4954643f86b","markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"80eb48790046"}]},{"_type":"block","style":"normal","_key":"3a98702a04cf","markDefs":[],"children":[{"_key":"92dbd3e0f91b0","_type":"span","marks":["em"],"text":"This transcript has been lightly edited for clarity."}]},{"style":"normal","_key":"a03604dd09fb","markDefs":[],"children":[{"text":"","_key":"b4b0ffcadb96","_type":"span","marks":[]}],"_type":"block"},{"_key":"dde69b3e45a7","markDefs":[],"children":[{"_type":"span","marks":["strong","underline"],"text":"Transcript","_key":"e3edb2fb9e0d"}],"_type":"block","style":"normal"},{"children":[{"text":"","_key":"e87dd21e27cb","_type":"span","marks":[]}],"_type":"block","style":"normal","_key":"87cc847da619","markDefs":[]},{"children":[{"_type":"span","marks":["strong"],"text":"Could you provide an overview of the current treatment landscape for relapsed/refractory DLBCL and follicular lymphoma?","_key":"f6737e840e3e0"}],"_type":"block","style":"normal","_key":"079cd0b1b0e1","markDefs":[]},{"markDefs":[],"children":[{"marks":[],"text":"","_key":"50493e12faf5","_type":"span"}],"_type":"block","style":"normal","_key":"cc94b858900f"},{"_type":"block","style":"normal","_key":"a5a754e75d0e","markDefs":[],"children":[{"_type":"span","marks":[],"text":"Starting with diffuse large B cell lymphoma [DLBCL], until a few years ago, when we had a relapse patient, we were thinking about autologous stem cell transplantation as a treatment option if the patient was transplant eligible. Sometimes in those patients, relapsing after an autologous transplant, or after several lines of chemotherapy, an allogeneic stem cell transplantation was also taken into consideration. Of course, the rest of the treatment was based on the use of different chemotherapy strategies. ","_key":"09205ac906be0"}]},{"_type":"block","style":"normal","_key":"5a4e2d204c30","markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"4c2182a11263"}]},{"_key":"81a6510f11af","markDefs":[],"children":[{"_type":"span","marks":[],"text":"In the last few years, this treatment landscape has significantly changed. I would like to mention, first of all, probably the 2 strategies that I think are going to significantly change the way that we treat patients. The first one is the introduction of CAR T-cells. We know that autologous anti-CD-19 CAR T-cells constitute a curative treatment strategy for a significant proportion of patients who have failed at least 2 prior lines of therapy. CAR Ts have moved to the second line, and there are prospective clinical trials looking at the role of CAR Ts in high-risk novel diffuse large B-cell lymphoma. ","_key":"5751d6cb717b"}],"_type":"block","style":"normal"},{"children":[{"_type":"span","marks":[],"text":"","_key":"d3ccdc3d3b38"}],"_type":"block","style":"normal","_key":"9ef82ecbeb42","markDefs":[]},{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"The other group of drugs that I would like to mention are bispecific monoclonal antibodies that are coming into the field. They have more recent developments with respect to CAR Ts, and, nowadays, have been approved and starting to be reimbursed in Europe in third line or plus. Of course, they are also quickly moving to earlier lines of therapy. ","_key":"356ee591cb13"}],"_type":"block","style":"normal","_key":"44b8e544f48d"},{"_key":"1a46b89fc470","markDefs":[],"children":[{"_key":"63fb56267ce1","_type":"span","marks":[],"text":""}],"_type":"block","style":"normal"},{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"We have other classes of different treatment strategies, so we have to think about ADCs, or antibody-drug conjugates. The two best examples are polatuzumab vedotin given in combination with rituximab and bendamustine. Also, loncastuximab tesirine has been approved for patients with multiple relapses if they have large B cell lymphoma. Also, anti-CD-19 monoclonal antibodies, like tafasitamab, are basically combined with lenalidomide for patients who are not transplant eligible. So, as you can see, the treatment landscape is very much populated in this specific disease. ","_key":"96a0c288f9ef"}],"_type":"block","style":"normal","_key":"2a6c3bd3113d"},{"children":[{"_key":"1fa8c5462d9c","_type":"span","marks":[],"text":""}],"_type":"block","style":"normal","_key":"cb8a287a5ead","markDefs":[]},{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"If we move to follicular lymphoma, the evolution has some similarities. Until recent years, we were basically treating these patients with chemotherapy. Of course, associated with monoclonal antibodies using rituximab as a maintenance therapy strategy. ","_key":"e1aec170b3e5"}],"_type":"block","style":"normal","_key":"6e111b633e19"},{"_key":"a1217c18f6b8","markDefs":[],"children":[{"_key":"03cfe83461d3","_type":"span","marks":[],"text":""}],"_type":"block","style":"normal"},{"markDefs":[],"children":[{"text":"For those patients with relapsed disease, we have the possibility to use a chemo-free strategy, the R","_key":"1880864aca5c","_type":"span","marks":[]},{"_type":"span","marks":["superscript"],"text":"2","_key":"8d6d27644257"},{"text":" regimen, including lenalidomide and rituximab. Those patients that have an early relapse, the ones that we call POD24 positive, have always been considered a high-risk population of patients, and, of course, autologous stem cell transplantation has been for many years the standard of care for them. At some point, we were also considering allogeneic stem cell transplant. ","_key":"b5ca38dca205","_type":"span","marks":[]}],"_type":"block","style":"normal","_key":"ccfeb7946639"},{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"7426250ede0f"}],"_type":"block","style":"normal","_key":"2c933db4579e"},{"style":"normal","_key":"3f290ae6e020","markDefs":[],"children":[{"_type":"span","marks":[],"text":"These treatment strategies have been significantly modified in the last few years with the introduction of small molecules and targeted therapies, but, once again, I want to mention CAR T-cells. They are still pending to demonstrate the curative potential in these patients basically because the follow-up after CAR T-cell infusion in patients included in pivotal trials is not so long, but they are able to give really impressive overall response rates, complete remission rates, and progression-free and overall survival. ","_key":"1acd1eb943b2"}],"_type":"block"},{"children":[{"_type":"span","marks":[],"text":"","_key":"e896468def1b"}],"_type":"block","style":"normal","_key":"3bf892142fd5","markDefs":[]},{"_key":"0a4e11a796eb","markDefs":[],"children":[{"_type":"span","marks":[],"text":"Of course, bispecifics constitute probably the second group of tracks that have demonstrated to be very effective in the inpatient setting with patients with relapsed/refractory disease and moving really fast to earlier lines of therapies.","_key":"fe953c250891"}],"_type":"block","style":"normal"}]},{"articleType":"Commentary","summary":"Ann LaCasce, MD, MMSc, director of the Dana-Farber/Mass General Brigham fellowship in hematology/oncology and chair of the Lymphoma Research Foundation’s Scientific Advisory Board, discusses T-cell engager therapies in the diffuse large B-cell lymphoma (DLBCL) landscape.","thumbnail":{"asset":{"url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/b3cf913180d16149af8afb7d582c55f389b097f4-882x500.png","path":"images/0vv8moc6/ajmc/b3cf913180d16149af8afb7d582c55f389b097f4-882x500.png","size":635609,"_updatedAt":"2024-02-02T21:44:23Z","mimeType":"image/png","_id":"image-b3cf913180d16149af8afb7d582c55f389b097f4-882x500-png","extension":"png","_rev":"HQBcDLuXZwx0xKDEZjcIDm","_createdAt":"2024-02-02T21:44:23Z","metadata":{"blurHash":"McKK+it8~ptRwH_MWXjZj?M{t6ayV@oKbb","_type":"sanity.imageMetadata","palette":{"darkMuted":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.89,"background":"#4e3e2b"},"muted":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":2.29,"background":"#a57b67"},"lightVibrant":{"background":"#fcccb1","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#000","population":0.01},"darkVibrant":{"background":"#1e0a04","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0.18},"lightMuted":{"_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff","population":0.35,"background":"#ccc2ab"},"vibrant":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0,"background":"#e14b1e"},"dominant":{"title":"#fff","population":2.29,"background":"#a57b67","_type":"sanity.imagePaletteSwatch","foreground":"#fff"},"_type":"sanity.imagePalette"},"hasAlpha":true,"lqip":"data:image/png;base64,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","dimensions":{"aspectRatio":1.764,"height":500,"_type":"sanity.imageDimensions","width":882},"isOpaque":true},"uploadId":"2ZKuk0RRNWrOqNOI7zJh7CkUYVgrd5Rc","_type":"sanity.imageAsset","sha1hash":"b3cf913180d16149af8afb7d582c55f389b097f4","assetId":"b3cf913180d16149af8afb7d582c55f389b097f4","originalFilename":"Screen Shot 2024-02-02 at 4.33.23 PM.png"}},"_type":"article","ExcludeFromPubMedXML":false,"seoTag":["DLBCL","diffuse large B-cell lymphoma","T-cell engager therapy","CAR T cells","bispecific antibodies"],"is_visible":true,"authorMapping":[{"lastName":"McNulty","_id":"9243ec08-02c0-4c8e-b586-619334f7f95d","biography":[{"markDefs":[],"children":[{"marks":[],"text":"Rose is an associate editorial director at ","_key":"123612bd9b2b0","_type":"span"},{"marks":["em"],"text":"The American Journal of Managed Care","_key":"2cd28f20d2b9","_type":"span"},{"_key":"032c8e723210","_type":"span","marks":["superscript"],"text":"®"},{"_type":"span","marks":[],"text":" (","_key":"e2d5625eae03"},{"_type":"span","marks":["em"],"text":"AJMC","_key":"3af109dc927a"},{"_type":"span","marks":["superscript"],"text":"®","_key":"1903cd426eb6"},{"_type":"span","marks":[],"text":").","_key":"688f269c2ad0"}],"_type":"block","style":"normal","_key":"3a2b873558e3"},{"_type":"block","style":"normal","_key":"3a18842aed2b","markDefs":[{"nofollow":true,"blank":true,"_type":"link","href":"https://www.linkedin.com/in/rose-mcnulty-652a09126/","_key":"a1a427c7e90e"}],"children":[{"_type":"span","marks":[],"text":"She has a BA in journalism \u0026 media studies and Spanish from Rutgers University. You can connect with Rose on ","_key":"3abc796e3805"},{"_type":"span","marks":["a1a427c7e90e"],"text":"LinkedIn","_key":"123612bd9b2b1"},{"_type":"span","marks":[],"text":".","_key":"123612bd9b2b2"}]}],"profileImage":{"_type":"mainImage","alt":"Rose McNulty","asset":{"_ref":"image-8445b436ab605560bc20c7e9c6f4f60912e914df-430x430-png","_type":"reference"}},"firstName":"Rose","_createdAt":"2020-10-06T12:46:55Z","_rev":"N7mKycgLbGtEq6btkTWlrd","_type":"author","_updatedAt":"2024-06-13T13:26:39Z","url":{"current":"rose-mcnulty","_type":"slug"},"displayName":"Rose McNulty"}],"published":"2024-02-08T14:12:17.539Z","_id":"b3acf2b4-b822-4cf4-b6e0-81e49c22711d","taxonomyMapping":[{"parent":{"_type":"reference","_ref":"297fa3d1-5216-46eb-bf51-66c5f77c3c8a"},"cmeType":"per","_type":"taxonomy","name":"Non-Hodgkin Lymphoma (NHL) ","_id":"8bbafbf9-c0ab-4a9b-9def-f0fbe182c451","identifier":"nhl","perKeywordMapping":["Hematologic Cancer","Health Equity Diversity \u0026 Inclusion"],"_createdAt":"2023-02-28T21:39:54Z","_rev":"rmdpbbz4U7GL9ExaGp97i6","usedForRecommendations":false,"_updatedAt":"2024-06-25T17:42:29Z"},{"_createdAt":"2020-04-14T19:37:19Z","_rev":"sBk7YzjWMuBuhiatU3dlrp","_type":"taxonomy","name":"Providers","_id":"e6d00060-6fac-4bf6-9b44-4be71a23cb38","_updatedAt":"2020-04-14T19:37:19Z","identifier":"providers","parent":{"_ref":"5aa8e7d5-8a2d-44dd-99fc-fc43f03e2bed","_type":"reference"}},{"_createdAt":"2020-05-04T23:46:13Z","_rev":"HexDiduX8d6Nqnq1ECriVF","_type":"taxonomy","_id":"topic_clinical","_updatedAt":"2022-02-18T12:13:55Z","summary":[{"_type":"block","style":"normal","_key":"dd8ad578cd0b","markDefs":[],"children":[{"_type":"span","marks":[],"text":"The ","_key":"e80c79954e08"},{"_type":"span","marks":["em"],"text":"AJMC","_key":"a8e0f75c5d05"},{"_type":"span","marks":["superscript"],"text":"®","_key":"f7d4dddf7edd"},{"_type":"span","marks":[],"text":" clinical page includes all the published content across AJMC.com, ","_key":"0f03d46e3b3a"},{"_type":"span","marks":["em"],"text":"The American Journal of Managed Care","_key":"cc409f2da7da"},{"_key":"2babb3e59bb3","_type":"span","marks":["superscript"],"text":"®"},{"_type":"span","marks":[],"text":" and ","_key":"d86a5bb12052"},{"marks":["em"],"text":"Evidence-Based Oncology","_key":"40b2eaba6c17","_type":"span"},{"_key":"b59bef533cdf","_type":"span","marks":[],"text":"™ on a variety of specialties, including dermatology, cardiology, oncology, and rheumatology."}]}],"identifier":"clinical","parent":{"_ref":"15012229-f713-4f0a-8f82-7667530bb382","_type":"reference"},"name":"Clinical"},{"name":"Interviews","_id":"2d909731-8acf-4e3d-8962-d59b0da85320","_updatedAt":"2023-10-30T17:48:32Z","identifier":"interviews","_createdAt":"2020-03-30T19:16:54Z","sortOrder":3,"_rev":"xqhc4WIQcOa1P2rns6bqkh","_type":"taxonomy"}],"body":[{"_type":"video","videoID":"6346431244112","disableAutoPlayVideo":false,"source":"brightcove","_key":"55b2cae55276","videoObject":{"_type":"videoDetails","videoTitle":"Dr Ann LaCasce on T-Cell Engagers in DLBCL","thumbnail":{"_type":"image","asset":{"_ref":"image-b3cf913180d16149af8afb7d582c55f389b097f4-882x500-png","_type":"reference"}},"videoDuration":"PT1M57S","videoDescription":"Dr Ann LaCasce on T-Cell Engagers in DLBCL"}},{"children":[{"_type":"span","marks":[],"text":"With T-cell engagers such as chimeric antigen receptor (CAR) T-cell therapies and bispecific antibodies moving into earlier lines of therapy, answering questions about which patients will benefit most from these therapies is a key next step, said Ann LaCasce, MD, MMSc, director of the Dana-Farber/Mass General Brigham fellowship in hematology/oncology and chair of the Lymphoma Research Foundation’s Scientific Advisory Board. ","_key":"a99ff72949920"}],"_type":"block","style":"normal","_key":"88b19f4125d7","markDefs":[]},{"children":[{"_type":"span","marks":[],"text":"","_key":"3759c37e2fc3"}],"_type":"block","style":"normal","_key":"be0b1ac0e955","markDefs":[]},{"_key":"630863b65895","markDefs":[],"children":[{"_type":"span","marks":["strong","underline"],"text":"Transcript","_key":"24faa2695e84"}],"_type":"block","style":"normal"},{"_type":"block","style":"normal","_key":"6161437b1bc5","markDefs":[],"children":[{"_type":"span","marks":["strong"],"text":"T-cell engager therapies such as CAR T cells and bispecific antibodies have become preferred regimens in guidelines for certain relapsed/refractory lymphomas. How do you see this space evolving moving forward?","_key":"62b2c7108a7c0"}]},{"style":"normal","_key":"90e9b99ed997","markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"57662b47efc7"}],"_type":"block"},{"children":[{"_type":"span","marks":[],"text":"I think these have been really important additions to our therapeutic options. In diffuse large B-cell lymphoma 7 or 8 years ago, when patients relapsed quickly after initial therapy or were primary refractory, we had very little we could do. And now with the availability and the approvals of second-line CAR T-cell treatment, this has really been a huge improvement. ","_key":"50b1b6f2eec60"}],"_type":"block","style":"normal","_key":"c775bf8e877f","markDefs":[]},{"_type":"block","style":"normal","_key":"feec8b886c3a","markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"33c9fd974ec3"}]},{"children":[{"_type":"span","marks":[],"text":"I think the question now is, how do we predict who's going to be a long-term remitter or cured with CAR T-cell therapy? And what are those mechanisms of resistance? And how can we better understand why the patients who fail CAR T, why do they fail? Do we need CARs that are different that engage more than 1 receptor, [like] combined CD19/CD20? Or do we need different costimulatory molecules? Or should we be adding bispecifics to CAR T?","_key":"96a0bd70b90f"}],"_type":"block","style":"normal","_key":"20e058fb155f","markDefs":[]},{"_key":"69090759c3f8","markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"73c77a70e6d3"}],"_type":"block","style":"normal"},{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"There's all kinds of directions that this is going in, but I think the key is going to be, in diffuse large B-cell lymphoma, to really understand the biology of these diseases and try to predict who's going to benefit and who's not. And can we use some of these new techniques like MRD [minimal residual disease] to predict early that patients are destined to relapse? Because we know that all of these treatments really are most effective when patients have asymptomatic, relatively low-burden disease. So, I think integrating the science is going to be key to moving this field forward.","_key":"bf13d6ef131c"}],"_type":"block","style":"normal","_key":"7dc85f740f35"}],"link":"/view/dr-ann-lacasce-t-cell-engagers-have-improved-dlbcl-outcomes-but-questions-on-optimal-use-remain","factCheckAuthorMapping":null,"contentCategory":{"name":"Videos","_id":"ee14ccb3-3542-4414-9046-927be1198c76","_updatedAt":"2020-04-03T20:03:44Z","_createdAt":"2020-04-03T20:03:44Z","_rev":"Yw6MEKZDMdk6hC2JCPjfiB","_type":"contentCategory"},"_updatedAt":"2024-02-08T14:12:19Z","_rev":"xw71Y6IxVzwb0NP833nVxD","url":{"current":"dr-ann-lacasce-t-cell-engagers-have-improved-dlbcl-outcomes-but-questions-on-optimal-use-remain","_type":"slug"},"updatedOn":null,"title":"Dr Ann LaCasce: T-Cell Engagers Have Improved DLBCL Outcomes, but Questions on Optimal Use Remain","_createdAt":"2024-02-07T21:47:56Z","source":null},{"summary":"Tycel Phillips, MD, hematologist-oncologist at City of Hope in Duarte, CA, discussed the utility of epcoritamab in diffuse large B-cell lymphoma (DLBCL) and the potential impacts the bispecific antibody's recent approval will have in the community oncology setting. ","title":"Epcoritamab Approval Expands Treatment Armamentarium for DLBCL","link":"/view/epcoritamab-approval-expands-treatment-armamentarium-for-dlbcl","updatedOn":null,"taxonomyMapping":[{"_createdAt":"2023-02-28T21:39:54Z","_rev":"rmdpbbz4U7GL9ExaGp97i6","usedForRecommendations":false,"_updatedAt":"2024-06-25T17:42:29Z","identifier":"nhl","perKeywordMapping":["Hematologic Cancer","Health Equity Diversity \u0026 Inclusion"],"_type":"taxonomy","name":"Non-Hodgkin Lymphoma (NHL) ","_id":"8bbafbf9-c0ab-4a9b-9def-f0fbe182c451","parent":{"_type":"reference","_ref":"297fa3d1-5216-46eb-bf51-66c5f77c3c8a"},"cmeType":"per"},{"summary":[{"children":[{"_type":"span","marks":[],"text":"The ","_key":"53357d6c1d10"},{"_type":"span","marks":["em"],"text":"AJMC","_key":"122b18d05e3c"},{"_type":"span","marks":["superscript"],"text":"® ","_key":"461dab9da6c6"},{"marks":[],"text":"Product Approvals and Launches page will cover the latest FDA product approvals, as well as product launches in the United States.","_key":"e9256ecb5332","_type":"span"}],"_type":"block","style":"normal","_key":"a08634bd8b5b","markDefs":[]}],"identifier":"fda-approvals","_createdAt":"2021-07-20T15:08:02Z","_rev":"LrtUTIK6MzyeYqVxGijM86","_type":"taxonomy","name":"Approvals Launches","_id":"a39b59ec-5475-424a-b270-06d6cc201842","_updatedAt":"2022-02-18T12:15:33Z"},{"identifier":"news","_createdAt":"2020-03-30T18:05:45Z","_rev":"OU32WOWh4YetHW0RkWbkso","_type":"taxonomy","name":"News","_id":"39be7351-bd4c-4e98-82b3-0d675ae4671b","_updatedAt":"2022-01-19T10:20:16Z"},{"summary":[{"style":"normal","_key":"dd8ad578cd0b","markDefs":[],"children":[{"_type":"span","marks":[],"text":"The ","_key":"e80c79954e08"},{"_type":"span","marks":["em"],"text":"AJMC","_key":"a8e0f75c5d05"},{"_type":"span","marks":["superscript"],"text":"®","_key":"f7d4dddf7edd"},{"_type":"span","marks":[],"text":" clinical page includes all the published content across AJMC.com, ","_key":"0f03d46e3b3a"},{"_type":"span","marks":["em"],"text":"The American Journal of Managed Care","_key":"cc409f2da7da"},{"_key":"2babb3e59bb3","_type":"span","marks":["superscript"],"text":"®"},{"_type":"span","marks":[],"text":" and ","_key":"d86a5bb12052"},{"marks":["em"],"text":"Evidence-Based Oncology","_key":"40b2eaba6c17","_type":"span"},{"_key":"b59bef533cdf","_type":"span","marks":[],"text":"™ on a variety of specialties, including dermatology, cardiology, oncology, and rheumatology."}],"_type":"block"}],"identifier":"clinical","parent":{"_ref":"15012229-f713-4f0a-8f82-7667530bb382","_type":"reference"},"name":"Clinical","_createdAt":"2020-05-04T23:46:13Z","_rev":"HexDiduX8d6Nqnq1ECriVF","_type":"taxonomy","_id":"topic_clinical","_updatedAt":"2022-02-18T12:13:55Z"},{"_id":"2d909731-8acf-4e3d-8962-d59b0da85320","_updatedAt":"2023-10-30T17:48:32Z","identifier":"interviews","_createdAt":"2020-03-30T19:16:54Z","sortOrder":3,"_rev":"xqhc4WIQcOa1P2rns6bqkh","_type":"taxonomy","name":"Interviews"}],"_id":"ffaec385-c422-48ff-964e-b69aefe950be","_type":"article","factCheckAuthorMapping":null,"url":{"_type":"slug","current":"epcoritamab-approval-expands-treatment-armamentarium-for-dlbcl"},"ExcludeFromPubMedXML":false,"published":"2023-06-09T21:08:49.408Z","source":null,"_updatedAt":"2023-06-09T21:21:44Z","thumbnail":{"asset":{"mimeType":"image/png","sha1hash":"fdb7f0c1219bd696ea4df915749776882346572b","size":1995664,"_createdAt":"2023-06-09T19:46:10Z","_id":"image-fdb7f0c1219bd696ea4df915749776882346572b-1682x972-png","originalFilename":"Screen Shot 2023-06-09 at 3.43.53 PM.png","uploadId":"xtWXmvwYwf1UcFYWIQ6ng8qfJOrY9ygi","_type":"sanity.imageAsset","url":"https://cdn.sanity.io/images/0vv8moc6/ajmc/fdb7f0c1219bd696ea4df915749776882346572b-1682x972.png","assetId":"fdb7f0c1219bd696ea4df915749776882346572b","extension":"png","metadata":{"isOpaque":true,"blurHash":"MHKw?|pJ_NxvIW-:M{4nM{WBg2M{IURjtQ","_type":"sanity.imageMetadata","palette":{"dominant":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":5.78,"background":"#807065"},"_type":"sanity.imagePalette","darkMuted":{"title":"#fff","population":5.61,"background":"#563f33","_type":"sanity.imagePaletteSwatch","foreground":"#fff"},"muted":{"title":"#fff","population":5.78,"background":"#807065","_type":"sanity.imagePaletteSwatch","foreground":"#fff"},"lightVibrant":{"title":"#000","population":0.02,"background":"#faf5ec","_type":"sanity.imagePaletteSwatch","foreground":"#000"},"darkVibrant":{"population":0.1,"background":"#392414","_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff"},"lightMuted":{"population":5.77,"background":"#ccc3b1","_type":"sanity.imagePaletteSwatch","foreground":"#000","title":"#fff"},"vibrant":{"_type":"sanity.imagePaletteSwatch","foreground":"#fff","title":"#fff","population":0,"background":"#bc7742"}},"hasAlpha":true,"lqip":"data:image/png;base64,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","dimensions":{"_type":"sanity.imageDimensions","width":1682,"aspectRatio":1.7304526748971194,"height":972}},"_rev":"TMxEdWkpP22cqhfBO1p5LF","path":"images/0vv8moc6/ajmc/fdb7f0c1219bd696ea4df915749776882346572b-1682x972.png","_updatedAt":"2023-06-09T19:46:10Z"}},"body":[{"_type":"block","style":"normal","_key":"a5a15c6d5ee8","markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"33abdd970784"}]},{"disableAutoPlayVideo":false,"source":"brightcove","_key":"c673c26c7d66","_type":"video","videoID":"6329108410112"},{"children":[{"_type":"span","marks":[],"text":"","_key":"03cbe33dcdfb"}],"_type":"block","style":"normal","_key":"0e4cbd9b379b","markDefs":[]},{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"Tycel Phillips, MD, associate professor, Department of ","_key":"ef439bdfe535"},{"_type":"span","marks":["em"],"text":"Hematology","_key":"6349bf0968eb"},{"marks":[],"text":" and Hematopoietic Cell Transplantation, Division of Lymphoma, City of Hope in Duarte, CA, discussed the utility of epcoritamab in diffuse large B-cell lymphoma and the potential impacts the drug's recent approval will have in the community oncology setting. ","_key":"24c42f4daa5c","_type":"span"}],"_type":"block","style":"normal","_key":"74b9e2f3edc7"},{"children":[{"_type":"span","marks":[],"text":"","_key":"a654b3305986"}],"_type":"block","style":"normal","_key":"26af07b569bd","markDefs":[]},{"markDefs":[],"children":[{"_type":"span","marks":["strong","underline"],"text":"Transcript","_key":"81eb5d69ae83"}],"_type":"block","style":"normal","_key":"22d9e87c22e8"},{"_key":"1d37b8fd58df","markDefs":[],"children":[{"_type":"span","marks":["strong"],"text":"Can you describe the mechanism of action of epcoritamab?","_key":"418e3522d361"}],"_type":"block","style":"normal"},{"_key":"32770a31f58b","markDefs":[],"children":[{"_key":"4a48b441b6a0","_type":"span","marks":[],"text":"Epcoritamab is part of a class of drugs called bispecific T-cell engagers. In essence, epcoritamab has 2 binding epitopes, 1 to CD20, which would target malignant or normal B cells, and the other CD3, which targets our T cells. Upon engagement, epcoritamab sort of brings the T cell and the B cell into close proximity, which allows the T cell to sort of release proinflammatory cytokines, which hopefully kills off, in our case, the malignant B cells, or cancerous B cells and induce cell death. So, with each of these infusions, we are causing some T cell stimulation, which induces hopefully more and more of these T cells to engage the tumor, and ultimately leading to response—which is quite different from what we typically see with chemotherapy, which, in essence, is something that just damages DNA of fast-growing cells. So, different mechanism of action from what we see from chemo, and potentially has an avenue of causing efficacy in patients who may be refractory to chemotherapy, as the cancer cells will find ways to sort of avoid being killed off by the chemotherapy approach, which, although we have very, very different quantities and qualities of chemotherapy drugs, I mean, they all in essence function in very similar ways as far as how they cause cell death."}],"_type":"block","style":"normal"},{"markDefs":[],"children":[{"marks":[],"text":"","_key":"a479f02eb43b0","_type":"span"}],"_type":"block","style":"normal","_key":"57e897805026"},{"_key":"ea3844d39040","markDefs":[],"children":[{"_type":"span","marks":["strong"],"text":"How can epcoritamab help patients who cannot wait for CAR T-cell therapy?","_key":"4f3d39faf3f2"}],"_type":"block","style":"normal"},{"markDefs":[],"children":[{"_key":"31fe760951230","_type":"span","marks":[],"text":"Well, I think it's 2-fold. It's not even those who can't wait—as I mentioned, there's quite a few patients who can't even get access to CAR T. With the data we have from epcoritamab, we do have about a 60% overall response rate and a CR rate somewhere a little bit above 40%, which is a complete response rate for those who are CAR T–naïve. Ideally, if you can get a patient to CAR T, you should, but for those who can't for the various reasons we discussed, whether it's location, socioeconomic-wise where they can't have a caregiver with them for the 30 days required for CAR T, or they just can't take off work or anything else that comes with requirements for CAR T, these could be options for those patients, with the hope that you can get durability of response. That's one thing we don't have right now is the durability data on epcoritamab and how long patients will stay in remission. And potentially, if any of these patients are potentially cured. But specifically to your question, the drug wasn't necessarily studied as a bridge treatment to CAR T. I mean, we have data regarding its use in patients who had not received CAR T and its use in patients who have previously failed CAR T. But as a bridge therapy, I think that's an area of research that's being explored for this patient population. But we really don't have any clear-cut data about how effective it will be as a bridge therapy and sort of what he would do to the CAR T-cell product once you collect after epcoritamab."}],"_type":"block","style":"normal","_key":"07493bc62ee8"},{"_type":"block","style":"normal","_key":"041d8dd4110e","markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"9c868ae1b8eb"}]},{"_type":"block","style":"normal","_key":"14817b1de1f8","markDefs":[],"children":[{"marks":["strong"],"text":"How does the side effect profile of epcoritamab compare with other treatments for DLBCL?","_key":"faa267374e3b0","_type":"span"}]},{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"The easy answer is with chemotherapy, it doesn't really compare. Because at least with this, we don't see the nausea, the vomiting, the early onset cytopenias, the significant fatigue, hair loss, neuropathy, or mouth sores that we typically see with chemotherapy. But it does have its own unique toxicity profile, mainly being what we call cytokine release syndrome, or CRS, and that is a based on sort of those poor inflammatory cytokines released when the T cell engages with the B cell with the help of epcoritamab. What you'll see is elevation in temperature—fever is usually the first indicator of CRS. Thereafter, you can see alterations in blood pressure and breathing difficulties.","_key":"d0c42bfeb3560"}],"_type":"block","style":"normal","_key":"589faf439b82"},{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"04f37bf74e1b0"}],"_type":"block","style":"normal","_key":"68e06bc04ce9"},{"_type":"block","style":"normal","_key":"323f4d870968","markDefs":[],"children":[{"_type":"span","marks":[],"text":"The side-effect profile is very similar to what we see with CAR T. The main points that we know with CRS and ICANS with bispecifics compared to what we see with CAR T, specifically with CRS: the onset appears to be a bit earlier, the duration appears to be not as long, and we don't necessarily see as many grade 3 or 4 cytokine release syndrome events, which is good, especially given that these drugs will hopefully be in the hands of community physicians who don't necessarily have access to an ICU, per se, or necessarily have significant experience with managing cytokine release syndrome. Albeit grade 1, we typically can manage very easily with steroids and sometimes with just antipyretics. Grade 2 is when you tend to sometimes consider use of a drug called tocilizumab, which is an IL-6 [inhibitor used prior to] CAR T. Again, because of the ability to have to store tocilizumab, that may sometimes require a bit more escalation of care because that is generally not something we can give in an outpatient setting.","_key":"a066bb3fe5cb0"}]},{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"25dcb57e2b2a0"}],"_type":"block","style":"normal","_key":"5c08f5fb55f3"},{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"Now when we look at ICANS, the ICANS events are very low when we look at bispecifics compared to CAR T. The events can still happen, but it's generally not something that's a major concern for the bispecific antibodies. Because of the nature of how by specifics work, we also do run into issues with infections, because again, they are very good at depleting normal as well as malignant B cells. And obviously, if our B cells are depleted, we do run into issues as far as viral infections and other things. And with some of these drugs, we have maybe seen some late-onset neutropenia, which also increases your risk of bacterial infections. But again, these profiles are a bit different from what you typically expect with chemotherapy. And because of some of the unique nature of CRS, this is something that will be a bit of a learning curve for all physicians when they eventually start using these bispecific antibodies, especially those who have not had previous experience with dealing with these types of treatments from CAR T therapy.","_key":"d305249d566d0"}],"_type":"block","style":"normal","_key":"73d18f628f18"},{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"a620659dac21"}],"_type":"block","style":"normal","_key":"38b68753bf45"},{"markDefs":[],"children":[{"_type":"span","marks":["strong"],"text":"Can epcoritamab be administered in the community setting?\n","_key":"547e5aa55850"},{"marks":[],"text":"I think the whole premise of these bispecific antibodies, besides reducing the time to treat that we sometimes see with CAR T with the vein to vein—from the collection to when you get the manufactured cells back—is the fact that you would hope that these drugs, the bispecifics, would be able to get into more places than what we can with CAR T, which are limited to therapy centers, they have to be accredited to give CAR T. But that's going to take some time and a level of comfortability with dealing with the adverse event profile. Because again, CRS [and] ICANS are unique and things that we don't typically or have seen with some of these other sort of treatments that are available in the community. It's very different from the immune infusion reaction we see with rituximab or some of the other sort of CD20 antibodies. But it's also different from tumor lysis syndrome, from what we see with venetoclax.","_key":"1a3674c70ad7","_type":"span"}],"_type":"block","style":"normal","_key":"ed3e04577d91"},{"_key":"351723ca5c49","markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"661353ec1b380"}],"_type":"block","style":"normal"},{"children":[{"_type":"span","marks":[],"text":"I'm bringing these up as examples, as these are also obstacles that community physicians had to overcome to start giving these drugs on a more daily basis. But they did, and they use these drugs quite readily. So, with an expected learning curve, I expect these drugs to be used quite readily in most community centers as they get more comfortable with the side effect profile and more comfortable being able to predict who will have issues and who won't. The good thing with CRS and ICANS, at least from what we're getting from these studies, we are getting very good at predicting when these events are most likely to happen. Based on the different bispecific antibodies, specifically with epcoritamab, it seems that most of these events happen on cycle 1, day 15, which is when you get the first full dose.","_key":"355a085395b20"}],"_type":"block","style":"normal","_key":"76dc5eeae424","markDefs":[]},{"markDefs":[],"children":[{"_type":"span","marks":[],"text":"So that will allow them to plan more accordingly [and say], “Okay, 61% of patients are going to have CRS on this day, so this is likely when I need to start planning for sure.” Albeit you do need to be on lookout and aware of these events happening prior. But again, the majority of the patients, if they're going to have a problem, it will be on that day. With the other bispecifics, the profiles are a bit different, but it’s just keeping in mind what drug you're using and when you would [most likely] expect CRS to happen and sort of what are your mitigation plan. But as I said, I would expect within a matter of years that community physicians will be very comfortable with these drugs and will be using them, because I do think they will be quite effective and will provide quite a bit of benefit for our patients, whether either in CAR T settings where they fail CAR T or they can't get the CAR T, or eventually as we mentioned before, based on if we get more data, as a bridge to CAR T. But I do think they will provide a level of treatment that we don't necessarily have with some of these other drugs that are currently available today.","_key":"cfae074cb3950"}],"_type":"block","style":"normal","_key":"062f34f2d119"},{"_key":"668bc20a445d","markDefs":[],"children":[{"_type":"span","marks":[],"text":"","_key":"62b8a258dab00"}],"_type":"block","style":"normal"}],"_createdAt":"2023-06-09T19:49:35Z","_rev":"ISon8M3s927kPDQzrQtxOJ","contentCategory":{"_type":"contentCategory","name":"Videos","_id":"ee14ccb3-3542-4414-9046-927be1198c76","_updatedAt":"2020-04-03T20:03:44Z","_createdAt":"2020-04-03T20:03:44Z","_rev":"Yw6MEKZDMdk6hC2JCPjfiB"},"seoTag":["epcoritamab","DLBCL"],"authorMapping":[{"url":{"current":"mary-caffrey","_type":"slug"},"displayName":"Mary Caffrey","_createdAt":"2020-05-05T10:50:00Z","_rev":"fWre465xUeSiaQm83HJghZ","_type":"author","_id":"author_6732921f288a3775abb89da57903428b","biography":[{"_type":"block","style":"normal","_key":"80606b0b2412","markDefs":[],"children":[{"_type":"span","marks":[],"text":"Mary Caffrey is the Executive Editor for The American Journal of Managed Care® (","_key":"9737335da1ed0"},{"_type":"span","marks":["em"],"text":"AJMC","_key":"b8dda18bb0dc"},{"marks":[],"text":"®). She joined AJMC® in 2013 and is the primary staff editor for ","_key":"f56917041c08","_type":"span"},{"_type":"span","marks":["em"],"text":"Evidence-Based Oncology, ","_key":"8c710bb1d962"},{"_key":"1b94f48924f3","_type":"span","marks":[],"text":"the multistakeholder publication that reaches 22,000+ oncology providers, policy makers and formulary decision makers. She is also part of the team that oversees speaker recruitment and panel preparations for "},{"_type":"span","marks":["em"],"text":"AJMC","_key":"3c5f9805f644"},{"_type":"span","marks":[],"text":"®'s premier annual oncology meeting, Patient-Centered Oncology Care®. For more than a decade, Mary has covered ASCO, ASH, ACC and other leading scientific meetings for ","_key":"d533ba55a862"},{"_type":"span","marks":["em"],"text":"AJMC","_key":"953d8c643cce"},{"_type":"span","marks":[],"text":" readers. ","_key":"182af2348b04"}]},{"markDefs":[{"blank":true,"_type":"link","href":"https://www.linkedin.com/in/marykcaffrey/","_key":"4f88673cb2c4","nofollow":true}],"children":[{"marks":[],"text":"Mary has a BA in communications and philosophy from Loyola University New Orleans. You can connect with Mary on ","_key":"c2027cf5a357","_type":"span"},{"_type":"span","marks":["4f88673cb2c4"],"text":"LinkedIn","_key":"9737335da1ed1"},{"_type":"span","marks":[],"text":".","_key":"9737335da1ed2"}],"_type":"block","style":"normal","_key":"a03d32973d6e"}],"_updatedAt":"2023-10-12T05:02:06Z"},{"biography":[{"_type":"block","style":"normal","_key":"3a2b873558e3","markDefs":[],"children":[{"marks":[],"text":"Rose is an associate editorial director at ","_key":"123612bd9b2b0","_type":"span"},{"marks":["em"],"text":"The American Journal of Managed Care","_key":"2cd28f20d2b9","_type":"span"},{"_key":"032c8e723210","_type":"span","marks":["superscript"],"text":"®"},{"_type":"span","marks":[],"text":" (","_key":"e2d5625eae03"},{"_type":"span","marks":["em"],"text":"AJMC","_key":"3af109dc927a"},{"_type":"span","marks":["superscript"],"text":"®","_key":"1903cd426eb6"},{"_type":"span","marks":[],"text":").","_key":"688f269c2ad0"}]},{"children":[{"_type":"span","marks":[],"text":"She has a BA in journalism \u0026 media studies and Spanish from Rutgers University. You can connect with Rose on ","_key":"3abc796e3805"},{"_type":"span","marks":["a1a427c7e90e"],"text":"LinkedIn","_key":"123612bd9b2b1"},{"_type":"span","marks":[],"text":".","_key":"123612bd9b2b2"}],"_type":"block","style":"normal","_key":"3a18842aed2b","markDefs":[{"_key":"a1a427c7e90e","nofollow":true,"blank":true,"_type":"link","href":"https://www.linkedin.com/in/rose-mcnulty-652a09126/"}]}],"profileImage":{"_type":"mainImage","alt":"Rose McNulty","asset":{"_ref":"image-8445b436ab605560bc20c7e9c6f4f60912e914df-430x430-png","_type":"reference"}},"firstName":"Rose","lastName":"McNulty","_id":"9243ec08-02c0-4c8e-b586-619334f7f95d","_type":"author","_updatedAt":"2024-06-13T13:26:39Z","url":{"current":"rose-mcnulty","_type":"slug"},"displayName":"Rose McNulty","_createdAt":"2020-10-06T12:46:55Z","_rev":"N7mKycgLbGtEq6btkTWlrd"}],"is_visible":true}],"topArticlesData":[{"_id":"bab387ea-dd2a-475c-baa6-4fa615de245b","thumbnail":{"_type":"mainImage","alt":"Non-Hodgkin Lymphoma | Image credit: Saiful52 - stock.adobe.com","caption":"Non-Hodgkin Lymphoma | Image credit: Saiful52 - stock.adobe.com","asset":{"_ref":"image-d51b9738c42ccbde57b68d8ab61bfa5566fd66c3-2445x1787-jpg","_type":"reference"}},"summary":"A new analysis of real-world data show that just as in solid tumors, higher tumor mutational burden (TMB) and PD-L1 expression in blood cancers are linked to less-optimistic prognoses.","authors":[{"displayName":"Gayle Turim Dickstein","url":"gayle-turim-dickstein"}],"factCheckAuthors":null,"title":"Higher TMB, PD-L1 Expression Correlate With Shorter Survival in Hematologic Malignancies ","url":"higher-tmb-pd-l1-expression-correlate-with-shorter-survival-in-hematologic-malignancies","published":"2024-10-30T14:39:57.067Z","updatedOn":null,"source":null},{"title":"Miles Matter: The Geographic Disparity That Impacts Access to CAR T Therapy","thumbnail":{"_type":"mainImage","alt":"Thomas Jefferson | Image: Thomas Jefferson University ","caption":"Thomas Jefferson | Image: Thomas Jefferson University ","asset":{"_ref":"image-3d97f41753d5036fe06a27339f606f5bb4fd9d8f-2400x1600-jpg","_type":"reference"}},"summary":null,"updatedOn":null,"authors":[{"displayName":"Ryan Flinn","url":"ryan-flinn"}],"_id":"7c70804f-67ec-43f7-b394-2e297286b18e","url":"miles-matter-the-geographic-disparity-that-impacts-access-to-car-t-therapy","published":"2024-10-13T15:15:00.000Z","source":null,"factCheckAuthors":null},{"title":"Preclinical Model Suggests Efficacy of Combining Capivasertib With Venetoclax Against DLBCL","published":"2024-10-08T15:48:22.723Z","authors":[{"displayName":"Karen Jacobson-Sive","url":"karen-jacobson-sive"}],"factCheckAuthors":null,"source":null,"_id":"ba49ecb6-4cd1-451b-9c45-a386282b861b","url":"preclinical-model-suggests-efficacy-of-combining-capivasertib-with-venetoclax-against-dlbcl","thumbnail":{"_type":"mainImage","alt":"Microbiologist conducts research in laboratory | Image Credit: © Seventyfour - stock.adobe.com","asset":{"_ref":"image-a329387e322ca781d0a66405a3ad00034bd346e8-1280x853-jpg","_type":"reference"}},"summary":"Capivasertib, in combination with venetoclax, produced promising responses in preclinical models of diffuse large B-cell lymphoma (DLBCL).","updatedOn":null},{"_id":"c7c97c69-1768-485b-b996-4a9123a1d74d","title":"Combination of Magrolimab and Rituximab Well Tolerated in Patients With Refractory/Relapsed Indolent NHL","updatedOn":null,"factCheckAuthors":null,"url":"combination-of-magrolimab-and-rituximab-well-tolerated-in-patients-with-refractory-relapsed-indolent-nhl","thumbnail":{"alt":"Lymphoma word block image | Image Credit: © airdone- stock.adobe.com","asset":{"_ref":"image-14565e78f839b82f71b7c7b220c5d33d373e67b2-1200x724-jpg","_type":"reference"},"_type":"mainImage"},"summary":"A 3-year follow-up of patients with refractory/relapsed indolent non-Hodgkin (NHL) treated with a combination of magrolimab and rituximab showed no new treatment-emergent adverse events, suggesting long-term safety. The treatment also confirmed magrolimab penetration into the tumor.","published":"2024-09-25T19:30:52.784Z","source":null,"authors":[{"displayName":"Nameera Temkar, MD","url":"nameera-temkar-md"}]},{"factCheckAuthors":null,"url":"lenalidomide-obinutuzumab-combo-yields-promising-results-in-relapsed-nhl","published":"2024-09-21T14:22:00.000Z","thumbnail":{"_type":"mainImage","alt":"NHL cells | image credit: sovova - stock.adobe.com","caption":"NHL cells | image credit: sovova - stock.adobe.com","asset":{"_ref":"image-357ec216737f69151df0afb267a2b92d55922db3-8064x5376-jpg","_type":"reference"}},"summary":"A new study demonstrates that the combination of lenalidomide (Revlimid) and obinutuzumab (Gazyva) is effective and well-tolerated in treating relapsed indolent non-Hodgkin lymphoma (NHL). ","updatedOn":null,"source":null,"authors":[{"displayName":"Kimberly Rath, PharmD","url":"kimberly-rath-pharmd"}],"_id":"4cdda5d8-c656-479e-9598-7fbafd9ef362","title":"Lenalidomide-Obinutuzumab Combo Yields Promising Results in Relapsed NHL"}],"features":[],"cmeData":{"msg":"","data":[{"id":"355d9b46-713d-4d48-84a7-2968d82157e5","brandName":"Ajmc","dataType":"ptce","title":"ASH Annual Meeting Coverage: Highlighting the Recent Updates in TKI Use in the Treatment of CML – Insights and Application for Managed Care","thumbnail":"https://d36ai2hkxl16us.cloudfront.net/thoughtindustries/image/upload/v1/course-uploads/d2afb412-3c3e-4f73-b3d6-2388078622a3/s7o31mkufl76-PTCE_ASH-CML_Webinar_110524v1_800x385.png","description":"December 18, 2024 | 1:00 PM \u0026 8:00 PM ET","releaseDate":"2024-07-18T04:00:00.000Z","expirationDate":"2024-12-19","creditType":"Live","creditAmount":"1.0","created_at":"2024-11-12T12:05:52.433765+00:00","TI_id":"eae2665d-bf7f-42eb-a26a-99bbfbf06427","slug":"ash-annual-meeting-coverage-highlighting-the-recent-updates-in-tki-use-in-the-treatment-of-cml-insights-and-application-for-managed-care","delReference":true,"contentTypeLabel":"Webinar Registration","activity-type":null,"specialty":"[\"Oncology\",\"Hematology\",\"Hematologic Cancer\"]","creditCertificate":null,"courseEndDate":"2024-12-19T04:59:59.999+00:00","cventUrl":""},{"id":"3b3937de-a7a5-4ebd-bb5c-6192a7da7102","brandName":"Ajmc","dataType":"ptce","title":"Recent Advances in BCMA-Directed Treatment in Multiple Myeloma: Insights and Application for Managed Care","thumbnail":"https://d36ai2hkxl16us.cloudfront.net/thoughtindustries/image/upload/v1/course-uploads/d2afb412-3c3e-4f73-b3d6-2388078622a3/d051f9s6a2ac-PTCE_MM_Webinar_111623v1_800x385.png","description":"1.0 Credits / Hematologic Cancer, Oncology","releaseDate":"2023-12-21T05:00:00.000Z","expirationDate":"2024-12-22","creditType":"On-Demand","creditAmount":"1","created_at":"2024-11-12T12:05:53.299762+00:00","TI_id":"5568bba0-655c-4a88-afe5-febf5a5e9fc3","slug":"recent-advances-in-bcma-directed-treatment-in-multiple-myeloma-insights-and-application-for-managed-care-enduring","delReference":true,"contentTypeLabel":"On-Demand Webinar","activity-type":null,"specialty":"[\"Hematologic Cancer\",\"Oncology\"]","creditCertificate":null,"courseEndDate":"2024-12-22T04:59:59.999+00:00","cventUrl":""},{"id":"9453bbb8-c0d5-459e-9058-a97e9e0cdb97","brandName":"Ajmc","dataType":"ptce","title":"Keeping Pace With New Developments in Multiple Myeloma: Updates and Strategies to Optimize Bispecific Antibodies and CAR T-Cell Therapy","thumbnail":"https://d36ai2hkxl16us.cloudfront.net/thoughtindustries/image/upload/v1/course-uploads/d2afb412-3c3e-4f73-b3d6-2388078622a3/hvzihm9lmt65-PTCE_AMCP-2024_MM_Enduring_043024v1_800x385.png","description":"1.5 Credits / Oncology, Hematology, Hematologic Cancer","releaseDate":"2024-05-03T04:00:00.000Z","expirationDate":"2025-05-04","creditType":"On-Demand","creditAmount":"1.5","created_at":"2024-11-12T12:05:53.144574+00:00","TI_id":"e2a1de76-f5f4-4393-85a1-e17a243a9853","slug":"keeping-pace-with-new-developments-in-multiple-myeloma-updates-and-strategies-to-optimize-bispecific-antibodies-and-car-t-cell-therapy-tcdv","delReference":true,"contentTypeLabel":"On-Demand Virtual Symposium","activity-type":null,"specialty":"[\"Oncology\",\"Hematology\",\"Hematologic Cancer\"]","creditCertificate":null,"courseEndDate":"2025-05-04T03:59:59.999+00:00","cventUrl":""},{"id":"54fbd28a-f02c-44b9-8d31-f0863e5d2455","brandName":"Ajmc","dataType":"ptce","title":"Addressing the Gaps and Clinical Challenges in Chronic Lymphocytic Leukemia: Updates and Strategies for Managed Care","thumbnail":"https://d36ai2hkxl16us.cloudfront.net/thoughtindustries/image/upload/v1/course-uploads/d2afb412-3c3e-4f73-b3d6-2388078622a3/22wqid3lilcb-PTCE_AMCP-2024_CLL_Enduring_043024v2_800x385.png","description":"1.5 Credits / Hematology, Hematologic Cancer, Oncology","releaseDate":"2024-05-03T04:00:00.000Z","expirationDate":"2025-05-04","creditType":"On-Demand","creditAmount":"1.5","created_at":"2024-11-12T12:05:53.222033+00:00","TI_id":"3f5fc85c-88a5-4d21-9e76-047d384b88f2","slug":"addressing-the-gaps-and-clinical-challenges-in-chronic-lymphocytic-leukemia-updates-and-strategies-for-managed-care-dxq5","delReference":true,"contentTypeLabel":"On-Demand Virtual Symposium","activity-type":null,"specialty":"[\"Hematology\",\"Hematologic Cancer\",\"Oncology\"]","creditCertificate":null,"courseEndDate":"2025-05-04T03:59:59.999+00:00","cventUrl":""}],"fail":false},"videoData":{}},"queryString":{"slug":["compendium","nhl"]}},"host":"www.ajmc.com"},"__N_SSP":true},"page":"/[...slug]","query":{"slug":["compendium","nhl"]},"buildId":"jIKMoC-9mMyLq4v4Ma7Tv","isFallback":false,"gssp":true,"appGip":true,"scriptLoader":[]}</script></body></html>